primaryid;Indication;drug name;dose (mg/UI);manufacturerName;age;sex;Outcome;SideReaction
100654764;Glioblastoma;AFINITOR;5;NOVARTIS;56;F;Death;Pulmonary embolism
101678656;Systemic lupus erythematosus;Belimumab;10;GLAXOSMITHKLINE;53;F;Hospitalization - Initial or Prolonged;Klebsiella sepsis
101980392;Plasma cell myeloma;REVLIMID;15;CELGENE;77;M;Death;Myocardial infarction
103011729;Neuralgia;LYRICA;200;PFIZER;60;M;Other Serious (Important Medical Event);Fall
103829296;Fabry's disease;FABRAZYME;70;SANOFI AVENTIS;31;M;NA;Body temperature increased
104456557;Diabetic neuropathy;LYRICA;50;PFIZER;49;M;NA;Drug ineffective
104803043;Gaucher's disease;Velaglucerase alfa;3600;TAKEDA;52;F;Death;Diarrhoea
104833856;Basal cell carcinoma;ERIVEDGE;150;ROCHE;51;F;Other Serious (Important Medical Event);Alopecia
107082202;Plasma cell myeloma;REVLIMID;25;CELGENE;76;F;Other Serious (Important Medical Event);Diverticular perforation
107341882;Plasma cell myeloma;REVLIMID;25;CELGENE;67;M;Hospitalization - Initial or Prolonged;Dyspnoea
107526832;Plasma cell myeloma;REVLIMID;15;CELGENE;91;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
108032902;Plasma cell myeloma;REVLIMID;15;CELGENE;67;F;Other Serious (Important Medical Event);Coronary artery disease
108604323;Plasma cell myeloma;REVLIMID;10;CELGENE;73;M;Other Serious (Important Medical Event);Dyspnoea
108673555;Plasma cell myeloma;REVLIMID;10;CELGENE;62;M;Hospitalization - Initial or Prolonged;Basal cell carcinoma
108930083;NA;NA;NA;CELGENE;72;M;Hospitalization - Initial or Prolonged;Pancytopenia
109228774;Plasma cell myeloma;REVLIMID;10;CELGENE;82;F;Other Serious (Important Medical Event);Dehydration
109543792;Plasma cell myeloma;REVLIMID;25;CELGENE;50;F;Hospitalization - Initial or Prolonged;Pneumonia respiratory syncytial viral
109680226;Narcolepsy;XYREM;3;JAZZ;56;M;Other Serious (Important Medical Event);Cardiac disorder
109705882;Plasma cell myeloma;REVLIMID;15;CELGENE;66;M;Hospitalization - Initial or Prolonged;Pneumonia
109793992;Plasma cell myeloma;REVLIMID;25;CELGENE;75;M;Other Serious (Important Medical Event);Hypotension
109837324;Plasma cell myeloma;REVLIMID;15;CELGENE;66;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
109953332;Plasma cell myeloma;REVLIMID;25;CELGENE;80;F;Hospitalization - Initial or Prolonged;Biliary dyskinesia
110229263;Plasma cell myeloma;REVLIMID;25;CELGENE;33;M;Other Serious (Important Medical Event);Pneumonia
110450415;Plasma cell myeloma;REVLIMID;25;CELGENE;65;M;Hospitalization - Initial or Prolonged;Angina pectoris
110839482;Plasma cell myeloma;REVLIMID;10;CELGENE;67;M;Other Serious (Important Medical Event);Renal failure
111048356;Plasma cell myeloma;REVLIMID;25;CELGENE;74;F;Other Serious (Important Medical Event);Chronic gastritis
111140142;Plasma cell myeloma;REVLIMID;20;CELGENE;87;M;Other Serious (Important Medical Event);Neutropenia
111234763;Plasma cell myeloma;REVLIMID;15;CELGENE;57;F;Hospitalization - Initial or Prolonged;Pneumonia
111530912;Plasma cell myeloma;REVLIMID;25;CELGENE;58;M;Hospitalization - Initial or Prolonged;Pneumonia
111601922;Plasma cell myeloma;REVLIMID;25;CELGENE;64;F;Hospitalization - Initial or Prolonged;Pneumonia
111791005;Plasma cell myeloma;REVLIMID;25;CELGENE;67;M;Other Serious (Important Medical Event);Anaemia
111811932;Plasma cell myeloma;THALOMID;100;CELGENE;74;F;Other Serious (Important Medical Event);Neutropenia
111935483;Plasma cell myeloma;REVLIMID;10;CELGENE;48;F;Other Serious (Important Medical Event);Pancreatitis
111950182;Plasma cell myeloma;REVLIMID;10;CELGENE;72;M;Other Serious (Important Medical Event);Chills
111966937;Post herpetic neuralgia;LYRICA;75;PFIZER;73;F;Other Serious (Important Medical Event);Eye disorder
112334352;Plasma cell myeloma;REVLIMID;25;CELGENE;78;M;Other Serious (Important Medical Event);Dyspnoea
112550422;Plasma cell myeloma;REVLIMID;20;CELGENE;59;F;Hospitalization - Initial or Prolonged;Septic shock
113253242;Plasma cell myeloma;REVLIMID;10;CELGENE;73;M;Other Serious (Important Medical Event);Urinary tract infection bacterial
114273577;Fabry's disease;FABRAZYME;0.99;SANOFI AVENTIS;40;F;Hospitalization - Initial or Prolonged;Anxiety
114343914;NA;NA;NA;JOHNSON AND JOHNSON;36;F;Hospitalization - Initial or Prolonged;Cellulitis
114778912;Fibromyalgia;XYREM;3;JAZZ;65;F;NA;Anxiety
114790362;Narcolepsy;XYREM;1.5;JAZZ;35;F;NA;Condition aggravated
114807992;Narcolepsy;XYREM;2.25;JAZZ;36;F;NA;Abdominal pain upper
114878542;Narcolepsy;XYREM;2.25;JAZZ;42;F;NA;Nasopharyngitis
114885984;Anaemia;MIRCERA;150;ROCHE;70;M;NA;Hypersensitivity
116571622;Plasma cell myeloma;REVLIMID;5;CELGENE;78;M;Other Serious (Important Medical Event);Deep vein thrombosis
116883646;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;55;M;NA;Dizziness
116883784;Plasma cell myeloma;REVLIMID;25;CELGENE;62;M;Other Serious (Important Medical Event);Thrombosis
117382144;Hormone replacement therapy;PREMARIN;1.25;PFIZER;75;F;Other Serious (Important Medical Event);Conjunctival hyperaemia
117961113;Plasma cell myeloma;REVLIMID;15;CELGENE;66;M;Hospitalization - Initial or Prolonged;Deep vein thrombosis
118161524;Fibromyalgia;XYREM;3;JAZZ;47;F;Hospitalization - Initial or Prolonged;Parkinson's disease
118808975;Plasma cell myeloma;REVLIMID;25;CELGENE;59;M;Other Serious (Important Medical Event);Anaemia
119119832;Hodgkin's disease;brentuximab vedotin;1.8;SEATTLE GENETICS;16;M;Hospitalization - Initial or Prolonged;Embolism
119369753;Plasma cell myeloma;REVLIMID;10;CELGENE;66;M;Hospitalization - Initial or Prolonged;Clostridium difficile colitis
119515824;Gait disturbance;AMPYRA;10;ACORDA;70;F;Life-Threatening;Arrhythmia
120780724;Neuropathy peripheral;LYRICA;225;PFIZER;52;F;Other Serious (Important Medical Event);Condition aggravated
120896799;Fibromyalgia;LYRICA;75;PFIZER;52;F;Other Serious (Important Medical Event);Drug ineffective
121498993;Plasma cell myeloma;REVLIMID;25;CELGENE;52;M;Other Serious (Important Medical Event);Appendicitis perforated
121692562;NA;NA;NA;TAKEDA;38;F;Other Serious (Important Medical Event);Fistula
122004105;Multiple sclerosis;TECFIDERA;240;BIOGEN;52;F;NA;Alopecia
122309908;Short-bowel syndrome;Teduglutide;0.5;TAKEDA;31;M;Disability;Anaemia
122726952;Plasma cell myeloma;REVLIMID;25;CELGENE;63;F;Other Serious (Important Medical Event);Mental status changes
122767287;Fibromyalgia;LYRICA;200;PFIZER;77;F;NA;Cough
123187006;Crohn's disease;HUMIRA;40;ABBVIE;14;M;Hospitalization - Initial or Prolonged;Acute kidney injury
124230756;Breast cancer metastatic;IBRANCE;125;PFIZER;76;F;Death;Balance disorder
124399693;Plasma cell myeloma;REVLIMID;5;CELGENE;71;F;Hospitalization - Initial or Prolonged;Syncope
124428272;Plasma cell myeloma;POMALYST;3;CELGENE;73;M;Hospitalization - Initial or Prolonged;Pneumonia bacterial
124433987;Hormone replacement therapy;PREMARIN;0.625;PFIZER;82;F;Other Serious (Important Medical Event);Asthenia
124447842;Plasma cell myeloma;REVLIMID;25;CELGENE;60;M;Hospitalization - Initial or Prolonged;Pneumonia
124490452;Plasma cell myeloma;THALOMID;200;CELGENE;46;F;Other Serious (Important Medical Event);Acute kidney injury
124608163;Plasma cell myeloma;REVLIMID;10;CELGENE;79;M;Other Serious (Important Medical Event);Acute kidney injury
124736302;Plasma cell myeloma;REVLIMID;5;CELGENE;42;M;Hospitalization - Initial or Prolonged;Pneumonia influenzal
124765212;Plasma cell myeloma;REVLIMID;15;CELGENE;59;M;Hospitalization - Initial or Prolonged;Dyspnoea
124810138;Partial lipodystrophy;Metreleptin;5;AEGERION;17;F;Hospitalization - Initial or Prolonged;Abdominal pain
124902822;Plasma cell myeloma;REVLIMID;10;CELGENE;83;M;Life-Threatening;Pneumonia
124904362;Plasma cell myeloma;REVLIMID;25;CELGENE;73;M;Other Serious (Important Medical Event);Pain in extremity
124927842;Plasma cell myeloma;REVLIMID;25;CELGENE;65;M;Hospitalization - Initial or Prolonged;Arthritis infective
124977452;Plasma cell myeloma;REVLIMID;5;CELGENE;53;M;Hospitalization - Initial or Prolonged;Pneumonia
125275772;Basal cell carcinoma;VISMODEGIB;150;ROCHE;45;M;Other Serious (Important Medical Event);Cardiac failure congestive
125565162;Plasma cell myeloma;REVLIMID;25;CELGENE;60;F;Hospitalization - Initial or Prolonged;Pyrexia
125682202;Plasma cell myeloma;REVLIMID;10;CELGENE;66;F;Hospitalization - Initial or Prolonged;Pneumonitis
125807809;Nerve injury;LYRICA;50;PFIZER;68;F;Hospitalization - Initial or Prolonged;Arthralgia
125975964;Paralysis;LYRICA;75;PFIZER;83;F;Other Serious (Important Medical Event);Abdominal pain upper
125979602;Plasma cell myeloma;REVLIMID;10;CELGENE;63;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
126006862;Plasma cell myeloma;REVLIMID;25;CELGENE;56;F;Hospitalization - Initial or Prolonged;Clostridium difficile infection
126030792;Plasma cell myeloma;REVLIMID;5;CELGENE;83;M;Hospitalization - Initial or Prolonged;Deep vein thrombosis
126073862;Plasma cell myeloma;REVLIMID;15;CELGENE;73;M;Hospitalization - Initial or Prolonged;Rectal haemorrhage
126085982;Plasma cell myeloma;REVLIMID;15;CELGENE;73;M;Hospitalization - Initial or Prolonged;Chest pain
126195922;Plasma cell myeloma;REVLIMID;5;CELGENE;56;F;Hospitalization - Initial or Prolonged;Pancreatitis
126241282;Plasma cell myeloma;REVLIMID;15;CELGENE;63;M;Hospitalization - Initial or Prolonged;Septic shock
126304695;Lung neoplasm malignant;RAPAMUNE;2;PFIZER;40;F;NA;Gingival bleeding
126558852;Nephrogenic anaemia;MIRCERA;75;ROCHE;60;F;Hospitalization - Initial or Prolonged;Chest pain
126558862;Unknown;MIRCERA;150;ROCHE;20;F;NA;Dyspnoea
126559592;Unknown;MIRCERA;100;ROCHE;61;M;NA;Back pain
126559812;Unknown;MIRCERA;100;ROCHE;73;F;NA;Pruritus
126559822;Unknown;MIRCERA;50;ROCHE;50;M;NA;Arthralgia
126559862;Unknown;MIRCERA;150;ROCHE;46;M;NA;Back pain
126559882;Unknown;MIRCERA;150;ROCHE;31;F;NA;Anxiety
126559922;Nephrogenic anaemia;MIRCERA;50;ROCHE;48;M;NA;Back pain
126559972;Unknown;MIRCERA;50;ROCHE;84;M;Hospitalization - Initial or Prolonged;Chest pain
126560002;Anaemia;MIRCERA;75;ROCHE;40;M;NA;Headache
126560012;Unknown;MIRCERA;50;ROCHE;66;M;NA;Burning sensation
126560052;Unknown;MIRCERA;50;ROCHE;57;F;NA;Pruritus
126560072;Anaemia;MIRCERA;75;ROCHE;24;M;Hospitalization - Initial or Prolonged;Anaphylactic reaction
126560082;Unknown;MIRCERA;50;ROCHE;41;F;NA;Chest pain
126560122;NA;NA;NA;ROCHE;62;F;NA;Erythema
126560132;Unknown;MIRCERA;50;ROCHE;40;F;NA;Dyspnoea
126560142;Unknown;MIRCERA;100;ROCHE;40;F;NA;Diarrhoea
126560252;Unknown;MIRCERA;50;ROCHE;58;M;NA;Hyperhidrosis
126560602;Anaemia;MIRCERA;75;ROCHE;47;M;Hospitalization - Initial or Prolonged;Seizure
126560632;Nephrogenic anaemia;MIRCERA;200;ROCHE;48;F;NA;Pruritus
126560692;Nephrogenic anaemia;MIRCERA;50;ROCHE;77;M;NA;Erythema
126560702;Unknown;MIRCERA;75;ROCHE;75;F;NA;Chest pain
126810552;Plasma cell myeloma;REVLIMID;25;CELGENE;81;F;Hospitalization - Initial or Prolonged;Pneumonia
127042643;Plasma cell myeloma;THALOMID;100;CELGENE;70;M;Other Serious (Important Medical Event);Arthritis bacterial
127082802;Plasma cell myeloma;REVLIMID;25;CELGENE;58;M;Hospitalization - Initial or Prolonged;Compression fracture
127214013;Plasma cell myeloma;REVLIMID;25;CELGENE;52;F;Hospitalization - Initial or Prolonged;Febrile neutropenia
128288262;Multiple sclerosis;TERIFLUNOMIDE;7;SANOFI AVENTIS;63;F;NA;Ear pruritus
128379702;Plasma cell myeloma;REVLIMID;25;CELGENE;61;M;Other Serious (Important Medical Event);Asthenia
128545053;Plasma cell myeloma;REVLIMID;25;CELGENE;70;F;Other Serious (Important Medical Event);Urosepsis
128663676;Neuropathy peripheral;LYRICA;150;PFIZER;67;F;Hospitalization - Initial or Prolonged;Condition aggravated
128863036;Neuropathy peripheral;LYRICA;150;PFIZER;67;F;Hospitalization - Initial or Prolonged;Drug dependence
129178182;Plasma cell myeloma;POMALYST;2;CELGENE;71;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
129246454;Partial lipodystrophy;Metreleptin;2.5;AEGERION;15;F;Other Serious (Important Medical Event);Autoimmune hepatitis
129448762;Lupus nephritis;MYCOPHENOLATE MOFETIL;1000;ROCHE;19;F;Hospitalization - Initial or Prolonged;Death neonatal
129503102;Plasma cell myeloma;REVLIMID;25;CELGENE;72;M;Hospitalization - Initial or Prolonged;Acute kidney injury
129749296;Non-alcoholic steatohepatitis;Metreleptin;7.5;AEGERION;58;F;Hospitalization - Initial or Prolonged;Cellulitis
130092244;Plasma cell myeloma;THALOMID;50;CELGENE;67;F;Hospitalization - Initial or Prolonged;Plasma cell myeloma
130237442;Chronic inflammatory demyelinating polyradiculoneuropathy;GAMUNEX C;30;GRIFOLS;57;M;Life-Threatening;Asthenia
130369532;Plasma cell myeloma;REVLIMID;25;CELGENE;56;M;Other Serious (Important Medical Event);Pulmonary embolism
130427272;Plasma cell myeloma;REVLIMID;25;CELGENE;73;M;Other Serious (Important Medical Event);Pneumonia
130720073;Plasma cell myeloma;REVLIMID;15;CELGENE;67;F;Life-Threatening;Atrial fibrillation
130824462;Plasma cell myeloma;REVLIMID;25;CELGENE;50;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
130897115;Rheumatoid arthritis;XELJANZ;5;PFIZER;69;M;Life-Threatening;Bronchitis
130977552;Plasma cell myeloma;REVLIMID;25;CELGENE;84;F;Hospitalization - Initial or Prolonged;Pneumonia
131027192;Plasma cell myeloma;REVLIMID;10;CELGENE;67;M;Hospitalization - Initial or Prolonged;Pneumonia
131141884;Fibromyalgia;LYRICA;100;PFIZER;52;F;Hospitalization - Initial or Prolonged;Fall
131168794;Lung neoplasm malignant;IBRANCE;125;PFIZER;57;F;NA;Arthralgia
131170956;Multiple sclerosis;EXTAVIA;0.25;NOVARTIS;50;F;NA;Contusion
131222902;Plasma cell myeloma;REVLIMID;15;CELGENE;74;F;Hospitalization - Initial or Prolonged;Acute respiratory failure
131233303;Plasma cell myeloma;REVLIMID;10;CELGENE;82;M;Hospitalization - Initial or Prolonged;Pain
131308012;Plasma cell myeloma;REVLIMID;15;CELGENE;74;M;Hospitalization - Initial or Prolonged;Pulmonary embolism
131316442;Plasma cell myeloma;REVLIMID;15;CELGENE;76;F;Hospitalization - Initial or Prolonged;Upper respiratory tract infection
131351752;Plasma cell myeloma;POMALYST;3;CELGENE;58;M;Other Serious (Important Medical Event);Pancytopenia
131351774;Plasma cell myeloma;POMALYST;4;CELGENE;82;F;Other Serious (Important Medical Event);Asthenia
131549983;Plasma cell myeloma;POMALYST;3;CELGENE;71;M;Hospitalization - Initial or Prolonged;Pneumonia
131586014;Chemotherapy;VINCRISTINE SULFATE;1.97;PFIZER;13;F;Other Serious (Important Medical Event);Febrile neutropenia
131675414;Hypertonic bladder;TOVIAZ;8;PFIZER;52;M;Death;Ganglioneuroma
131718604;Rheumatoid arthritis;XELJANZ;5;PFIZER;67;M;NA;Antipsychotic drug level increased
131875082;Migraine;RELPAX;40;PFIZER;42;F;NA;Condition aggravated
131892513;Plasma cell myeloma;REVLIMID;25;CELGENE;60;F;Hospitalization - Initial or Prolonged;Back pain
132787544;Myeloid leukaemia;BOSULIF;500;PFIZER;43;F;NA;Abdominal pain upper
133058762;Plasma cell myeloma;REVLIMID;25;CELGENE;74;M;Other Serious (Important Medical Event);Pneumonia
133257503;Plasma cell myeloma;REVLIMID;25;CELGENE;85;F;Other Serious (Important Medical Event);Pain
133438214;Plasma cell myeloma;POMALYST;3;CELGENE;66;M;Death;Coronavirus infection
133662522;Plasma cell myeloma;REVLIMID;14;CELGENE;68;M;Hospitalization - Initial or Prolonged;Septic shock
133685465;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;57;F;Hospitalization - Initial or Prolonged;Bronchitis
133812074;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;73;F;Hospitalization - Initial or Prolonged;Bronchitis
134069622;Plasma cell myeloma;REVLIMID;25;CELGENE;56;M;Hospitalization - Initial or Prolonged;Pleural effusion
134161222;Plasma cell myeloma;REVLIMID;25;CELGENE;64;F;Hospitalization - Initial or Prolonged;Cellulitis
134288753;Plasma cell myeloma;REVLIMID;10;CELGENE;66;M;Hospitalization - Initial or Prolonged;Cerebellar infarction
134388427;Thrombosis prophylaxis;APIXABAN;2.5;BRISTOL MYERS SQUIBB;9;M;Other Serious (Important Medical Event);Cardiac arrest
134694142;Plasma cell myeloma;REVLIMID;5;CELGENE;70;M;Death;Pneumonia respiratory syncytial viral
134922869;Arthralgia;LYRICA;300;PFIZER;55;F;NA;Insomnia
134999882;Plasma cell myeloma;REVLIMID;25;CELGENE;57;F;Hospitalization - Initial or Prolonged;Acute kidney injury
135045152;Plasma cell myeloma;POMALYST;2;CELGENE;59;F;Other Serious (Important Medical Event);Respiratory syncytial virus infection
135154643;Plasma cell myeloma;REVLIMID;25;CELGENE;75;M;Hospitalization - Initial or Prolonged;Dyspnoea
135156782;Plasma cell myeloma;POMALYST;4;CELGENE;60;M;Death;Pneumonia
135291232;Plasma cell myeloma;POMALYST;2;CELGENE;81;M;Life-Threatening;Atrial fibrillation
135325632;Plasma cell myeloma;REVLIMID;15;CELGENE;62;M;Hospitalization - Initial or Prolonged;Lung infiltration
135402785;Malignant melanoma;DABRAFENIB;150;NOVARTIS;53;M;Hospitalization - Initial or Prolonged;Cellulitis
135529198;Drug dependence;LYRICA;150;PFIZER;48;F;Hospitalization - Initial or Prolonged;Back pain
135580445;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;82;F;NA;Cough
135622782;Plasma cell myeloma;carfilzomib;56;AMGEN;74;F;Life-Threatening;Asthenia
135918033;Plasma cell myeloma;POMALYST;2;CELGENE;60;M;Hospitalization - Initial or Prolonged;Electrolyte imbalance
135986595;Fibromyalgia;LYRICA;100;PFIZER;57;F;Hospitalization - Initial or Prolonged;Abnormal behaviour
136087405;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;60;M;Hospitalization - Initial or Prolonged;Concussion
136125494;Unknown;EFFEXOR;75;PFIZER;51;F;Hospitalization - Initial or Prolonged;Lipase increased
136440462;Plasma cell myeloma;REVLIMID;15;CELGENE;56;F;Hospitalization - Initial or Prolonged;Diarrhoea
136547453;Ovarian cancer;Niraparib;300;GLAXOSMITHKLINE;72;F;Other Serious (Important Medical Event);Anaemia
136729573;Plasma cell myeloma;REVLIMID;20;CELGENE;70;M;Hospitalization - Initial or Prolonged;Pulmonary embolism
136845102;Plasma cell myeloma;REVLIMID;10;CELGENE;71;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
136913062;Renal transplant;CELLCEPT;500;ROCHE;40;F;Hospitalization - Initial or Prolonged;Basal cell carcinoma
137088336;Plasma cell myeloma;REVLIMID;5;CELGENE;71;F;Hospitalization - Initial or Prolonged;Herpes oesophagitis
137143972;Plasma cell myeloma;REVLIMID;25;CELGENE;52;F;Death;Arthralgia
137337272;Plasma cell myeloma;REVLIMID;10;CELGENE;76;F;Hospitalization - Initial or Prolonged;Breast cancer
137344842;Plasma cell myeloma;REVLIMID;15;CELGENE;68;F;Other Serious (Important Medical Event);Cellulitis
137513868;Hypertonic bladder;MYRBETRIQ;25;ASTELLAS;83;F;NA;Alopecia
137528762;Plasma cell myeloma;REVLIMID;10;CELGENE;86;M;Other Serious (Important Medical Event);Pneumonia
137608567;Chronic myeloid leukaemia recurrent;Ponatinib;45;TAKEDA;60;F;Hospitalization - Initial or Prolonged;Cerebrovascular accident
137656582;Plasma cell myeloma;REVLIMID;10;CELGENE;86;M;Hospitalization - Initial or Prolonged;Pneumonia
137769098;Plasma cell myeloma;REVLIMID;25;CELGENE;76;M;Hospitalization - Initial or Prolonged;Basal cell carcinoma
137864952;Heritable pulmonary arterial hypertension;REMODULIN;0.08;UNITED THERAPEUTICS;17;F;Hospitalization - Initial or Prolonged;Device intolerance
138317392;Plasma cell myeloma;REVLIMID;25;CELGENE;59;M;Death;Hypotension
138355402;Plasma cell myeloma;POMALYST;2;CELGENE;68;F;Other Serious (Important Medical Event);Pneumonia
138596044;Breast cancer metastatic;IBRANCE;125;PFIZER;68;F;Hospitalization - Initial or Prolonged;Abdominal pain
138680517;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;82;M;Hospitalization - Initial or Prolonged;Clostridium difficile infection
138692664;Light anaesthesia;FENTANYL CITRATE;250;PFIZER;66;F;Hospitalization - Initial or Prolonged;Supraventricular tachycardia
138704006;Narcolepsy;XYREM;2.5;JAZZ;51;M;Hospitalization - Initial or Prolonged;Arrhythmia
138790343;Plasma cell myeloma;REVLIMID;10;CELGENE;69;M;Hospitalization - Initial or Prolonged;Pneumonia
138790944;Plasma cell myeloma;THALOMID;200;CELGENE;70;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
139183416;Fabry's disease;AGALSIDASE BETA;1;SANOFI AVENTIS;50;M;Hospitalization - Initial or Prolonged;Acute myocardial infarction
139268032;Plasma cell myeloma recurrent;REVLIMID;25;CELGENE;55;M;Hospitalization - Initial or Prolonged;Pulmonary embolism
139301616;Hyperkalaemia;VELTASSA;8.4;VIFOR;71;F;Hospitalization - Initial or Prolonged;Arthropathy
139514586;Narcolepsy;XYREM;1.5;JAZZ;33;F;NA;Asthma
139619144;Colitis ulcerative;HUMIRA;40;ABBVIE;63;F;Hospitalization - Initial or Prolonged;Hypothyroidism
139872493;Plasma cell myeloma;REVLIMID;10;CELGENE;83;M;Hospitalization - Initial or Prolonged;Neck pain
139882092;Plasma cell myeloma;REVLIMID;15;CELGENE;87;F;Hospitalization - Initial or Prolonged;Acute respiratory failure
139992534;Ovarian epithelial cancer;VISMODEGIB;150;ROCHE;70;F;Other Serious (Important Medical Event);Obesity
140074514;NA;NA;NA;TAKEDA;46;F;NA;Arthralgia
140459284;Mucopolysaccharidosis VI;NAGLAZYME;25;BIOMARIN;33;F;Hospitalization - Initial or Prolonged;Device related infection
140486212;Plasma cell myeloma;REVLIMID;25;CELGENE;85;F;Other Serious (Important Medical Event);Asthenia
140543552;Plasma cell myeloma;REVLIMID;10;CELGENE;73;F;Other Serious (Important Medical Event);Anaemia
140711213;NA;NA;NA;TAKEDA;70;M;Hospitalization - Initial or Prolonged;Sepsis
140829652;Plasma cell myeloma;POMALYST;4;CELGENE;66;M;Other Serious (Important Medical Event);Listeriosis
141076392;Plasma cell myeloma;POMALYST;4;CELGENE;55;F;Life-Threatening;Acute kidney injury
141231574;Juvenile idiopathic arthritis;TOCILIZUMAB;4;ROCHE;37;F;Hospitalization - Initial or Prolonged;Maternal exposure during pregnancy
141339954;Plasma cell myeloma;REVLIMID;25;CELGENE;68;F;Hospitalization - Initial or Prolonged;Fall
141458305;Neoplasm;ZYKADIA;600;NOVARTIS;71;M;Other Serious (Important Medical Event);Atrial fibrillation
141503923;Narcolepsy;XYREM;2.25;JAZZ;42;F;Hospitalization - Initial or Prolonged;Deep vein thrombosis
141836653;Acute lymphocytic leukaemia recurrent;KYMRIAH;1;NOVARTIS;6;M;Hospitalization - Initial or Prolonged;C-reactive protein increased
141848504;Plasma cell myeloma;NINLARO;2.3;TAKEDA;66;F;Other Serious (Important Medical Event);Fatigue
141889032;Plasma cell myeloma;REVLIMID;2.5;CELGENE;70;F;Hospitalization - Initial or Prolonged;Pneumonia
141969372;Plasma cell myeloma;REVLIMID;10;CELGENE;66;M;Hospitalization - Initial or Prolonged;Osteomyelitis
142001156;Metastatic renal cell carcinoma;SUTENT;37.5;PFIZER;91;F;Other Serious (Important Medical Event);Abdominal pain
142122622;Plasma cell myeloma;REVLIMID;15;CELGENE;66;F;Hospitalization - Initial or Prolonged;Death
142306296;Paraesthesia;LYRICA;150;PFIZER;75;F;Hospitalization - Initial or Prolonged;Intentional product misuse
142409913;Plasma cell myeloma;REVLIMID;5;CELGENE;63;F;Hospitalization - Initial or Prolonged;Pneumonia legionella
142485967;Breast cancer metastatic;IBRANCE;125;PFIZER;68;F;Other Serious (Important Medical Event);Accident
142491813;Plasma cell myeloma;REVLIMID;10;CELGENE;74;M;Hospitalization - Initial or Prolonged;Pneumonia
142818274;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;73;F;Hospitalization - Initial or Prolonged;Cataract
142877472;Takayasu's arteritis;TOCILIZUMAB;8;ROCHE;29;F;Hospitalization - Initial or Prolonged;Cardiac failure
142893004;Menopause;PREMPRO;1;PFIZER;64;F;NA;Dizziness
142899622;Plasma cell myeloma;NINLARO;4;TAKEDA;60;F;NA;Accidental exposure to product
143028372;Plasma cell myeloma;REVLIMID;10;CELGENE;75;F;Life-Threatening;Pneumonia
143078124;Progressive multiple sclerosis;OCREVUS;300;ROCHE;57;F;Other Serious (Important Medical Event);Ageusia
143096792;NA;NA;NA;CELGENE;68;M;Hospitalization - Initial or Prolonged;Mental status changes
143277617;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;78;F;NA;Blood cholesterol increased
143314407;Rosai-Dorfman syndrome;COBIMETINIB;60;ROCHE;79;M;Hospitalization - Initial or Prolonged;Abdominal pain
143524432;Plasma cell myeloma;REVLIMID;10;CELGENE;70;M;Other Serious (Important Medical Event);Neutropenia
143607272;Plasma cell myeloma;POMALYST;3;CELGENE;69;M;Hospitalization - Initial or Prolonged;Hyperkalaemia
143820275;Acute myeloid leukaemia;VIDAZA;100;CELGENE;71;M;Hospitalization - Initial or Prolonged;Normocytic anaemia
143852892;Breast cancer female;TAXOTERE;1;SANOFI AVENTIS;41;F;Other Serious (Important Medical Event);Alopecia
144189612;Plasma cell myeloma;POMALYST;4;CELGENE;82;F;Disability;Pneumonia influenzal
144613553;Multiple sclerosis;AMPYRA;10;ACORDA;59;F;Hospitalization - Initial or Prolonged;Bacterial test positive
144922416;Plasma cell myeloma;BORTEZOMIB;3;TAKEDA;79;M;Hospitalization - Initial or Prolonged;Bronchitis
145097447;Atrial fibrillation;TIKOSYN;500;PFIZER;71;F;NA;Nasopharyngitis
145097607;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;74;F;NA;Diarrhoea
145146712;Plasma cell myeloma;POMALYST;2;CELGENE;81;M;Hospitalization - Initial or Prolonged;Pulmonary embolism
145172072;NA;NA;NA;TAKEDA;39;F;Hospitalization - Initial or Prolonged;Headache
145302202;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;62;F;NA;Movement disorder
145423942;Plasma cell myeloma;POMALYST;2;CELGENE;68;F;Hospitalization - Initial or Prolonged;Influenza
145591268;Rheumatoid arthritis;XELJANZ;5;PFIZER;86;F;Hospitalization - Initial or Prolonged;Dizziness
145794422;Plasma cell myeloma;REVLIMID;10;CELGENE;60;M;Other Serious (Important Medical Event);Appendicitis
145977818;Hypophysectomy;Genotropin MQ;0.4;PFIZER;82;M;NA;Human epidermal growth factor receptor decreased
145978037;Intervertebral disc degeneration;LYRICA;100;PFIZER;72;F;Hospitalization - Initial or Prolonged;Dry mouth
146059952;Plasma cell myeloma;REVLIMID;10;CELGENE;65;F;Hospitalization - Initial or Prolonged;Pneumonia
146092972;Plasma cell myeloma;POMALYST;4;CELGENE;63;F;Hospitalization - Initial or Prolonged;Viral upper respiratory tract infection
146120032;Plasma cell myeloma;REVLIMID;15;CELGENE;65;F;Hospitalization - Initial or Prolonged;Small intestinal obstruction
146133255;Breast cancer metastatic;IBRANCE;125;PFIZER;75;F;Other Serious (Important Medical Event);Abdominal distension
146158719;Ovarian cancer;ATEZOLIZUMAB;1200;ROCHE;74;F;Hospitalization - Initial or Prolonged;Colitis
146279882;Plasma cell myeloma;REVLIMID;10;CELGENE;70;F;Hospitalization - Initial or Prolonged;Dehydration
146319742;Plasma cell myeloma;REVLIMID;10;CELGENE;79;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
146359628;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;76;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
146730326;Multiple sclerosis;OCREVUS;300;ROCHE;70;F;Hospitalization - Initial or Prolonged;Colonic abscess
146736712;Ovarian cancer stage III;Niraparib;300;GLAXOSMITHKLINE;63;F;Life-Threatening;Acute myeloid leukaemia
146883942;Plasma cell myeloma;REVLIMID;5;CELGENE;68;F;Hospitalization - Initial or Prolonged;Migraine
146884202;Pain;BUPRENORPHINE ACTAVIS;8;TEVA;0;F;Other Serious (Important Medical Event);Apnoea
146957752;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;70;M;Hospitalization - Initial or Prolonged;Muscle rupture
147001093;Rheumatoid arthritis;XELJANZ;5;PFIZER;80;F;Hospitalization - Initial or Prolonged;Spinal disorder
147053426;NA;NA;NA;PFIZER;72;F;Other Serious (Important Medical Event);Acute kidney injury
147053439;NA;NA;NA;PFIZER;61;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
147058477;NA;NA;NA;PFIZER;58;M;Hospitalization - Initial or Prolonged;Acute kidney injury
147065782;Plasma cell myeloma;REVLIMID;10;CELGENE;65;M;Hospitalization - Initial or Prolonged;Neutropenia
147144555;NA;NA;NA;PERRIGO;46;F;Other Serious (Important Medical Event);Acute kidney injury
147161048;NA;NA;NA;PFIZER;73;M;Death;Acute kidney injury
147164867;NA;NA;NA;PFIZER;58;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
147164928;NA;NA;NA;PFIZER;64;F;Other Serious (Important Medical Event);Acute kidney injury
147169042;Plasma cell myeloma;REVLIMID;15;CELGENE;83;M;Hospitalization - Initial or Prolonged;Anaemia
147242912;Plasma cell myeloma;REVLIMID;25;CELGENE;74;M;Other Serious (Important Medical Event);Neutropenia
147299488;NA;NA;NA;PFIZER;33;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
147300034;NA;NA;NA;PFIZER;68;F;Hospitalization - Initial or Prolonged;Acute kidney injury
147300908;NA;NA;NA;PFIZER;60;F;Other Serious (Important Medical Event);Chronic kidney disease
147301537;NA;NA;NA;PFIZER;47;M;Hospitalization - Initial or Prolonged;Acute kidney injury
147305837;NA;NA;NA;PFIZER;57;F;Other Serious (Important Medical Event);Chronic kidney disease
147306079;NA;NA;NA;PFIZER;70;F;Hospitalization - Initial or Prolonged;Acute kidney injury
147307125;NA;NA;NA;PFIZER;78;M;Hospitalization - Initial or Prolonged;Chronic kidney disease
147307698;NA;NA;NA;PFIZER;74;M;Hospitalization - Initial or Prolonged;Acute kidney injury
147330834;Primary progressive multiple sclerosis;OCREVUS;300;ROCHE;73;M;Other Serious (Important Medical Event);Asthenia
147339106;Gastrooesophageal reflux disease;PREVACID 24 HR;15;PERRIGO;50;F;Hospitalization - Initial or Prolonged;Acute kidney injury
147343704;Flatulence;NEXIUM;40;ASTRAZENECA;28;M;Hospitalization - Initial or Prolonged;Affect lability
147355117;NA;NA;NA;PFIZER;64;F;Hospitalization - Initial or Prolonged;Acute kidney injury
147377546;NA;NA;NA;PFIZER;74;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
147480505;Mucopolysaccharidosis IV;VIMIZIM;2;BIOMARIN;5;F;Other Serious (Important Medical Event);Sepsis
147551816;Anxiety;CLONAZEPAM;2;ROCHE;46;F;Hospitalization - Initial or Prolonged;Amnesia
147562669;NA;NA;NA;BRISTOL MYERS SQUIBB;29;F;Hospitalization - Initial or Prolonged;Diabetic ketoacidosis
147642405;NA;NA;NA;PFIZER;53;M;Disability;Pharyngeal haemorrhage
147648633;NA;NA;NA;PERRIGO;79;M;Hospitalization - Initial or Prolonged;Acute kidney injury
147808382;Plasma cell myeloma;POMALYST;3;CELGENE;78;F;Death;Basal cell carcinoma
147892154;NA;NA;NA;NOVARTIS;8;M;Other Serious (Important Medical Event);Acidosis
148089522;Plasma cell myeloma;POMALYST;4;CELGENE;62;M;Hospitalization - Initial or Prolonged;Cellulitis
148172242;Plasma cell myeloma;POMALYST;2;CELGENE;45;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
148349497;NA;NA;NA;PFIZER;61;F;Hospitalization - Initial or Prolonged;Acute kidney injury
148386046;Neuroblastoma;GENOTROPIN;1.4;PFIZER;10;M;Other Serious (Important Medical Event);Circumstance or information capable of leading to medication error
148491732;Plasma cell myeloma;REVLIMID;10;CELGENE;87;F;Hospitalization - Initial or Prolonged;Pain
148545662;Plasma cell myeloma;POMALYST;4;CELGENE;57;M;Other Serious (Important Medical Event);Neutropenia
148590072;HER2 positive breast cancer;DOCETAXEL Sagent;180;TEVA;48;F;Hospitalization - Initial or Prolonged;Alopecia areata
148714495;Short-bowel syndrome;Teduglutide;5;TAKEDA;62;F;Hospitalization - Initial or Prolonged;Intestinal perforation
148977408;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;68;F;Hospitalization - Initial or Prolonged;Blister
149038772;NA;NA;NA;TAKEDA;68;F;Other Serious (Important Medical Event);Acute kidney injury
149110273;Dyslipidaemia;evolocumab;1;AMGEN;72;M;Hospitalization - Initial or Prolonged;Vascular dementia
149144663;Narcolepsy;XYREM;2.25;JAZZ;31;F;Hospitalization - Initial or Prolonged;Anxiety
149146032;Plasma cell myeloma;DEXAMETHASONE IV;40;CELGENE;73;F;Hospitalization - Initial or Prolonged;Non-cardiac chest pain
149180483;NA;NA;NA;TAKEDA;64;F;Hospitalization - Initial or Prolonged;Acute kidney injury
149187387;Gastrointestinal stromal tumour;SUTENT;50;PFIZER;55;M;Other Serious (Important Medical Event);Cerebrovascular accident
149207052;Plasma cell myeloma;THALOMID;50;CELGENE;73;F;Hospitalization - Initial or Prolonged;Pneumonia
149223966;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;69;F;NA;Arthralgia
149259102;NA;NA;NA;BIOGEN;47;F;Hospitalization - Initial or Prolonged;Multiple sclerosis relapse
149328713;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;68;F;NA;Aggression
149383383;Langerhans' cell histiocytosis;COBIMETINIB;60;ROCHE;54;M;Death;Acute kidney injury
149444826;Malignant melanoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;63;F;Hospitalization - Initial or Prolonged;Arthritis
149495146;Acute myeloid leukaemia;NINTEDANIB;200;BOEHRINGER INGELHEIM;46;M;Life-Threatening;Febrile neutropenia
149559109;Erdheim-Chester disease;COBIMETINIB;60;ROCHE;54;F;Other Serious (Important Medical Event);Acute kidney injury
149646242;Plasma cell myeloma;carfilzomib;56;AMGEN;75;F;Hospitalization - Initial or Prolonged;Infection
149648707;Relapsing multiple sclerosis;KESIMPTA;20;NOVARTIS;24;F;Hospitalization - Initial or Prolonged;Appendicitis
149811792;Plasma cell myeloma;REVLIMID;10;CELGENE;53;F;Other Serious (Important Medical Event);Pyrexia
149863059;Narcolepsy;XYREM;2.25;JAZZ;39;F;Other Serious (Important Medical Event);Amenorrhoea
149863592;Plasma cell myeloma;REVLIMID;5;CELGENE;84;F;Other Serious (Important Medical Event);Influenza
150158603;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;57;F;Hospitalization - Initial or Prolonged;Alopecia
150227406;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;41;F;Other Serious (Important Medical Event);Aortic thrombosis
150278042;Unknown;ERYTHROMYCIN;250;PFIZER;41;F;NA;Drug hypersensitivity
150420683;Unknown;XELJANZ;5;PFIZER;62;F;Other Serious (Important Medical Event);Arthralgia
150587242;Plasma cell myeloma;REVLIMID;15;CELGENE;64;M;Other Serious (Important Medical Event);Bone pain
150599073;Breast cancer female;TAXOTERE;145;SANOFI AVENTIS;46;F;Other Serious (Important Medical Event);Alopecia
150766665;Insulin-like growth factor increased;SOMAVERT;20;PFIZER;52;M;Other Serious (Important Medical Event);Blood cholesterol increased
150801732;Plasma cell myeloma;REVLIMID;25;CELGENE;56;F;Other Serious (Important Medical Event);Deep vein thrombosis
151122173;Breast cancer female;IBRANCE;125;PFIZER;62;F;NA;Neoplasm progression
151146015;Hormone-refractory prostate cancer;Enzalutamide;160;ASTELLAS;88;M;Death;Death
151245827;Unknown;LYRICA;150;PFIZER;77;M;Other Serious (Important Medical Event);Death
151485453;Prostate cancer;LUPRON DEPOT;22.5;ABBVIE;75;M;Other Serious (Important Medical Event);Acute kidney injury
151642299;Routine health maintenance;LYRICA;75;PFIZER;58;F;NA;Cough
151711669;Crohn's disease;XELJANZ;5;PFIZER;32;M;Hospitalization - Initial or Prolonged;Off label use
151801143;Rheumatoid arthritis;XELJANZ;5;PFIZER;78;F;Other Serious (Important Medical Event);Aphasia
152005062;NA;NA;NA;TAKEDA;61;F;NA;Blood magnesium abnormal
152082914;Plasma cell myeloma;POMALYST;2;CELGENE;45;M;Other Serious (Important Medical Event);Febrile neutropenia
152297432;Breast cancer female;Docetaxel Accord;124;ACCORD;57;F;Other Serious (Important Medical Event);Alopecia
152297462;Breast cancer;Docetaxel Accord;141;ACCORD;65;F;Other Serious (Important Medical Event);Alopecia
152297542;Breast cancer metastatic;Docetaxel Accord;1;ACCORD;55;F;Other Serious (Important Medical Event);Alopecia
152300292;Breast cancer;Docetaxel Accord;116;ACCORD;59;F;Other Serious (Important Medical Event);Alopecia
152300553;Breast cancer;Docetaxel Accord;148;ACCORD;33;F;Other Serious (Important Medical Event);Alopecia
152300622;Breast cancer;Docetaxel Accord;150;ACCORD;70;F;Other Serious (Important Medical Event);Alopecia
152301782;Breast cancer;Docetaxel Accord;75;ACCORD;52;F;Other Serious (Important Medical Event);Alopecia
152302052;Breast cancer;Docetaxel Accord;134;ACCORD;68;F;Other Serious (Important Medical Event);Alopecia
152302093;Breast cancer;Docetaxel Accord;75;ACCORD;67;F;Other Serious (Important Medical Event);Alopecia
152302962;Breast cancer;Docetaxel Accord;140;ACCORD;63;F;Hospitalization - Initial or Prolonged;Alopecia
152305456;Malignant melanoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;37;M;Other Serious (Important Medical Event);Enterocolitis
152310263;Breast cancer;Docetaxel Accord;150;ACCORD;51;F;Disability;Alopecia
152327672;Plasma cell myeloma;REVLIMID;10;CELGENE;70;M;Other Serious (Important Medical Event);Orthostatic hypotension
152349113;Breast cancer metastatic;Docetaxel Accord;138;ACCORD;65;F;Other Serious (Important Medical Event);Alopecia
152459815;Mycobacterium avium complex infection;LAMPRENE;100;NOVARTIS;82;F;Other Serious (Important Medical Event);Alopecia
152522283;Immune system disorder;Lanadelumab;300;TAKEDA;41;F;Hospitalization - Initial or Prolonged;Ear infection
152539412;NA;NA;NA;ROCHE;51;F;Other Serious (Important Medical Event);Condition aggravated
152654285;NA;NA;NA;PFIZER;65;M;Hospitalization - Initial or Prolonged;Depressed level of consciousness
152696115;Relapsing-remitting multiple sclerosis;OCREVUS;300;ROCHE;53;F;Other Serious (Important Medical Event);Clostridium difficile infection
152895303;NA;NA;NA;TAKEDA;77;F;NA;Diarrhoea
152950636;Arthritis;XELJANZ;5;PFIZER;63;F;NA;Bronchitis
152958369;Alveolar soft part sarcoma;ATEZOLIZUMAB;1200;ROCHE;33;F;Death;Fracture
152975742;Plasma cell myeloma;POMALYST;3;CELGENE;68;F;Hospitalization - Initial or Prolonged;Neutropenia
153130292;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;Other Serious (Important Medical Event);Febrile neutropenia
153178364;Ovarian cancer;Niraparib;300;GLAXOSMITHKLINE;71;F;Other Serious (Important Medical Event);Acute myeloid leukaemia
153234393;Breast cancer female;TAXOTERE;124;SANOFI AVENTIS;49;F;Life-Threatening;Alopecia
153278264;Bronchial carcinoma;ALECENSA;600;ROCHE;79;F;NA;Fatigue
153310853;Breast cancer female;DOCETAXEL;131;PFIZER;67;F;NA;Alopecia
153454095;NA;NA;NA;TAKEDA;74;M;Other Serious (Important Medical Event);Abdominal distension
153583332;Hot flush;EVAMIST;1.53;PERRIGO;75;F;NA;Incorrect dose administered
153587842;Plasma cell myeloma;POMALYST;2;CELGENE;54;M;Hospitalization - Initial or Prolonged;Dyspnoea
153668615;Growth hormone deficiency;GENOTROPIN;1.4;PFIZER;10;M;NA;Bone density increased
153723084;Langerhans' cell histiocytosis;GSK1120212;0.5;NOVARTIS;57;M;Hospitalization - Initial or Prolonged;Chest pain
153736763;Migraine;LYRICA;300;PFIZER;21;F;NA;Drug ineffective for unapproved indication
154290396;Insulin-like growth factor increased;SOMAVERT;30;PFIZER;33;M;NA;Blood glucose increased
154347433;Gastrooesophageal reflux disease;PANTOPRAZOLE;40;PFIZER;57;M;Hospitalization - Initial or Prolonged;Acute kidney injury
154391227;Neuropathy peripheral;LYRICA;200;PFIZER;60;F;Other Serious (Important Medical Event);Anxiety
154509816;Astrocytoma, low grade;AFINITOR;10;NOVARTIS;18;F;Other Serious (Important Medical Event);Decreased appetite
154531692;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;35;F;Hospitalization - Initial or Prolonged;Alopecia
154622504;Plasma cell myeloma;POMALYST;4;CELGENE;78;F;Other Serious (Important Medical Event);Acute kidney injury
154701647;Acute myeloid leukaemia;VIDAZA;100;CELGENE;71;M;Disability;Chronic obstructive pulmonary disease
154743486;Plasma cell myeloma;DEXAMETHASONE ORAL;20;CELGENE;60;F;Death;Acute kidney injury
154957423;Colon cancer metastatic;MEKINIST;2;NOVARTIS;46;M;Hospitalization - Initial or Prolonged;Alanine aminotransferase increased
154960452;Plasma cell myeloma;REVLIMID;10;CELGENE;60;M;Other Serious (Important Medical Event);Acute kidney injury
155188342;Plasma cell myeloma;POMALYST;2;CELGENE;69;M;Hospitalization - Initial or Prolonged;Acute kidney injury
155259872;Plasma cell myeloma;DEXAMETHASONE IV;8;CELGENE;69;M;Other Serious (Important Medical Event);Atrial fibrillation
155453087;Unknown;DESVENLAFAXINE SUCCINATE MONOHYDRATE;50;PFIZER;58;F;Other Serious (Important Medical Event);Anger
155656566;Neoplasm malignant;Niraparib;300;GLAXOSMITHKLINE;67;F;Other Serious (Important Medical Event);Acute myeloid leukaemia
155738535;Multiple sclerosis;GLATOPA;40;NOVARTIS;28;F;NA;Abdominal discomfort
155980015;Relapsing-remitting multiple sclerosis;Glatiramer Acetate Injection;40;MYLAN;50;F;Disability;Asthenia
156034675;Short-bowel syndrome;Teduglutide;5;TAKEDA;52;M;Other Serious (Important Medical Event);Acute kidney injury
156052562;Plasma cell myeloma;REVLIMID;15;CELGENE;56;F;Hospitalization - Initial or Prolonged;Back pain
156130702;Plasma cell myeloma;POMALYST;2;CELGENE;69;F;Other Serious (Important Medical Event);Acute kidney injury
156147302;Plasma cell myeloma;REVLIMID;25;CELGENE;79;F;Hospitalization - Initial or Prolonged;Colitis ischaemic
156217637;Neuropathy peripheral;LYRICA;150;PFIZER;70;F;Hospitalization - Initial or Prolonged;Withdrawal syndrome
156236992;Plasma cell myeloma;REVLIMID;25;CELGENE;81;F;Hospitalization - Initial or Prolonged;Sepsis
156268453;Rheumatoid arthritis;XELJANZ;5;PFIZER;80;F;Death;Fall
156283842;Thrombosis prophylaxis;APIXABAN;2.5;BRISTOL MYERS SQUIBB;12;M;Hospitalization - Initial or Prolonged;Hepatic enzyme increased
156335013;Breast cancer female;TAXOTERE;197;SANOFI AVENTIS;50;F;Hospitalization - Initial or Prolonged;Alopecia
156336855;Breast cancer female;TAXOTERE;20;SANOFI AVENTIS;63;F;Hospitalization - Initial or Prolonged;Alopecia
156436893;Psoriasis;XELJANZ XR;11;PFIZER;52;F;Other Serious (Important Medical Event);Arthropathy
156482763;Rheumatoid arthritis;XELJANZ;5;PFIZER;75;F;Hospitalization - Initial or Prolonged;Condition aggravated
156521964;HIV infection;VIREAD;300;GILEAD;44;M;Other Serious (Important Medical Event);Anhedonia
156615652;Plasma cell myeloma;POMALYST;4;CELGENE;55;M;Death;Pneumonitis
156650018;Ovarian cancer;ATEZOLIZUMAB;1200;ROCHE;60;F;Hospitalization - Initial or Prolonged;Febrile neutropenia
156736627;Plasma cell myeloma;Ixazomib;4;TAKEDA;59;M;Hospitalization - Initial or Prolonged;Diarrhoea
156868445;Hypopituitarism;GENOTROPIN;2.4;PFIZER;15;M;NA;Device issue
156935786;Ovarian cancer;ATEZOLIZUMAB;1200;ROCHE;54;F;Hospitalization - Initial or Prolonged;Pericardial effusion
156990243;Agoraphobia;VENLAFAXINE HCL;37.5;PFIZER;62;M;NA;Drug hypersensitivity
156996913;NA;NA;NA;HIKMA;12;M;Other Serious (Important Medical Event);Asthenia
157011632;Plasma cell myeloma;POMALYST;3;CELGENE;62;M;Hospitalization - Initial or Prolonged;Clostridium difficile colitis
157202903;Immunodeficiency common variable;CUVITRU;22;TAKEDA;71;F;Other Serious (Important Medical Event);Abdominal pain upper
157303834;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;63;F;Hospitalization - Initial or Prolonged;Alopecia
157356262;Plasma cell myeloma;REVLIMID;15;CELGENE;53;M;Other Serious (Important Medical Event);Thrombosis
157383423;Ovarian cancer stage III;BEVACIZUMAB;737.5;ROCHE;69;F;Other Serious (Important Medical Event);Colitis
157414712;Plasma cell myeloma;POMALYST;2;CELGENE;79;F;Hospitalization - Initial or Prolonged;Glaucoma
157420483;Ovarian cancer;Niraparib;100;GLAXOSMITHKLINE;69;F;Other Serious (Important Medical Event);Acute myeloid leukaemia
157468138;Rheumatoid arthritis;XELJANZ;5;PFIZER;60;M;Other Serious (Important Medical Event);Basal cell carcinoma
157600463;Diffuse large B-cell lymphoma;KYMRIAH;30;NOVARTIS;18;M;Hospitalization - Initial or Prolonged;Abdominal tenderness
157634562;Plasma cell myeloma;REVLIMID;25;CELGENE;71;F;Other Serious (Important Medical Event);Neuropathy peripheral
157692084;NA;NA;NA;ROCHE;51;F;Death;Bronchitis
158002703;Short-bowel syndrome;Teduglutide;3.1;TAKEDA;63;F;Death;Hydronephrosis
158062078;Psoriatic arthropathy;XELJANZ;5;PFIZER;72;F;NA;Malaise
158227984;Multiple sclerosis;GLATOPA;20;NOVARTIS;67;F;NA;Cerebral disorder
158264325;Neuropathy peripheral;LYRICA;300;PFIZER;72;M;Hospitalization - Initial or Prolonged;Acute respiratory failure
158340439;Psoriatic arthropathy;XELJANZ XR;11;PFIZER;67;F;Hospitalization - Initial or Prolonged;Cardiac disorder
158538165;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;66;F;NA;Cough
158539339;Gastrooesophageal reflux disease;PROTONIX;40;PFIZER;52;F;Other Serious (Important Medical Event);Abdominal discomfort
158574932;Plasma cell myeloma;REVLIMID;5;CELGENE;61;M;Hospitalization - Initial or Prolonged;Pneumonia
158623112;Plasma cell myeloma;REVLIMID;10;CELGENE;71;M;Other Serious (Important Medical Event);Confusional state
158937732;NA;NA;NA;ROCHE;46;F;NA;Diarrhoea
159032272;NA;NA;NA;NOVARTIS;17;M;Other Serious (Important Medical Event);Abdominal pain
159179332;Plasma cell myeloma;REVLIMID;5;CELGENE;71;M;Other Serious (Important Medical Event);Influenza
159314076;Macular degeneration;LUCENTIS;0.3;ROCHE;78;M;Other Serious (Important Medical Event);Blindness
159358427;Acromegaly;SOMAVERT;10;PFIZER;51;M;Other Serious (Important Medical Event);Basophil count increased
159433608;NA;NA;NA;NOVARTIS;51;F;Other Serious (Important Medical Event);Respiratory tract infection viral
159469338;Neuropathy peripheral;LYRICA;150;PFIZER;68;M;Other Serious (Important Medical Event);Dry skin
159525074;Fibromyalgia;LYRICA;50;PFIZER;74;F;Other Serious (Important Medical Event);Body height decreased
159929002;Plasma cell myeloma;REVLIMID;10;CELGENE;87;M;Other Serious (Important Medical Event);Disseminated varicella zoster virus infection
160098873;NA;NA;NA;ASTRAZENECA;73;M;Other Serious (Important Medical Event);Chronic kidney disease
160115595;Neurodermatitis;XELJANZ;10;PFIZER;60;F;NA;Drug ineffective
160168858;Neuropathy peripheral;LYRICA;300;PFIZER;76;F;Other Serious (Important Medical Event);Amnesia
160491523;NA;NA;NA;PFIZER;55;F;Hospitalization - Initial or Prolonged;Anxiety
160564474;NA;NA;NA;ROCHE;80;F;Other Serious (Important Medical Event);Pyrexia
160572234;Sciatica;LYRICA;150;PFIZER;52;F;NA;Drug ineffective
160573294;Sciatica;LYRICA;50;PFIZER;64;F;NA;Contusion
160590833;Plasma cell myeloma;REVLIMID;10;CELGENE;80;M;Hospitalization - Initial or Prolonged;Pneumonia
160615506;NA;NA;NA;PFIZER;61;F;Other Serious (Important Medical Event);Dizziness
160629086;Neuropathy peripheral;LYRICA;300;PFIZER;54;F;Other Serious (Important Medical Event);Back pain
160655722;NA;NA;NA;TAKEDA;63;F;NA;Cystitis
160672362;Plasma cell myeloma;REVLIMID;10;CELGENE;88;F;Other Serious (Important Medical Event);Dizziness
160774669;Relapsing-remitting multiple sclerosis;OCREVUS;300;ROCHE;47;M;Other Serious (Important Medical Event);Amnesia
160790345;Breast cancer metastatic;IBRANCE;125;PFIZER;63;F;NA;White blood cell count decreased
160832662;Plasma cell myeloma;POMALYST;4;CELGENE;70;M;Disability;Dehydration
160908989;Acute lymphocytic leukaemia;VINCRISTINE SULFATE;2;PFIZER;12;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
160918112;Plasma cell myeloma;REVLIMID;15;CELGENE;77;F;Other Serious (Important Medical Event);Breast cancer
160997206;Blood pressure abnormal;LIPITOR;40;PFIZER;90;F;Other Serious (Important Medical Event);Back injury
161228902;Acute myeloid leukaemia;VIDAZA;100;CELGENE;71;M;Hospitalization - Initial or Prolonged;Pain in extremity
161231402;Acute myeloid leukaemia;VIDAZA;100;CELGENE;71;M;Other Serious (Important Medical Event);Haemoptysis
161265092;Cholangiocarcinoma;ATEZOLIZUMAB;840;ROCHE;57;F;Other Serious (Important Medical Event);Pyrexia
161267334;Acute myeloid leukaemia;VIDAZA;100;CELGENE;71;M;Death;Neutropenic sepsis
161338937;Non-small cell lung cancer;ATEZOLIZUMAB;1200;ROCHE;65;M;Other Serious (Important Medical Event);Pneumonitis
161487823;NA;NA;NA;TAKEDA;60;M;Hospitalization - Initial or Prolonged;Constipation
161489232;Plasma cell myeloma;REVLIMID;10;CELGENE;73;F;Other Serious (Important Medical Event);Asthenia
161568172;Plasma cell myeloma;REVLIMID;15;CELGENE;60;F;Hospitalization - Initial or Prolonged;Haemorrhage intracranial
161585954;Gastrointestinal stromal tumour;SUTENT;37.5;PFIZER;70;F;NA;Insomnia
161610454;Hormone replacement therapy;Testosterone Topical Solution, 30 mg/15 mL Actuation, CIII;30;LUPIN;62;M;NA;Asthenia
161681478;Neuralgia;LYRICA;300;PFIZER;42;F;Hospitalization - Initial or Prolonged;Cerebrovascular accident
161714142;Immunodeficiency common variable;CUVITRU;10;TAKEDA;60;F;Life-Threatening;Fungal infection
161714193;Acute myeloid leukaemia;VIDAZA;100;CELGENE;70;M;Other Serious (Important Medical Event);Pancytopenia
161750836;Chronic myeloid leukaemia;Ponatinib;15;TAKEDA;55;M;Hospitalization - Initial or Prolonged;Cardiomegaly
161794327;Growth hormone deficiency;GENOTROPIN;1.6;PFIZER;22;F;NA;Bone density decreased
161869133;Immunodeficiency common variable;CUVITRU;8;TAKEDA;73;F;Other Serious (Important Medical Event);Diverticular perforation
161872174;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;60;F;Hospitalization - Initial or Prolonged;Acute myeloid leukaemia
161967442;Plasma cell myeloma;REVLIMID;25;CELGENE;42;M;Other Serious (Important Medical Event);Pneumonia
161979883;Asthma;DUPILUMAB;600;SANOFI AVENTIS;39;F;Hospitalization - Initial or Prolonged;Ageusia
162000813;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;55;F;Death;Alopecia
162075509;Cystitis;PREMARIN;1;PFIZER;64;F;Hospitalization - Initial or Prolonged;Drug effective for unapproved indication
162132622;Plasma cell myeloma;REVLIMID;5;CELGENE;77;F;Hospitalization - Initial or Prolonged;Diarrhoea
162135772;Plasma cell myeloma;REVLIMID;5;CELGENE;77;F;Hospitalization - Initial or Prolonged;Back pain
162143204;NA;NA;NA;PFIZER;50;F;Hospitalization - Initial or Prolonged;Acute kidney injury
162307492;Plasma cell myeloma;POMALYST;4;CELGENE;58;M;Hospitalization - Initial or Prolonged;Femur fracture
162308312;Plasma cell myeloma;POMALYST;4;CELGENE;58;M;Hospitalization - Initial or Prolonged;Respiratory failure
162332369;NA;NA;NA;PFIZER;73;F;Other Serious (Important Medical Event);Cerebral thrombosis
162425638;Neuropathy peripheral;LYRICA;300;PFIZER;65;F;Death;Osteomyelitis
162525532;Plasma cell myeloma;REVLIMID;15;CELGENE;82;F;Other Serious (Important Medical Event);Vomiting
162549542;Plasma cell myeloma;POMALYST;4;CELGENE;58;M;Other Serious (Important Medical Event);Spinal cord compression
162579746;Non-small cell lung cancer;NIVOLUMAB;278;BRISTOL MYERS SQUIBB;76;M;Hospitalization - Initial or Prolonged;Sinus node dysfunction
162622852;Plasma cell myeloma;REVLIMID;25;CELGENE;74;M;Hospitalization - Initial or Prolonged;Basal cell carcinoma
162626225;Plasma cell myeloma;NINLARO;2.3;TAKEDA;81;F;Hospitalization - Initial or Prolonged;Alopecia
162644705;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;53;F;NA;COVID-19
162660766;Neuralgia;LYRICA;300;PFIZER;43;M;NA;Insomnia
162661805;Bone disorder;PREMARIN;0.625;PFIZER;50;F;Hospitalization - Initial or Prolonged;Gastric disorder
162668269;Neoplasm;LENVATINIB;20;EISAI;56;F;Other Serious (Important Medical Event);Adrenal insufficiency
162669412;Plasma cell myeloma;REVLIMID;25;CELGENE;77;M;Hospitalization - Initial or Prolonged;Basal cell carcinoma
162758352;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;37;F;Hospitalization - Initial or Prolonged;Alopecia
162762225;Dermatitis atopic;DUPIXENT;300;SANOFI AVENTIS;54;F;NA;Eczema
162814092;Menopause;ESTRADIOL TRANSDERMAL SYSTEM;0.025;MYLAN;56;F;NA;Product adhesion issue
162859972;Diabetic neuropathy;LYRICA;75;PFIZER;70;M;NA;Dyskinesia
162861269;Rheumatoid arthritis;XELJANZ;5;PFIZER;79;F;NA;Blood pressure increased
162879889;Pain;LYRICA;75;PFIZER;68;F;Other Serious (Important Medical Event);Dyspnoea
162906862;Neuropathy peripheral;LYRICA;200;PFIZER;64;F;Other Serious (Important Medical Event);Fall
162960458;Factor VIII deficiency;ELOCTATE;2235;SANOFI AVENTIS;8;M;Other Serious (Important Medical Event);Fall
162974607;Fibromyalgia;LYRICA;300;PFIZER;62;F;NA;Abdominal pain upper
162987692;Plasma cell myeloma;REVLIMID;15;CELGENE;70;F;Other Serious (Important Medical Event);Bacteraemia
163114656;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;81;F;Other Serious (Important Medical Event);Arthralgia
163114882;Plasma cell myeloma;POMALYST;3;CELGENE;79;F;Disability;Spinal cord compression
163125456;Gastrooesophageal reflux disease;PREVACID 24 HR;15;PERRIGO;45;F;Other Serious (Important Medical Event);Blood urine present
163140097;NA;NA;NA;PFIZER;82;F;Hospitalization - Initial or Prolonged;Arthritis
163202134;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;62;F;Hospitalization - Initial or Prolonged;Candida infection
163230102;Androgen deficiency;Testosterone Topical Solution, 30 mg/15 mL Actuation, CIII;30;LUPIN;50;M;NA;Blood testosterone decreased
163243712;Plasma cell myeloma;REVLIMID;25;CELGENE;64;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
163266723;Plasma cell myeloma;DARATUMUMAB;1309;JOHNSON AND JOHNSON;78;M;Other Serious (Important Medical Event);Pneumonia herpes viral
163275378;Hereditary angioedema;Lanadelumab;300;TAKEDA;35;F;Other Serious (Important Medical Event);Anaphylactic reaction
163278985;Ovarian cancer;BEVACIZUMAB;15;ROCHE;78;F;Hospitalization - Initial or Prolonged;Intestinal obstruction
163346564;NA;NA;NA;NOVARTIS;11;M;Other Serious (Important Medical Event);Acute lymphocytic leukaemia recurrent
163430897;Cystitis interstitial;ELMIRON;100;JOHNSON AND JOHNSON;41;F;Hospitalization - Initial or Prolonged;Incorrect dose administered
163435888;Pain;LYRICA;150;PFIZER;60;F;Hospitalization - Initial or Prolonged;Drug ineffective
163576712;NA;NA;NA;CELGENE;75;M;Other Serious (Important Medical Event);Cardiac failure congestive
163658594;Hypertension;PRINIVIL;2.5;MERCK;78;F;Other Serious (Important Medical Event);Autonomic failure syndrome
163675569;Fibromyalgia;LYRICA;75;PFIZER;67;F;Other Serious (Important Medical Event);Pain
163824912;Plasma cell myeloma;POMALYST;1;CELGENE;85;F;Life-Threatening;Syncope
163974655;Hiatus hernia;DEXILANT;60;TAKEDA;86;F;Hospitalization - Initial or Prolonged;Diarrhoea
163977794;Chronic myeloid leukaemia;BOSULIF;500;PFIZER;63;F;Death;Blood creatinine increased
164084894;NA;NA;NA;PERRIGO;75;F;Hospitalization - Initial or Prolonged;Acute kidney injury
164113442;Plasma cell myeloma;REVLIMID;25;CELGENE;56;F;Other Serious (Important Medical Event);Myelodysplastic syndrome
164121002;Plasma cell myeloma;POMALYST;2;CELGENE;76;M;Other Serious (Important Medical Event);Myocardial infarction
164146023;Plasma cell myeloma;DARZALEX;16;JOHNSON AND JOHNSON;63;M;Other Serious (Important Medical Event);Acute respiratory failure
164148927;Colon cancer metastatic;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;72;M;Death;Acute kidney injury
164223073;Breast cancer metastatic;PIQRAY;300;NOVARTIS;57;F;Hospitalization - Initial or Prolonged;Arthralgia
164253447;Ovarian cancer;BEVACIZUMAB;15;ROCHE;68;F;Other Serious (Important Medical Event);Ataxia
164368752;NA;NA;NA;VIFOR;41;F;NA;Drug hypersensitivity
164469114;Cardiac amyloidosis;TAFAMIDIS;61;PFIZER;78;M;Other Serious (Important Medical Event);Acute kidney injury
164470752;Plasma cell myeloma;REVLIMID;15;CELGENE;70;M;Other Serious (Important Medical Event);Pneumonia
164492933;Plasma cell myeloma;REVLIMID;10;CELGENE;68;M;Hospitalization - Initial or Prolonged;Pneumonia
164527783;Breast cancer female;TAXOTERE;135;SANOFI AVENTIS;50;F;Hospitalization - Initial or Prolonged;Alopecia
164600682;Plasma cell myeloma;REVLIMID;20;CELGENE;37;F;Other Serious (Important Medical Event);Hyperviscosity syndrome
164601652;Plasma cell myeloma;POMALYST;4;CELGENE;65;M;Other Serious (Important Medical Event);Hyperglycaemia
164661257;Parkinson's disease;INBRIJA;2;ACORDA;74;M;NA;Condition aggravated
164684152;Plasma cell myeloma;POMALYST;2;CELGENE;77;M;Other Serious (Important Medical Event);Pyrexia
164734222;Diabetic neuropathy;LYRICA;150;PFIZER;51;F;Hospitalization - Initial or Prolonged;Bronchitis
164748802;Plasma cell myeloma;POMALYST;4;CELGENE;65;M;Hospitalization - Initial or Prolonged;Sepsis
164779744;NA;NA;NA;CELGENE;84;M;Other Serious (Important Medical Event);Prostate cancer
164822775;NA;NA;NA;ELI LILLY AND CO;46;F;Hospitalization - Initial or Prolonged;Abdominal distension
164827187;Ovarian cancer;ATEZOLIZUMAB;1200;ROCHE;65;F;Life-Threatening;Vaginal cuff dehiscence
164878165;Hodgkin's disease;brentuximab vedotin;1.8;SEATTLE GENETICS;4;M;Death;Enterocolitis infectious
164981372;Plasma cell myeloma;REVLIMID;15;CELGENE;68;F;Hospitalization - Initial or Prolonged;Pneumonia
165219642;Plasma cell myeloma;REVLIMID;2.5;CELGENE;66;M;Other Serious (Important Medical Event);Meningitis
165278252;Plasma cell myeloma;POMALYST;2;CELGENE;80;M;Other Serious (Important Medical Event);Acute myocardial infarction
165425613;Hepatic cancer;OPDIVO;240;BRISTOL MYERS SQUIBB;70;M;Hospitalization - Initial or Prolonged;Blood creatinine increased
165459732;Unknown;MYRBETRIQ;50;ASTELLAS;61;F;Hospitalization - Initial or Prolonged;Hypertension
165465422;Incontinence;MYRBETRIQ;25;ASTELLAS;68;F;Other Serious (Important Medical Event);Blood pressure increased
165466522;Hypertonic bladder;MYRBETRIQ;75;ASTELLAS;63;F;Hospitalization - Initial or Prolonged;Hypertension
165467072;Pollakiuria;MYRBETRIQ;25;ASTELLAS;92;F;Other Serious (Important Medical Event);Blood pressure increased
165487512;Plasma cell myeloma;POMALYST;2;CELGENE;80;M;Other Serious (Important Medical Event);Arteriovenous malformation
165581932;Plasma cell myeloma;POMALYST;2;CELGENE;51;F;Other Serious (Important Medical Event);Septic shock
165750474;Still's disease;ILARIS;82;NOVARTIS;8;F;Hospitalization - Initial or Prolonged;Haemophagocytic lymphohistiocytosis
165830836;Rheumatoid arthritis;LYRICA;100;PFIZER;62;F;Death;Drug dependence
165849167;Spinal muscular atrophy;ZOLGENSMA;1;NOVARTIS;0;F;Death;Alanine aminotransferase increased
165957636;Pancreatic carcinoma metastatic;ATEZOLIZUMAB;1200;ROCHE;65;M;Other Serious (Important Medical Event);Death
166113044;Asthma;DUPIXENT;300;SANOFI AVENTIS;50;F;NA;Asthma
166147329;Pollakiuria;DETROL LA;4;PFIZER;77;M;NA;Drug ineffective
166232383;Crohn's disease;CIMZIA;400;UCB;37;F;Hospitalization - Initial or Prolonged;Drug ineffective
166237993;Non-small cell lung cancer;PIRFENIDONE;267;ROCHE;64;M;Other Serious (Important Medical Event);Acute respiratory failure
166413952;Plasma cell myeloma;LENALIDOMIDE;5;CELGENE;94;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
166427009;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;69;F;Other Serious (Important Medical Event);Arthritis
166602364;Plasma cell myeloma;POMALIDOMIDE;4;CELGENE;75;M;Hospitalization - Initial or Prolonged;Hypoglycaemia
166638742;NA;NA;NA;NOVARTIS;22;F;Hospitalization - Initial or Prolonged;Acute kidney injury
166648452;Breast cancer;Docetaxel Accord;158.2;ACCORD;62;F;Other Serious (Important Medical Event);Alopecia
166650512;Breast cancer;Docetaxel Accord;180;ACCORD;48;F;Other Serious (Important Medical Event);Alopecia
166650722;Breast cancer;Docetaxel Accord;75;ACCORD;50;F;Hospitalization - Initial or Prolonged;Alopecia
166651592;Breast cancer;Docetaxel Accord;140;ACCORD;52;F;Hospitalization - Initial or Prolonged;Alopecia
166652272;Breast cancer;DOCETAXEL ACCORD;123;ACCORD;51;F;Hospitalization - Initial or Prolonged;Alopecia
166652352;Invasive ductal breast carcinoma;Docetaxel Accord;143;ACCORD;50;F;Hospitalization - Initial or Prolonged;Alopecia
166652452;Breast cancer;Docetaxel Accord;143;ACCORD;53;F;Hospitalization - Initial or Prolonged;Alopecia
166662113;Breast cancer;DOCETAXEL;142;ACCORD;61;F;Hospitalization - Initial or Prolonged;Alopecia
166667262;Breast cancer;Docetaxel Accord;130;ACCORD;56;F;Other Serious (Important Medical Event);Alopecia
166667432;Breast cancer;Docetaxel Accord;140;ACCORD;40;F;Hospitalization - Initial or Prolonged;Alopecia
166667533;Breast cancer;Docetaxel Accord;20;ACCORD;46;F;Hospitalization - Initial or Prolonged;Alopecia
166667542;Breast cancer;DOCETAXEL ACCORD;130;ACCORD;51;F;Other Serious (Important Medical Event);Alopecia
166721184;Prostate cancer;Enzalutamide;160;ASTELLAS;62;M;Other Serious (Important Medical Event);Death
166734739;Fibromyalgia;LYRICA;75;PFIZER;70;F;Hospitalization - Initial or Prolonged;Abnormal behaviour
166755124;Immunodeficiency;CUVITRU;8;TAKEDA;45;F;Death;Carpal tunnel syndrome
166784136;Neuralgia;LYRICA;150;PFIZER;66;F;NA;Fall
166823335;Pain;LYRICA;75;PFIZER;82;M;Hospitalization - Initial or Prolonged;Arteriovenous malformation
166860982;Plasma cell myeloma;REVLIMID;10;CELGENE;56;M;Other Serious (Important Medical Event);Respiratory distress
166890177;Hypertension;VALSARTAN ACTAVIS;80;TEVA;66;M;Hospitalization - Initial or Prolonged;Acute kidney injury
166932962;Plasma cell myeloma;POMALYST;4;CELGENE;68;F;Other Serious (Important Medical Event);Dyspnoea
167027603;Immunodeficiency common variable;CUVITRU;8;TAKEDA;52;F;Other Serious (Important Medical Event);Angioedema
167067734;Ovarian cancer;ATEZOLIZUMAB;1200;ROCHE;76;F;Hospitalization - Initial or Prolonged;Colitis
167074253;Plasma cell myeloma;REVLIMID;15;CELGENE;66;F;Hospitalization - Initial or Prolonged;Angina pectoris
167076987;Short-bowel syndrome;Teduglutide;4.35;TAKEDA;56;M;Other Serious (Important Medical Event);Dehydration
167142742;Plasma cell myeloma;THALOMID;50;CELGENE;77;M;Other Serious (Important Medical Event);Sepsis
167191262;Plasma cell myeloma;THALOMID;50;CELGENE;77;M;Other Serious (Important Medical Event);Haematuria
167309632;Plasma cell myeloma;REVLIMID;10;CELGENE;75;M;Hospitalization - Initial or Prolonged;Fall
167317602;Plasma cell myeloma;REVLIMID;10;CELGENE;70;M;Hospitalization - Initial or Prolonged;Acute kidney injury
167405917;Breast cancer female;IBRANCE;125;PFIZER;70;F;NA;Blood glucose increased
167442083;Neoplasm malignant;Trastuzumab Emtansine;3.6;ROCHE;69;M;Other Serious (Important Medical Event);Confusional state
167452939;Restless legs syndrome;LYRICA;150;PFIZER;75;M;NA;Confusional state
167501693;Colitis ulcerative;XELJANZ;5;PFIZER;59;M;NA;Condition aggravated
167542407;Diffuse large B-cell lymphoma;Vincristine;2;ROCHE;67;M;Hospitalization - Initial or Prolonged;Abdominal infection
167593133;Pulmonary arterial hypertension;AMBRISENTAN;5;GILEAD;14;F;Hospitalization - Initial or Prolonged;Nasopharyngitis
167648216;Spinal muscular atrophy;SPINRAZA;12;BIOGEN;44;M;Other Serious (Important Medical Event);Chronic respiratory failure
167703122;Plasma cell myeloma;REVLIMID;15;CELGENE;66;F;Other Serious (Important Medical Event);Angina pectoris
167776084;NA;NA;NA;PFIZER;78;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
167792504;Headache;LYRICA;400;PFIZER;40;F;NA;Illness
167871533;Breast cancer female;TAXOTERE;110;SANOFI AVENTIS;53;F;Life-Threatening;Alopecia
167872666;Spinal stenosis;LYRICA;75;PFIZER;81;F;NA;Anxiety
167916275;Neoplasm;TALAZOPARIB;0.75;PFIZER;64;M;Hospitalization - Initial or Prolonged;Death
167967402;Plasma cell myeloma;REVLIMID;25;CELGENE;83;F;Hospitalization - Initial or Prolonged;Encephalopathy
167974243;Secondary progressive multiple sclerosis;OCREVUS;600;ROCHE;71;M;Other Serious (Important Medical Event);Injection site extravasation
167984443;NA;NA;NA;ALLERGAN;65;F;NA;Feeling abnormal
168021028;Metastatic neoplasm;AUTOGENE CEVUMERAN;38;ROCHE;48;M;Hospitalization - Initial or Prolonged;Systemic immune activation
168184586;Dermatitis atopic;DUPIXENT;600;SANOFI AVENTIS;31;F;Other Serious (Important Medical Event);Blood electrolytes decreased
168268346;Post procedural hypoparathyroidism;Parathyroid Hormone;25;TAKEDA;50;F;Other Serious (Important Medical Event);Extra dose administered
168283683;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;63;F;Hospitalization - Initial or Prolonged;Alopecia
168284943;Breast cancer female;TAXOTERE;60;SANOFI AVENTIS;49;F;Life-Threatening;Alopecia
168339386;Nervous system disorder;LYRICA;50;PFIZER;57;F;Other Serious (Important Medical Event);Malaise
168351504;Breast cancer female;TAXOTERE;150;SANOFI AVENTIS;59;F;Hospitalization - Initial or Prolonged;Alopecia
168351745;Breast cancer female;TAXOTERE;150;SANOFI AVENTIS;51;F;Other Serious (Important Medical Event);Alopecia
168410913;Breast cancer female;TAXOTERE;180;SANOFI AVENTIS;52;F;Other Serious (Important Medical Event);Alopecia
168474955;Parkinson's disease;INBRIJA;84;ACORDA;82;F;NA;Aphonia
168475344;On and off phenomenon;INBRIJA;84;ACORDA;76;M;Other Serious (Important Medical Event);Arthralgia
168502622;Plasma cell myeloma;VELCADE;3.1;TAKEDA;72;M;Hospitalization - Initial or Prolonged;Acute kidney injury
168564612;Psoriasis;STELARA;45;JOHNSON AND JOHNSON;38;F;Other Serious (Important Medical Event);Ear infection
168592632;NA;NA;NA;BAXTER;61;M;Other Serious (Important Medical Event);Burning sensation
168625172;Plasma cell myeloma;DARATUMUMAB;1800;JOHNSON AND JOHNSON;72;M;Hospitalization - Initial or Prolonged;Acute kidney injury
168786185;Fabry's disease;FABRAZYME;80;SANOFI AVENTIS;35;M;Other Serious (Important Medical Event);Chest pain
168840273;Relapsing-remitting multiple sclerosis;OCREVUS;600;ROCHE;50;F;Hospitalization - Initial or Prolonged;Urinary tract infection
168840337;Post procedural hypoparathyroidism;Parathyroid Hormone;50;TAKEDA;26;F;Hospitalization - Initial or Prolonged;Gastrointestinal motility disorder
168845948;Fibromyalgia;LYRICA;75;PFIZER;70;F;Other Serious (Important Medical Event);Angina pectoris
168875403;Cholangiocarcinoma;ATEZOLIZUMAB;840;ROCHE;64;F;Other Serious (Important Medical Event);Acute respiratory distress syndrome
168918065;Acute myeloid leukaemia;CYTARABINE;260;PFIZER;57;M;Other Serious (Important Medical Event);Stomatitis
168945262;Peripheral T-cell lymphoma unspecified;ADRIAMYCIN;50;PFIZER;30;M;Other Serious (Important Medical Event);Clostridium difficile infection
169005492;Diffuse large B-cell lymphoma;NIVOLUMAB;257;BRISTOL MYERS SQUIBB;71;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
169019455;Diffuse large B-cell lymphoma;ATEZOLIZUMAB;840;ROCHE;77;M;Other Serious (Important Medical Event);Fatigue
169025984;0;Human Immunoglobulin;0;TAKEDA;57;F;Hospitalization - Initial or Prolonged;Injection site pain
169034799;Chronic myeloid leukaemia;BOSULIF;100;PFIZER;87;F;NA;Diarrhoea
169118693;Breast cancer female;TAXOTERE;160;SANOFI AVENTIS;52;F;Death;Alopecia
169168818;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;36;F;Life-Threatening;Bedridden
169169862;0;Human Immunoglobulin;0;TAKEDA;56;F;NA;Bacterial infection
169212778;Fabry's disease;FABRAZYME;45;SANOFI AVENTIS;15;M;NA;Arthralgia
169249924;Unknown;PREGABALIN;225;PFIZER;63;F;NA;Agitation
169261867;Plasma cell myeloma;NINLARO;4;TAKEDA;45;M;Death;Accidental exposure to product
169268673;NA;NA;NA;NOVARTIS;17;M;Hospitalization - Initial or Prolonged;Achromobacter infection
169277493;Renal transplant;CFZ533;450;NOVARTIS;47;F;Other Serious (Important Medical Event);Stomatitis
169332793;Chronic spontaneous urticaria;XOLAIR;300;ROCHE;55;M;Other Serious (Important Medical Event);Anaphylactic reaction
169350254;Relapsing-remitting multiple sclerosis;OCREVUS;600;ROCHE;35;M;Other Serious (Important Medical Event);Bronchitis
169444862;Hodgkin's disease;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;19;M;Hospitalization - Initial or Prolonged;Colitis
169458544;Cardiac amyloidosis;TAFAMIDIS;61;PFIZER;73;F;Hospitalization - Initial or Prolonged;Presyncope
169497797;Alpha-1 antitrypsin deficiency;CUVITRU;12;TAKEDA;77;F;Other Serious (Important Medical Event);Atrial fibrillation
169556443;Growth hormone deficiency;GENOTROPIN;0.8;PFIZER;6;M;NA;Device breakage
169580777;Plasma cell myeloma;NINLARO;4;TAKEDA;70;F;NA;Adverse drug reaction
169609564;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;57;F;Hospitalization - Initial or Prolonged;Biopsy bone marrow
169616132;Plasma cell myeloma;REVLIMID;15;CELGENE;78;F;Hospitalization - Initial or Prolonged;Syncope
169631122;Chronic lymphocytic leukaemia;VENETOCLAX;20;ABBVIE;47;M;Hospitalization - Initial or Prolonged;Pneumonia
169711185;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;73;F;Other Serious (Important Medical Event);Anxiety
169817753;Combined immunodeficiency;GAMMAGARD LIQUID;7.5;TAKEDA;36;F;NA;Injection site pain
169953068;Alpha-1 antitrypsin deficiency;CUVITRU;12;TAKEDA;70;F;Other Serious (Important Medical Event);Adverse drug reaction
169953378;Immunodeficiency common variable;CUVITRU;8;TAKEDA;69;F;Hospitalization - Initial or Prolonged;Clostridium difficile infection
170030717;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;29;F;Other Serious (Important Medical Event);Catheter site pain
170149642;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;58;F;NA;Hypersensitivity
170198598;Immunodeficiency;CUVITRU;12;TAKEDA;27;F;Death;Injection site extravasation
170270113;Phenylketonuria;PALYNZIQ;20;BIOMARIN;17;M;NA;Dizziness
170314423;Breast cancer female;IBRANCE;125;PFIZER;80;F;NA;Dizziness
170333993;Breast cancer female;TAXOTERE;140;SANOFI AVENTIS;56;F;Other Serious (Important Medical Event);Alopecia
170377078;NA;NA;NA;ROCHE;77;M;Hospitalization - Initial or Prolonged;Vitreous haemorrhage
170389118;Plasma cell myeloma refractory;Ixazomib;4;TAKEDA;62;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
170389493;Constipation;RELISTOR;12;BAUSCH AND LOMB;81;F;NA;Cold sweat
170547233;Depression;SPRAVATO;84;JOHNSON AND JOHNSON;45;F;NA;Feeling drunk
170561804;Acute lymphocytic leukaemia;KYMRIAH;12;NOVARTIS;25;F;Life-Threatening;Acute leukaemia
170589653;Immunodeficiency common variable;CUVITRU;20;TAKEDA;78;F;NA;Allergy to immunoglobulin therapy
170646534;Breast cancer female;IBRANCE;125;PFIZER;66;F;NA;Arthralgia
170680497;Metastatic malignant melanoma;IPILIMUMAB;170.1;BRISTOL MYERS SQUIBB;70;F;Other Serious (Important Medical Event);Hypophysitis
170705666;Atrial fibrillation;XARELTO;20;JOHNSON AND JOHNSON;72;M;Hospitalization - Initial or Prolonged;Epistaxis
170706264;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;82;F;Life-Threatening;Fibula fracture
170709072;Multiple sclerosis;Glatiramer Acetate Injection;40;MYLAN;50;F;NA;Illness
170715085;Psoriasis;Tildrakizumab;100;RANBAXY;73;M;Hospitalization - Initial or Prolonged;Bronchitis
170790264;Immunodeficiency common variable;CUVITRU;16;TAKEDA;61;F;Hospitalization - Initial or Prolonged;Cough
170790494;Psoriatic arthropathy;CIMZIA;400;UCB;67;F;Hospitalization - Initial or Prolonged;Blood pressure increased
170848696;Prophylaxis;NOXAFIL;300;MERCK;62;F;Hospitalization - Initial or Prolonged;Electrocardiogram QT prolonged
170889308;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;91;F;Other Serious (Important Medical Event);Atypical pneumonia
171030614;NA;NA;NA;ABBVIE;83;U;Hospitalization - Initial or Prolonged;Atrial fibrillation
171052533;Breast cancer metastatic;DOCETAXEL;1;SANOFI AVENTIS;32;F;Hospitalization - Initial or Prolonged;Alopecia
171141217;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;25;F;Hospitalization - Initial or Prolonged;Bronchitis
171161705;Colitis ulcerative;XELJANZ;5;PFIZER;67;M;Other Serious (Important Medical Event);Condition aggravated
171200964;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;51;F;Hospitalization - Initial or Prolonged;Pneumonia
171201955;Chronic lymphocytic leukaemia;IMBRUVICA;140;ABBVIE;70;M;Hospitalization - Initial or Prolonged;Glioblastoma multiforme
171206705;Chronic lymphocytic leukaemia;VENETOCLAX;20;ROCHE;67;F;Other Serious (Important Medical Event);Hypertension
171232466;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;59;F;Hospitalization - Initial or Prolonged;Bronchitis
171252945;Hereditary angioedema;Lanadelumab;300;TAKEDA;65;F;Other Serious (Important Medical Event);Drug ineffective
171290415;Unknown;LYRICA;75;PFIZER;71;F;Hospitalization - Initial or Prolonged;Hypoacusis
171304978;Primary immunodeficiency syndrome;CUVITRU;18;TAKEDA;66;F;Hospitalization - Initial or Prolonged;Accident at home
171312722;NA;NA;NA;NOVARTIS;2;M;Hospitalization - Initial or Prolonged;Acute lymphocytic leukaemia
171431156;Hypoparathyroidism;Parathyroid Hormone;100;TAKEDA;40;F;Hospitalization - Initial or Prolonged;Blood calcium decreased
171589067;Neuropathy peripheral;LYRICA;75;PFIZER;59;F;Hospitalization - Initial or Prolonged;Musculoskeletal disorder
171599283;Breast cancer female;TAXOTERE;120;SANOFI AVENTIS;71;F;Other Serious (Important Medical Event);Alopecia
171600153;Breast cancer female;TAXOTERE;140;SANOFI AVENTIS;51;F;Hospitalization - Initial or Prolonged;Alopecia
171683195;Unknown;CUVITRU;2;TAKEDA;9;F;Other Serious (Important Medical Event);Blood sodium decreased
171801348;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;82;M;Other Serious (Important Medical Event);Atrial fibrillation
171829483;Myelofibrosis;Fedratinib;300;CELGENE;78;M;NA;Vitamin B1 decreased
171865384;Chronic lymphocytic leukaemia;IMBRUVICA;280;ABBVIE;87;F;Other Serious (Important Medical Event);Cardiac failure chronic
171867433;Primary immunodeficiency syndrome;CUVITRU;16;TAKEDA;37;F;Other Serious (Important Medical Event);COVID-19
171883713;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;12;M;NA;Cough
171886853;Parkinson's disease;INBRIJA;84;ACORDA;63;F;NA;Device delivery system issue
171897592;0;Human Immunoglobulin;0;TAKEDA;69;M;NA;Device infusion issue
171965948;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;73;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
171987423;NA;NA;NA;TEVA;64;F;Hospitalization - Initial or Prolonged;Alopecia areata
172018915;Hypocalcaemia;Parathyroid Hormone;75;TAKEDA;47;F;Hospitalization - Initial or Prolonged;Abdominal pain
172043443;Peripheral T-cell lymphoma unspecified refractory;Ixazomib;4;TAKEDA;67;M;Life-Threatening;Fatigue
172045473;Mycobacterium abscessus infection;LAMPRENE;100;NOVARTIS;77;F;Other Serious (Important Medical Event);Abdominal discomfort
172063643;Hyperkalaemia;VELTASSA;8.4;VIFOR;47;F;Other Serious (Important Medical Event);Illness
172086032;Rheumatoid arthritis;XELJANZ;5;PFIZER;68;F;NA;Bronchitis
172086335;Fibromyalgia;LYRICA;100;PFIZER;70;F;NA;Anxiety
172087724;Breast cancer metastatic;IBRANCE;125;PFIZER;68;F;NA;Abdominal discomfort
172099035;NA;NA;NA;BIOGEN;58;F;Hospitalization - Initial or Prolonged;Anxiety
172104132;NA;NA;NA;CELGENE;16;F;Death;Norovirus infection
172110103;Acute lymphocytic leukaemia;CYCLOPHOSPHAMIDE FOR INJECTION, USP;760;BAXTER;3;M;Other Serious (Important Medical Event);Abdominal pain
172113317;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;75;M;Death;Acute coronary syndrome
172116875;Immunodeficiency common variable;CUVITRU;12;TAKEDA;47;F;Other Serious (Important Medical Event);COVID-19 immunisation
172124586;Immunodeficiency common variable;CUVITRU;30;TAKEDA;64;M;Hospitalization - Initial or Prolonged;COVID-19
172139112;Breast cancer metastatic;IBRANCE;125;PFIZER;74;F;NA;Cystitis
172139223;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;51;F;Hospitalization - Initial or Prolonged;Gait inability
172167003;Transitional cell carcinoma;ATEZOLIZUMAB;1200;ROCHE;69;M;Death;Dehydration
172168146;Immunodeficiency common variable;HUMAN NORMAL IMMUNOGLOBULIN;12;TAKEDA;81;M;Hospitalization - Initial or Prolonged;Fall
172186765;Multiple sclerosis relapse;OCREVUS;300;ROCHE;64;F;Hospitalization - Initial or Prolonged;Bronchitis
172208053;Acute lymphocytic leukaemia;VINCRISTINE SULFATE;1.14;PFIZER;3;M;Life-Threatening;Abdominal pain
172269065;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;60;TAKEDA;58;F;NA;Arthralgia
172279868;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;57;F;Other Serious (Important Medical Event);Asthma
172286793;NA;NA;NA;TAKEDA;70;M;Death;Pneumonia
172288133;Plasma cell myeloma;REVLIMID;25;CELGENE;50;F;Other Serious (Important Medical Event);Human chorionic gonadotropin increased
172296873;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;40;M;Other Serious (Important Medical Event);Brain injury
172308357;Hereditary angioedema;Lanadelumab;300;TAKEDA;33;F;Other Serious (Important Medical Event);Endometriosis
172324724;Immunodeficiency common variable;CUVITRU;32;TAKEDA;64;F;Other Serious (Important Medical Event);COVID-19
172428475;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;4328;TAKEDA;82;F;Other Serious (Important Medical Event);Abdominal abscess
172428873;Plasma cell myeloma;DARATUMUMAB;16;JOHNSON AND JOHNSON;70;M;Other Serious (Important Medical Event);Pneumonia
172430875;Chronic lymphocytic leukaemia;IMBRUVICA;280;ABBVIE;88;F;Other Serious (Important Medical Event);Non-cardiac chest pain
172435319;NA;NA;NA;TAKEDA;53;M;Other Serious (Important Medical Event);Anaemia
172448282;NA;NA;NA;ABBVIE;72;M;Other Serious (Important Medical Event);Atrial fibrillation
172465102;Multiple sclerosis;GILENYA;0.5;NOVARTIS;34;F;Other Serious (Important Medical Event);Atrioventricular block
172527598;Factor VIII deficiency;ELOCTATE;2500;SANOFI AVENTIS;15;M;Other Serious (Important Medical Event);Arthropathy
172573144;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;76;F;Other Serious (Important Medical Event);Cough
172573844;Breast cancer metastatic;IBRANCE;125;PFIZER;79;F;NA;Amino acid level decreased
172581057;NA;NA;NA;PFIZER;68;F;Death;Fall
172595063;NA;NA;NA;TAKEDA;14;M;Other Serious (Important Medical Event);Hypercalciuria
172609523;Plasma cell myeloma;REVLIMID;15;CELGENE;71;F;Hospitalization - Initial or Prolonged;Nephrolithiasis
172652664;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;77;F;Hospitalization - Initial or Prolonged;Body temperature abnormal
172653818;Pancreatic carcinoma metastatic;ATEZOLIZUMAB;840;ROCHE;58;M;Other Serious (Important Medical Event);Chills
172654719;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;73;F;NA;Arthralgia
172687492;Non-24-hour sleep-wake disorder;HETLIOZ;20;VANDA PHARMACEUTICALS;52;F;NA;Insomnia
172688212;Non-24-hour sleep-wake disorder;HETLIOZ;20;VANDA PHARMACEUTICALS;67;M;NA;Drug ineffective
172690642;Non-24-hour sleep-wake disorder;HETLIOZ;20;VANDA PHARMACEUTICALS;50;F;NA;Abnormal dreams
172714773;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;14;M;NA;Chills
172775763;Acute lymphocytic leukaemia;DEXAMETHASONE;4;HIKMA;3;M;Hospitalization - Initial or Prolonged;Abdominal pain
172776944;Acute myeloid leukaemia;CYTARABINE;5;PFIZER;41;F;Other Serious (Important Medical Event);Neutropenic sepsis
172791575;Neuralgia;LYRICA;75;PFIZER;55;F;Hospitalization - Initial or Prolonged;Paralysis
172862993;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;64;M;NA;Multiple allergies
172895145;Plasma cell myeloma;NINLARO;4;TAKEDA;52;M;Death;Drug hypersensitivity
172916503;Contraception;MIRENA;20;BAYER;32;F;Hospitalization - Initial or Prolonged;Complication of device removal
172955622;Neuropathy peripheral;LYRICA;150;PFIZER;76;M;Other Serious (Important Medical Event);Death
172970254;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;79;F;Hospitalization - Initial or Prolonged;Cystitis
172993972;Plasma cell myeloma;POMALYST;4;CELGENE;60;M;Other Serious (Important Medical Event);Asthenia
173017448;Non-small cell lung cancer;COMPARATOR DOCETAXEL;150;NOVARTIS;71;M;Other Serious (Important Medical Event);Acute kidney injury
173074363;Unknown;GILENYA;0.5;NOVARTIS;48;F;NA;Dysphagia
173149377;Primary immunodeficiency syndrome;CUVITRU;11;TAKEDA;65;F;Hospitalization - Initial or Prolonged;Fall
173186783;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;74;F;Life-Threatening;Hypoaesthesia
173229872;Short-bowel syndrome;Teduglutide;0.09;TAKEDA;4;F;NA;Dehydration
173237934;Neutropenia;NEULASTA;6;AMGEN;53;F;NA;Accidental exposure to product
173299663;NA;NA;NA;MYLAN;28;F;Hospitalization - Initial or Prolonged;Abortion spontaneous
173342143;NA;NA;NA;ROCHE;62;M;Death;Diarrhoea
173344575;Vascular malformation;PIQRAY;250;NOVARTIS;34;F;Other Serious (Important Medical Event);Acne
173494033;Chronic lymphocytic leukaemia;OBINUTUZUMAB;1000;ROCHE;59;M;Hospitalization - Initial or Prolonged;Angina pectoris
173505325;Plasma cell myeloma;POMALYST;4;CELGENE;71;F;NA;Arthralgia
173515092;Plasma cell myeloma;REVLIMID;10;CELGENE;72;M;Hospitalization - Initial or Prolonged;Urinary tract infection
173521114;Short-bowel syndrome;Teduglutide;2.93;TAKEDA;66;F;Hospitalization - Initial or Prolonged;Mycobacterial infection
173574382;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;63;M;Death;Neutrophil count decreased
173588865;Immunodeficiency common variable;CUVITRU;16;TAKEDA;71;F;Hospitalization - Initial or Prolonged;Eating disorder
173595318;Transitional cell cancer of renal pelvis and ureter metastatic;NIVOLUMAB;360;BRISTOL MYERS SQUIBB;64;F;Hospitalization - Initial or Prolonged;Death
173599136;Non-small cell lung cancer;PIRFENIDONE;267;ROCHE;73;M;Hospitalization - Initial or Prolonged;Acute kidney injury
173657654;Plasma cell myeloma;REVLIMID;5;CELGENE;78;M;Other Serious (Important Medical Event);Myelodysplastic syndrome
173726454;Breast cancer female;IBRANCE;125;PFIZER;61;F;NA;Blood count abnormal
173773788;Metastatic uterine cancer;IBRANCE;100;PFIZER;66;F;Hospitalization - Initial or Prolonged;Anaemia
173884008;Primary immunodeficiency syndrome;CUVITRU;16;TAKEDA;72;F;Hospitalization - Initial or Prolonged;Asthma
173904933;Immunodeficiency common variable;CUVITRU;20;TAKEDA;71;F;NA;Bronchitis
173906886;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;70;F;Life-Threatening;Atrial fibrillation
173907669;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;85;M;Other Serious (Important Medical Event);Adverse reaction
173908272;Plasma cell myeloma;VIDAZA;130;CELGENE;78;M;Death;Anaemia
173916974;0;Human Immunoglobulin;0;TAKEDA;70;M;Hospitalization - Initial or Prolonged;Fatigue
173927815;0;Human Immunoglobulin;0;TAKEDA;60;F;Hospitalization - Initial or Prolonged;Asthma
173934242;Selective IgG subclass deficiency;CUVITRU;25;TAKEDA;50;F;NA;COVID-19
173967015;Amyloidosis;VYNDAQEL;80;PFIZER;77;M;Death;Abdominal distension
174010224;Cerebrovascular accident prophylaxis;APIXABAN;2.5;BRISTOL MYERS SQUIBB;91;F;Hospitalization - Initial or Prolonged;Aortic injury
174028507;Neuropathy peripheral;LYRICA;150;PFIZER;74;M;Hospitalization - Initial or Prolonged;Blindness unilateral
174070015;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;76;F;Other Serious (Important Medical Event);Cellulitis
174082702;NA;NA;NA;PURDUE;53;U;NA;Anxiety
174113087;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;72;M;Other Serious (Important Medical Event);Oesophageal squamous cell carcinoma
174139556;HIV infection;VIREAD;300;GILEAD;45;M;Life-Threatening;Acquired cystic kidney disease
174148632;Immune reconstitution inflammatory syndrome;CUVITRU;18;TAKEDA;53;F;NA;COVID-19
174156803;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;18;F;NA;Cough
174181888;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;87;F;Other Serious (Important Medical Event);Balance disorder
174213092;Iron overload;JADENU;90;NOVARTIS;13;M;Other Serious (Important Medical Event);Abdominal pain
174266356;Urinary tract infection;ESTRING;2;PFIZER;79;F;Hospitalization - Initial or Prolonged;Confusional state
174272296;Hepatocellular carcinoma;ATEZOLIZUMAB;1200;ROCHE;67;M;Other Serious (Important Medical Event);Transaminases increased
174280175;NA;NA;NA;TAKEDA;63;F;Other Serious (Important Medical Event);Alopecia
174297064;Crohn's disease;HUMIRA;40;ABBVIE;19;F;Other Serious (Important Medical Event);Anaemia
174298984;Invasive ductal breast carcinoma;DOCETAXEL;165;PFIZER;53;F;NA;Alopecia
174338916;Hypogammaglobulinaemia;CUVITRU;4;TAKEDA;9;M;Other Serious (Important Medical Event);Autism spectrum disorder
174405683;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;84;F;Other Serious (Important Medical Event);Asthenia
174419473;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;33;F;Other Serious (Important Medical Event);Drug hypersensitivity
174496015;Fabry's disease;FABRAZYME;85;SANOFI AVENTIS;49;M;Hospitalization - Initial or Prolonged;Central venous catheter removal
174505866;Sickle cell disease;VOXELOTOR;1500;GLOBAL BLOOD THERAPEUTICS;14;F;Hospitalization - Initial or Prolonged;Platelet disorder
174529093;Immunodeficiency common variable;CUVITRU;10;TAKEDA;55;F;Other Serious (Important Medical Event);Cardiac failure congestive
174585173;Multiple sclerosis;MAYZENT;2;NOVARTIS;51;F;NA;Familial tremor
174598637;Thyroid cancer;CAPRELSA;300;SANOFI AVENTIS;67;F;Hospitalization - Initial or Prolonged;Ageusia
174643794;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;60;M;Other Serious (Important Medical Event);Chronic lymphocytic leukaemia
174684742;Plasma cell myeloma;VELCADE;1.3;TAKEDA;59;F;Other Serious (Important Medical Event);Abdominal pain
174694983;Plasma cell myeloma;REVLIMID;25;CELGENE;67;M;Other Serious (Important Medical Event);Sepsis
174719053;NA;NA;NA;NOVARTIS;35;F;NA;Maternal exposure during pregnancy
174775472;Acute lymphocytic leukaemia;VINCRISTINE SULFATE;2;PFIZER;15;M;Life-Threatening;Anaphylactic reaction
174781075;Nausea;LUMIZYME;19.96;SANOFI AVENTIS;53;F;NA;Abdominal pain upper
174886804;Acute lymphocytic leukaemia;METHOTREXATE INTRATHECAL;15;HIKMA;3;M;Other Serious (Important Medical Event);Accidental overdose
174950144;Parkinson's disease;RYTARY;1;AMNEAL;70;M;Hospitalization - Initial or Prolonged;Adverse event
174956349;Neuropathy peripheral;LYRICA;50;PFIZER;78;F;Other Serious (Important Medical Event);Confusional state
174967242;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;39;F;Other Serious (Important Medical Event);Alopecia
175001886;Ischaemic stroke;ACTIVASE;6.1;ROCHE;89;F;Life-Threatening;Bradycardia
175086385;Immunodeficiency common variable;GAMMAGARD S/D;50;TAKEDA;52;F;Hospitalization - Initial or Prolonged;Anxiety
175089894;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;66;F;Death;COVID-19
175142346;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;58;F;Hospitalization - Initial or Prolonged;Foot operation
175191189;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;22;F;Death;Ear infection
175191256;Immunodeficiency common variable;CUVITRU;24;TAKEDA;57;F;Hospitalization - Initial or Prolonged;Gastroenteritis norovirus
175233862;Short-bowel syndrome;Teduglutide;0.318;TAKEDA;93;M;Hospitalization - Initial or Prolonged;Pemphigoid
175288016;Immunodeficiency common variable;CUVITRU;10;TAKEDA;70;F;Other Serious (Important Medical Event);Death
175335054;NA;NA;NA;VERTEX;4;M;NA;Alanine aminotransferase increased
175349247;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;80;M;NA;Aspartate aminotransferase abnormal
175349417;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;77;F;NA;Bacterial test positive
175349426;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;73;M;NA;Bacterial test positive
175351765;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;75;M;NA;Back injury
175356962;Angiosarcoma;IPILIMUMAB;100;BRISTOL MYERS SQUIBB;42;F;Other Serious (Important Medical Event);Diarrhoea
175424732;Acute lymphocytic leukaemia;CYTARABINE;160;HIKMA;15;M;Death;Anaphylactic reaction
175436706;0;Human Immunoglobulin;0;TAKEDA;78;F;Hospitalization - Initial or Prolonged;Back disorder
175465024;0;Human Immunoglobulin;0;TAKEDA;79;F;Other Serious (Important Medical Event);Arthritis
175536244;MG;INFLIXIMAB;Intravenous (not otherwise specified);JOHNSON AND JOHNSON;19;M;Other Serious (Important Medical Event);Hodgkin's disease
175579222;NA;NA;NA;TAKEDA;38;F;NA;Fluid imbalance
175611167;Severe myoclonic epilepsy of infancy;DIACOMIT;600;BIOCODEX;3;M;Other Serious (Important Medical Event);Aggression
175675929;NA;NA;NA;NOVARTIS;0;F;Other Serious (Important Medical Event);Acute respiratory failure
175691053;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;76;F;NA;Foot fracture
175691942;Hypertension;LOSARTAN;100;NOVARTIS;69;M;Life-Threatening;Hypotension
175718988;0;Human Immunoglobulin;0;TAKEDA;67;F;Hospitalization - Initial or Prolonged;Back pain
175817615;Short-bowel syndrome;Teduglutide;3;TAKEDA;43;M;Other Serious (Important Medical Event);Constipation
175834817;Triple negative breast cancer;CARBOPLATIN;530;ROCHE;55;F;Hospitalization - Initial or Prolonged;Asthenia
175836509;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;3387;TAKEDA;73;F;Hospitalization - Initial or Prolonged;Abdominal hernia
175836957;Immunodeficiency;CUVITRU;16;TAKEDA;71;F;Other Serious (Important Medical Event);Bronchitis
175853259;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;69;M;Other Serious (Important Medical Event);Influenza
175927589;Chronic lymphocytic leukaemia stage 4;IMBRUVICA;140;ABBVIE;63;F;Hospitalization - Initial or Prolonged;Pneumonitis
175933625;Immune system disorder;Lanadelumab;300;TAKEDA;55;M;Hospitalization - Initial or Prolonged;Dyspnoea
175950359;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;40;F;Other Serious (Important Medical Event);COVID-19
175973924;0;Human Immunoglobulin;0;TAKEDA;42;F;NA;Inappropriate schedule of product administration
176044653;Selective IgG subclass deficiency;GAMMAGARD S/D;30;TAKEDA;64;F;NA;Body temperature abnormal
176048936;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;56;F;Hospitalization - Initial or Prolonged;Blood glucose increased
176065805;Immunodeficiency common variable;CUVITRU;20;TAKEDA;55;F;Hospitalization - Initial or Prolonged;Asthma
176104544;Paraesthesia;LYRICA;200;PFIZER;25;M;NA;Hypoacusis
176116158;Immunodeficiency common variable;CUVITRU;33;TAKEDA;72;M;Other Serious (Important Medical Event);Dehydration
176116336;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;70;F;Other Serious (Important Medical Event);Animal bite
176178388;Hypoparathyroidism;Parathyroid Hormone;50;TAKEDA;53;F;Hospitalization - Initial or Prolonged;Arthralgia
176178405;NA;NA;NA;TAKEDA;58;F;Other Serious (Important Medical Event);Acute kidney injury
176190967;Crohn's disease;HUMIRA;40;ABBVIE;14;M;Hospitalization - Initial or Prolonged;Crohn's disease
176219866;HIV infection;Dolutegravir;50;VIIV;18;F;Other Serious (Important Medical Event);Nephrolithiasis
176353948;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;67;M;Other Serious (Important Medical Event);Acute hepatic failure
176474794;Unknown;BREO ELLIPTA;1;GLAXOSMITHKLINE;88;F;Hospitalization - Initial or Prolonged;Dyspnoea
176483812;Psoriasis;COSENTYX;300;NOVARTIS;67;F;NA;Dry mouth
176525809;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;70;F;Other Serious (Important Medical Event);Abdominal discomfort
176541047;NA;NA;NA;NOVARTIS;29;F;Other Serious (Important Medical Event);Abortion spontaneous
176578717;0;Human Immunoglobulin;0;TAKEDA;71;M;Other Serious (Important Medical Event);Back disorder
176600153;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;63;F;NA;Asthenia
176607145;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;66;M;NA;Lymphoedema
176632466;Narcolepsy;XYREM;2.25;JAZZ;54;F;Other Serious (Important Medical Event);Blood glucose fluctuation
176652392;NA;NA;NA;PERRIGO;66;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
176653492;Gastrooesophageal reflux disease;PREVACID 24 HR;30;PERRIGO;58;M;Death;Blood creatinine increased
176682122;Cystic fibrosis;PULMOZYME;2.5;ROCHE;11;M;Hospitalization - Initial or Prolonged;Pneumonia
176695648;Immunodeficiency common variable;CUVITRU;20;TAKEDA;58;F;Other Serious (Important Medical Event);Device infusion issue
176715645;Chronic lymphocytic leukaemia;VENETOCLAX;20;ROCHE;55;M;Hospitalization - Initial or Prolonged;Blood lactate dehydrogenase increased
176750688;0;Human Immunoglobulin;0;TAKEDA;63;M;Hospitalization - Initial or Prolonged;Burning sensation
176763543;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;49;F;NA;Back injury
176785117;Bladder cancer;ATEZOLIZUMAB;1200;ROCHE;82;M;Hospitalization - Initial or Prolonged;Acute kidney injury
176797607;NA;NA;NA;TAKEDA;59;F;Other Serious (Important Medical Event);Malnutrition
176807243;Cerebrovascular accident prophylaxis;APIXABAN;5;BRISTOL MYERS SQUIBB;68;M;Hospitalization - Initial or Prolonged;Cardiac disorder
176853392;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;47;F;Other Serious (Important Medical Event);Alopecia
176853473;Breast cancer female;TAXOTERE;75;SANOFI AVENTIS;37;F;Death;Alopecia
176863717;Hormone-refractory prostate cancer;XL184;40;EXELIXIS;64;M;Other Serious (Important Medical Event);Cholecystitis
176875835;Short-bowel syndrome;Teduglutide;2.54;TAKEDA;55;F;NA;Anal incontinence
176879982;Selective IgA immunodeficiency;CUVITRU;8;TAKEDA;49;F;NA;COVID-19
176903123;NA;NA;NA;NOVARTIS;54;M;Other Serious (Important Medical Event);Acute kidney injury
176918337;Immunodeficiency common variable;CUVITRU;14;TAKEDA;78;F;Other Serious (Important Medical Event);Haemoptysis
176919106;Hormone-refractory prostate cancer;ATEZOLIZUMAB;1200;ROCHE;64;M;Hospitalization - Initial or Prolonged;Cholecystitis
176932219;NA;NA;NA;PFIZER;83;M;Other Serious (Important Medical Event);Acute kidney injury
176996025;Blood cholesterol increased;REPATHA;140;AMGEN;59;F;NA;Accidental exposure to product
177023923;NA;NA;NA;PURDUE;50;F;Hospitalization - Initial or Prolonged;Bedridden
177031459;Hypoparathyroidism;NATPARA (PARATHYROID HORMONE);50;TAKEDA;58;F;Other Serious (Important Medical Event);Arthralgia
177042436;Short-bowel syndrome;Teduglutide;0.35;TAKEDA;73;F;Hospitalization - Initial or Prolonged;Abdominal distension
177053965;NA;NA;NA;GILEAD;47;M;Other Serious (Important Medical Event);Bone density decreased
177092337;Multiple sclerosis;TYSABRI;300;BIOGEN;48;F;Hospitalization - Initial or Prolonged;Abdominal distension
177104998;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;60;TAKEDA;70;M;Other Serious (Important Medical Event);Abdominal pain
177124539;Chronic lymphocytic leukaemia;IMBRUVICA;280;ABBVIE;77;M;Death;Angina pectoris
177125063;Amyloidosis;VYNDAMAX;61;PFIZER;82;M;Other Serious (Important Medical Event);Laryngeal cancer
177130627;Immunodeficiency;CUVITRU;11;TAKEDA;65;F;Hospitalization - Initial or Prolonged;Bronchitis
177158693;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;60;TAKEDA;77;F;Disability;Bronchitis
177189436;Colitis ulcerative;GAMMAGARD S/D;50;TAKEDA;45;F;Other Serious (Important Medical Event);Hospitalisation
177196553;Pain;DILAUDID;1;PURDUE;72;M;Hospitalization - Initial or Prolonged;Confusional state
177201496;Back pain;OXYCONTIN;40;PURDUE;60;M;Other Serious (Important Medical Event);Alcoholism
177278676;Polychondritis;XELJANZ;5;PFIZER;56;F;Other Serious (Important Medical Event);Coordination abnormal
177282102;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;62;F;NA;Ear infection
177294035;Primary immunodeficiency syndrome;CUVITRU;4;TAKEDA;6;F;Hospitalization - Initial or Prolonged;Arthropathy
177313325;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;68;M;NA;Alanine aminotransferase abnormal
177313334;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;75;F;NA;Device difficult to use
177399506;Plasma cell myeloma;NINLARO;4;TAKEDA;77;M;Other Serious (Important Medical Event);Abdominal pain
177406929;NA;NA;NA;GLAXOSMITHKLINE;62;F;Other Serious (Important Medical Event);Atypical pneumonia
177411775;Unknown;ILARIS;150;NOVARTIS;36;F;NA;Inappropriate schedule of product administration
177414445;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;50;F;NA;Flushing
177419897;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;58;F;Disability;Fibromyalgia
177474363;NA;NA;NA;PFIZER;63;F;NA;Alopecia
177482796;NA;NA;NA;PURDUE;45;M;Death;Cardiac hypertrophy
177501209;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;41;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
177554514;Calculus urinary;TOVIAZ;8;PFIZER;48;F;NA;Cystitis interstitial
177587644;Ovarian cancer;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;70;F;Other Serious (Important Medical Event);Febrile neutropenia
177600477;Immunodeficiency common variable;CUVITRU;12;TAKEDA;70;M;Life-Threatening;Cough
177602122;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;72;F;Other Serious (Important Medical Event);Axillary pain
177645892;Congenital hypogammaglobulinaemia;CUVITRU;5;TAKEDA;20;F;NA;Arthralgia
177649333;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;67;F;Hospitalization - Initial or Prolonged;Blood pressure increased
177651236;Chronic lymphocytic leukaemia;IMBRUVICA;240;ABBVIE;84;M;Other Serious (Important Medical Event);COVID-19
177655944;Transient hypogammaglobulinaemia of infancy;GAMMAGARD S/D;5;TAKEDA;65;F;NA;Blood glucose increased
177667545;Selective IgG subclass deficiency;CUVITRU;16;TAKEDA;41;F;Other Serious (Important Medical Event);Cerebrospinal fluid leakage
177675342;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;Other Serious (Important Medical Event);Colon cancer
177732409;Multiple sclerosis;TYSABRI;300;BIOGEN;51;F;Other Serious (Important Medical Event);Cholelithiasis
177747173;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;67;F;NA;Confusional state
177758872;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;83;M;NA;Delusion
177780944;Plasma cell myeloma;POMALYST;3;CELGENE;64;F;NA;Balance disorder
177793852;Pain;BUPRENORPHINE;300;BIODELIVERY SCIENCES INTERNATIONAL;67;F;NA;Dermatitis psoriasiform
177827374;Relapsing-remitting multiple sclerosis;Glatiramer Acetate Injection;40;MYLAN;56;F;Hospitalization - Initial or Prolonged;Ageusia
177837222;Plasma cell myeloma;REVLIMID;10;CELGENE;80;F;Hospitalization - Initial or Prolonged;Alopecia
177843033;Triple positive breast cancer;DOCETAXEL;75;PFIZER;48;F;NA;Alopecia
177963269;Rheumatoid arthritis;RITUXAN;1000;ROCHE;62;F;Other Serious (Important Medical Event);Abdominal pain lower
177997408;Growth hormone deficiency;GENOTROPIN;3.6;PFIZER;74;F;Hospitalization - Initial or Prolonged;Asthenia
178009944;Immune system disorder;C1 Inhibitor (Human);1000;TAKEDA;73;F;Life-Threatening;COVID-19 pneumonia
178036622;Selective IgG subclass deficiency;CUVITRU;10;TAKEDA;68;F;Other Serious (Important Medical Event);Kidney infection
178058062;Plasma cell myeloma;NINLARO;4;TAKEDA;77;M;NA;Drug ineffective
178062779;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;19;F;Other Serious (Important Medical Event);Affect lability
178085978;NA;NA;NA;EISAI;67;F;Disability;Asthenia
178121736;NA;NA;NA;PERRIGO;53;F;Other Serious (Important Medical Event);Acute kidney injury
178147204;Multiple sclerosis;GILENYA;0.5;NOVARTIS;36;F;NA;Maternal exposure during pregnancy
178197654;Alpha-1 antitrypsin deficiency;CUVITRU;14;TAKEDA;37;M;Hospitalization - Initial or Prolonged;Cerebrovascular accident
178214526;Spinal muscular atrophy;ZOLGENSMA;55;NOVARTIS;2;M;Hospitalization - Initial or Prolonged;Alanine aminotransferase increased
178237594;Breast cancer metastatic;IBRANCE;100;PFIZER;68;F;Death;Blood chloride decreased
178248796;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;67;F;Other Serious (Important Medical Event);Asthma
178250032;Glycogen storage disease type II;LUMIZYME;1000;SANOFI AVENTIS;25;M;NA;Fall
178285133;Fibromyalgia;LYRICA;300;PFIZER;37;F;NA;Expired product administered
178309304;Uterine leiomyoma;ACTIVELLA;1;AMNEAL;51;F;Hospitalization - Initial or Prolonged;Intervertebral disc protrusion
178353387;Multiple sclerosis;MAYZENT;2;NOVARTIS;43;F;Hospitalization - Initial or Prolonged;Abdominal pain
178354856;Pollakiuria;TOVIAZ;4;PFIZER;72;F;Other Serious (Important Medical Event);Headache
178377233;Diffuse large B-cell lymphoma refractory;AXICABTAGENE CILOLEUCEL;68;GILEAD;49;M;Other Serious (Important Medical Event);Cytokine release syndrome
178393544;NA;NA;NA;NOVARTIS;22;M;Hospitalization - Initial or Prolonged;Depressed level of consciousness
178405265;Acute lymphocytic leukaemia;Ponatinib;30;TAKEDA;83;F;Life-Threatening;Acute lymphocytic leukaemia recurrent
178455569;Spinal stenosis;LYRICA;200;PFIZER;46;F;Hospitalization - Initial or Prolonged;Arthralgia
178467153;Breast cancer;DOCETAXEL;100;SANOFI AVENTIS;50;F;Hospitalization - Initial or Prolonged;Alopecia
178467922;NA;NA;NA;ROCHE;55;F;Other Serious (Important Medical Event);Febrile neutropenia
178478299;Immunodeficiency common variable;CUVITRU;34;TAKEDA;77;F;Other Serious (Important Medical Event);Abdominal pain upper
178488656;0;Human Immunoglobulin;0;TAKEDA;66;F;Other Serious (Important Medical Event);COVID-19
178514096;0;Human Immunoglobulin;0;TAKEDA;72;F;Death;Bronchitis
178538935;Neoplasm;IPILIMUMAB;3;BRISTOL MYERS SQUIBB;78;F;Hospitalization - Initial or Prolonged;Colitis
178544552;Asthma;DUPIXENT;300;SANOFI AVENTIS;43;F;NA;Drug ineffective
178545486;Hypopituitarism;GENOTROPIN;1.3;PFIZER;12;F;NA;Device leakage
178553088;Rheumatoid arthritis;XELJANZ;5;PFIZER;66;F;Other Serious (Important Medical Event);Arthralgia
178581527;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;19;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
178595883;Growth disorder;GENOTROPIN;1.2;PFIZER;11;M;NA;Device information output issue
178635783;Hypoparathyroidism;Parathyroid Hormone;75;TAKEDA;26;F;Other Serious (Important Medical Event);Blood calcium decreased
178636103;Rheumatoid arthritis;HUMIRA;40;ABBVIE;67;M;Hospitalization - Initial or Prolonged;Coronary artery occlusion
178659963;Asthma;DUPILUMAB;600;SANOFI AVENTIS;61;F;Life-Threatening;Abscess fungal
178667372;Breast cancer female;TAXOTERE;113;SANOFI AVENTIS;64;F;Other Serious (Important Medical Event);Alopecia
178691704;Chronic inflammatory demyelinating polyradiculoneuropathy;GAMMAGARD LIQUID;1000;TAKEDA;59;F;Hospitalization - Initial or Prolonged;Asthenia
178756388;Immunodeficiency common variable;CUVITRU;10;TAKEDA;57;F;NA;Asthma
178768333;Dermatitis atopic;DUPILUMAB;600;SANOFI AVENTIS;57;M;NA;Dry skin
178804766;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;54;F;Other Serious (Important Medical Event);COVID-19
178822598;Immunodeficiency common variable;CUVITRU;19;TAKEDA;66;F;Other Serious (Important Medical Event);Anaemia
178827474;Immunodeficiency;CUVITRU;5;TAKEDA;10;F;Other Serious (Important Medical Event);Ear infection
178848116;Prader-Willi syndrome;GENOTROPIN;3.5;PFIZER;14;M;NA;Device issue
178852902;Hypertension;VALSARTAN ACTAVIS;320;TEVA;75;M;Hospitalization - Initial or Prolonged;Hepatic cancer metastatic
178864515;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;80;M;Other Serious (Important Medical Event);Chest discomfort
178933707;Immunodeficiency common variable;CUVITRU;10;TAKEDA;66;F;Other Serious (Important Medical Event);Anaphylactic reaction
178979263;Immunodeficiency;CUVITRU;20;TAKEDA;64;F;NA;Fatigue
179069224;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;64;M;Other Serious (Important Medical Event);Fracture
179085188;Weight decreased;BELVIQ;10;EISAI;51;F;Hospitalization - Initial or Prolonged;Drug ineffective
179106143;Immunodeficiency common variable;CUVITRU;20;TAKEDA;47;F;NA;Fatigue
179116042;Breast cancer female;DOCETAXEL;120;PFIZER;71;F;NA;Alopecia
179145043;Cystic fibrosis;ORKAMBI;1;VERTEX;4;F;NA;Hepatic enzyme increased
179209814;Triple negative breast cancer;ATEZOLIZUMAB;1200;ROCHE;40;F;Other Serious (Important Medical Event);Alanine aminotransferase increased
179246996;Parkinson's disease;INBRIJA;84;ACORDA;71;F;NA;Condition aggravated
179267168;0;Human Immunoglobulin;0;TAKEDA;40;F;Hospitalization - Initial or Prolonged;Blood pressure increased
179282033;HIV wasting syndrome;SEROSTIM;5;EMD SERONO INC;62;F;Other Serious (Important Medical Event);Coronary artery disease
179296744;Sciatica;LYRICA;200;PFIZER;61;F;NA;Body height decreased
179337936;Acute lymphocytic leukaemia;Ponatinib;30;TAKEDA;74;F;Hospitalization - Initial or Prolonged;Anorectal discomfort
179343067;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;53;F;NA;Breast mass
179394362;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;66;F;Other Serious (Important Medical Event);Back pain
179420253;Breast cancer female;TAXOTERE;185;SANOFI AVENTIS;57;F;Life-Threatening;Alopecia
179437575;0;Human Immunoglobulin;0;TAKEDA;55;M;Disability;COVID-19 pneumonia
179500936;Hormone receptor positive HER2 negative breast cancer;KISQALI;400;NOVARTIS;80;F;Other Serious (Important Medical Event);Diverticulitis
179503604;NA;NA;NA;ROCHE;69;F;Other Serious (Important Medical Event);Arthritis
179587808;Pneumonia;VFEND;300;PFIZER;73;M;Hospitalization - Initial or Prolonged;Asthenia
179599757;Non-small cell lung cancer;BINIMETINIB;45;PFIZER;61;M;Other Serious (Important Medical Event);Cerebrovascular accident
179601193;Lung adenocarcinoma;COBIMETINIB;60;ROCHE;59;F;Hospitalization - Initial or Prolonged;Dermatitis acneiform
179651102;Still's disease;ILARIS;90;NOVARTIS;7;F;NA;Abdominal pain upper
179657103;Immunodeficiency common variable;CUVITRU;12;TAKEDA;73;M;Other Serious (Important Medical Event);Herpes zoster
179667154;NA;NA;NA;ROCHE;66;F;Hospitalization - Initial or Prolonged;Dysarthria
179674113;Pain;FENTANYL TRANSDERMAL SYSTEM;50;MYLAN;57;M;NA;Abdominal discomfort
179677054;Neuropathy peripheral;LYRICA;150;PFIZER;84;F;Other Serious (Important Medical Event);Death
179747872;NA;NA;NA;GILEAD;66;F;Other Serious (Important Medical Event);Myelodysplastic syndrome
179786923;Growth hormone deficiency;GENOTROPIN;0.5;PFIZER;8;M;NA;Device breakage
179808623;Immunodeficiency common variable;CUVITRU;12;TAKEDA;66;M;NA;Laboratory test abnormal
179810052;Relapsing-remitting multiple sclerosis;OCREVUS;300;ROCHE;37;F;Other Serious (Important Medical Event);Dizziness
179842402;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;21;F;Hospitalization - Initial or Prolonged;Intentional product use issue
179851193;Asthma;Mepolizumab;100;GLAXOSMITHKLINE;38;F;Death;Abortion incomplete
179924392;Mesothelioma malignant;ATEZOLIZUMAB;1200;ROCHE;71;M;Life-Threatening;Death
179933022;Acute lymphocytic leukaemia;METHOTREXATE;15;HIKMA;12;M;Other Serious (Important Medical Event);Body temperature increased
179949433;Embryonal rhabdomyosarcoma;TEMSIROLIMUS;10;PFIZER;2;F;Hospitalization - Initial or Prolonged;Gastric ulcer
179951269;Primary immunodeficiency syndrome;CUVITRU;7;TAKEDA;43;F;Death;Bronchitis
179998657;Breast cancer;IBRANCE;125;PFIZER;84;F;Other Serious (Important Medical Event);Chest pain
180009877;NA;NA;NA;TAKEDA;56;F;Hospitalization - Initial or Prolonged;Condition aggravated
180019197;Relapsing-remitting multiple sclerosis;OCRELIZUMAB;312;ROCHE;34;M;Other Serious (Important Medical Event);Gastroenteritis
180026322;NA;NA;NA;ASTELLAS;85;F;Other Serious (Important Medical Event);Pharyngeal swelling
180030552;Urge incontinence;MYRBETRIQ;25;ASTELLAS;84;F;Death;Blood pressure increased
180047004;Malignant melanoma;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;85;M;Other Serious (Important Medical Event);Pleural effusion
180090152;Muscle spasticity;LIORESAL;930;SAOL THERAPEUTICS;36;F;Hospitalization - Initial or Prolonged;Implant site erosion
180090372;Unknown;LIORESAL;440;SAOL THERAPEUTICS;23;M;Hospitalization - Initial or Prolonged;Device dislocation
180090572;NA;NA;NA;SAOL THERAPEUTICS;50;F;Hospitalization - Initial or Prolonged;Complication associated with device
180120064;Plasma cell myeloma;REVLIMID;25;CELGENE;74;F;Life-Threatening;Bladder disorder
180125549;NA;NA;NA;PFIZER;62;F;Death;Circumstance or information capable of leading to medication error
180129699;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;3788;TAKEDA;68;F;Other Serious (Important Medical Event);Bite
180162335;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;73;F;NA;Fall
180168773;Non-24-hour sleep-wake disorder;HETLIOZ;20;VANDA PHARMACEUTICALS;76;F;NA;Incorrect dose administered
180211789;Diarrhoea;Teduglutide;0.325;TAKEDA;60;F;Hospitalization - Initial or Prolonged;Abdominal pain
180225204;Still's disease;ILARIS;120;NOVARTIS;8;M;NA;Back pain
180251383;Breast cancer female;IBRANCE;125;PFIZER;69;F;Other Serious (Important Medical Event);Alopecia
180272278;Hypogammaglobulinaemia;CUVITRU;12;TAKEDA;43;F;Other Serious (Important Medical Event);Cellulitis
180294603;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;28;F;NA;Emotional disorder
180330207;Thyroid cancer;CAPRELSA;300;SANOFI AVENTIS;71;M;Other Serious (Important Medical Event);Acne
180379264;Dwarfism;GENOTROPIN;1.1;PFIZER;9;F;NA;Device failure
180382989;Immunodeficiency common variable;CUVITRU;28;TAKEDA;62;F;Other Serious (Important Medical Event);Blood pressure increased
180395365;Immunodeficiency common variable;GAMMAGARD LIQUID;37.5;TAKEDA;64;F;NA;Blood pressure increased
180401413;Liver disorder;XIFAXAN;550;BAUSCH AND LOMB;70;M;Hospitalization - Initial or Prolonged;Confusional state
180420122;Migraine;AIMOVIG;140;AMGEN;43;F;NA;Accidental exposure to product
180430975;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;46;F;NA;Alopecia
180441395;Immunodeficiency common variable;CUVITRU;10;TAKEDA;39;F;Other Serious (Important Medical Event);Cough
180447224;B precursor type acute leukaemia;blinatumomab;26;AMGEN;9;M;Hospitalization - Initial or Prolonged;Acute kidney injury
180448055;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;63;F;Hospitalization - Initial or Prolonged;Blood glucose increased
180457156;Immunodeficiency common variable;CUVITRU;22;TAKEDA;79;F;Other Serious (Important Medical Event);Asthma
180458058;Unknown;CUVITRU;5;TAKEDA;3;F;Hospitalization - Initial or Prolonged;COVID-19
180461736;Immune system disorder;C1 Inhibitor (Human);500;TAKEDA;37;F;Other Serious (Important Medical Event);Arthropod bite
180463073;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;12;F;NA;Exposure to fungus
180492207;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;75;F;Life-Threatening;Accident
180504414;Neoplasm;LENVATINIB;20;EISAI;53;M;Other Serious (Important Medical Event);Abscess limb
180540713;NA;NA;NA;NOVARTIS;64;F;Hospitalization - Initial or Prolonged;Colitis
180564125;Immunodeficiency common variable;CUVITRU;24;TAKEDA;47;F;Death;COVID-19 pneumonia
180564584;NA;NA;NA;PURDUE;59;F;Other Serious (Important Medical Event);Acidosis
180573255;0;Human Immunoglobulin;0;TAKEDA;69;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
180581399;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;83;M;Other Serious (Important Medical Event);Bacterial test positive
180596442;Erectile dysfunction;EDEX;1;ENDO;69;M;NA;Groin pain
180609342;Hypertension;Valsartan Tablets, USP;160;MYLAN;87;F;Hospitalization - Initial or Prolonged;Lymphoma
180666746;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;14;M;Other Serious (Important Medical Event);Blood cholesterol abnormal
180677532;Dermatitis atopic;DUPILUMAB;200;SANOFI AVENTIS;19;F;NA;Dry skin
180692452;Precocious puberty;TRIPTODUR;22.5;ARBOR;8;F;Other Serious (Important Medical Event);Angioedema
180716555;Immunodeficiency common variable;CUVITRU;10;TAKEDA;30;F;NA;Adverse drug reaction
180734512;Plasma cell myeloma;NINLARO;4;TAKEDA;58;M;Hospitalization - Initial or Prolonged;Osteomyelitis
180763762;Hypothyroidism;SYNTHROID;25;ABBVIE;54;F;NA;Ageusia
180766517;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;68;F;Other Serious (Important Medical Event);COVID-19
180767443;Hepatic encephalopathy;XIFAXAN;550;BAUSCH AND LOMB;78;F;Hospitalization - Initial or Prolonged;Asthenia
180768434;Immunodeficiency common variable;CUVITRU;16;TAKEDA;29;F;NA;SARS-CoV-2 test positive
180768455;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;80;F;Other Serious (Important Medical Event);Anxiety
180861122;Alopecia;MINOXIDIL;1;PERRIGO;41;M;NA;Application site exfoliation
180878937;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;81;F;Death;Atrial fibrillation
180890973;Giant cell arteritis;ACTEMRA;162;ROCHE;70;F;Hospitalization - Initial or Prolonged;Gait inability
180920133;Hypoparathyroidism;Parathyroid Hormone;100;TAKEDA;51;F;NA;Blood calcium increased
180951553;Immunodeficiency common variable;CUVITRU;24;TAKEDA;58;F;Hospitalization - Initial or Prolonged;Accidental overdose
180956204;Psychotic disorder;CLOZAPINE;350;MYLAN;40;F;Other Serious (Important Medical Event);Drooling
180985263;Back disorder;LYRICA;200;PFIZER;55;M;Hospitalization - Initial or Prolonged;Cancer pain
181011795;0;Human Immunoglobulin;0;TAKEDA;53;F;Other Serious (Important Medical Event);COVID-19
181043509;0;Human Immunoglobulin;0;TAKEDA;55;F;Hospitalization - Initial or Prolonged;Arthralgia
181047286;0;Human Immunoglobulin;0;TAKEDA;74;F;Other Serious (Important Medical Event);Body temperature increased
181065766;Transitional cell carcinoma;Niraparib;200;GLAXOSMITHKLINE;62;M;Other Serious (Important Medical Event);Pancreatitis
181066303;Hormone-refractory prostate cancer;XL184;40;EXELIXIS;66;M;Other Serious (Important Medical Event);Deep vein thrombosis
181070426;Immunodeficiency common variable;GAMMAGARD S/D;45;TAKEDA;16;F;Other Serious (Important Medical Event);COVID-19
181070667;Hereditary angioedema;HAEGARDA;6000;CSL BEHRING;36;M;Hospitalization - Initial or Prolonged;Hereditary angioedema
181131775;Growth hormone deficiency;GENOTROPIN;1;PFIZER;12;M;NA;Device mechanical issue
181141097;Short-bowel syndrome;Teduglutide;0.3;TAKEDA;59;F;Life-Threatening;COVID-19
181146657;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;15;F;Disability;Appendix disorder
181147903;Erectile dysfunction;SILDENAFIL CITRATE;1;PFIZER;58;M;NA;Drug ineffective
181149922;Pain;Oxycodone Hydrochloride (similar to NDA 22 272);5;PURDUE;49;F;Death;Arteriosclerosis
181155195;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;76;F;NA;Condition aggravated
181156225;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;75;F;Other Serious (Important Medical Event);Cardiac pacemaker insertion
181160982;Weight decreased;BELVIQ;10;EISAI;46;F;Other Serious (Important Medical Event);Invasive lobular breast carcinoma
181171064;NA;NA;NA;TAKEDA;39;F;Hospitalization - Initial or Prolonged;Autoimmune thyroid disorder
181190735;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;28;F;NA;Maternal exposure during pregnancy
181195495;Growth hormone deficiency;GENOTROPIN;0.6;PFIZER;15;F;NA;Device mechanical issue
181196073;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;76;F;Death;Arthralgia
181212672;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;Hospitalization - Initial or Prolonged;Dyspnoea
181216725;Diffuse large B-cell lymphoma;ATEZOLIZUMAB;840;ROCHE;78;M;Hospitalization - Initial or Prolonged;Acute kidney injury
181237965;Immunodeficiency common variable;CUVITRU;14;TAKEDA;20;F;Hospitalization - Initial or Prolonged;COVID-19
181242498;NA;NA;NA;TAKEDA;61;F;Death;Bronchitis
181242844;Unknown;CUVITRU;10;TAKEDA;39;F;NA;Multiple allergies
181246394;Pain;DILAUDID;2;PURDUE;66;M;Other Serious (Important Medical Event);Alcohol abuse
181252604;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;59;F;Hospitalization - Initial or Prolonged;Blood calcium abnormal
181316014;Pleural mesothelioma malignant;ATEZOLIZUMAB;1200;ROCHE;74;M;Other Serious (Important Medical Event);Febrile neutropenia
181355426;Immunodeficiency common variable;CUVITRU;20;TAKEDA;52;F;Hospitalization - Initial or Prolonged;Dehydration
181362798;Unknown;ENTRESTO;200;NOVARTIS;52;M;NA;Blood glucose decreased
181364037;0;Human Immunoglobulin;0;TAKEDA;52;F;Other Serious (Important Medical Event);Anaemia
181372922;Plasma cell myeloma;REVLIMID;10;CELGENE;75;F;NA;Hyperhidrosis
181425052;Immunodeficiency common variable;CUVITRU;20;TAKEDA;25;M;Other Serious (Important Medical Event);Ear infection
181433025;Type 2 diabetes mellitus;LINAGLIPTIN;5;BOEHRINGER INGELHEIM;17;M;Hospitalization - Initial or Prolonged;Blood ketone body increased
181435363;Immunodeficiency common variable;GAMMAGARD LIQUID;105;TAKEDA;58;F;NA;Ear infection
181496543;NA;NA;NA;LEADING PHARMA;46;F;NA;Diarrhoea
181506952;NA;NA;NA;MYLAN;80;F;Other Serious (Important Medical Event);B-cell lymphoma stage IV
181507467;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;80;M;Other Serious (Important Medical Event);Asthma
181530746;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;60;F;Hospitalization - Initial or Prolonged;Arthralgia
181531688;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;87;M;Other Serious (Important Medical Event);Arthralgia
181559335;NA;NA;NA;NOVARTIS;65;F;Death;Abdominal mass
181586767;Gastrointestinal stromal tumour;DCC 2618;150;DECIPHERA PHARMACEUTICALS;51;F;Hospitalization - Initial or Prolonged;Malignant melanoma
181605327;HER2 negative breast cancer;PIQRAY;300;NOVARTIS;77;F;Other Serious (Important Medical Event);Pericardial effusion
181609826;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;71;F;Other Serious (Important Medical Event);Breast cancer
181611714;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;77;M;NA;Confusional state
181621002;Dermatitis atopic;DUPIXENT;600;SANOFI AVENTIS;58;F;NA;Device difficult to use
181625637;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;25;F;Hospitalization - Initial or Prolonged;Accident
181642486;Chemotherapy;FLUDARABINE PHOSPHATE;30;NOVARTIS;0;F;Life-Threatening;Cytokine release syndrome
181643877;Hypothalamo-pituitary disorder;GENOTROPIN;2;PFIZER;11;F;NA;Device issue
181651466;Neoplasm malignant;IBRANCE;100;PFIZER;81;F;Hospitalization - Initial or Prolonged;Cough
181698494;Growth failure;GENOTROPIN;0.4;PFIZER;5;M;NA;Device breakage
181711873;NA;NA;NA;BIOGEN;32;M;Life-Threatening;Flushing
181733774;Non-small cell lung cancer;ATEZOLIZUMAB;1200;ROCHE;59;F;Hospitalization - Initial or Prolonged;Disease progression
181734802;NA;NA;NA;AUROBINDO;69;F;Life-Threatening;Ageusia
181736574;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;65;M;NA;Cerebral disorder
181743544;Immunodeficiency common variable;CUVITRU;8;TAKEDA;51;F;NA;Abdominal distension
181763635;Selective IgG subclass deficiency;CUVITRU;15;TAKEDA;43;F;Other Serious (Important Medical Event);Adverse food reaction
181773397;Immunodeficiency common variable;GAMMAGARD S/D;10;TAKEDA;14;F;Death;Dyspnoea
181776439;Immunodeficiency;CUVITRU;12;TAKEDA;55;F;Other Serious (Important Medical Event);Application site discomfort
181803285;Hereditary angioedema;Lanadelumab;300;TAKEDA;45;F;Hospitalization - Initial or Prolonged;Hereditary angioedema
181805784;Immunodeficiency common variable;CUVITRU;6;TAKEDA;9;M;Other Serious (Important Medical Event);Croup infectious
181809492;Plasma cell myeloma;POMALYST;4;CELGENE;64;F;Death;Staphylococcal infection
181813689;0;Human Immunoglobulin;0;TAKEDA;32;F;Hospitalization - Initial or Prolonged;Blood glucose increased
181817322;NA;NA;NA;MYLAN;74;M;Other Serious (Important Medical Event);Hepatic cancer stage III
181834244;Spinal muscular atrophy;ZOLGENSMA;16.6;NOVARTIS;0;F;Other Serious (Important Medical Event);Alanine aminotransferase increased
181841893;Chronic lymphocytic leukaemia;IMBRUVICA;280;ABBVIE;79;M;Other Serious (Important Medical Event);Embolism
181869833;Immunodeficiency common variable;CUVITRU;27;TAKEDA;67;F;Other Serious (Important Medical Event);COVID-19 pneumonia
181882362;Selective IgG subclass deficiency;CUVITRU;24;TAKEDA;61;F;Other Serious (Important Medical Event);Cough
181883712;Myelodysplastic syndrome;AZACITIDINE;150;CELGENE;65;F;NA;Abdominal distension
181898566;Unknown;CUVITRU;21;TAKEDA;19;F;NA;Application site laceration
181910647;0;Human Immunoglobulin;0;TAKEDA;48;M;Other Serious (Important Medical Event);Bronchitis
181915498;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;43;F;Hospitalization - Initial or Prolonged;Basedow's disease
181916137;Transitional cell carcinoma;XL184;40;EXELIXIS;92;F;Other Serious (Important Medical Event);Dehydration
181930428;Immune system disorder;CUVITRU;20;TAKEDA;52;F;Death;Dermatitis contact
181934679;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;46;M;Other Serious (Important Medical Event);COVID-19
181934849;Hypogammaglobulinaemia;CUVITRU;12;TAKEDA;17;M;Hospitalization - Initial or Prolonged;Ammonia increased
181947979;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;49;F;Life-Threatening;Accident
181962582;Dizziness;KETOROLAC TROMETHAMINE 05%;10;ALLERGAN;67;F;NA;Depression
181963012;Pain;KETOROLAC;30;ALLERGAN;62;F;NA;Expired product administered
182003434;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;72;M;Other Serious (Important Medical Event);Death
182004093;Benign neoplasm of prostate;ESBRIET;267;ROCHE;83;M;Other Serious (Important Medical Event);Arrhythmia
182012295;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;60;F;Other Serious (Important Medical Event);Dizziness
182025197;Hepatic cirrhosis;XIFAXAN;550;BAUSCH AND LOMB;63;F;Other Serious (Important Medical Event);Back disorder
182032144;Blood growth hormone;GENOTROPIN;0.4;PFIZER;8;M;NA;Product dose omission issue
182055364;Hepatocellular carcinoma;XL184;40;EXELIXIS;48;M;Hospitalization - Initial or Prolonged;Abdominal pain
182058813;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;69;M;NA;Lower respiratory tract congestion
182073172;COVID-19;ALTEPLASE;50;ROCHE;62;F;Other Serious (Important Medical Event);Bacterial sepsis
182095154;Prostate cancer;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;48;M;Life-Threatening;Cardiac arrest
182136233;Type 2 diabetes mellitus;BASAGLAR;32;ELI LILLY AND CO;74;M;Hospitalization - Initial or Prolonged;Dementia with Lewy bodies
182137004;5q minus syndrome;REVLIMID;5;CELGENE;87;F;Hospitalization - Initial or Prolonged;5q minus syndrome
182153894;Prostate cancer;XL184;40;EXELIXIS;48;M;Other Serious (Important Medical Event);Cardiac arrest
182170874;Chronic inflammatory demyelinating polyradiculoneuropathy;GAMUNEX C;35;GRIFOLS;47;F;Other Serious (Important Medical Event);Rash
182172643;Immunodeficiency common variable;GAMUNEX C;30;GRIFOLS;44;M;Hospitalization - Initial or Prolonged;Infusion related reaction
182179653;Myasthenia gravis;GAMUNEX C;75;GRIFOLS;80;M;Hospitalization - Initial or Prolonged;Infusion related reaction
182190053;Stiff person syndrome;GAMUNEX C;40;GRIFOLS;33;F;Other Serious (Important Medical Event);Cough
182190656;0;Human Immunoglobulin;0;TAKEDA;66;F;Other Serious (Important Medical Event);Colon cancer
182235805;Chronic myeloid leukaemia;ICLUSIG;45;TAKEDA;31;M;NA;No adverse event
182238743;Polymyositis;GAMUNEX C;120;GRIFOLS;58;M;Death;Erythema
182242095;Diffuse large B-cell lymphoma;KYMRIAH;15;NOVARTIS;75;F;Hospitalization - Initial or Prolonged;Cytokine release syndrome
182245202;NA;NA;NA;PURDUE;53;M;Other Serious (Important Medical Event);Drug dependence
182262742;Pain;OXYCODONE AND ACETAMINOPHEN;3;AUROBINDO;51;F;NA;Abdominal pain upper
182269339;Immunodeficiency common variable;CUVITRU;10;TAKEDA;40;F;Hospitalization - Initial or Prolonged;Behcet's syndrome
182275668;Growth hormone deficiency;GENOTROPIN;3.4;PFIZER;15;F;NA;Device breakage
182275757;0;Human Immunoglobulin;0;TAKEDA;62;F;Hospitalization - Initial or Prolonged;Aspiration
182324052;Serum ferritin decreased;INJECTAFER;750;AMERICAN REGENT;26;F;NA;Dizziness
182336873;Immunodeficiency common variable;CUVITRU;20;TAKEDA;56;F;Other Serious (Important Medical Event);Bronchitis
182368429;Pyrexia;ILARIS;150;NOVARTIS;57;F;NA;Dizziness
182370823;Rheumatoid arthritis;ACTEMRA;200;ROCHE;70;F;Hospitalization - Initial or Prolonged;Drug ineffective
182386102;Essential thrombocythaemia;HYDROXYUREA;500;BRISTOL MYERS SQUIBB;75;M;Other Serious (Important Medical Event);Anaemia
182399667;Immunodeficiency common variable;CUVITRU;13;TAKEDA;73;M;Other Serious (Important Medical Event);Asthma
182435965;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;65;M;Other Serious (Important Medical Event);Cough
182444695;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;64;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
182474834;Immunodeficiency common variable;CUVITRU;14;TAKEDA;58;F;NA;Bronchitis
182504376;Pulmonary arterial hypertension;TRACLEER;16;JOHNSON AND JOHNSON;14;M;Other Serious (Important Medical Event);Anoplasty
182511912;Plasma cell myeloma;POMALIDOMIDE;4;CELGENE;79;M;Other Serious (Important Medical Event);Pyrexia
182523352;Neurotrophic keratopathy;OXERVATE;1;DOMPE FARMACEUTICI;67;F;Hospitalization - Initial or Prolonged;Blood potassium increased
182530148;Growth hormone deficiency;GENOTROPIN;1.8;PFIZER;11;F;NA;Device issue
182575457;Immunodeficiency common variable;CUVITRU;30;TAKEDA;81;M;NA;Blood creatinine increased
182620186;Immunodeficiency common variable;CUVITRU;4;TAKEDA;4;M;Other Serious (Important Medical Event);Bacterial infection
182621466;Type 2 diabetes mellitus;JARDIANCE;25;BOEHRINGER INGELHEIM;68;F;Hospitalization - Initial or Prolonged;Acute kidney injury
182661858;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;72;F;Other Serious (Important Medical Event);COVID-19
182675262;Intestinal haemorrhage;PROCTOFOAM HC;1;MYLAN;82;F;NA;Off label use
182685473;Hypogammaglobulinaemia;GAMUNEX C;20;GRIFOLS;72;F;Hospitalization - Initial or Prolonged;Infusion related reaction
182698283;Dermatomyositis;GAMUNEX C;60;GRIFOLS;52;F;Hospitalization - Initial or Prolonged;Back pain
182700346;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;35;F;Other Serious (Important Medical Event);Arthropathy
182708515;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;72;M;Death;Chills
182723428;Immunodeficiency common variable;CUVITRU;11;TAKEDA;67;F;Other Serious (Important Medical Event);Arthropod bite
182745829;Immunodeficiency common variable;CUVITRU;12;TAKEDA;36;M;Hospitalization - Initial or Prolonged;Asthma
182759504;NA;NA;NA;ROCHE;64;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
182781218;Growth hormone deficiency;GENOTROPIN;1.2;PFIZER;12;F;NA;Device leakage
182793555;0;Human Immunoglobulin;0;TAKEDA;51;F;Other Serious (Important Medical Event);Abdominal discomfort
182796753;Lumbar radiculopathy;LYRICA;75;PFIZER;71;F;Other Serious (Important Medical Event);Carotid artery thrombosis
182798052;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;22;M;NA;Product use in unapproved indication
182822186;Immunodeficiency common variable;CUVITRU;8;TAKEDA;87;F;NA;Contusion
182836348;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;45;F;Other Serious (Important Medical Event);Conjunctivitis
182844227;Immunodeficiency common variable;CUVITRU;7;TAKEDA;26;F;Other Serious (Important Medical Event);Coeliac disease
182857278;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;63;F;Other Serious (Important Medical Event);Bacteraemia
182872615;NA;NA;NA;SANOFI AVENTIS;64;F;Other Serious (Important Medical Event);Abdominal discomfort
182878394;Selective IgG subclass deficiency;CUVITRU;24;TAKEDA;34;F;NA;Infusion site bruising
182878574;Psoriasis;OTEZLA;30;AMGEN;54;F;Hospitalization - Initial or Prolonged;Alopecia
182890449;Acute myeloid leukaemia;ATEZOLIZUMAB;820;ROCHE;71;M;Hospitalization - Initial or Prolonged;Anaemia
182917473;Renal cell carcinoma;XL184;40;EXELIXIS;48;F;Other Serious (Important Medical Event);Alanine aminotransferase increased
182931346;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;73;F;Hospitalization - Initial or Prolonged;Herpes zoster
182934523;Parkinson's disease;INBRIJA;84;ACORDA;83;M;NA;Condition aggravated
182936933;Parkinson's disease;INBRIJA;2;ACORDA;62;F;NA;Asthenia
182954643;Pulmonary arterial hypertension;UPTRAVI;1600;JOHNSON AND JOHNSON;17;F;Other Serious (Important Medical Event);Headache
182956423;Growth hormone deficiency;GENOTROPIN;0.9;PFIZER;11;M;NA;Device issue
182961595;0;Human Immunoglobulin;0;TAKEDA;56;F;Life-Threatening;Arthralgia
182962144;Unknown;CUVITRU;7;TAKEDA;41;F;Hospitalization - Initial or Prolonged;Cough
182963553;Weight decreased;QSYMIA;1;VIVUS;45;F;NA;Dry mouth
182975463;Renal cell carcinoma;IPILIMUMAB;1;BRISTOL MYERS SQUIBB;48;F;Other Serious (Important Medical Event);Alanine aminotransferase increased
182988222;NA;NA;NA;TAKEDA;87;F;NA;Diarrhoea
182989183;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;52;M;Hospitalization - Initial or Prolonged;Cardiac arrest
182990114;Prostate cancer;ELIGARD;45;TOLMAR;73;M;Other Serious (Important Medical Event);Suicidal ideation
183001302;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;69;M;Other Serious (Important Medical Event);Anhedonia
183034634;Hereditary angioedema;Lanadelumab;300;TAKEDA;16;F;Other Serious (Important Medical Event);Hereditary angioedema
183077856;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;45;F;Hospitalization - Initial or Prolonged;Asthenia
183077984;Cardiac amyloidosis;VYNDAMAX;61;PFIZER;83;F;Other Serious (Important Medical Event);Condition aggravated
183088503;NA;NA;NA;PFIZER;70;F;Hospitalization - Initial or Prolonged;Depression
183135742;Hypogammaglobulinaemia;GAMUNEX C;40;GRIFOLS;53;F;Other Serious (Important Medical Event);Pruritus
183142238;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;39;F;Hospitalization - Initial or Prolonged;Body temperature increased
183142922;0;Human Immunoglobulin;0;TAKEDA;45;F;NA;Ear infection
183144653;Breast cancer metastatic;IBRANCE;100;PFIZER;60;F;NA;Abdominal pain upper
183147275;Alcoholism;VIVITROL;380;ALKERMES;54;F;NA;Dizziness
183151895;Immunodeficiency common variable;CUVITRU;13;TAKEDA;61;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
183181416;Breast cancer female;IBRANCE;125;PFIZER;61;F;NA;Neutrophil count decreased
183198113;Autoimmune disorder;GENOTROPIN;2.2;PFIZER;13;F;NA;Device breakage
183198256;Multiple sclerosis;TYSABRI;300;BIOGEN;48;F;Other Serious (Important Medical Event);Acute respiratory failure
183266372;Factor VIII deficiency;AFSTYLA ANTIHEMOPHILIC FACTOR (RECOMBINANT), SINGLE CHAIN;2400;CSL BEHRING;19;U;Hospitalization - Initial or Prolonged;Muscle haemorrhage
183277974;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;16;M;NA;COVID-19
183306323;Selective IgG subclass deficiency;CUVITRU;14;TAKEDA;62;F;Other Serious (Important Medical Event);Infusion site erythema
183319615;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;70;F;Other Serious (Important Medical Event);Acute myeloid leukaemia
183338833;Hypertension;CLONIDINE TRANSDERMAL SYSTEM;0.1;MYLAN;85;M;NA;Application site erythema
183350363;Food allergy;Epinephrine Injection USP Auto Injector;0.3;MYLAN;13;M;NA;Product quality issue
183358157;Immunodeficiency common variable;CUVITRU;10;TAKEDA;43;F;Other Serious (Important Medical Event);COVID-19
183362532;Arthralgia;OXYCONTIN;10;PURDUE;40;M;Hospitalization - Initial or Prolonged;Alcohol abuse
183371173;Basal cell carcinoma;ERIVEDGE;150;ROCHE;39;F;Other Serious (Important Medical Event);Blood pressure increased
183386672;Duchenne muscular dystrophy;EXONDYS 51;1700;SAREPTA THERAPEUTICS;22;M;NA;Intentional dose omission
183387202;Duchenne muscular dystrophy;EXONDYS 51;1900;SAREPTA THERAPEUTICS;15;M;NA;Asthenia
183387422;Duchenne muscular dystrophy;EXONDYS 51;400;SAREPTA THERAPEUTICS;3;M;NA;No adverse event
183387442;Duchenne muscular dystrophy;EXONDYS 51;700;SAREPTA THERAPEUTICS;9;M;NA;No adverse event
183387472;Muscular dystrophy;EXONDYS 51;2300;SAREPTA THERAPEUTICS;18;M;NA;Device issue
183387482;Duchenne muscular dystrophy;EXONDYS 51;1300;SAREPTA THERAPEUTICS;10;M;NA;Device issue
183387492;Duchenne muscular dystrophy;EXONDYS 51;800;SAREPTA THERAPEUTICS;8;M;NA;Accidental underdose
183387512;Duchenne muscular dystrophy;EXONDYS 51;1000;SAREPTA THERAPEUTICS;17;M;NA;No adverse event
183387552;Duchenne muscular dystrophy;EXONDYS 51;2900;SAREPTA THERAPEUTICS;16;M;NA;Catheter site pain
183387592;Duchenne muscular dystrophy;EXONDYS 51;400;SAREPTA THERAPEUTICS;4;M;NA;Hypersensitivity
183387622;Duchenne muscular dystrophy;EXONDYS 51;2000;SAREPTA THERAPEUTICS;17;M;NA;Dehydration
183387642;Duchenne muscular dystrophy;EXONDYS 51;2200;SAREPTA THERAPEUTICS;13;M;NA;Intentional dose omission
183387652;Duchenne muscular dystrophy;EXONDYS 51;1500;SAREPTA THERAPEUTICS;19;M;NA;No adverse event
183399435;Immunodeficiency common variable;CUVITRU;9;TAKEDA;65;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
183417826;Squamous cell carcinoma of the cervix;ATEZOLIZUMAB;1200;ROCHE;66;F;Hospitalization - Initial or Prolonged;Myocardial infarction
183430412;Migraine;Sumatriptan Tablets 50mg;50;AUROBINDO;54;M;NA;Foreign body in throat
183438642;Pulmonary arterial hypertension;OPSUMIT;10;JOHNSON AND JOHNSON;77;M;Other Serious (Important Medical Event);Oxygen saturation abnormal
183485797;Relapsing multiple sclerosis;KESIMPTA;20;NOVARTIS;37;F;NA;Arthralgia
183493104;Unknown;GENOTROPIN;7.2;PFIZER;32;M;NA;Device mechanical issue
183493865;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;83;F;Hospitalization - Initial or Prolonged;Non-cardiac chest pain
183504414;Plasma cell myeloma;NINLARO;4;TAKEDA;58;M;NA;Arthralgia
183563254;Non-small cell lung cancer;Brigatinib;180;TAKEDA;31;F;Other Serious (Important Medical Event);Abdominal discomfort
183565652;Hypersensitivity;EPIPEN;0.3;MYLAN;16;F;NA;Product quality issue
183585733;0;Human Immunoglobulin;0;TAKEDA;77;M;NA;Drug tolerance
183600383;NA;NA;NA;NOVARTIS;0;F;Hospitalization - Initial or Prolonged;Alanine aminotransferase increased
183610842;Lipidosis;FABRAZYME;0.99;SANOFI AVENTIS;55;M;NA;Chills
183612217;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;27;F;Other Serious (Important Medical Event);Asthma
183615153;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;4;M;NA;Dehydration
183627799;Immunodeficiency common variable;CUVITRU;11;TAKEDA;65;F;Other Serious (Important Medical Event);Device infusion issue
183659774;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;66;F;NA;Arthralgia
183673892;0;Human Immunoglobulin;0;TAKEDA;67;F;NA;Nausea
183685476;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;51;F;Hospitalization - Initial or Prolonged;Fall
183685786;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;78;F;Hospitalization - Initial or Prolonged;Arthralgia
183717906;NA;NA;NA;TAKEDA;50;M;Other Serious (Important Medical Event);Abdominal pain upper
183742714;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;19;M;NA;Gastroenteritis viral
183742734;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;67;F;Life-Threatening;Asthenia
183750134;NA;NA;NA;TAKEDA;69;M;Other Serious (Important Medical Event);Gastrointestinal disorder
183764097;Plasma cell myeloma in remission;NINLARO;3;TAKEDA;63;F;Hospitalization - Initial or Prolonged;Asthenia
183770456;Hypopituitarism;GENOTROPIN;0.4;PFIZER;7;M;NA;Device breakage
183775423;Endometriosis;ACTIVELLA;1;AMNEAL;38;F;Other Serious (Important Medical Event);Cholecystitis
183775792;Infective pulmonary exacerbation of cystic fibrosis;TOBI;300;MYLAN;23;F;Other Serious (Important Medical Event);Cystic fibrosis lung
183793984;Food allergy;Epinephrine Injection USP Auto Injector;1;MYLAN;18;M;NA;Product quality issue
183805267;Non-Hodgkin's lymphoma;MOSUNETUZUMAB;1;ROCHE;19;M;Hospitalization - Initial or Prolonged;COVID-19
183824105;Immunodeficiency common variable;CUVITRU;34;TAKEDA;73;M;Hospitalization - Initial or Prolonged;Anal fistula infection
183830023;Congenital hypogammaglobulinaemia;CUVITRU;9;TAKEDA;39;F;NA;Product dose omission issue
183832692;NA;NA;NA;MYLAN;54;M;Hospitalization - Initial or Prolonged;B-cell lymphoma
183832722;NA;NA;NA;MYLAN;60;M;Other Serious (Important Medical Event);Prostate cancer
183838084;Plasma cell myeloma refractory;CYCLOPHOSPHAMIDE FOR INJECTION, USP;650;BAXTER;61;F;Death;Febrile neutropenia
183863872;Plasma cell myeloma;REVLIMID;10;CELGENE;69;F;NA;Blood creatinine decreased
183875994;Follicular lymphoma;CC 5013;20;CELGENE;68;M;Other Serious (Important Medical Event);Bladder neoplasm
183902035;Immunodeficiency common variable;GAMMAGARD S/D;35;TAKEDA;52;F;Hospitalization - Initial or Prolonged;COVID-19
183902743;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;84;M;Other Serious (Important Medical Event);Fatigue
183918307;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;72;F;Hospitalization - Initial or Prolonged;Anaemia
183929264;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;68;F;Hospitalization - Initial or Prolonged;Asthma
183942255;Multiple sclerosis;KESIMPTA;20;NOVARTIS;56;F;NA;Chills
183944126;B-cell lymphoma refractory;BREXUCABTAGENE AUTOLEUCEL;1;GILEAD;75;M;Other Serious (Important Medical Event);Encephalopathy
183956743;Selective IgG subclass deficiency;CUVITRU;15;TAKEDA;46;F;NA;COVID-19
183957977;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;76;F;Other Serious (Important Medical Event);Cataract
183959144;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;53;M;Other Serious (Important Medical Event);Localised infection
183970645;0;Human Immunoglobulin;0;TAKEDA;78;F;NA;Fatigue
183974292;NA;NA;NA;TAKEDA;4;M;NA;Nausea
183992425;Breast cancer metastatic;IBRANCE;125;PFIZER;72;F;Hospitalization - Initial or Prolonged;Arthritis
184017806;NA;NA;NA;NOVARTIS;63;F;Death;Confusional state
184018564;Severe myoclonic epilepsy of infancy;FINTEPLA;1.6;ZOGENIX;12;F;Other Serious (Important Medical Event);Alopecia
184030112;Immunodeficiency common variable;GAMMAGARD S/D;30;TAKEDA;65;F;NA;Blood cholesterol increased
184037454;Immunodeficiency common variable;CUVITRU;8;TAKEDA;70;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
184047112;Lung carcinoma cell type unspecified stage IV;ALUNBRIG;90;TAKEDA;67;M;NA;Abdominal distension
184050129;Growth hormone deficiency;GENOTROPIN;2;PFIZER;13;M;NA;Device use issue
184126373;NA;NA;NA;NOVARTIS;55;F;Other Serious (Important Medical Event);Asthenia
184129462;Rheumatoid arthritis;UPADACITINIB;15;ABBVIE;58;M;Death;Deep vein thrombosis
184145762;Joint injury;CELEBREX;200;PFIZER;80;F;Other Serious (Important Medical Event);Cerebrovascular accident
184157142;Diabetic neuropathy;LYRICA;150;PFIZER;74;F;Other Serious (Important Medical Event);Localised infection
184158485;Growth hormone deficiency;GENOTROPIN;1.5;PFIZER;12;F;NA;Crying
184168662;NA;NA;NA;MYLAN;69;F;Hospitalization - Initial or Prolonged;Pancreatic carcinoma metastatic
184182109;Renal cell carcinoma;ATEZOLIZUMAB;1200;ROCHE;71;F;Hospitalization - Initial or Prolonged;Hypertension
184184454;Multiple sclerosis;AVONEX;30;BIOGEN;44;F;Other Serious (Important Medical Event);Drug ineffective
184220574;Back pain;LYRICA;150;PFIZER;74;F;Other Serious (Important Medical Event);Eye injury
184226434;Unknown;KESIMPTA;20;NOVARTIS;30;F;NA;Confusional state
184246864;Unknown;DUOPA;100;ABBVIE;81;F;Hospitalization - Initial or Prolonged;Renal artery stent placement
184248713;Lung neoplasm malignant;ALECENSA;4;ROCHE;77;F;Other Serious (Important Medical Event);Alopecia
184294284;NA;NA;NA;GILEAD;45;F;Other Serious (Important Medical Event);Cytokine release syndrome
184301593;Multiple sclerosis;TECFIDERA;240;BIOGEN;48;F;Other Serious (Important Medical Event);Seizure
184303853;NA;NA;NA;GLAXOSMITHKLINE;72;F;NA;Blister
184343105;Alpha-1 antitrypsin deficiency;GLASSIA;60;TAKEDA;59;M;Hospitalization - Initial or Prolonged;Bronchitis
184346322;Long-chain acyl-coenzyme A dehydrogenase deficiency;DOJOLVI;4;ULTRAGENYX PHARMACEUTICAL;0;F;NA;Decreased appetite
184363604;Bone cancer;IBRANCE;100;PFIZER;76;F;Other Serious (Important Medical Event);Dyspnoea exertional
184366504;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;64;M;NA;Bacterial test positive
184371212;Breast cancer metastatic;IBRANCE;125;PFIZER;69;F;Other Serious (Important Medical Event);Blood count abnormal
184379734;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;44;M;NA;Bacterial test positive
184379784;Polyneuropathy;TEGSEDI;284;AKCEA THERAPEUTICS;63;F;Hospitalization - Initial or Prolonged;Alanine aminotransferase abnormal
184381094;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;58;F;NA;Adverse drug reaction
184382254;Gastric cancer;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;71;M;Other Serious (Important Medical Event);Condition aggravated
184403653;NA;NA;NA;TAKEDA;52;F;Other Serious (Important Medical Event);Sepsis
184421483;Unknown;OXYCONTIN;40;PURDUE;31;M;Hospitalization - Initial or Prolonged;Cardiac failure
184421764;Hodgkin's disease;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;76;F;Other Serious (Important Medical Event);Hip fracture
184438474;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;65;F;NA;Back pain
184438662;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;77;M;NA;Blood bicarbonate increased
184454195;Unknown;GENOTROPIN;0.8;PFIZER;8;M;NA;Device issue
184457105;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;69;F;Other Serious (Important Medical Event);Contusion
184487224;Hereditary angioedema;Icatibant;30;TAKEDA;47;F;Hospitalization - Initial or Prolonged;Bone marrow transplant
184493523;B-cell type acute leukaemia;KTE X19;68;GILEAD;22;M;Other Serious (Important Medical Event);Cytokine release syndrome
184498883;Left ventricular failure;ENTRESTO;1;NOVARTIS;60;F;Hospitalization - Initial or Prolonged;Angioedema
184540952;Hodgkin's disease;NIVOLUMAB;360;BRISTOL MYERS SQUIBB;35;M;Other Serious (Important Medical Event);Confusional state
184565082;Squamous cell carcinoma of the tongue;VISMODEGIB;150;ROCHE;91;F;Hospitalization - Initial or Prolonged;Acute kidney injury
184578393;Pain;LIORESAL;37.006;SAOL THERAPEUTICS;70;F;Hospitalization - Initial or Prolonged;Device failure
184580563;Keratitis;OXERVATE;1;DOMPE FARMACEUTICI;73;F;NA;Eye pain
184592305;Cervix carcinoma stage III;CARBOPLATIN;220;PFIZER;44;F;Other Serious (Important Medical Event);Hepatitis B reactivation
184601966;Immunodeficiency common variable;CUVITRU;10;TAKEDA;18;M;Hospitalization - Initial or Prolonged;COVID-19
184606695;Renal cell carcinoma;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;63;F;Other Serious (Important Medical Event);Cholecystitis
184622072;Immunodeficiency common variable;CUVITRU;6;TAKEDA;73;F;Other Serious (Important Medical Event);Infection
184625546;NA;NA;NA;PFIZER;9;M;NA;Device breakage
184629739;Mucopolysaccharidosis;Idursulfase;12;TAKEDA;3;M;Hospitalization - Initial or Prolonged;Blood blister
184644447;Smoking cessation therapy;NICOTROL;10;PFIZER;76;F;NA;Fatigue
184689513;Malignant melanoma;MEKTOVI;45;PFIZER;72;F;Other Serious (Important Medical Event);Eye disorder
184702292;NA;NA;NA;PURDUE;48;F;Hospitalization - Initial or Prolonged;Aneurysm
184741446;NA;NA;NA;PFIZER;79;F;Hospitalization - Initial or Prolonged;Circumstance or information capable of leading to medication error
184743873;Short stature;GENOTROPIN;12;PFIZER;11;M;Other Serious (Important Medical Event);Device breakage
184745755;Lung neoplasm malignant;Brigatinib;180;TAKEDA;77;F;Other Serious (Important Medical Event);Adverse event
184761552;Pain;OXYCONTIN;30;PURDUE;38;F;Death;Amnesia
184763339;0;Human Immunoglobulin;0;TAKEDA;66;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
184772033;NA;NA;NA;TAKEDA;59;F;Life-Threatening;Addison's disease
184795472;Unknown;EVOMELA;130;AUROBINDO;67;M;Other Serious (Important Medical Event);Plasma cell leukaemia
184813603;Neck pain;OXYCONTIN;10;PURDUE;48;M;Death;Abscess
184818806;Relapsing-remitting multiple sclerosis;TYSABRI;300;BIOGEN;62;F;Hospitalization - Initial or Prolonged;Immune reconstitution inflammatory syndrome
184839322;Spinal muscular atrophy;EVRYSDI;5;ROCHE;47;F;Other Serious (Important Medical Event);Blood glucose increased
184855545;NA;NA;NA;PFIZER;11;M;NA;Device breakage
184870046;Metastatic malignant melanoma;BRAFTOVI;450;PFIZER;44;F;Other Serious (Important Medical Event);Femur fracture
184870612;Multiple sclerosis;KESIMPTA;20;NOVARTIS;32;F;NA;Chills
184888102;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;52;F;NA;Needle issue
184898502;Plasma cell myeloma;REVLIMID;25;CELGENE;74;M;Hospitalization - Initial or Prolonged;Deep vein thrombosis
184931213;0;Human Immunoglobulin;0;TAKEDA;74;F;Hospitalization - Initial or Prolonged;Chills
184932379;Immunodeficiency common variable;CUVITRU;5;TAKEDA;69;F;Other Serious (Important Medical Event);Blood pressure decreased
184933134;Short-bowel syndrome;Teduglutide;3;TAKEDA;44;M;Other Serious (Important Medical Event);COVID-19
184935025;Alveolar soft part sarcoma;ATEZOLIZUMAB;1200;ROCHE;40;M;Hospitalization - Initial or Prolonged;Brain oedema
184936018;Immunodeficiency common variable;CUVITRU;18;TAKEDA;64;F;Other Serious (Important Medical Event);Arthralgia
184936117;Immunodeficiency common variable;GAMMAGARD S/D;10;TAKEDA;43;F;Hospitalization - Initial or Prolonged;Arthritis
184936195;Unknown;CUVITRU;11;TAKEDA;26;F;Other Serious (Important Medical Event);Chest pain
184939596;Immunodeficiency common variable;CUVITRU;7;TAKEDA;63;F;NA;Asthma
184941146;Immune system disorder;CUVITRU;5;TAKEDA;4;M;Other Serious (Important Medical Event);Diarrhoea
184951463;Menopausal symptoms;COMBIPATCH;1;NOVARTIS;57;F;Other Serious (Important Medical Event);No adverse event
185003562;Non-small cell lung cancer;BEVACIZUMAB;1358;ROCHE;76;F;Other Serious (Important Medical Event);Anaemia
185019014;Chronic inflammatory demyelinating polyradiculoneuropathy;HUMAN NORMAL IMMUNOGLOBULIN;2000;TAKEDA;69;M;Hospitalization - Initial or Prolonged;Arthralgia
185026536;NA;NA;NA;VERTEX;25;M;NA;Alanine aminotransferase increased
185035203;Synovial sarcoma;BINIMETINIB;75;PFIZER;64;M;Hospitalization - Initial or Prolonged;Influenza like illness
185040799;Immunodeficiency common variable;CUVITRU;8;TAKEDA;72;F;Other Serious (Important Medical Event);Abdominal pain
185067454;Immunodeficiency common variable;CUVITRU;10;TAKEDA;49;F;Hospitalization - Initial or Prolonged;Infusion site extravasation
185073456;0;Human Immunoglobulin;0;TAKEDA;69;F;Other Serious (Important Medical Event);Atrial fibrillation
185074192;Transitional cell carcinoma;ERDAFITINIB;6;JOHNSON AND JOHNSON;77;F;Life-Threatening;Headache
185103624;Diffuse large B-cell lymphoma;KYMRIAH;19;NOVARTIS;67;M;Hospitalization - Initial or Prolonged;Atrial flutter
185114805;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;49;F;Disability;Coeliac disease
185124555;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;64;M;Other Serious (Important Medical Event);COVID-19
185139675;NA;NA;NA;ABBVIE;37;F;NA;Bone loss
185161654;Spinal muscular atrophy;ZOLGENSMA;5.5;NOVARTIS;0;M;Hospitalization - Initial or Prolonged;Crying
185203686;Giant cell arteritis;ACTEMRA;162;ROCHE;75;F;Other Serious (Important Medical Event);Back disorder
185231133;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;65;M;Hospitalization - Initial or Prolonged;Haematuria
185234788;Primary immunodeficiency syndrome;CUVITRU;8;TAKEDA;52;M;Hospitalization - Initial or Prolonged;Anxiety
185239782;Primary immunodeficiency syndrome;CUVITRU;8;TAKEDA;75;F;Other Serious (Important Medical Event);Embolic stroke
185258594;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;75;F;Other Serious (Important Medical Event);Condition aggravated
185265695;Pancreatic carcinoma metastatic;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;71;F;Death;Acute kidney injury
185268126;Ovarian cancer;Niraparib;300;GLAXOSMITHKLINE;55;F;Hospitalization - Initial or Prolonged;Hypotension
185282074;Acute lymphocytic leukaemia;KYMRIAH;16;NOVARTIS;17;M;Hospitalization - Initial or Prolonged;Acute lymphocytic leukaemia recurrent
185290987;Immune system disorder;Lanadelumab;300;TAKEDA;52;F;Other Serious (Important Medical Event);COVID-19
185306352;Asthma;CUVITRU;8;TAKEDA;61;F;NA;COVID-19
185306505;Multiple sclerosis;KESIMPTA;20;NOVARTIS;30;F;NA;Device issue
185376829;Acromegaly;SOMAVERT;25;PFIZER;75;F;Other Serious (Important Medical Event);Gingivitis
185377524;Metastatic renal cell carcinoma;NIVOLUMAB;360;BRISTOL MYERS SQUIBB;56;M;Hospitalization - Initial or Prolonged;Acute kidney injury
185380634;Multiple sclerosis;KESIMPTA;1;NOVARTIS;50;F;NA;Abdominal pain lower
185395163;Contraception;ANNOVERA;1;THERAPEUTICSMD;33;F;NA;Alopecia
185399298;Short stature;GENOTROPIN;5;PFIZER;8;F;NA;Device breakage
185400862;NA;NA;NA;PFIZER;77;F;Hospitalization - Initial or Prolonged;Anaemia
185427773;Short-bowel syndrome;Teduglutide;4.437;TAKEDA;56;F;Hospitalization - Initial or Prolonged;Incorrect dose administered
185450237;0;Human Immunoglobulin;0;TAKEDA;85;F;Other Serious (Important Medical Event);Abdominal discomfort
185463223;Fibromyalgia;LYRICA;225;PFIZER;58;F;NA;Disease recurrence
185498917;Multiple sclerosis;KESIMPTA;20;NOVARTIS;29;M;NA;Drug interaction
185502464;Immune thrombocytopenia;PROMACTA;75;NOVARTIS;37;F;NA;Alanine aminotransferase increased
185509284;0;Human Immunoglobulin;0;TAKEDA;50;F;Hospitalization - Initial or Prolonged;Fatigue
185512302;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;34;F;Hospitalization - Initial or Prolonged;Road traffic accident
185514472;NA;NA;NA;TAKEDA;60;F;Death;Abdominal injury
185564503;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;67;F;Other Serious (Important Medical Event);Fatigue
185579995;NA;NA;NA;AEGERION;27;F;Other Serious (Important Medical Event);Acidosis
185586546;Diabetes mellitus;METFORMIN;500;EMD SERONO INC;68;F;Hospitalization - Initial or Prolonged;Blood lactic acid increased
185587165;Short-bowel syndrome;Teduglutide;0.65;TAKEDA;4;M;Death;Inappropriate schedule of product administration
185588784;Immunodeficiency common variable;CUVITRU;20;TAKEDA;41;F;Death;COVID-19
185597203;Haemorrhoids;PROCTOFOAM HC;1;MYLAN;53;F;NA;Off label use
185600044;0;Human Immunoglobulin;0;TAKEDA;62;F;Other Serious (Important Medical Event);Costochondritis
185600406;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;78;F;Other Serious (Important Medical Event);Back pain
185600532;NA;NA;NA;MYLAN;70;M;Other Serious (Important Medical Event);Colorectal cancer stage II
185636185;Short-bowel syndrome;Teduglutide;0.24;TAKEDA;75;F;Other Serious (Important Medical Event);Chills
185644574;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;48;F;Hospitalization - Initial or Prolonged;COVID-19
185658633;Iron deficiency anaemia;INJECTAFER;750;AMERICAN REGENT;32;M;Death;Anhedonia
185663104;Mucopolysaccharidosis II;Idursulfase;24;TAKEDA;8;M;Other Serious (Important Medical Event);COVID-19
185664083;Renal cell carcinoma;NIVOLUMAB;179.4;BRISTOL MYERS SQUIBB;54;M;Other Serious (Important Medical Event);Encephalopathy
185665058;Short-bowel syndrome;Teduglutide;0.492;TAKEDA;55;F;Hospitalization - Initial or Prolonged;Accidental overdose
185688635;NA;NA;NA;LUPIN;89;M;NA;Device malfunction
185694557;Immunodeficiency common variable;CUVITRU;8;TAKEDA;71;F;Hospitalization - Initial or Prolonged;Angiopathy
185699453;Immune system disorder;Lanadelumab;300;TAKEDA;43;F;Other Serious (Important Medical Event);Catheter removal
185699753;Contraception;NORETHINDRONE;0.35;GLENMARK;31;F;Hospitalization - Initial or Prolonged;Drug ineffective
185702703;Immunodeficiency;CUVITRU;10;TAKEDA;42;F;NA;Incorrect product administration duration
185706194;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;21;M;Death;Abdominal pain upper
185718202;Pulmonary arterial hypertension;UPTRAVI;800;JOHNSON AND JOHNSON;65;F;Other Serious (Important Medical Event);Anaemia
185735375;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;44;F;NA;Alopecia
185758282;Pain;OXYCONTIN;40;PURDUE;59;M;Other Serious (Important Medical Event);Cardiac disorder
185760443;Renal transplant;GENOTROPIN;1.8;PFIZER;12;M;NA;Device breakage
185767304;NA;NA;NA;TAKEDA;56;F;Hospitalization - Initial or Prolonged;Asthenia
185771488;Cardiac failure;ENTRESTO;100;NOVARTIS;69;F;Life-Threatening;Arthralgia
185818937;Rheumatoid arthritis;RINVOQ;15;ABBVIE;66;F;Other Serious (Important Medical Event);COVID-19
185826055;Immunodeficiency common variable;GAMMAGARD S/D;25;TAKEDA;65;M;Hospitalization - Initial or Prolonged;Escherichia infection
185827043;Short-bowel syndrome;Teduglutide;0.6;TAKEDA;2;M;Hospitalization - Initial or Prolonged;Device malfunction
185827113;0;Human Immunoglobulin;0;TAKEDA;32;F;Other Serious (Important Medical Event);Conjunctivitis
185828653;Unknown;KESIMPTA;20;NOVARTIS;57;F;NA;Arthralgia
185856865;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;74;F;Hospitalization - Initial or Prolonged;Anaemia
185865155;Short-bowel syndrome;Teduglutide;4.5;TAKEDA;61;M;Other Serious (Important Medical Event);Acute respiratory failure
185869483;Short-bowel syndrome;Teduglutide;0.24;TAKEDA;68;F;Other Serious (Important Medical Event);Drug ineffective
185880574;Amyloidosis;VYNDAMAX;61;PFIZER;73;M;Disability;Fall
185881092;NA;NA;NA;TAKEDA;48;F;NA;Blood count abnormal
185883826;Primary amyloidosis;VENCLEXTA;20;ABBVIE;84;F;Other Serious (Important Medical Event);Diarrhoea
185887983;COVID-19;Bamlanivimab 700mg;700;ELI LILLY AND CO;65;F;Other Serious (Important Medical Event);Acute coronary syndrome
185909374;NA;NA;NA;TAKEDA;5;M;Other Serious (Important Medical Event);Device related sepsis
185912185;Depression;GEODON;80;PFIZER;70;F;Hospitalization - Initial or Prolonged;Brain injury
185941722;Toxic goitre;TEPEZZA;1200;HORIZON THERAPEUTICS;49;F;NA;Anxiety
185942634;Peripheral T-cell lymphoma unspecified;Belinostat;1790;AUROBINDO;43;F;Other Serious (Important Medical Event);Blood pressure increased
185951425;Psoriasis;COSENTYX;300;NOVARTIS;67;M;Hospitalization - Initial or Prolonged;Cough
185952702;Basedow's disease;TEPEZZA;800;HORIZON THERAPEUTICS;50;F;NA;Asthenopia
185956394;Breast cancer female;IBRANCE;100;PFIZER;63;F;Other Serious (Important Medical Event);Anxiety
185976656;Myelodysplastic syndrome;VENETOCLAX;400;ABBVIE;83;M;Other Serious (Important Medical Event);Pneumonia
185988572;Relapsing-remitting multiple sclerosis;GILENYA;0.5;NOVARTIS;35;F;NA;Cold sweat
186015632;Combined immunodeficiency;CUVITRU;30;TAKEDA;77;M;NA;Prostatitis
186049154;Multiple sclerosis relapse;MAYZENT;2;NOVARTIS;50;M;Other Serious (Important Medical Event);Accident
186083604;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;48;F;NA;Device malfunction
186087045;Type 1 diabetes mellitus;OZEMPIC;0.5;NOVO NORDISK;27;F;Other Serious (Important Medical Event);Diabetic ketoacidosis
186104183;Short stature;GENOTROPIN;1;PFIZER;10;M;NA;Device leakage
186111378;Autoimmune thyroiditis;LIOTHYRONINE SODIUM;200;PFIZER;65;F;Other Serious (Important Medical Event);Abdominal distension
186117464;Rheumatoid arthritis;RINVOQ;15;ABBVIE;61;F;Life-Threatening;Intervertebral disc degeneration
186127266;HIV infection;EMTRICITABINE/RILPIVIRINE/TENOFOVIR ALAFENAMIDE;1;GILEAD;0;F;Other Serious (Important Medical Event);Aberrant aortic arch
186154102;Unknown;EVOMELA;134.4;AUROBINDO;63;M;Hospitalization - Initial or Prolonged;Benign neoplasm
186172176;Hypopituitarism;GENOTROPIN;2.6;PFIZER;13;M;NA;Device physical property issue
186179874;Alpha-1 antitrypsin deficiency;GLASSIA;4200;TAKEDA;59;F;Other Serious (Important Medical Event);Arthralgia
186193073;Immune system disorder;C1 Inhibitor (Human);1000;TAKEDA;60;M;Other Serious (Important Medical Event);Cardiac dysfunction
186198454;Short-bowel syndrome;Teduglutide;0.13;TAKEDA;70;F;Hospitalization - Initial or Prolonged;Acute kidney injury
186203292;Acute lymphocytic leukaemia;MERCAPTOPURINE;85;HIKMA;12;F;Other Serious (Important Medical Event);Anxiety
186232942;Axial spondyloarthritis;UPADACITINIB;15;ABBVIE;30;F;Hospitalization - Initial or Prolonged;Pulmonary embolism
186238463;Plasma cell myeloma;NINLARO;5;TAKEDA;81;F;Other Serious (Important Medical Event);Diarrhoea
186239988;Psoriasis;COSENTYX;300;NOVARTIS;68;F;Death;Dry skin
186240706;Plasma cell myeloma;Ixazomib;3;TAKEDA;80;F;Hospitalization - Initial or Prolonged;Ammonia increased
186248924;0;Human Immunoglobulin;0;TAKEDA;69;F;NA;Body temperature increased
186250335;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;65;F;NA;Device issue
186271492;Plasma cell myeloma;REVLIMID;10;CELGENE;71;F;NA;Amnesia
186274864;Malignant melanoma;ZYKADIA;300;NOVARTIS;82;F;Hospitalization - Initial or Prolonged;Abdominal pain
186277273;Short-bowel syndrome;Teduglutide;0.05;TAKEDA;47;F;Hospitalization - Initial or Prolonged;Intestinal obstruction
186292319;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;41;F;Other Serious (Important Medical Event);Abscess oral
186327103;Multiple sclerosis;OCRELIZUMAB;600;ROCHE;40;F;Hospitalization - Initial or Prolonged;Abortion spontaneous
186331962;NA;NA;NA;SPECGX;65;F;Other Serious (Important Medical Event);Death
186335845;NA;NA;NA;PFIZER;14;F;NA;Device information output issue
186336122;Rheumatoid arthritis;XELJANZ;5;PFIZER;65;M;Disability;Lymphocyte count decreased
186366202;0;Human Immunoglobulin;0;TAKEDA;70;F;NA;Sinusitis
186376494;Mucopolysaccharidosis;Idursulfase;36;TAKEDA;12;M;Other Serious (Important Medical Event);Catheter placement
186387534;NA;NA;NA;ABBVIE;40;F;NA;Bone density decreased
186393112;NA;NA;NA;UNITED THERAPEUTICS;75;F;Other Serious (Important Medical Event);Abdominal distension
186409152;NA;NA;NA;ROCHE;37;F;Other Serious (Important Medical Event);Amnesia
186444793;NA;NA;NA;PERRIGO;61;F;Other Serious (Important Medical Event);Acute kidney injury
186450812;Metastatic renal cell carcinoma;LENVATINIB;14;EISAI;38;M;Hospitalization - Initial or Prolonged;Abdominal pain
186459475;Psoriasis;SKYRIZI;150;ABBVIE;37;F;Disability;COVID-19
186467854;Parkinson's disease;INBRIJA;2;ACORDA;78;M;Other Serious (Important Medical Event);Adverse event
186513298;Cervix carcinoma;ATEZOLIZUMAB;1200;ROCHE;45;F;Other Serious (Important Medical Event);Clostridium difficile infection
186519479;Colitis ulcerative;HUMIRA;40;ABBVIE;69;F;Hospitalization - Initial or Prolonged;Aortic arteriosclerosis
186527933;0;Human Immunoglobulin;0;TAKEDA;55;M;Other Serious (Important Medical Event);Fall
186554762;NA;NA;NA;PFIZER;70;F;NA;Contraindicated product administered
186570632;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;59;F;Other Serious (Important Medical Event);Neutrophil count decreased
186571714;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;85;M;Other Serious (Important Medical Event);Cerebrovascular accident
186572353;Crohn's disease;Vedolizumab;300;TAKEDA;45;M;Hospitalization - Initial or Prolonged;Abdominal pain upper
186575522;Short-bowel syndrome;Teduglutide;0.05;TAKEDA;60;M;Other Serious (Important Medical Event);Bacteraemia
186590842;Metastasis;Brigatinib;120;TAKEDA;77;F;NA;Asthma
186613633;Factor VIII deficiency;ADVATE;2000;TAKEDA;23;M;Hospitalization - Initial or Prolonged;Administration site pain
186619677;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;72;M;Other Serious (Important Medical Event);Blood pressure increased
186619902;Immune system disorder;Lanadelumab;300;TAKEDA;25;F;NA;Exposure during pregnancy
186649444;Multiple sclerosis;OCRELIZUMAB;1200;ROCHE;46;F;Hospitalization - Initial or Prolonged;Pneumonia
186690658;Primary immunodeficiency syndrome;CUVITRU;12;TAKEDA;47;F;Other Serious (Important Medical Event);Abdominal discomfort
186713562;Crohn's disease;XELJANZ;10;PFIZER;41;F;NA;Drug ineffective for unapproved indication
186724935;Immune system disorder;Icatibant;30;TAKEDA;54;M;Life-Threatening;Cardiac operation
186736545;Lung neoplasm malignant;Brigatinib;180;TAKEDA;52;F;NA;Blood cholesterol increased
186754802;Uterine leiomyoma;ACTIVELLA;1;AMNEAL;50;F;Hospitalization - Initial or Prolonged;COVID-19
186755366;Plasma cell myeloma;Ixazomib;4;TAKEDA;73;M;Other Serious (Important Medical Event);Deep vein thrombosis
186755652;NA;NA;NA;NOVARTIS;81;F;Other Serious (Important Medical Event);Fluid overload
186771393;Hypertension;Valsartan Tablets, USP;320;MYLAN;75;F;Death;Colorectal cancer stage III
186772425;NA;NA;NA;NOVARTIS;77;F;Other Serious (Important Medical Event);Atrial fibrillation
186773566;NA;NA;NA;JOHNSON AND JOHNSON;73;M;Other Serious (Important Medical Event);Deep vein thrombosis
186781058;NA;NA;NA;TAKEDA;86;F;Hospitalization - Initial or Prolonged;Arthralgia
186808396;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;59;M;Other Serious (Important Medical Event);Febrile neutropenia
186812834;Diffuse large B-cell lymphoma;ATEZOLIZUMAB;840;ROCHE;61;F;Hospitalization - Initial or Prolonged;Aspiration
186846477;Metastatic malignant melanoma;IPILIMUMAB;201.9;BRISTOL MYERS SQUIBB;49;F;Other Serious (Important Medical Event);Fluid overload
186856584;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;68;M;Hospitalization - Initial or Prolonged;Anaemia
186873775;Immunoglobulins abnormal;CUVITRU;20;TAKEDA;53;F;Other Serious (Important Medical Event);SARS-CoV-2 test positive
186880764;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;66;M;Hospitalization - Initial or Prolonged;Blood pressure increased
186896572;Metastatic malignant melanoma;talimogene laherparepvec;4;AMGEN;41;M;Hospitalization - Initial or Prolonged;Tumour haemorrhage
186915422;0;Human Immunoglobulin;0;TAKEDA;20;F;NA;SARS-CoV-2 test positive
186957555;Major depression;SPRAVATO;84;JOHNSON AND JOHNSON;66;F;NA;Anxiety
186959987;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;120;TAKEDA;74;F;Other Serious (Important Medical Event);Abdominal pain
186960352;NA;NA;NA;CELGENE;45;F;Hospitalization - Initial or Prolonged;Infusion related reaction
186962025;Immunodeficiency common variable;CUVITRU;4;TAKEDA;6;M;NA;Erythema
186976807;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;83;F;Other Serious (Important Medical Event);Clostridium difficile infection
187061102;Hypertension;Valsartan Tablets, USP;302;MYLAN;68;M;Other Serious (Important Medical Event);Plasma cell myeloma
187067312;Unknown;OSPHENA;60;DUCHESNAY;58;F;Other Serious (Important Medical Event);Back pain
187095626;Spinal muscular atrophy;EVRYSDI;2.7;ROCHE;3;F;Death;Drug interaction
187097745;Short-bowel syndrome;Teduglutide;0.54;TAKEDA;4;M;Hospitalization - Initial or Prolonged;Central venous catheterisation
187115232;NA;NA;NA;BRISTOL MYERS SQUIBB;61;F;Other Serious (Important Medical Event);Abdominal abscess
187126912;Haemorrhoids;PROCTOFOAM HC;1;MYLAN;72;M;NA;Product delivery mechanism issue
187176965;Immunodeficiency common variable;CUVITRU;8;TAKEDA;67;F;Other Serious (Important Medical Event);Abdominal pain
187212606;Multiple sclerosis;KESIMPTA;20;NOVARTIS;26;F;Other Serious (Important Medical Event);Aphasia
187253217;NA;NA;NA;NOVARTIS;37;F;NA;COVID-19
187263564;Immune system disorder;Lanadelumab;300;TAKEDA;23;F;Other Serious (Important Medical Event);Heart rate increased
187274414;Dermatomyositis;ABATACEPT;125;BRISTOL MYERS SQUIBB;71;F;Hospitalization - Initial or Prolonged;Dehydration
187276512;Short-bowel syndrome;Teduglutide;0.25;TAKEDA;62;F;Hospitalization - Initial or Prolonged;Arthropathy
187297945;HER2 negative breast cancer;KISQALI;400;NOVARTIS;53;F;Other Serious (Important Medical Event);Device related infection
187319045;Multiple sclerosis;KESIMPTA;20;NOVARTIS;46;F;Life-Threatening;Asthenia
187319722;Breast cancer stage IV;IBRANCE;100;PFIZER;76;F;NA;Arthritis
187350894;Selective IgG subclass deficiency;CUVITRU;24;TAKEDA;62;F;Hospitalization - Initial or Prolonged;COVID-19
187357252;Hypertension;Valsartan Tablets, USP;320;MYLAN;68;F;Death;Plasma cell myeloma
187367382;Hypertension;Valsartan and Hydrochlorothiazide Tablets, USP;320;MYLAN;55;M;Other Serious (Important Medical Event);Oesophageal carcinoma
187369194;Multiple sclerosis;Glatiramer Acetate Injection;40;MYLAN;54;M;Other Serious (Important Medical Event);Amnesia
187382982;Toxic goitre;TEPEZZA;1614;HORIZON THERAPEUTICS;30;F;NA;Head discomfort
187397926;Idiopathic pulmonary fibrosis;OFEV;150;BOEHRINGER INGELHEIM;78;F;Hospitalization - Initial or Prolonged;Death
187431572;NA;NA;NA;NOVO NORDISK;50;M;Hospitalization - Initial or Prolonged;Cholelithiasis
187440974;Psoriasis;SKYRIZI;150;ABBVIE;67;F;Other Serious (Important Medical Event);Atrial fibrillation
187450058;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;59;M;Other Serious (Important Medical Event);Gastroenteritis norovirus
187472144;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;68;M;Hospitalization - Initial or Prolonged;Myelodysplastic syndrome
187483483;Chronic myeloid leukaemia;TASIGNA;300;NOVARTIS;69;F;Other Serious (Important Medical Event);Femur fracture
187491614;Short-bowel syndrome;Teduglutide;1.86;TAKEDA;10;M;Hospitalization - Initial or Prolonged;Klebsiella sepsis
187493383;NA;NA;NA;TAKEDA;46;F;Other Serious (Important Medical Event);Illness
187529482;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;44;M;NA;Sinusitis
187530923;Immune system disorder;Lanadelumab;300;TAKEDA;59;F;Hospitalization - Initial or Prolonged;Arthropathy
187542145;Crohn's disease;HUMIRA;40;ABBVIE;76;M;Other Serious (Important Medical Event);Chronic obstructive pulmonary disease
187543254;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;82;F;Hospitalization - Initial or Prolonged;Clumsiness
187556472;NA;NA;NA;ROCHE;75;M;Other Serious (Important Medical Event);Blood urine present
187603552;NA;NA;NA;PFIZER;17;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
187609035;NA;NA;NA;ABBVIE;38;F;NA;Ankle fracture
187609195;NA;NA;NA;ABBVIE;49;F;NA;Bone density decreased
187621575;Spinal muscular atrophy;ZOLGENSMA;22;NOVARTIS;0;M;Other Serious (Important Medical Event);Alanine aminotransferase increased
187697182;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;52;F;NA;Headache
187701732;Severe myoclonic epilepsy of infancy;FINTEPLA;1.4;ZOGENIX;11;F;NA;Decreased appetite
187702553;Severe myoclonic epilepsy of infancy;FINTEPLA;0.8;ZOGENIX;11;M;NA;Appetite disorder
187702732;Severe myoclonic epilepsy of infancy;FINTEPLA;3;ZOGENIX;17;M;NA;Hypersomnia
187702782;Severe myoclonic epilepsy of infancy;FINTEPLA;5.9;ZOGENIX;12;M;NA;Diarrhoea
187713132;Fallopian tube cancer stage III;Rucaparib;600;CLOVIS ONCOLOGY;46;F;Other Serious (Important Medical Event);Pancytopenia
187721995;Chronic myeloid leukaemia;Ponatinib;15;TAKEDA;79;F;Hospitalization - Initial or Prolonged;Blood pressure increased
187759886;Lung neoplasm malignant;ALUNBRIG;180;TAKEDA;69;F;NA;Anxiety
187791753;NA;NA;NA;ROCHE;66;M;Other Serious (Important Medical Event);COVID-19
187804213;Relapsing multiple sclerosis;OCREVUS;300;ROCHE;34;F;Other Serious (Important Medical Event);COVID-19
187834976;Immune system disorder;C1 Inhibitor (Human);1000;TAKEDA;69;F;Other Serious (Important Medical Event);Adverse reaction
187852779;Congenital hypogammaglobulinaemia;CUVITRU;6;TAKEDA;8;M;Hospitalization - Initial or Prolonged;Arthropod sting
187858726;Acute lymphocytic leukaemia;Ponatinib;15;TAKEDA;69;F;Other Serious (Important Medical Event);Arthralgia
187858732;Lung neoplasm malignant;ALUNBRIG;30;TAKEDA;77;F;Life-Threatening;Central nervous system infection
187866262;Fallopian tube cancer stage III;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;46;F;Hospitalization - Initial or Prolonged;Pancytopenia
187867832;Immune system disorder;C1 Inhibitor (Human);1000;TAKEDA;43;F;Other Serious (Important Medical Event);Hereditary angioedema
187873926;Gait disturbance;AMPYRA;10;ACORDA;53;M;Hospitalization - Initial or Prolonged;Asthenia
187896514;Plasma cell myeloma;DARATUMUMAB;1232;JOHNSON AND JOHNSON;89;M;Other Serious (Important Medical Event);Atrial fibrillation
187904687;Plasma cell myeloma;Ixazomib;4;TAKEDA;75;F;Death;Abdominal discomfort
187912147;HER2 positive breast cancer;TRASTUZUMAB DERUXTECAN;5.4;DAIICHI;73;F;Other Serious (Important Medical Event);Nausea
187938867;Renal cell carcinoma;IPILIMUMAB;1;BRISTOL MYERS SQUIBB;78;M;Hospitalization - Initial or Prolonged;Autoimmune neuropathy
187946803;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;74;F;Hospitalization - Initial or Prolonged;Medical procedure
187978133;Rectal cancer;COBIMETINIB;40;ROCHE;70;M;Hospitalization - Initial or Prolonged;Confusional state
187999172;Diabetes mellitus;FARXIGA;5;ASTRAZENECA;41;F;Hospitalization - Initial or Prolonged;Confusional state
188000663;Unknown;GENOTROPIN;0.4;PFIZER;79;M;NA;Device mechanical issue
188001054;Lung cancer metastatic;LORBRENA;100;PFIZER;63;F;NA;Balance disorder
188002192;Pain;OXYCONTIN;20;PURDUE;32;M;Life-Threatening;Agitation
188025965;Myelodysplastic syndrome;VENETOCLAX;400;ABBVIE;65;M;Death;Cellulitis
188079369;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;62;F;Hospitalization - Initial or Prolonged;Abdominal pain
188088952;Antiviral prophylaxis;VALCYTE;450;ROCHE;71;F;Hospitalization - Initial or Prolonged;Diarrhoea
188177102;Relapsing multiple sclerosis;OCREVUS;600;ROCHE;58;F;NA;COVID-19
188215064;Colorectal cancer metastatic;Tucatinib;300;SEATTLE GENETICS;59;F;Other Serious (Important Medical Event);Overdose
188217543;Rheumatoid arthritis;XELJANZ;5;PFIZER;76;M;Other Serious (Important Medical Event);Asthenia
188245024;Squamous cell carcinoma of head and neck;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;63;M;Hospitalization - Initial or Prolonged;Ventricular tachycardia
188401783;NA;NA;NA;SANOFI AVENTIS;76;M;Other Serious (Important Medical Event);Chronic obstructive pulmonary disease
188405605;NA;NA;NA;NOVARTIS;67;F;Hospitalization - Initial or Prolonged;Drug ineffective
188422902;Relapsing multiple sclerosis;OCREVUS;600;ROCHE;47;F;NA;COVID-19
188431474;Primary progressive multiple sclerosis;OCREVUS;600;ROCHE;47;F;Other Serious (Important Medical Event);COVID-19 pneumonia
188453477;Immune system disorder;Lanadelumab;300;TAKEDA;70;F;Hospitalization - Initial or Prolonged;Drug ineffective
188461593;Breast cancer female;IBRANCE;125;PFIZER;72;F;NA;Abdominal pain upper
188461633;Fall;LYRICA;75;PFIZER;82;F;NA;Fibromyalgia
188468524;Parkinson's disease;DUOPA;100;ABBVIE;65;F;Other Serious (Important Medical Event);Atrial fibrillation
188471302;Rheumatoid arthritis;XELJANZ;5;PFIZER;58;F;Other Serious (Important Medical Event);Staphylococcal infection
188471313;Oestrogen receptor assay positive;IBRANCE;200;PFIZER;75;F;NA;Chronic obstructive pulmonary disease
188482894;NA;NA;NA;TAKEDA;54;M;Hospitalization - Initial or Prolonged;Abdominal pain upper
188484902;Colorectal adenocarcinoma;GSK2118436;150;NOVARTIS;43;M;Other Serious (Important Medical Event);Large intestine perforation
188488608;B-cell lymphoma;CARBOPLATIN;750;NOVARTIS;40;M;Other Serious (Important Medical Event);Cytokine release syndrome
188491432;Unknown;KESIMPTA;20;NOVARTIS;35;M;NA;Abdominal pain upper
188507544;Multiple sclerosis;GILENYA;0.5;NOVARTIS;48;F;Life-Threatening;COVID-19
188516202;Multiple sclerosis;KESIMPTA;20;NOVARTIS;32;M;Hospitalization - Initial or Prolonged;Asthenia
188536974;Depression;PRISTIQ EXTENDED RELEASE;50;PFIZER;53;F;NA;COVID-19
188538556;Benign prostatic hyperplasia;Tadalafil Tablets USP, 5 mg;5;LUPIN;70;M;NA;Drug ineffective
188546502;Uterine fibrosis;ACTIVELLA;1;AMNEAL;46;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
188566854;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;47;F;NA;Adverse event
188607313;Neoplasm malignant;IBRANCE;75;PFIZER;70;F;Death;Amnesia
188611305;Sickle cell anaemia with crisis;ADAKVEO;190;NOVARTIS;16;F;NA;Bone pain
188622472;NA;NA;NA;PURDUE;76;F;NA;Application site erythema
188635802;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;56;F;Hospitalization - Initial or Prolonged;Arthralgia
188636942;NA;NA;NA;MYLAN;68;M;Other Serious (Important Medical Event);Hepatic cancer
188639105;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;55;F;Other Serious (Important Medical Event);Blood pressure increased
188640403;Plasma cell myeloma;REVLIMID;25;CELGENE;60;M;Hospitalization - Initial or Prolonged;Cardiac arrest
188689183;Pituitary tumour;MYCAPSSA;40;CHIASMA;80;M;Other Serious (Important Medical Event);Embolic stroke
188695312;NA;NA;NA;JOHNSON AND JOHNSON;79;F;NA;Drug ineffective
188698333;Hypersensitivity;Epinephrine Injection USP Auto Injector;0.3;MYLAN;69;F;NA;Liquid product physical issue
188705682;Unknown;TADALAFIL;2;ELI LILLY AND CO;58;F;Other Serious (Important Medical Event);COVID-19
188715432;Magnetic resonance imaging;GADAVIST;11;BAYER;61;M;Hospitalization - Initial or Prolonged;Urticaria
188754232;NA;NA;NA;MYLAN;84;F;Death;Bladder cancer
188757054;Rheumatoid arthritis;HUMIRA;40;ABBVIE;57;M;Other Serious (Important Medical Event);COVID-19
188758443;COVID-19;Bamlanivimab 700mg;700;ELI LILLY AND CO;81;M;Other Serious (Important Medical Event);Blood alcohol increased
188767933;Asthma;FASENRA;30;ASTRAZENECA;38;M;Hospitalization - Initial or Prolonged;Anaphylactic reaction
188773073;Haemophilia A without inhibitors;HEMLIBRA;102;ROCHE;84;M;Other Serious (Important Medical Event);Acute myocardial infarction
188774357;Plasma cell myeloma;DARATUMUMAB;16;JOHNSON AND JOHNSON;77;F;Other Serious (Important Medical Event);Gout
188802166;Rectal cancer;COBIMETINIB;40;ROCHE;49;F;Other Serious (Important Medical Event);Proctalgia
188802523;Mucopolysaccharidosis II;Idursulfase;0.5;TAKEDA;20;M;Death;Agitation
188811802;Plasma cell myeloma;VENETOCLAX;800;ABBVIE;71;M;Hospitalization - Initial or Prolonged;Diverticulitis
188811835;NA;NA;NA;TAKEDA;34;F;Other Serious (Important Medical Event);Cellulitis
188818153;Plasma cell myeloma;BORTEZOMIB;2.8;TAKEDA;91;M;Other Serious (Important Medical Event);Cardiac failure acute
188827935;Unknown;KESIMPTA;20;NOVARTIS;36;F;NA;Fear of injection
188837784;Colorectal cancer;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;69;F;Hospitalization - Initial or Prolonged;Troponin I increased
188839103;Fabry's disease;FABRAZYME;65;SANOFI AVENTIS;53;F;Disability;Blood pressure increased
188847548;Renal cell carcinoma;CABOMETYX;40;EXELIXIS;77;M;Hospitalization - Initial or Prolonged;Autoimmune neuropathy
188869772;Dermatitis atopic;DUPIXENT;300;SANOFI AVENTIS;45;F;Hospitalization - Initial or Prolonged;Injection site pain
188874434;Pulmonary arterial hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;44;M;Other Serious (Important Medical Event);Blood pressure decreased
188874966;Plasma cell myeloma;NINLARO;3;TAKEDA;59;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
188909182;Dermatitis atopic;DUPIXENT;200;SANOFI AVENTIS;13;F;NA;Off label use
188932474;Relapsing-remitting multiple sclerosis;OCREVUS;300;ROCHE;33;F;Death;Accidental overdose
188932483;Psoriatic arthropathy;TREMFYA;100;JOHNSON AND JOHNSON;69;F;NA;Contusion
188934025;Hormone receptor positive HER2 negative breast cancer;TYKERB;1250;NOVARTIS;75;F;Other Serious (Important Medical Event);Arthritis
188959413;Juvenile idiopathic arthritis;ILARIS;150;NOVARTIS;35;F;NA;Incorrect dose administered
188988392;Psoriatic arthropathy;COSENTYX;300;NOVARTIS;57;F;Other Serious (Important Medical Event);Cellulitis
188990483;Polyneuropathy;HUMAN NORMAL IMMUNOGLOBULIN;110;TAKEDA;52;M;NA;Blood pressure increased
188990496;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;63;F;Hospitalization - Initial or Prolonged;Pneumonia
188997582;Asthma;DUPIXENT;300;SANOFI AVENTIS;51;F;NA;Influenza like illness
189024329;Relapsing-remitting multiple sclerosis;TYSABRI;300;BIOGEN;61;F;Death;Prescribed underdose
189025305;Non-small cell lung cancer;XL184;40;EXELIXIS;64;F;Other Serious (Important Medical Event);Transient ischaemic attack
189061723;Acute myeloid leukaemia;VENETOCLAX;100;ABBVIE;83;F;Other Serious (Important Medical Event);Leukopenia
189069783;Hyperkalaemia;VELTASSA;8.4;VIFOR;65;F;NA;Arteriovenous fistula operation
189084273;Skin wrinkling;DYSPORT;50;IPSEN;34;F;NA;Headache
189088103;Type 2 diabetes mellitus;TRULICITY;0.75;ELI LILLY AND CO;59;M;Other Serious (Important Medical Event);Abdominal pain upper
189089077;Unknown;ENTRESTO;100;NOVARTIS;63;M;Other Serious (Important Medical Event);Atrial fibrillation
189106744;NA;NA;NA;TAKEDA;77;F;Other Serious (Important Medical Event);Abdominal pain
189146574;NA;NA;NA;BIOMARIN;15;M;NA;Anxiety
189159234;Acute lymphocytic leukaemia;VINCRISTINE SULFATE;2;PFIZER;16;M;Other Serious (Important Medical Event);Febrile neutropenia
189168875;Immune system disorder;Lanadelumab;300;TAKEDA;14;F;Hospitalization - Initial or Prolonged;Gastrointestinal bacterial infection
189172653;Immune system disorder;Icatibant;30;TAKEDA;75;F;Other Serious (Important Medical Event);Dehydration
189173065;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;71;M;Other Serious (Important Medical Event);Angina pectoris
189173366;Immunodeficiency common variable;CUVITRU;12;TAKEDA;83;F;Hospitalization - Initial or Prolonged;Adrenal insufficiency
189176948;Drug dependence;VIVITROL;380;ALKERMES;57;M;NA;Back pain
189181513;NA;NA;NA;CELGENE;66;M;Death;Atypical pneumonia
189210583;Plasma cell myeloma;POMALYST;2;CELGENE;64;F;NA;Headache
189212419;Acute myeloid leukaemia;CC 90009;3;CELGENE;68;F;Other Serious (Important Medical Event);Fungal sepsis
189214203;Adenocarcinoma of colon;ATEZOLIZUMAB;840;ROCHE;68;M;Other Serious (Important Medical Event);Hypertension
189227464;NA;NA;NA;CELGENE;75;M;Other Serious (Important Medical Event);Febrile neutropenia
189233704;Acute lymphocytic leukaemia recurrent;Ponatinib;30;TAKEDA;37;M;Hospitalization - Initial or Prolonged;Asthenia
189236985;Atrial fibrillation;XARELTO;20;JOHNSON AND JOHNSON;79;F;Hospitalization - Initial or Prolonged;Chest pain
189248006;NA;NA;NA;MYLAN;59;F;NA;Abdominal discomfort
189254362;Cardiac failure;PLACEBO;100;JOHNSON AND JOHNSON;45;M;Life-Threatening;Choking
189279223;Chronic lymphocytic leukaemia;OBINUTUZUMAB;1000;ROCHE;50;M;Hospitalization - Initial or Prolonged;Anaemia
189295224;NA;NA;NA;EISAI;55;F;Other Serious (Important Medical Event);Back pain
189295873;Immunodeficiency common variable;CUVITRU;12;TAKEDA;49;F;Hospitalization - Initial or Prolonged;Appendicitis
189301924;Iron deficiency anaemia;INJECTAFER;750;AMERICAN REGENT;56;F;Other Serious (Important Medical Event);Anhedonia
189310016;NA;NA;NA;CELGENE;68;M;Hospitalization - Initial or Prolonged;COVID-19
189322504;Psoriasis;STELARA;45;JOHNSON AND JOHNSON;39;F;NA;Needle issue
189323522;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;79;F;Hospitalization - Initial or Prolonged;Ataxia
189324985;Rheumatoid arthritis;RINVOQ;15;ABBVIE;78;F;Hospitalization - Initial or Prolonged;Arthralgia
189327995;Asthma;DUPIXENT;300;SANOFI AVENTIS;41;F;Disability;Back pain
189334093;NA;NA;NA;ROCHE;78;F;Hospitalization - Initial or Prolonged;COVID-19
189355914;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;77;F;Hospitalization - Initial or Prolonged;Arthralgia
189358924;NA;NA;NA;UNITED THERAPEUTICS;66;F;NA;Chest discomfort
189361034;Short-bowel syndrome;Teduglutide;5;TAKEDA;59;F;Hospitalization - Initial or Prolonged;Abdominal distension
189377803;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;36;M;Other Serious (Important Medical Event);Cellulitis
189381228;NA;NA;NA;PFIZER;59;F;Other Serious (Important Medical Event);Uterine cancer
189381494;Colon cancer metastatic;BINIMETINIB;45;PFIZER;32;F;Hospitalization - Initial or Prolonged;Haemorrhage intracranial
189404532;Plasma cell myeloma;REVLIMID;10;CELGENE;86;F;NA;Joint swelling
189413867;Post-traumatic stress disorder;RISPERDAL CONSTA;37.5;JOHNSON AND JOHNSON;38;M;Other Serious (Important Medical Event);Drug delivery system malfunction
189444964;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;74;M;Other Serious (Important Medical Event);Death
189449516;Systemic lupus erythematosus;Belimumab;80;GLAXOSMITHKLINE;61;F;Other Serious (Important Medical Event);Glioblastoma multiforme
189472284;NA;NA;NA;CELGENE;87;M;Hospitalization - Initial or Prolonged;Acute kidney injury
189493505;0;Human Immunoglobulin;0;TAKEDA;42;F;Life-Threatening;Cardiac ablation
189513624;Hereditary angioedema;HAEGARDA;5000;CSL BEHRING;20;M;Hospitalization - Initial or Prolonged;Hereditary angioedema
189514385;Multiple sclerosis;TECFIDERA;120;BIOGEN;53;M;Death;Abdominal discomfort
189530247;Ovarian cancer;ZEJULA;200;GLAXOSMITHKLINE;77;F;Other Serious (Important Medical Event);Balance disorder
189544669;NA;NA;NA;FRESENIUS KABI;62;F;Hospitalization - Initial or Prolonged;Peripheral sensory neuropathy
189547523;Chronic myeloid leukaemia;Ponatinib;45;TAKEDA;71;M;Other Serious (Important Medical Event);Coagulopathy
189548853;Secondary progressive multiple sclerosis;OCREVUS;300;ROCHE;51;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
189550675;Multiple sclerosis;KESIMPTA;20;NOVARTIS;53;F;NA;Chills
189552415;Hypogammaglobulinaemia;CUVITRU;5;TAKEDA;12;M;Other Serious (Important Medical Event);Autism spectrum disorder
189554022;Bipolar disorder;EFFEXOR XR;225;PFIZER;79;F;Other Serious (Important Medical Event);Dementia
189560982;Anaemia of malignant disease;LUSPATERCEPT;1;CELGENE;75;F;Hospitalization - Initial or Prolonged;Acute myeloid leukaemia
189571624;Multiple sclerosis;GILENYA;0.5;NOVARTIS;55;F;Other Serious (Important Medical Event);Headache
189591822;Immune system disorder;FIRAZYR;30;TAKEDA;53;F;NA;Fatigue
189599813;Relapsing-remitting multiple sclerosis;KESIMPTA;20;NOVARTIS;39;F;NA;Chills
189605283;Giant cell arteritis;ACTEMRA;162;ROCHE;87;F;Other Serious (Important Medical Event);Appetite disorder
189606607;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;65;F;Other Serious (Important Medical Event);Abdominal pain upper
189612254;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;72;F;NA;Weight decreased
189618882;Haematological malignancy;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;82;F;Other Serious (Important Medical Event);COVID-19
189629853;NA;NA;NA;CELGENE;78;F;Other Serious (Important Medical Event);Cytokine release syndrome
189629972;0;Human Immunoglobulin;0;TAKEDA;62;M;NA;Diarrhoea
189635895;Angioimmunoblastic T-cell lymphoma;IPI 145;25;SECURA BIO;47;F;Hospitalization - Initial or Prolonged;Dehydration
189647506;Psoriatic arthropathy;ORENCIA;125;BRISTOL MYERS SQUIBB;58;F;NA;Glucose tolerance impaired
189655263;Cerebrovascular accident prophylaxis;APIXABAN;2.5;BRISTOL MYERS SQUIBB;78;M;Other Serious (Important Medical Event);Gingival bleeding
189660397;Chronic lymphocytic leukaemia;Umbralisib;800;TG THERAPEUTICS;75;M;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
189683045;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;60;M;Hospitalization - Initial or Prolonged;Blood pressure increased
189697582;Multiple sclerosis;OCREVUS;600;ROCHE;45;M;Other Serious (Important Medical Event);Acute respiratory distress syndrome
189703198;Multiple sclerosis;KESIMPTA;20;NOVARTIS;38;F;Hospitalization - Initial or Prolonged;Cough
189719684;Type 2 diabetes mellitus;JARDIANCE;10;BOEHRINGER INGELHEIM;70;F;Hospitalization - Initial or Prolonged;Coronary artery occlusion
189724149;B-cell lymphoma;CARBOPLATIN;384.5;NOVARTIS;72;M;Other Serious (Important Medical Event);Sepsis
189737187;Renal transplant;MYCOPHENOLATE MOFETIL;750;NOVARTIS;56;F;Other Serious (Important Medical Event);Adenovirus infection
189741452;NA;NA;NA;BRISTOL MYERS SQUIBB;71;F;NA;Dry throat
189750548;Unknown;COSENTYX;150;NOVARTIS;66;F;Hospitalization - Initial or Prolonged;Arthralgia
189756248;Hepatocellular carcinoma;ATEZOLIZUMAB;1200;ROCHE;86;M;Other Serious (Important Medical Event);Small intestinal obstruction
189759892;NA;NA;NA;NOVARTIS;56;F;NA;Injection site pruritus
189774323;Sickle cell anaemia with crisis;ADAKVEO;5;NOVARTIS;54;M;Life-Threatening;Back pain
189783142;Unknown;NEXPLANON;1;ORGANON;19;F;NA;Complication of device insertion
189788262;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;70;M;NA;Gout
189799522;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;49;F;NA;COVID-19
189810222;Multiple sclerosis;OCREVUS;600;ROCHE;56;F;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
189813866;Hypertension;AMLODIPINE;5;LUPIN;76;F;Life-Threatening;Blood pressure systolic increased
189820664;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;82;F;Hospitalization - Initial or Prolonged;Anorectal operation
189821302;Pruritus;GADAVIST;10;BAYER;22;F;Other Serious (Important Medical Event);Pruritus
189831533;Gastrointestinal stromal tumour;CABOMETYX;40;EXELIXIS;41;M;Disability;Balance disorder
189845684;Rheumatoid arthritis;RINVOQ;15;ABBVIE;77;F;Death;Back disorder
189855786;Contraception;NEXPLANON;68;ORGANON;18;F;NA;Caesarean section
189882724;Plasma cell myeloma;NINLARO;3;TAKEDA;57;F;NA;Constipation
189891842;Rheumatoid arthritis;ABATACEPT;125;BRISTOL MYERS SQUIBB;68;F;NA;Device breakage
189909273;Seizure;Brivaracetam;100;UCB;81;M;Hospitalization - Initial or Prolonged;COVID-19 immunisation
189909655;Short-bowel syndrome;Teduglutide;2.2;TAKEDA;58;M;Other Serious (Important Medical Event);Abdominal distension
189913687;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;35;F;Other Serious (Important Medical Event);Bacterial vaginosis
189915337;Multiple sclerosis;ZEPOSIA;0.23;CELGENE;43;F;Hospitalization - Initial or Prolonged;Multiple sclerosis
189915977;Atrophic vulvovaginitis;ESTRING;1;PFIZER;71;F;Other Serious (Important Medical Event);Device defective
189926932;Haemorrhoids;PROCTOFOAM HC;1;MYLAN;54;M;NA;Off label use
189927714;Body height abnormal;GENOTROPIN;1.8;PFIZER;10;F;NA;Device issue
189928576;0;Human Immunoglobulin;0;TAKEDA;68;M;Other Serious (Important Medical Event);Ankle operation
189938853;Primary biliary cholangitis;OCALIVA;5;INTERCEPT PHARMACEUTICALS;74;F;Other Serious (Important Medical Event);Abdominal pain upper
189951793;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;83;F;NA;Weight decreased
189965362;Philadelphia positive acute lymphocytic leukaemia;CYTARABINE;150;HIKMA;16;M;Hospitalization - Initial or Prolonged;Appetite disorder
189969212;Idiopathic pulmonary fibrosis;ESBRIET;267;ROCHE;74;F;Other Serious (Important Medical Event);Myocardial infarction
189978562;Acute lymphocytic leukaemia;CYTARABINE;170;HIKMA;17;M;Other Serious (Important Medical Event);Atelectasis
190001952;Unknown;METOPROLOL;100;TOPROL ACQUISITION;66;F;Death;Fracture
190010455;HER2 negative breast cancer;KISQALI;400;NOVARTIS;70;F;Hospitalization - Initial or Prolonged;Pulmonary embolism
190015333;Neurotrophic keratopathy;OXERVATE;1;DOMPE FARMACEUTICI;63;M;NA;Drug ineffective
190024442;Rheumatoid arthritis;ABATACEPT;125;BRISTOL MYERS SQUIBB;61;F;Other Serious (Important Medical Event);Accidental exposure to product
190027973;Contraception;MEDROXYPROGESTERONE ACETATE;150;PFIZER;49;F;NA;Device malfunction
190030003;Mucopolysaccharidosis II;Idursulfase;16;TAKEDA;10;M;Other Serious (Important Medical Event);Blood sodium decreased
190030624;Pulmonary hypertension;SELEXIPAG;200;JOHNSON AND JOHNSON;71;F;Other Serious (Important Medical Event);Pancreatitis
190036962;Adrenocortical carcinoma;OPDIVO;290;BRISTOL MYERS SQUIBB;43;M;Death;Hepatorenal failure
190037325;COVID-19;Bamlanivimab 700mg;700;ELI LILLY AND CO;82;M;Other Serious (Important Medical Event);Cerebral atrophy
190041413;NA;NA;NA;ROCHE;74;F;Hospitalization - Initial or Prolonged;Bladder transitional cell carcinoma
190043996;Idiopathic pulmonary fibrosis;OFEV;150;BOEHRINGER INGELHEIM;84;M;Other Serious (Important Medical Event);Atrioventricular block
190079666;Multiple sclerosis;ZEPOSIA;0.23;CELGENE;47;F;Death;Crohn's disease
190079695;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;46;F;NA;Accidental exposure to product
190087266;Chronic lymphocytic leukaemia;IMBRUVICA;140;ABBVIE;85;F;Hospitalization - Initial or Prolonged;Acute respiratory failure
190088073;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;56;F;NA;Adverse drug reaction
190090237;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;80;F;Other Serious (Important Medical Event);Adverse event
190095602;Leiomyosarcoma;IPILIMUMAB;1;BRISTOL MYERS SQUIBB;67;M;Disability;Lower gastrointestinal haemorrhage
190100843;Unknown;KESIMPTA;20;NOVARTIS;52;F;NA;Arthralgia
190111742;NA;NA;NA;MYLAN;74;M;Hospitalization - Initial or Prolonged;Acute respiratory failure
190115585;Infection prophylaxis;PREVYMIS;480;MERCK;61;F;Other Serious (Important Medical Event);Acute graft versus host disease in intestine
190130033;0;EMTRICITABINE;0;GILEAD;0;F;Other Serious (Important Medical Event);Acoustic stimulation tests abnormal
190146625;Rheumatoid arthritis;HUMIRA;40;ABBVIE;77;F;Other Serious (Important Medical Event);Deafness unilateral
190193193;Still's disease;ILARIS;245;NOVARTIS;32;F;NA;Condition aggravated
190205453;Neuroendocrine tumour;SUTENT;25;PFIZER;69;M;Hospitalization - Initial or Prolonged;Diarrhoea
190207032;NA;NA;NA;BRISTOL MYERS SQUIBB;22;F;Hospitalization - Initial or Prolonged;Arthritis infective
190211063;Pulmonary arterial hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;65;F;Other Serious (Important Medical Event);Hypertensive crisis
190242243;NA;NA;NA;AMGEN;44;F;NA;Off label use
190245883;Multiple sclerosis;KESIMPTA;20;NOVARTIS;49;F;NA;Chills
190265843;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;56;M;Hospitalization - Initial or Prolonged;Hypocalcaemia
190270782;Immunodeficiency common variable;CUVITRU;18;TAKEDA;69;F;Hospitalization - Initial or Prolonged;Hospitalisation
190280822;0;Human Immunoglobulin;0;TAKEDA;27;F;NA;Device infusion issue
190292442;Diabetes mellitus;HUMALOG;3;ELI LILLY AND CO;67;M;Other Serious (Important Medical Event);Asthenia
190295102;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;79;M;Hospitalization - Initial or Prolonged;Death
190323093;NA;NA;NA;TAKEDA;16;M;Hospitalization - Initial or Prolonged;Abdominal distension
190328023;Alcoholism;VIVITROL;380;ALKERMES;53;F;NA;Eczema
190343834;Cardiac failure congestive;ENTRESTO;50;NOVARTIS;86;M;Other Serious (Important Medical Event);Dizziness
190348662;Immune system disorder;Icatibant;30;TAKEDA;37;F;NA;Inappropriate schedule of product administration
190349044;Hereditary angioedema;Lanadelumab;300;TAKEDA;59;F;Other Serious (Important Medical Event);Hereditary angioedema
190353153;Parkinson's disease;INBRIJA;84;ACORDA;74;M;NA;Abdominal pain
190353372;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;58;F;NA;Back pain
190368376;Idiopathic pulmonary fibrosis;OFEV;150;BOEHRINGER INGELHEIM;78;M;Hospitalization - Initial or Prolonged;Cardiomyopathy
190368712;Brain neoplasm malignant;QINLOCK;150;DECIPHERA PHARMACEUTICALS;16;F;Hospitalization - Initial or Prolonged;Abdominal pain
190389618;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;63;F;Other Serious (Important Medical Event);Chronic lymphocytic leukaemia
190392333;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;67;M;Death;Acute kidney injury
190394292;Short-bowel syndrome;Teduglutide;2.8;TAKEDA;52;F;Other Serious (Important Medical Event);Cholangitis acute
190405562;Colorectal cancer metastatic;ATEZOLIZUMAB;840;ROCHE;44;F;Hospitalization - Initial or Prolonged;COVID-19
190406923;NA;NA;NA;TAKEDA;17;M;Hospitalization - Initial or Prolonged;Bronchoscopy abnormal
190420474;Plasma cell myeloma;REVLIMID;10;CELGENE;84;M;Death;Chronic obstructive pulmonary disease
190422012;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;85;M;NA;Product temperature excursion issue
190430292;NA;NA;NA;TAKEDA;65;M;Other Serious (Important Medical Event);Acute kidney injury
190432266;Cardiac failure;ENTRESTO;1;NOVARTIS;51;M;NA;Bursitis
190467702;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;45;F;NA;Abdominal discomfort
190482023;Osteoporosis;Alendronate Sodium Tablets USP 70mg;1;AUROBINDO;65;F;Other Serious (Important Medical Event);Barrett's oesophagus
190487216;Schizoaffective disorder;CLOZAPINE;325;MYLAN;34;M;Other Serious (Important Medical Event);Benign ethnic neutropenia
190487624;Rheumatoid arthritis;ABATACEPT;125;BRISTOL MYERS SQUIBB;75;F;Hospitalization - Initial or Prolonged;Device malfunction
190496813;Plasma cell myeloma;REVLIMID;10;CELGENE;75;F;NA;Chest discomfort
190499602;Colorectal cancer;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;44;M;Other Serious (Important Medical Event);Diarrhoea
190505992;Short-bowel syndrome;Teduglutide;3.5;TAKEDA;60;M;Other Serious (Important Medical Event);Acute kidney injury
190517862;Short-bowel syndrome;Teduglutide;0.05;TAKEDA;56;F;Hospitalization - Initial or Prolonged;Bacteraemia
190523993;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;79;F;Other Serious (Important Medical Event);Atrial fibrillation
190558832;NA;NA;NA;BRISTOL MYERS SQUIBB;83;F;Hospitalization - Initial or Prolonged;Intentional product use issue
190570024;Psoriasis;COSENTYX;300;NOVARTIS;69;F;Other Serious (Important Medical Event);Mycobacterium tuberculosis complex test positive
190572773;Hereditary angioedema;ORLADEYO;150;BIOCRYST PHARMACEUTICALS;69;F;NA;Hereditary angioedema
190578734;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;82;M;Hospitalization - Initial or Prolonged;Immune thrombocytopenia
190584004;Rheumatoid arthritis;SIMPONI ARIA;2;JOHNSON AND JOHNSON;44;F;NA;Wrong product administered
190584452;Short-bowel syndrome;Teduglutide;2.5;TAKEDA;48;M;Hospitalization - Initial or Prolonged;Enterocutaneous fistula
190585462;Factor IX deficiency;ALPROLIX;7000;SANOFI AVENTIS;21;M;NA;Dizziness
190615972;Colon cancer stage III;ATEZOLIZUMAB;840;ROCHE;50;M;Death;Blood lactic acid increased
190619642;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;78;F;NA;Burning sensation
190636664;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;59;F;Other Serious (Important Medical Event);Drug ineffective
190670412;Multiple sclerosis;AUBAGIO;14;SANOFI AVENTIS;45;F;Hospitalization - Initial or Prolonged;Gait disturbance
190671733;Connective tissue disorder;RITUXAN;1000;ROCHE;61;M;Other Serious (Important Medical Event);Death
190677947;Plasma cell myeloma;LENALIDOMIDE;10;CELGENE;76;M;Other Serious (Important Medical Event);Fall
190678139;Idiopathic pulmonary fibrosis;OFEV;200;BOEHRINGER INGELHEIM;76;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
190692452;Short-bowel syndrome;Teduglutide;1.6;TAKEDA;49;M;Hospitalization - Initial or Prolonged;Device related bacteraemia
190698643;Short-bowel syndrome;Teduglutide;2.45;TAKEDA;67;F;Other Serious (Important Medical Event);Constipation
190703435;Plasma cell myeloma;POMALIDOMIDE;3;CELGENE;71;M;Hospitalization - Initial or Prolonged;Guillain-Barre syndrome
190705485;Unknown;NEXPLANON;1;ORGANON;39;F;Hospitalization - Initial or Prolonged;Complication associated with device
190714772;NA;NA;NA;AMGEN;63;M;Other Serious (Important Medical Event);Acute kidney injury
190718492;Contraception;MIRENA;20;BAYER;15;F;NA;Device expulsion
190719782;Contraception;KYLEENA;17.5;BAYER;20;F;Life-Threatening;Abdominal pain
190725562;Liposarcoma metastatic;VOTRIENT;800;NOVARTIS;56;M;NA;Blood pressure increased
190740836;Breast cancer;PALBOCICLIB;125;PFIZER;64;F;Hospitalization - Initial or Prolonged;Embolism
190745153;Contraception;SKYLA;14;BAYER;20;F;NA;Complication of device insertion
190751903;NA;NA;NA;ELI LILLY AND CO;65;F;Other Serious (Important Medical Event);Blood glucose decreased
190759525;Type 2 diabetes mellitus;JARDIANCE;10;BOEHRINGER INGELHEIM;60;F;Other Serious (Important Medical Event);Fournier's gangrene
190780602;Selective IgG subclass deficiency;CUVITRU;10;TAKEDA;63;F;Hospitalization - Initial or Prolonged;Epstein-Barr virus infection
190786435;Unknown;KESIMPTA;20;NOVARTIS;32;F;Other Serious (Important Medical Event);Dizziness
190790314;Short-bowel syndrome;Teduglutide;0.272;TAKEDA;75;F;Other Serious (Important Medical Event);Catheter management
190798834;PIK3CA related overgrowth spectrum;PIQRAY;50;NOVARTIS;6;F;Death;Alanine aminotransferase increased
190805543;Acute myeloid leukaemia;VENETOCLAX;100;ABBVIE;83;F;Hospitalization - Initial or Prolonged;Leukopenia
190805745;Plasma cell myeloma;POMALIDOMIDE;4;CELGENE;50;F;Hospitalization - Initial or Prolonged;Peripheral motor neuropathy
190805914;Unknown;MIRCERA;150;VIFOR;46;F;Disability;Drug hypersensitivity
190805945;Immunodeficiency common variable;CUVITRU;32;TAKEDA;66;M;Other Serious (Important Medical Event);Chronic kidney disease
190810522;NA;NA;NA;PFIZER;52;M;Hospitalization - Initial or Prolonged;Deep vein thrombosis
190824755;Psoriasis;COSENTYX;300;NOVARTIS;84;F;Other Serious (Important Medical Event);Aortic occlusion
190834963;Rheumatoid arthritis;XELJANZ;5;PFIZER;54;F;Other Serious (Important Medical Event);Deep vein thrombosis
190837544;Clinically isolated syndrome;MAYZENT;2;NOVARTIS;62;F;Other Serious (Important Medical Event);Dizziness
190838542;Rheumatoid arthritis;XELJANZ;5;PFIZER;57;F;Hospitalization - Initial or Prolonged;Deep vein thrombosis
190838572;NA;NA;NA;PFIZER;63;F;Life-Threatening;Deep vein thrombosis
190840433;Rheumatoid arthritis;XELJANZ;5;PFIZER;69;F;Hospitalization - Initial or Prolonged;Deep vein thrombosis
190847514;Epilepsy;PERAMPANEL;0.5;EISAI;2;M;Other Serious (Important Medical Event);Encephalopathy
190848264;Contraception;NEXPLANON;1;ORGANON;16;F;Hospitalization - Initial or Prolonged;Caesarean section
190853103;COVID-19;Bamlanivimab 700mg;700;ELI LILLY AND CO;86;M;Other Serious (Important Medical Event);Acute kidney injury
190854602;Invasive breast carcinoma;BLINDED Placebo for Tucatinib;300;SEATTLE GENETICS;47;F;Other Serious (Important Medical Event);Platelet count decreased
190857732;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;83;M;Other Serious (Important Medical Event);Death
190858654;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;88;M;NA;Back pain
190864244;Chronic hepatitis C;EPCLUSA;1;GILEAD;7;F;NA;Abdominal discomfort
190871294;Immune system disorder;Icatibant;30;TAKEDA;42;F;Hospitalization - Initial or Prolonged;COVID-19
190885562;NA;NA;NA;ABBVIE;42;F;Other Serious (Important Medical Event);Acute kidney injury
190887674;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;66;F;NA;Accidental exposure to product
190897142;Immunodeficiency common variable;CUVITRU;20;TAKEDA;45;M;Other Serious (Important Medical Event);Bone operation
190898977;Psoriasis;STELARA;45;JOHNSON AND JOHNSON;64;M;NA;Product container seal issue
190904443;Colon cancer;OPDIVO;181.5;BRISTOL MYERS SQUIBB;51;M;Hospitalization - Initial or Prolonged;Death
190915932;COVID-19;Bamlanivimab 700mg;700;ELI LILLY AND CO;62;F;Other Serious (Important Medical Event);Acute kidney injury
190926348;Multiple sclerosis;TYSABRI;300;BIOGEN;49;M;Death;Blood loss anaemia
190930544;Thrombosis prophylaxis;APIXABAN;5;BRISTOL MYERS SQUIBB;62;M;Hospitalization - Initial or Prolonged;Anaemia
190930624;Plasma cell myeloma;NINLARO;3;TAKEDA;70;F;NA;Ageusia
190931613;Psoriasis;Certolizumab pegol;400;UCB;64;F;Other Serious (Important Medical Event);Injection site bruising
190949534;Phenylketonuria;PALYNZIQ;30;BIOMARIN;34;F;Other Serious (Important Medical Event);Foot operation
190951192;Prostate cancer metastatic;ABIRATERONE ACETATE;1000;JOHNSON AND JOHNSON;72;M;Other Serious (Important Medical Event);Pulmonary embolism
190957092;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;69;M;NA;Gait disturbance
190963234;Neurofibromatosis;Brigatinib;180;TAKEDA;64;F;NA;Adverse event
190967362;Turner's syndrome;GENOTROPIN;2;PFIZER;11;F;NA;Device breakage
190974845;Carcinoid tumour of the duodenum;LUTATHERA;202.47;NOVARTIS;85;F;Hospitalization - Initial or Prolonged;Blood creatinine increased
190988022;Contraception;MIRENA;20;BAYER;37;F;NA;Abdominal pain
190994874;Seizure;ONFI;20;LUNDBECK;32;M;Other Serious (Important Medical Event);Bronchitis
190997318;Neutropenia;NEULASTA;6;AMGEN;57;F;NA;Wrong technique in product usage process
190997992;Philadelphia positive acute lymphocytic leukaemia;CYTARABINE;150;HIKMA;16;M;Hospitalization - Initial or Prolonged;Abdominal tenderness
191006083;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;71;F;NA;Device delivery system issue
191009785;K-ras gene mutation;ATEZOLIZUMAB;1200;ROCHE;72;F;Other Serious (Important Medical Event);Non-small cell lung cancer
191018052;Renal cell carcinoma;OPDIVO;480;BRISTOL MYERS SQUIBB;58;M;Other Serious (Important Medical Event);Neurotoxicity
191018845;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;53;F;Hospitalization - Initial or Prolonged;Fatigue
191033754;Adenocarcinoma of colon;ATEZOLIZUMAB;840;ROCHE;79;F;Hospitalization - Initial or Prolonged;Colitis
191037842;Unknown;CUVITRU;14;TAKEDA;53;F;NA;Respiratory disorder
191039614;Chronic lymphocytic leukaemia;Umbralisib;800;TG THERAPEUTICS;84;M;Hospitalization - Initial or Prolonged;Asthma
191039663;Rheumatoid arthritis;XELJANZ XR;1;PFIZER;78;F;Other Serious (Important Medical Event);Cerebrovascular accident
191049254;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;76;F;Death;COVID-19 pneumonia
191059062;Chemotherapy;LEUCOVORIN;750;HIKMA;73;F;Hospitalization - Initial or Prolonged;Delirium
191061494;Crohn's disease;HUMIRA;40;ABBVIE;45;F;Life-Threatening;Colitis
191069508;Skin cancer;ATEZOLIZUMAB;1200;ROCHE;53;M;Other Serious (Important Medical Event);Abdominal pain
191093314;Lung neoplasm malignant;Brigatinib;90;TAKEDA;73;F;NA;Abdominal distension
191095313;Giant cell arteritis;ACTEMRA;162;ROCHE;77;M;Hospitalization - Initial or Prolonged;Hepatic cirrhosis
191100083;Crohn's disease;REMICADE;10;JOHNSON AND JOHNSON;43;F;Other Serious (Important Medical Event);Drug specific antibody
191100562;Seronegative arthritis;XELJANZ;5;PFIZER;64;F;NA;Insomnia
191125386;Acute myeloid leukaemia;CC 90009;3;CELGENE;80;F;Other Serious (Important Medical Event);Sepsis
191132943;Spinal muscular atrophy;ZOLGENSMA;5;NOVARTIS;0;M;NA;Hepatic enzyme increased
191167412;Deep vein thrombosis;ELIQUIS;5;BRISTOL MYERS SQUIBB;78;F;Other Serious (Important Medical Event);Arthritis
191173484;Phenylketonuria;PALYNZIQ;40;BIOMARIN;15;M;Hospitalization - Initial or Prolonged;Chest discomfort
191195562;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;76;M;Death;Asthenia
191208162;Psoriasis;COSENTYX;300;NOVARTIS;61;M;NA;Diarrhoea
191208283;Contraception;KYLEENA;17.5;BAYER;19;F;Other Serious (Important Medical Event);Drug ineffective
191208952;Short-bowel syndrome;Teduglutide;0.45;TAKEDA;67;F;Other Serious (Important Medical Event);Abdominal distension
191232666;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;101;F;Hospitalization - Initial or Prolonged;Asthenia
191242362;NA;NA;NA;UNITED THERAPEUTICS;64;M;Other Serious (Important Medical Event);Gastric infection
191249743;Multiple sclerosis;OCREVUS;600;ROCHE;63;F;Hospitalization - Initial or Prolonged;Hepatic infection
191257682;Schizophrenia;CAPLYTA;42;INTRA-CELLULAR THERAPIES;20;M;NA;Diarrhoea
191267622;Psoriasis;COSENTYX;300;NOVARTIS;41;F;NA;Incorrect route of product administration
191305203;Plasma cell myeloma;CC 4047;3;CELGENE;78;M;Other Serious (Important Medical Event);Myelodysplastic syndrome
191305665;Breast cancer metastatic;PIQRAY;150;NOVARTIS;64;F;Other Serious (Important Medical Event);Asthenia
191316745;Relapsing multiple sclerosis;KESIMPTA;20;NOVARTIS;49;F;Disability;Cerebrovascular accident
191324093;Pulmonary arterial hypertension;UPTRAVI;400;JOHNSON AND JOHNSON;75;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
191338532;Plasma cell myeloma;NINLARO;3;TAKEDA;74;F;Other Serious (Important Medical Event);Asthenia
191341113;Familial mediterranean fever;ILARIS;32;NOVARTIS;5;F;NA;Weight increased
191342032;Neuralgia;LYRICA CR;165;PFIZER;69;F;NA;Headache
191390133;Breast cancer;KISQALI;400;NOVARTIS;75;F;Hospitalization - Initial or Prolonged;Compression fracture
191416352;NA;NA;NA;AMERICAN REGENT;35;F;Other Serious (Important Medical Event);Abdominal pain
191416863;Pulmonary fibrosis;OFEV;150;BOEHRINGER INGELHEIM;54;F;Other Serious (Important Medical Event);Anxiety
191423682;Plasma cell myeloma;REVLIMID;10;CELGENE;80;M;NA;Rash
191423853;Squamous cell carcinoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;87;M;Death;Dyspnoea
191431514;Hormone-refractory prostate cancer;XL184;40;EXELIXIS;66;M;Disability;Atrial fibrillation
191441433;Migraine;AJOVY;675;TEVA;54;F;NA;Dyspnoea
191441713;Ovarian cancer;ATEZOLIZUMAB;1200;ROCHE;58;F;Hospitalization - Initial or Prolonged;Abdominal pain
191443083;Metastatic malignant melanoma;OPDIVO;120;BRISTOL MYERS SQUIBB;43;F;Other Serious (Important Medical Event);Infusion related reaction
191462352;NA;NA;NA;TAKEDA;55;F;Other Serious (Important Medical Event);Antinuclear antibody increased
191466624;Pulmonary hypertension;UPTRAVI;1600;JOHNSON AND JOHNSON;12;M;Hospitalization - Initial or Prolonged;Catheter site erythema
191478802;Renal transplant;NULOJIX;500;BRISTOL MYERS SQUIBB;58;F;NA;Product storage error
191483603;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;67;F;NA;Rash pruritic
191484944;Multiple sclerosis;KESIMPTA;20;NOVARTIS;50;F;NA;Chest discomfort
191493692;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;74;M;NA;Weight decreased
191498954;Seizure;Brivaracetam;150;UCB;67;M;Other Serious (Important Medical Event);Fall
191500326;Cardiac failure;ENTRESTO;50;NOVARTIS;66;F;Hospitalization - Initial or Prolonged;Chest pain
191500394;Unknown;KESIMPTA;20;NOVARTIS;54;F;Other Serious (Important Medical Event);Inappropriate schedule of product administration
191513176;Type 2 diabetes mellitus;Semaglutide 14 mg;14;NOVO NORDISK;71;M;Hospitalization - Initial or Prolonged;Acute kidney injury
191518662;Adenocarcinoma of colon;ATEZOLIZUMAB;840;ROCHE;25;M;Hospitalization - Initial or Prolonged;COVID-19
191532443;Carnitine palmitoyltransferase deficiency;DOJOLVI;10;ULTRAGENYX PHARMACEUTICAL;15;F;Other Serious (Important Medical Event);Blood test
191546158;NA;NA;NA;BRISTOL MYERS SQUIBB;29;F;Life-Threatening;Anaemia
191554132;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;71;M;Other Serious (Important Medical Event);Pancreatic carcinoma
191566592;Parkinson's disease;NUPLAZID;34;ACADIA PHARMACEUTICALS;63;M;NA;Abnormal behaviour
191572914;Multiple sclerosis;MAYZENT;1;NOVARTIS;59;M;Hospitalization - Initial or Prolonged;Accident at work
191574712;0;Human Immunoglobulin;0;TAKEDA;75;M;Hospitalization - Initial or Prolonged;Hip arthroplasty
191587503;Plasma cell myeloma;Ixazomib;4;TAKEDA;71;M;Other Serious (Important Medical Event);Acute respiratory failure
191589533;Hereditary angioedema;Lanadelumab;300;TAKEDA;67;F;Other Serious (Important Medical Event);Cancer surgery
191592983;Hypothyroidism;Parathyroid Hormone;100;TAKEDA;36;F;Hospitalization - Initial or Prolonged;Central venous catheterisation
191599903;Iron deficiency;VENOFER;100;AMERICAN REGENT;46;F;Other Serious (Important Medical Event);Drug hypersensitivity
191606832;Psoriasis;STELARA;45;JOHNSON AND JOHNSON;11;F;NA;Off label use
191613025;Breast cancer metastatic;Trastuzumab Emtansine;3.6;ROCHE;65;F;Other Serious (Important Medical Event);Confusional state
191615685;Gastrointestinal carcinoma;TAS 102;50;TAIHO ONCOLOGY INC;73;F;Other Serious (Important Medical Event);Anaemia
191619203;Crohn's disease;STELARA;520;JOHNSON AND JOHNSON;43;F;NA;Burning sensation
191624714;Psoriatic arthropathy;HUMIRA;40;ABBVIE;66;F;Other Serious (Important Medical Event);Back pain
191638352;Non-small cell lung cancer;ATEZOLIZUMAB;840;ROCHE;77;M;Hospitalization - Initial or Prolonged;Colitis
191640363;Metastatic neoplasm;ATEZOLIZUMAB;1200;ROCHE;66;M;Other Serious (Important Medical Event);Complication associated with device
191642253;Non-small cell lung cancer;COBIMETINIB;40;ROCHE;49;M;Hospitalization - Initial or Prolonged;Pleural effusion
191644776;NA;NA;NA;NOVARTIS;74;M;Hospitalization - Initial or Prolonged;Abdominal pain
191648622;Skin ulcer;NUZYRA;300;PARATEK PHARMACEUTICALS;51;F;NA;Blood alkaline phosphatase increased
191650012;Unknown;ZYTIGA;1000;JOHNSON AND JOHNSON;91;M;Other Serious (Important Medical Event);Hypoxia
191653842;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;90;F;Other Serious (Important Medical Event);Cardiac failure
191656412;Severe myoclonic epilepsy of infancy;FINTEPLA;6;ZOGENIX;23;M;Other Serious (Important Medical Event);Aphasia
191656592;Severe myoclonic epilepsy of infancy;FINTEPLA;4.9;ZOGENIX;17;F;NA;Decreased appetite
191656802;Lennox-Gastaut syndrome;FINTEPLA;2.7;ZOGENIX;13;M;Other Serious (Important Medical Event);Decreased appetite
191657482;Amyloidosis;VYNDAMAX;1;PFIZER;84;M;Hospitalization - Initial or Prolonged;Death
191659234;Lupus nephritis;LUPKYNIS;23.7;AURINIA PHARMACEUTICALS;40;F;Hospitalization - Initial or Prolonged;Angioedema
191659905;NA;NA;NA;NOVARTIS;74;F;Death;Blood glucose increased
191661293;Plasma cell myeloma;NINLARO;4;TAKEDA;60;F;Other Serious (Important Medical Event);Asthenia
191661492;Crohn's disease;HUMIRA;40;ABBVIE;83;F;Other Serious (Important Medical Event);Anaemia
191662162;Hypoparathyroidism;Parathyroid Hormone;100;TAKEDA;42;F;Hospitalization - Initial or Prolonged;Hydronephrosis
191662584;Diffuse large B-cell lymphoma;IBRUTINIB;560;ABBVIE;57;U;Other Serious (Important Medical Event);Drug reaction with eosinophilia and systemic symptoms
191664654;Non-small cell lung cancer;XL184;60;EXELIXIS;61;F;Hospitalization - Initial or Prolonged;Deep vein thrombosis
191667893;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;60;F;Other Serious (Important Medical Event);Dehydration
191668213;Acute myeloid leukaemia;IDHIFA;100;CELGENE;83;F;NA;Fatigue
191669682;Hypertension;AMLODIPINE W/VALSARTAN TEVA;1;TEVA;58;M;Hospitalization - Initial or Prolonged;Adenocarcinoma of colon
191676287;Colorectal cancer;COBIMETINIB;40;ROCHE;53;M;Other Serious (Important Medical Event);Anaemia
191677604;NA;NA;NA;CLINIGEN;66;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
191684612;Multiple sclerosis;REBIF;44;EMD SERONO INC;53;M;Other Serious (Important Medical Event);Atelectasis
191688602;Type 2 diabetes mellitus;TRULICITY;1.5;ELI LILLY AND CO;66;F;Other Serious (Important Medical Event);Activated partial thromboplastin time prolonged
191698602;Breast cancer female;IBRANCE;125;PFIZER;59;F;NA;Constipation
191705562;Plasma cell myeloma;REVLIMID;25;CELGENE;63;F;Hospitalization - Initial or Prolonged;Arthralgia
191720855;Unknown;KESIMPTA;20;NOVARTIS;57;F;NA;Appetite disorder
191721914;Muscular weakness;PYRIDOSTIGMINE BROMIDE TABLETS;2;BAUSCH AND LOMB;55;F;NA;Abdominal pain upper
191722032;Unknown;KESIMPTA;20;NOVARTIS;49;F;NA;Headache
191723132;Colon cancer stage III;ATEZOLIZUMAB;840;ROCHE;71;M;Other Serious (Important Medical Event);Acute kidney injury
191739953;Chronic lymphocytic leukaemia;Umbralisib;800;TG THERAPEUTICS;67;M;Hospitalization - Initial or Prolonged;Small intestinal obstruction
191745642;Triple negative breast cancer;BYL719;300;NOVARTIS;26;F;Life-Threatening;Back pain
191746112;Endometriosis;ORILISSA;150;ABBVIE;30;F;NA;Abnormal uterine bleeding
191753934;Trisomy 21;SYNAGIS;15;BIOVITRUM;1;M;Hospitalization - Initial or Prolonged;Abdominal discomfort
191763904;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;78;M;Other Serious (Important Medical Event);Failure to thrive
191774278;Neutropenia;NEULASTA;6;AMGEN;44;F;NA;Device occlusion
191781354;Rheumatoid arthritis;RINVOQ;15;ABBVIE;52;F;Hospitalization - Initial or Prolonged;Acute kidney injury
191794856;Ovarian cancer;Niraparib;100;GLAXOSMITHKLINE;67;F;Other Serious (Important Medical Event);Pneumocystis jirovecii pneumonia
191799292;Contraception;MIRENA;20;BAYER;35;F;NA;Complication of device insertion
191800912;Thyroid cancer;CAPRELSA;200;SANOFI AVENTIS;22;F;Hospitalization - Initial or Prolonged;Acne
191801654;Fabry's disease;GALAFOLD;123;AMICUS THERAPEUTICS;44;F;Other Serious (Important Medical Event);Anger
191805032;Renal cancer;SUTENT;50;PFIZER;46;M;Hospitalization - Initial or Prolonged;Arthralgia
191814453;NA;NA;NA;BAYER;49;M;Other Serious (Important Medical Event);Diabetes mellitus
191818204;Blepharitis;TOBRAMYCIN AND DEXAMETHASONE;1;BAUSCH AND LOMB;70;F;NA;Dizziness
191820563;Ankylosing spondylitis;HUMIRA;40;ABBVIE;76;F;Hospitalization - Initial or Prolonged;Gene mutation
191824043;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;80;M;NA;Agitation
191826865;Lung squamous cell carcinoma metastatic;Brigatinib;90;TAKEDA;76;F;NA;Abdominal distension
191828396;Psoriasis;COSENTYX;150;NOVARTIS;52;F;Hospitalization - Initial or Prolonged;Deafness
191845727;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;58;F;Other Serious (Important Medical Event);Asthenia
191854894;Breast cancer metastatic;IBRANCE;125;PFIZER;50;F;NA;Alopecia
191857982;Bipolar disorder;CAPLYTA;42;INTRA-CELLULAR THERAPIES;24;F;Hospitalization - Initial or Prolonged;Off label use
191858095;NA;NA;NA;NOVARTIS;54;M;Hospitalization - Initial or Prolonged;Asthenia
191859253;Bladder cancer;ATEZOLIZUMAB;1200;ROCHE;42;M;Other Serious (Important Medical Event);Lymphocyte count decreased
191861866;Chronic lymphocytic leukaemia;IMBRUVICA;280;ABBVIE;85;F;Hospitalization - Initial or Prolonged;Agitation
191863392;Psoriasis;TALTZ;80;ELI LILLY AND CO;17;M;Hospitalization - Initial or Prolonged;Pancreatitis acute
191863604;Immune system disorder;Lanadelumab;300;TAKEDA;22;F;Other Serious (Important Medical Event);Allergy to vaccine
191867212;NA;NA;NA;AMERICAN REGENT;50;F;Other Serious (Important Medical Event);Anhedonia
191868592;Psoriasis;COSENTYX;300;NOVARTIS;64;M;Hospitalization - Initial or Prolonged;COVID-19
191871822;NA;NA;NA;BIOGEN;48;M;Hospitalization - Initial or Prolonged;Gait inability
191872752;Myelodysplastic syndrome;REVLIMID;10;CELGENE;64;M;NA;Diarrhoea
191876094;Pulmonary arterial hypertension;TRACLEER;125;JOHNSON AND JOHNSON;73;F;Hospitalization - Initial or Prolonged;Large intestine polyp
191878812;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;73;F;NA;Abscess limb
191880893;Psoriasis;COSENTYX;150;NOVARTIS;63;F;NA;COVID-19
191882033;Ovarian cancer;ATEZOLIZUMAB;800;ROCHE;73;F;Other Serious (Important Medical Event);Asthenia
191882465;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;69;F;Other Serious (Important Medical Event);Febrile neutropenia
191884932;Plasma cell myeloma recurrent;REVLIMID;10;CELGENE;75;M;Other Serious (Important Medical Event);Plasma cell myeloma recurrent
191885283;Plasma cell myeloma;POMALYST;4;CELGENE;68;F;Other Serious (Important Medical Event);Death
191891042;Long-chain acyl-coenzyme A dehydrogenase deficiency;DOJOLVI;20;ULTRAGENYX PHARMACEUTICAL;16;M;NA;Abdominal pain upper
191891692;Contraception;DEPO PROVERA;1;PFIZER;14;F;NA;Inappropriate schedule of product administration
191892672;Epithelioid mesothelioma;OPDIVO;196;BRISTOL MYERS SQUIBB;72;M;Hospitalization - Initial or Prolonged;Back pain
191893042;Malignant melanoma;RITUXIMAB;375;ROCHE;69;F;Other Serious (Important Medical Event);Ischaemia
191898572;Plasma cell myeloma;Selinexor;60;KARYOPHARM THERAPEUTICS;54;M;Other Serious (Important Medical Event);Asthenia
191913004;Unknown;Tolvaptan;45;OTSUKA;56;M;Hospitalization - Initial or Prolonged;Abdominal pain
191913102;Malignant melanoma;NIVOLUMAB;100;BRISTOL MYERS SQUIBB;81;M;Other Serious (Important Medical Event);Costochondritis
191916592;Type 2 diabetes mellitus;TRULICITY;0.75;ELI LILLY AND CO;66;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
191917003;Dyskinesia;GOCOVRI;137;ADAMAS PHARMA;68;F;Disability;Acute kidney injury
191922622;Plasma cell myeloma;REVLIMID;25;CELGENE;75;F;Other Serious (Important Medical Event);Muscle spasms
191923505;Urinary tract infection;Sulfamethoxazole and Trimethoprim Tablets USP 800/160 mg;1;AUROBINDO;65;M;Hospitalization - Initial or Prolonged;Blood urine present
191927353;Sickle cell anaemia;ADAKVEO;275;NOVARTIS;30;M;NA;Chest pain
191937962;Contraception;MIRENA;20;BAYER;21;F;Other Serious (Important Medical Event);Abdominal pain
191938013;Contraception;KYLEENA;17.5;BAYER;19;F;Hospitalization - Initial or Prolonged;Complication of device insertion
191941253;Growth hormone deficiency;GENOTROPIN;0.7;PFIZER;9;F;NA;Device mechanical issue
191945955;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;70;M;Other Serious (Important Medical Event);Dizziness
191948005;Malignant peritoneal neoplasm;Niraparib;200;GLAXOSMITHKLINE;67;F;Hospitalization - Initial or Prolonged;Constipation
191948042;Systemic lupus erythematosus;Belimumab;10;GLAXOSMITHKLINE;0;M;Other Serious (Important Medical Event);Congenital torticollis
191948654;Hypophosphatasia;STRENSIQ;120;ALEXION;50;F;NA;Anxiety
191952122;Magnetic resonance imaging abdominal;DOTAREM;20;GUERBET;45;M;NA;Pruritus
191955442;Acute lymphocytic leukaemia;MERCAPTOPURINE;75;HIKMA;18;M;Other Serious (Important Medical Event);Basophil count decreased
191957268;Breast cancer metastatic;IBRANCE;75;PFIZER;85;F;Hospitalization - Initial or Prolonged;Alopecia
191961272;Plasma cell myeloma;POMALYST;4;CELGENE;90;F;NA;Back pain
191965453;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;76;M;Other Serious (Important Medical Event);Nephrolithiasis
191973485;Immune system disorder;Icatibant;30;TAKEDA;65;F;Other Serious (Important Medical Event);Cataract
191999383;Short stature;GENOTROPIN;1.8;PFIZER;13;M;NA;Device information output issue
192014502;Drug dependence;VIVITROL;380;ALKERMES;21;M;NA;General physical condition abnormal
192017772;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;64;F;Death;Abscess
192020213;Psoriasis;OTEZLA;30;AMGEN;45;M;Other Serious (Important Medical Event);Cerebral cyst
192021052;Soft tissue neoplasm;TURALIO;200;DAIICHI;53;F;NA;No adverse event
192025186;Breast cancer;Dostarlimab;500;GLAXOSMITHKLINE;39;F;Hospitalization - Initial or Prolonged;Rash
192027592;Papillary thyroid cancer;TAFINLAR;100;NOVARTIS;98;F;Other Serious (Important Medical Event);Acute kidney injury
192036485;Neutropenia;NEULASTA;6;AMGEN;38;F;NA;Device malfunction
192063452;Psoriasis;COSENTYX;150;NOVARTIS;41;F;Hospitalization - Initial or Prolonged;COVID-19
192064496;Unknown;KESIMPTA;20;NOVARTIS;46;M;NA;Feeling abnormal
192065123;Chordoma;OPDIVO;41;BRISTOL MYERS SQUIBB;5;M;Other Serious (Important Medical Event);Intentional product use issue
192068803;Carcinoid tumour;REVLIMID;20;CELGENE;61;M;Hospitalization - Initial or Prolonged;Diarrhoea
192073682;Type 2 diabetes mellitus;OZEMPIC;0.25;NOVO NORDISK;68;M;Other Serious (Important Medical Event);Bacteriuria
192073862;Chronic kidney disease;CUVITRU;6;TAKEDA;10;M;Other Serious (Important Medical Event);Kidney transplant rejection
192081362;Weight decreased;QSYMIA;1;VIVUS;59;F;Other Serious (Important Medical Event);Arrhythmia
192082532;Pulmonary arterial hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;65;F;Other Serious (Important Medical Event);Hypotension
192088762;Rheumatoid arthritis;HUMIRA;40;ABBVIE;65;F;Hospitalization - Initial or Prolonged;Blood glucose decreased
192103299;Diffuse large B-cell lymphoma;MOSUNETUZUMAB;5;ROCHE;78;M;Life-Threatening;Oedema peripheral
192103952;Nerve compression;PREGABALIN;100;DR REDDYS;65;M;Hospitalization - Initial or Prolonged;Arthralgia
192108503;Type 2 diabetes mellitus;BASAGLAR;10;ELI LILLY AND CO;82;M;Hospitalization - Initial or Prolonged;Hepatic cancer
192123044;Nephroblastoma;PALBOCICLIB;75;PFIZER;7;F;Other Serious (Important Medical Event);Shock
192124654;NA;NA;NA;ROCHE;84;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
192131448;Lysosomal acid lipase deficiency;KANUMA;40;ALEXION;3;F;Other Serious (Important Medical Event);Bacteraemia
192134502;Immune system disorder;Icatibant;30;TAKEDA;57;M;Hospitalization - Initial or Prolonged;Hereditary angioedema
192135086;Plasma cell myeloma;NINLARO;4;TAKEDA;73;F;Other Serious (Important Medical Event);Illness
192137702;Leiomyosarcoma;NIVOLUMAB;208;BRISTOL MYERS SQUIBB;56;F;Other Serious (Important Medical Event);Intentional product use issue
192145533;Contraception;NEXPLANON;1;ORGANON;24;F;Hospitalization - Initial or Prolonged;Capsular contracture associated with implant
192152732;Phenylketonuria;PALYNZIQ;20;BIOMARIN;40;M;Hospitalization - Initial or Prolonged;Blood potassium decreased
192155063;Crohn's disease;HUMIRA;40;ABBVIE;66;F;Other Serious (Important Medical Event);Abdominal pain
192174342;Pulmonary arterial hypertension;BOSENTAN;62.5;HIKMA;12;M;NA;Pharyngitis
192180184;NA;NA;NA;CELGENE;66;F;Other Serious (Important Medical Event);Gastroenteritis norovirus
192185334;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;63;F;NA;Device defective
192197493;Rheumatoid arthritis;CIMZIA;400;UCB;57;F;Life-Threatening;Pruritus
192212693;Acute lymphocytic leukaemia;PREDNISONE TABLETS USP;40;NOVARTIS;80;M;Hospitalization - Initial or Prolonged;Asthenia
192217512;Rheumatoid arthritis;HUMIRA;40;ABBVIE;61;F;Hospitalization - Initial or Prolonged;Systemic lupus erythematosus rash
192224262;Plasma cell myeloma;REVLIMID;5;CELGENE;83;M;Other Serious (Important Medical Event);Death
192226883;Recurrent cancer;VENETOCLAX;170;ABBVIE;11;M;Hospitalization - Initial or Prolonged;Anaemia
192229584;Non-small cell lung cancer stage IV;KEYTRUDA;200;MERCK;66;F;Other Serious (Important Medical Event);Abdominal pain upper
192238882;Atrial fibrillation;XARELTO;15;JOHNSON AND JOHNSON;76;M;Hospitalization - Initial or Prolonged;Atrial thrombosis
192256853;Menopausal symptoms;ESTRING;2;PFIZER;65;F;NA;Abdominal distension
192262383;Primary immunodeficiency syndrome;GAMUNEX C;10;GRIFOLS;41;F;Other Serious (Important Medical Event);Cough
192269172;Unknown;ASPIRIN (CARDIO);1;BAYER;76;M;Congenital Anomaly;Chest discomfort
192276127;NA;NA;NA;UNITED THERAPEUTICS;58;F;Other Serious (Important Medical Event);Dyspnoea
192277352;Unknown;CARVEDILOL;6.25;GLAXOSMITHKLINE;68;F;Death;Acute kidney injury
192289633;Cardiac failure;ENTRESTO;50;NOVARTIS;64;M;Hospitalization - Initial or Prolonged;Acute kidney injury
192290564;Multiple sclerosis;KESIMPTA;20;NOVARTIS;56;F;NA;Asthenia
192297605;Unknown;KESIMPTA;20;NOVARTIS;43;F;NA;Abdominal discomfort
192304644;Chronic lymphocytic leukaemia;OBINUTUZUMAB;1000;ROCHE;61;F;Hospitalization - Initial or Prolonged;Subdural haematoma
192305292;Renal cell carcinoma;NIVOLUMAB;889.2;BRISTOL MYERS SQUIBB;56;F;Other Serious (Important Medical Event);Sepsis
192309073;Iron deficiency anaemia;INJECTAFER;750;AMERICAN REGENT;42;F;Hospitalization - Initial or Prolonged;Anhedonia
192310323;Prostate cancer metastatic;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;72;M;Other Serious (Important Medical Event);Cerebrovascular accident
192313773;Malignant melanoma;BLINDED NIVOLUMAB;100;BRISTOL MYERS SQUIBB;81;M;Other Serious (Important Medical Event);Dehydration
192321523;Psychotic disorder;GEODON;60;PFIZER;65;F;Hospitalization - Initial or Prolonged;Hyponatraemia
192328095;Chronic lymphocytic leukaemia;VENETOCLAX;20;ROCHE;75;M;Hospitalization - Initial or Prolonged;Asthenia
192329548;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;75;M;Other Serious (Important Medical Event);Acute kidney injury
192340314;Seizure;LACOSAMIDE;200;UCB;53;M;Hospitalization - Initial or Prolonged;Cerebrovascular accident
192342112;Type 2 diabetes mellitus;JARDIANCE;10;BOEHRINGER INGELHEIM;72;F;Life-Threatening;Abscess
192342604;Plasma cell myeloma;NINLARO;2.3;TAKEDA;77;M;Other Serious (Important Medical Event);Balance disorder
192343886;Crohn's disease;STELARA;520;JOHNSON AND JOHNSON;51;F;Other Serious (Important Medical Event);Chest discomfort
192344663;Rheumatoid arthritis;Certolizumab pegol;200;UCB;57;F;Hospitalization - Initial or Prolonged;Hot flush
192351173;Contraception;NEXPLANON;1;ORGANON;32;F;Hospitalization - Initial or Prolonged;Complication associated with device
192357232;Psoriatic arthropathy;ORENCIA;125;BRISTOL MYERS SQUIBB;41;M;NA;Device malfunction
192361444;NA;NA;NA;UNITED THERAPEUTICS;57;M;Other Serious (Important Medical Event);Cardiac failure
192361702;Haematological malignancy;Belinostat IND;1297.5;AUROBINDO;69;F;Hospitalization - Initial or Prolonged;Diarrhoea
192365654;Plasma cell myeloma;POMALYST;4;CELGENE;77;M;Other Serious (Important Medical Event);Malaise
192369044;NA;NA;NA;GLAXOSMITHKLINE;55;F;Hospitalization - Initial or Prolonged;Dyspnoea
192379763;Alcoholism;VIVITROL;380;ALKERMES;40;F;NA;Abdominal distension
192380172;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;48;F;Other Serious (Important Medical Event);Bronchitis
192383773;Malignant melanoma;ATEZOLIZUMAB;1200;ROCHE;74;F;Other Serious (Important Medical Event);Cytokine release syndrome
192389824;NA;NA;NA;GLAXOSMITHKLINE;67;F;Death;Platelet count decreased
192390832;Plasma cell myeloma;NINLARO;3;TAKEDA;71;F;Other Serious (Important Medical Event);Hospitalisation
192392682;Contraception;NEXPLANON;68;ORGANON;19;F;NA;Device breakage
192394085;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;73;F;Other Serious (Important Medical Event);Arthralgia
192399262;Multiple sclerosis;TYSABRI;300;BIOGEN;53;F;Other Serious (Important Medical Event);Major depression
192399272;Multiple sclerosis;TECFIDERA;120;BIOGEN;41;F;NA;Diarrhoea
192401413;Hepatocellular carcinoma;ATEZOLIZUMAB;1200;ROCHE;73;M;Other Serious (Important Medical Event);Gout
192401873;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;75;M;NA;Anaemia
192402282;Plasma cell myeloma;REVLIMID;25;CELGENE;65;F;NA;Neutrophil count decreased
192403733;Ankylosing spondylitis;Certolizumab pegol;400;UCB;63;F;Other Serious (Important Medical Event);Chest pain
192403823;Cerebrovascular accident prophylaxis;ELIQUIS;2.5;BRISTOL MYERS SQUIBB;84;F;Hospitalization - Initial or Prolonged;Cholangiocarcinoma
192412242;Non-small cell lung cancer;ATEZOLIZUMAB;1680;ROCHE;73;F;Hospitalization - Initial or Prolonged;Cerebrovascular accident
192412393;Factor VIII deficiency;HEMLIBRA;175.8;ROCHE;69;F;Other Serious (Important Medical Event);Alopecia
192413554;B precursor type acute leukaemia;blinatumomab;15;AMGEN;16;F;Death;Acute kidney injury
192415584;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;75;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
192428374;Psoriasis;HUMIRA;40;ABBVIE;66;F;Other Serious (Important Medical Event);Asthenia
192430883;Myelosuppression;COSELA;465;G1 THERAPEUTICS;67;M;Hospitalization - Initial or Prolonged;Epistaxis
192432343;NA;NA;NA;CELGENE;82;F;Death;Death
192433234;NA;NA;NA;ROCHE;78;M;Life-Threatening;Arthritis infective
192440392;Skin swelling;OLUX E;0.5;MYLAN;56;F;NA;Drug ineffective
192443695;Plasma cell myeloma;Ixazomib;4;TAKEDA;57;M;Hospitalization - Initial or Prolonged;Cardiac failure
192448382;Psoriatic arthropathy;HUMIRA;40;ABBVIE;65;F;Other Serious (Important Medical Event);Abdominal discomfort
192460048;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;70;M;Hospitalization - Initial or Prolonged;Sinus tachycardia
192464015;Plasma cell myeloma;REVLIMID;25;CELGENE;47;F;Other Serious (Important Medical Event);Human chorionic gonadotropin increased
192464984;Plasma cell myeloma;POMALIDOMIDE;3;CELGENE;57;M;Hospitalization - Initial or Prolonged;Arthralgia
192466794;Plasma cell myeloma;Ixazomib;4;TAKEDA;57;M;Other Serious (Important Medical Event);Arthralgia
192478118;Immunosuppression;SIROLIMUS;0.92;PFIZER;13;M;Hospitalization - Initial or Prolonged;Abdominal pain
192479523;Sickle cell disease;ADAKVEO;5;NOVARTIS;17;F;Other Serious (Important Medical Event);Arthralgia
192482082;Contraception;MIRENA;20;BAYER;25;F;Other Serious (Important Medical Event);Complication of device insertion
192482182;Transitional cell carcinoma metastatic;ATEZOLIZUMAB;1200;ROCHE;71;F;Hospitalization - Initial or Prolonged;Oesophageal obstruction
192484132;B precursor type acute leukaemia;blinatumomab;28;AMGEN;65;F;Other Serious (Important Medical Event);Cardiac failure
192493713;Breast cancer metastatic;ENHERTU;4.4;DAIICHI;49;F;Hospitalization - Initial or Prolonged;Acute kidney injury
192511042;Psoriatic arthropathy;OTEZLA;30;AMGEN;59;F;Hospitalization - Initial or Prolonged;Psoriatic arthropathy
192511373;Gastrointestinal stromal tumour;CABOMETYX;60;EXELIXIS;30;M;Other Serious (Important Medical Event);Burns third degree
192512362;Plasma cell myeloma;Ixazomib;3;TAKEDA;87;M;Hospitalization - Initial or Prolonged;Cerebral haemorrhage
192512473;Plasma cell myeloma;NINLARO;3;TAKEDA;76;M;Other Serious (Important Medical Event);Haemoglobin abnormal
192521912;Plasma cell myeloma;REVLIMID;25;CELGENE;70;F;NA;Hypertension
192534442;Depression;SPRAVATO;56;JOHNSON AND JOHNSON;43;F;Other Serious (Important Medical Event);Irritability
192540542;Mucopolysaccharidosis;ALDURAZYME;52.2;SANOFI AVENTIS;15;M;NA;Cartilage operation
192543632;Crohn's disease;HUMIRA;40;ABBVIE;67;M;Life-Threatening;Capsule endoscopy
192550863;Tendonitis;LIDOCAINE HCL;2;PFIZER;65;M;NA;Off label use
192550913;Tendon disorder;LIDOCAINE HCL;1;PFIZER;35;F;Hospitalization - Initial or Prolonged;Pain
192554243;Plasma cell myeloma;REVLIMID;25;CELGENE;67;M;NA;Anaemia
192555485;T-cell type acute leukaemia;ISATUXIMAB;20;SANOFI AVENTIS;17;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
192560332;Type 2 diabetes mellitus;BYETTA;5;ASTRAZENECA;44;M;NA;Blood glucose increased
192566942;Nephrogenic anaemia;MIRCERA;150;VIFOR;46;F;NA;Back pain
192568284;Hepatitis C;SOFOSBUVIR W/VELPATASVIR;1;GILEAD;32;M;Hospitalization - Initial or Prolonged;Constipation
192569423;Posterior tibial nerve injury;LIDOCAINE HCL;1;PFIZER;33;F;Other Serious (Important Medical Event);Compartment syndrome
192569684;NA;NA;NA;PFIZER;25;F;Hospitalization - Initial or Prolonged;Pain
192576233;Psoriasis;COSENTYX;300;NOVARTIS;64;F;NA;Dyspnoea
192578094;Plasma cell myeloma;Selinexor;60;KARYOPHARM THERAPEUTICS;57;M;Other Serious (Important Medical Event);Cardiac failure
192586123;NA;NA;NA;PERRIGO;60;F;Hospitalization - Initial or Prolonged;Acute kidney injury
192587243;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;36;M;Other Serious (Important Medical Event);COVID-19
192588044;Short-bowel syndrome;Teduglutide;0.33;TAKEDA;62;F;Hospitalization - Initial or Prolonged;Hunger
192588683;Hormone replacement therapy;ESTRADIOL;1;PFIZER;47;F;Other Serious (Important Medical Event);Breast cancer
192591813;Plasma cell myeloma;NINLARO;3;TAKEDA;63;M;NA;Adverse drug reaction
192594125;Colon cancer metastatic;BINIMETINIB;15;PFIZER;32;F;Life-Threatening;Presyncope
192594582;Plasma cell myeloma;POMALYST;3;CELGENE;84;M;NA;Drug intolerance
192595464;Crohn's disease;HUMIRA;40;ABBVIE;19;F;Hospitalization - Initial or Prolonged;Abdominal pain
192606554;Recurrent cancer;VENETOCLAX;100;ABBVIE;18;F;Other Serious (Important Medical Event);Bacteraemia
192613494;Unknown;TREMFYA;100;JOHNSON AND JOHNSON;29;M;NA;Needle issue
192614102;Neuroendocrine tumour;LUTATHERA;7400;NOVARTIS;60;M;Hospitalization - Initial or Prolonged;Ascites
192615714;Contraception;NEXPLANON;1;ORGANON;36;F;NA;Complication of device insertion
192630743;Rheumatoid arthritis;HUMIRA;40;ABBVIE;32;F;Other Serious (Important Medical Event);Cauda equina syndrome
192632266;Hereditary angioedema;HAEGARDA;5800;CSL BEHRING;46;F;Hospitalization - Initial or Prolonged;Hereditary angioedema
192634072;Seizure;LACOSAMIDE;200;UCB;74;F;Death;Cerebrovascular accident
192635352;Transplant rejection;NULOJIX;5;BRISTOL MYERS SQUIBB;68;M;Other Serious (Important Medical Event);Haemoptysis
192635832;Diabetes mellitus;RYBELSUS;3;NOVO NORDISK;68;M;Hospitalization - Initial or Prolonged;Urinary retention
192642126;Ovarian cancer recurrent;COBIMETINIB;60;ROCHE;61;F;Hospitalization - Initial or Prolonged;Pancreatitis
192646506;Neutropenia;NEULASTA;6;AMGEN;44;F;NA;Device adhesion issue
192651463;Immune system disorder;Lanadelumab;300;TAKEDA;31;M;Other Serious (Important Medical Event);Hereditary angioedema
192652092;Depression;SPRAVATO;56;JOHNSON AND JOHNSON;37;M;Hospitalization - Initial or Prolonged;Pulmonary hypertension
192657282;Plasma cell myeloma;REVLIMID;25;CELGENE;74;F;Hospitalization - Initial or Prolonged;Pneumonia
192660932;Bipolar disorder;CLOZAPINE;25;MYLAN;11;F;Other Serious (Important Medical Event);Neutropenia
192663552;Marginal zone lymphoma;Umbralisib;800;TG THERAPEUTICS;88;F;NA;Drug ineffective
192667534;NA;NA;NA;JOHNSON AND JOHNSON;47;M;Hospitalization - Initial or Prolonged;Aggression
192675424;NA;NA;NA;UNITED THERAPEUTICS;65;F;Other Serious (Important Medical Event);Cough
192676752;NA;NA;NA;ADMA BIOLOGICS;60;F;Hospitalization - Initial or Prolonged;Back pain
192689957;Liver transplant;MYCOPHENOLATE MOFETIL;750;NOVARTIS;66;M;Other Serious (Important Medical Event);Disseminated varicella zoster virus infection
192693504;Unknown;NEXPLANON;1;ORGANON;20;F;NA;Complication of device insertion
192698722;Rheumatoid arthritis;RINVOQ;15;ABBVIE;63;M;Hospitalization - Initial or Prolonged;Knee arthroplasty
192704335;Plasma cell myeloma;REVLIMID;15;CELGENE;64;F;Other Serious (Important Medical Event);Candida infection
192704373;Neuromyelitis optica spectrum disorder;UPLIZNA;300;VIELA BIO;74;F;Hospitalization - Initial or Prolonged;Blindness
192712782;Migraine;EMGALITY;240;ELI LILLY AND CO;50;F;Death;Blood bicarbonate decreased
192721812;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;80;F;Other Serious (Important Medical Event);Malaise
192723764;Pulmonary hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;59;F;Hospitalization - Initial or Prolonged;Fluid overload
192733612;Multiple sclerosis;OCRELIZUMAB;600;ROCHE;67;M;Other Serious (Important Medical Event);COVID-19 pneumonia
192736543;Chronic lymphocytic leukaemia;IMBRUVICA;140;ABBVIE;82;M;Other Serious (Important Medical Event);Colitis
192737722;Cerebrovascular accident prophylaxis;APIXABAN;2.5;BRISTOL MYERS SQUIBB;77;F;NA;Rash
192739712;Lupus nephritis;MYCOPHENOLATE MOFETIL;1500;ROCHE;18;F;Hospitalization - Initial or Prolonged;Abortion spontaneous
192740633;Adenocarcinoma of colon;TRASTUZUMAB;535.2;ROCHE;25;M;Other Serious (Important Medical Event);Stevens-Johnson syndrome
192744312;NA;NA;NA;BAYER;86;M;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
192755154;Colitis ulcerative;HUMIRA;40;ABBVIE;40;M;Hospitalization - Initial or Prolonged;Pseudopolyposis
192758472;Renal transplant;NULOJIX;312.5;BRISTOL MYERS SQUIBB;76;F;Other Serious (Important Medical Event);Anorectal disorder
192763332;Multiple sclerosis;OCREVUS;600;ROCHE;39;F;Other Serious (Important Medical Event);COVID-19 pneumonia
192763354;Rheumatoid arthritis;Certolizumab pegol;400;UCB;69;F;Other Serious (Important Medical Event);Blood pressure increased
192763412;Plasma cell myeloma;REVLIMID;25;CELGENE;73;F;Other Serious (Important Medical Event);Arthropathy
192766113;Plasma cell myeloma;NINLARO;4;TAKEDA;71;M;NA;Abdominal pain
192766122;Plasma cell myeloma;Ixazomib;4;TAKEDA;60;F;Other Serious (Important Medical Event);COVID-19
192768413;NA;NA;NA;ABBVIE;34;F;NA;Bone density decreased
192773184;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;53;M;NA;Accidental exposure to product
192774182;NA;NA;NA;ABBVIE;58;M;Hospitalization - Initial or Prolonged;Abdominal adhesions
192778503;Primary progressive multiple sclerosis;OCREVUS;600;ROCHE;55;F;Death;Appendicitis perforated
192782935;Haemochromatosis;FERRIPROX;1500;CHIESI;36;F;Other Serious (Important Medical Event);Bacterial infection
192785923;Contraception;SKYLA;14;BAYER;24;F;Other Serious (Important Medical Event);Embedded device
192789713;Pulmonary hypertension;BOSENTAN;125;JOHNSON AND JOHNSON;74;F;Other Serious (Important Medical Event);Back injury
192791153;Chronic lymphocytic leukaemia;VENETOCLAX;20;ROCHE;51;F;Hospitalization - Initial or Prolonged;COVID-19
192793057;NA;NA;NA;CELGENE;46;F;Hospitalization - Initial or Prolonged;Inflammation
192793972;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;63;F;Death;Device malfunction
192794292;Pancreatic carcinoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;56;F;Other Serious (Important Medical Event);Acute kidney injury
192795613;Asthma;XOLAIR;300;ROCHE;77;F;Other Serious (Important Medical Event);Alopecia
192796934;Crohn's disease;HUMIRA;40;ABBVIE;83;F;Hospitalization - Initial or Prolonged;Anaemia postoperative
192798837;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;77;F;Other Serious (Important Medical Event);Neutrophilic dermatosis
192799024;Relapsing-remitting multiple sclerosis;OCRELIZUMAB;300;ROCHE;63;M;Other Serious (Important Medical Event);Pneumonia
192800452;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;72;M;NA;Weight increased
192801762;Unknown;BINIMETINIB;30;PFIZER;67;M;Hospitalization - Initial or Prolonged;Pneumonia
192803832;Unknown;ORENCIA;125;BRISTOL MYERS SQUIBB;46;F;NA;Weight increased
192806003;Dyslipidaemia;evolocumab;1;AMGEN;64;M;Hospitalization - Initial or Prolonged;Cardiac disorder
192806173;Crohn's disease;HUMIRA;20;ABBVIE;15;F;Other Serious (Important Medical Event);Depression
192808355;Hairy cell leukaemia;MEKTOVI;450;PFIZER;70;F;Hospitalization - Initial or Prolonged;Lipase increased
192816812;Chronic lymphocytic leukaemia;Umbralisib;600;TG THERAPEUTICS;64;M;Hospitalization - Initial or Prolonged;Intussusception
192818053;Adenocarcinoma;Niraparib;100;GLAXOSMITHKLINE;49;F;Hospitalization - Initial or Prolonged;Cancer pain
192820402;Gastrointestinal stromal tumour;GLEEVEC;400;NOVARTIS;67;M;Other Serious (Important Medical Event);Pneumonia
192820542;Contraception;NEXPLANON;1;ORGANON;23;F;NA;Complication of device removal
192821266;Plasma cell myeloma;BELANTAMAB MAFODOTIN;2.5;GLAXOSMITHKLINE;60;M;Death;Corneal epithelium defect
192822162;Type 2 diabetes mellitus;TRULICITY;0.75;ELI LILLY AND CO;67;M;NA;Abdominal pain upper
192822672;Myelodysplastic syndrome;REVLIMID;10;CELGENE;64;M;Life-Threatening;Drug ineffective
192822942;Weight decreased;TOPAMAX;10;JOHNSON AND JOHNSON;59;F;NA;Drug screen positive
192827353;Pulmonary embolism;ELIQUIS;10;BRISTOL MYERS SQUIBB;51;M;NA;Diarrhoea
192833992;Plasma cell myeloma;REVLIMID;10;CELGENE;74;M;NA;Constipation
192851942;Leiomyosarcoma metastatic;NIVOLUMAB;158;BRISTOL MYERS SQUIBB;61;F;Disability;Abdominal pain
192868944;Transitional cell carcinoma;ATEZOLIZUMAB;1200;ROCHE;79;M;Hospitalization - Initial or Prolonged;Pleural effusion
192871962;Alcoholism;VIVITROL;380;ALKERMES;35;M;NA;Dizziness
192878385;Hereditary angioedema;Lanadelumab;300;TAKEDA;18;F;Hospitalization - Initial or Prolonged;COVID-19
192878793;Migraine prophylaxis;NURTEC ODT;75;BIOHAVEN PHARMACEUTICALS;72;F;Death;Dehydration
192882304;Sickle cell disease;ADAKVEO;300;NOVARTIS;24;M;NA;Abdominal pain
192883684;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;40;F;Other Serious (Important Medical Event);Blood pressure increased
192888783;Pancreatic carcinoma;Niraparib;200;GLAXOSMITHKLINE;58;M;Hospitalization - Initial or Prolonged;Abdominal pain
192907923;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;60;F;NA;Back pain
192908766;Contraception;NEXPLANON;1;ORGANON;32;F;Other Serious (Important Medical Event);Device dislocation
192910832;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;60;M;NA;Device malfunction
192913172;Seizure;LACOSAMIDE;200;UCB;73;M;Other Serious (Important Medical Event);Altered state of consciousness
192914563;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;47;F;NA;Incorrect route of product administration
192918715;Spinal muscular atrophy;EVRYSDI;5;ROCHE;42;M;Hospitalization - Initial or Prolonged;Ankylosing spondylitis
192918782;Unknown;ELIQUIS;5;BRISTOL MYERS SQUIBB;76;F;Other Serious (Important Medical Event);Death
192920162;Acute lymphocytic leukaemia;CYTARABINE;132;HIKMA;12;M;Hospitalization - Initial or Prolonged;Adrenal disorder
192952133;Alcoholism;VIVITROL;380;ALKERMES;45;F;NA;Injection site erythema
192952783;Mycobacterial infection;NUZYRA;300;PARATEK PHARMACEUTICALS;34;F;Other Serious (Important Medical Event);Haemoptysis
192957582;Hypertension;VALSARTAN ACTAVIS;160;TEVA;60;F;Hospitalization - Initial or Prolonged;Dyspepsia
192970682;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;61;F;NA;Meniscus injury
192979033;Rheumatoid arthritis;SIMPONI;50;JOHNSON AND JOHNSON;60;F;NA;Drug delivery system issue
192979313;Multiple sclerosis;MAYZENT;0.25;NOVARTIS;45;F;NA;Dizziness
192983992;Relapsing multiple sclerosis;OCREVUS;600;ROCHE;57;F;NA;COVID-19
192987363;NA;NA;NA;UNITED THERAPEUTICS;78;F;Other Serious (Important Medical Event);Fall
192990035;Mantle cell lymphoma;RITUXIMAB;720;ROCHE;70;M;Death;Clostridium difficile colitis
192990974;Plasma cell myeloma;REVLIMID;25;CELGENE;75;M;NA;Full blood count increased
192992223;Unknown;TAFAMIDIS MEGLUMINE;80;PFIZER;75;M;Disability;Death
192996052;Immunodeficiency;CUVITRU;18;TAKEDA;69;M;Hospitalization - Initial or Prolonged;Gallbladder operation
193003864;Gene mutation;DOJOLVI;1.5;ULTRAGENYX PHARMACEUTICAL;9;F;Other Serious (Important Medical Event);Blood triglycerides increased
193008498;Acute myeloid leukaemia;AZACITIDINE;36;CELGENE;56;F;Life-Threatening;Non-cardiac chest pain
193013762;Unknown;PROMACTA;150;NOVARTIS;67;M;Other Serious (Important Medical Event);Aplastic anaemia
193022664;NA;NA;NA;TAKEDA;34;F;Disability;Deep vein thrombosis
193023512;Nausea;TIGAN;300;PFIZER;59;F;NA;Drug ineffective
193045143;Psoriasis;SKYRIZI;150;ABBVIE;54;M;Other Serious (Important Medical Event);Cerebrovascular accident
193057872;Unknown;NEXPLANON;68;ORGANON;26;F;NA;Device breakage
193058935;Pulmonary arterial hypertension;UPTRAVI;400;JOHNSON AND JOHNSON;82;F;Hospitalization - Initial or Prolonged;Contusion
193061434;Ankylosing spondylitis;CIMZIA;200;UCB;70;F;Other Serious (Important Medical Event);Cough
193065332;Multiple sclerosis;VUMERITY;462;BIOGEN;31;F;Disability;Multiple sclerosis
193078652;Contraception;MIRENA;20;BAYER;39;F;Hospitalization - Initial or Prolonged;Device dislocation
193086922;Plasma cell myeloma;REVLIMID;25;CELGENE;66;F;Hospitalization - Initial or Prolonged;Urinary tract infection
193089223;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;80;M;Hospitalization - Initial or Prolonged;Abdominal discomfort
193094264;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;30;F;NA;Drug delivery system malfunction
193094882;Pulmonary embolism;XARELTO;15;JOHNSON AND JOHNSON;90;M;Other Serious (Important Medical Event);Deep vein thrombosis
193096522;Unknown;ENTRESTO;50;NOVARTIS;85;M;Hospitalization - Initial or Prolonged;Cough
193097782;Type 2 diabetes mellitus;FARXIGA;5;ASTRAZENECA;68;F;Hospitalization - Initial or Prolonged;Acute kidney injury
193097986;NA;NA;NA;NOVARTIS;86;F;Other Serious (Important Medical Event);Blindness
193100942;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;16000;TAKEDA;60;M;Disability;Haemoptysis
193106313;Plasma cell myeloma;DARATUMUMAB;1800;JOHNSON AND JOHNSON;54;F;Other Serious (Important Medical Event);Febrile neutropenia
193106863;HER2 positive breast cancer;Tucatinib;300;SEATTLE GENETICS;43;F;Hospitalization - Initial or Prolonged;Constipation
193107124;Follicular lymphoma;OBINUTUZUMAB;1000;ROCHE;70;M;Hospitalization - Initial or Prolonged;COVID-19
193107515;NA;NA;NA;CELGENE;33;M;Other Serious (Important Medical Event);Feeling hot
193110224;Crohn's disease;HUMIRA;40;ABBVIE;72;F;Hospitalization - Initial or Prolonged;Adverse food reaction
193112602;Endometrial cancer;Dostarlimab;500;GLAXOSMITHKLINE;62;F;Other Serious (Important Medical Event);Asthenia
193120244;Plasma cell myeloma;DARATUMUMAB;16;JOHNSON AND JOHNSON;44;F;Other Serious (Important Medical Event);Cellulitis
193121466;Neutropenia;NEULASTA;6;AMGEN;69;F;NA;Device occlusion
193123053;Relapsing-remitting multiple sclerosis;TERIFLUNOMIDE;2;SANOFI AVENTIS;49;F;Death;Alanine aminotransferase increased
193127533;Still's disease;ILARIS;300;NOVARTIS;39;F;NA;Nodule
193135182;Seizure;LACOSAMIDE;150;UCB;74;F;Hospitalization - Initial or Prolonged;Infection
193138182;Age-related macular degeneration;BEOVU;6;NOVARTIS;90;F;NA;Drug ineffective
193146114;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;32;F;NA;Abdominal discomfort
193164524;Attention deficit hyperactivity disorder;VYVANSE;60;TAKEDA;25;M;NA;Drug ineffective
193164663;NA;NA;NA;UNITED THERAPEUTICS;42;F;Other Serious (Important Medical Event);Cardiogenic shock
193173482;Colorectal cancer metastatic;STIVARGA;80;BAYER;63;F;Life-Threatening;Confusional state
193174542;Plasma cell myeloma;POMALYST;3;CELGENE;70;M;NA;Abdominal pain
193186212;Chronic lymphocytic leukaemia;VENETOCLAX;20;ABBVIE;59;M;Hospitalization - Initial or Prolonged;COVID-19
193187393;Hypertension;AMLODIPINE BESILATE;10;PFIZER;78;F;Other Serious (Important Medical Event);Anaemia
193202753;Selective IgA immunodeficiency;GAMUNEX C;70;GRIFOLS;34;M;Other Serious (Important Medical Event);Burning sensation
193204093;Kaposi's sarcoma;POMALYST;4;CELGENE;44;M;Hospitalization - Initial or Prolonged;Kaposi's sarcoma
193210462;Depression;SPRAVATO;56;JOHNSON AND JOHNSON;35;M;Other Serious (Important Medical Event);Epistaxis
193219313;NA;NA;NA;UNITED THERAPEUTICS;38;M;Other Serious (Important Medical Event);Fluid retention
193221353;Myelodysplastic syndrome;REVLIMID;10;CELGENE;75;M;Hospitalization - Initial or Prolonged;Fall
193221445;Relapsing multiple sclerosis;OCREVUS;600;ROCHE;36;F;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
193230845;Glycogen storage disease type II;LUMIZYME;1200;SANOFI AVENTIS;10;M;Other Serious (Important Medical Event);Dry skin
193254616;Metastatic malignant melanoma;TABRECTA;400;NOVARTIS;65;M;Hospitalization - Initial or Prolonged;Venous thrombosis
193257782;Contraception;MIRENA;20;BAYER;21;F;Death;Abdominal pain
193271493;Growth hormone deficiency;GENOTROPIN;0.8;PFIZER;69;M;NA;Device defective
193273474;Blood cholesterol increased;REPATHA;140;AMGEN;55;M;NA;Accidental exposure to product
193275932;Non-24-hour sleep-wake disorder;HETLIOZ;20;VANDA PHARMACEUTICALS;72;F;Hospitalization - Initial or Prolonged;Diverticulitis
193281214;Unknown;NEXPLANON;1;ORGANON;20;F;Other Serious (Important Medical Event);Complication associated with device
193287513;Gallbladder cancer;FLUOROURACIL (Manufacturer unknown);2400;FRESENIUS KABI;69;F;Hospitalization - Initial or Prolonged;Acute kidney injury
193287655;Non-small cell lung cancer metastatic;ATEZOLIZUMAB;1200;ROCHE;69;M;Hospitalization - Initial or Prolonged;Lymphocyte count decreased
193288812;Plasma cell myeloma;REVLIMID;5;CELGENE;70;M;NA;Fatigue
193308813;Plasma cell myeloma;NINLARO;4;TAKEDA;71;F;Other Serious (Important Medical Event);Constipation
193310722;Unknown;KESIMPTA;20;NOVARTIS;55;F;NA;Arthralgia
193317072;30;DEXTROAMPHET SACCHARAT;AMPHETAMINE ASPARTATE\AMPHETAMINE SULFATE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE SULFATE;EPIC PHARM;64;F;NA;Drug ineffective
193369542;Colitis ulcerative;STELARA;90;JOHNSON AND JOHNSON;77;M;NA;Inappropriate schedule of product administration
193369663;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;81;M;Disability;Febrile neutropenia
193391894;Psoriatic arthropathy;TREMFYA;100;JOHNSON AND JOHNSON;77;F;Hospitalization - Initial or Prolonged;Accidental exposure to product
193502132;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;64;F;NA;Arthralgia
193502742;NA;NA;NA;ESPERION THERAPEUTICS;56;M;NA;Blood cholesterol decreased
193503123;Plasma cell myeloma;REVLIMID;10;CELGENE;85;M;Disability;Deep vein thrombosis
193503233;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;63;M;Other Serious (Important Medical Event);Hyperkalaemia
193509423;NA;NA;NA;GLAXOSMITHKLINE;65;F;Hospitalization - Initial or Prolonged;Blood creatinine abnormal
193509994;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;73;F;Other Serious (Important Medical Event);Adverse drug reaction
193517652;NA;NA;NA;ROCHE;79;F;Death;Ovarian cancer metastatic
193519432;Renal cell carcinoma;INLYTA;5;PFIZER;66;M;NA;Diarrhoea
193523303;Alcoholism;VIVITROL;380;ALKERMES;57;F;NA;Abdominal discomfort
193525508;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;84;F;Other Serious (Important Medical Event);Fall
193526003;NA;NA;NA;CELGENE;56;F;Hospitalization - Initial or Prolonged;Disease progression
193541237;Unknown;KESIMPTA;20;NOVARTIS;53;F;NA;Cough
193542662;NA;NA;NA;BRISTOL MYERS SQUIBB;67;M;Other Serious (Important Medical Event);Diarrhoea
193559962;Lung neoplasm malignant;OPDIVO;480;BRISTOL MYERS SQUIBB;63;F;NA;Pain in extremity
193567032;Gastrointestinal stromal tumour;AYVAKIT;100;BLUEPRINT MEDICINES;68;M;NA;Off label use
193571716;Ovarian cancer;ZEJULA;200;GLAXOSMITHKLINE;65;F;NA;Abdominal distension
193582462;Contraception;MIRENA;20;BAYER;40;F;Death;Device issue
193583815;Depression;SPRAVATO;84;JOHNSON AND JOHNSON;52;M;NA;Device malfunction
193584253;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;47;F;NA;Needle issue
193587484;Non-Hodgkin's lymphoma;OXALIPLATIN;180;NOVARTIS;60;F;Death;Cytokine release syndrome
193588842;Unknown;ELIQUIS;5;BRISTOL MYERS SQUIBB;79;F;Other Serious (Important Medical Event);Hypoacusis
193591014;Neoplasm;Dostarlimab;500;GLAXOSMITHKLINE;42;F;Other Serious (Important Medical Event);Neuromyelitis optica spectrum disorder
193599923;Cerebrovascular accident prophylaxis;ELIQUIS;2.5;BRISTOL MYERS SQUIBB;90;F;Other Serious (Important Medical Event);Asthenia
193601182;Mycobacterium abscessus infection;LAMPRENE;100;NOVARTIS;68;F;Other Serious (Important Medical Event);Aphonia
193603224;Renal cell carcinoma;NIVOLUMAB;201.6;BRISTOL MYERS SQUIBB;62;M;Hospitalization - Initial or Prolonged;Aspartate aminotransferase increased
193606304;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;60;M;NA;Accidental exposure to product
193607893;NA;NA;NA;BRISTOL MYERS SQUIBB;46;M;Other Serious (Important Medical Event);Acetabulum fracture
193619975;Arthralgia;XELJANZ XR;11;PFIZER;72;F;Death;Arthralgia
193622772;K-ras gene mutation;AMG 510;960;AMGEN;64;F;Hospitalization - Initial or Prolonged;Cellulitis
193625334;Pancreatic carcinoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;72;M;Other Serious (Important Medical Event);Anaemia
193634786;Neutropenia;NEULASTA;6;AMGEN;67;M;NA;Accidental exposure to product
193637512;Sickle cell anaemia;CRIZANLIZUMAB;400;NOVARTIS;17;M;Hospitalization - Initial or Prolonged;Infusion related reaction
193642982;Plasma cell myeloma;LENALIDOMIDE;10;CELGENE;68;M;Hospitalization - Initial or Prolonged;Cerebral infarction
193644292;Depression;SPRAVATO;84;JOHNSON AND JOHNSON;79;F;NA;Shoulder arthroplasty
193644723;Deep vein thrombosis;ELIQUIS;5;BRISTOL MYERS SQUIBB;76;F;Hospitalization - Initial or Prolonged;Death
193648464;Non-small cell lung cancer;OPDIVO;480;BRISTOL MYERS SQUIBB;87;F;Hospitalization - Initial or Prolonged;Pneumonitis
193665752;Fallopian tube cancer;ATEZOLIZUMAB;800;ROCHE;75;F;Hospitalization - Initial or Prolonged;Asthenia
193667052;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;59;M;NA;Device malfunction
193667412;Contraception;MIRENA;20;BAYER;30;F;Other Serious (Important Medical Event);Complication of device insertion
193669312;Contraception;MIRENA;20;BAYER;35;F;Other Serious (Important Medical Event);Complication of device insertion
193670572;Chronic myeloid leukaemia;BOSUTINIB;500;PFIZER;66;F;Hospitalization - Initial or Prolonged;Constipation
193673032;B-cell lymphoma;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;71;M;Other Serious (Important Medical Event);Anaemia
193675683;Colon cancer;XELODA;1500;ROCHE;63;M;Hospitalization - Initial or Prolonged;Acute kidney injury
193684432;Depression;SPRAVATO;56;JOHNSON AND JOHNSON;41;F;Hospitalization - Initial or Prolonged;Agitation
193686624;Plasma cell myeloma refractory;ISATUXIMAB;900;SANOFI AVENTIS;53;F;Other Serious (Important Medical Event);Urinary tract infection
193696063;Non-small cell lung cancer;XL184;40;EXELIXIS;83;F;Hospitalization - Initial or Prolonged;Drug hypersensitivity
193697442;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;35;M;NA;Product complaint
193708372;Alcoholism;VIVITROL;380;ALKERMES;58;M;NA;Dizziness
193708792;Plasma cell myeloma;COBIMETINIB;60;ROCHE;69;M;Hospitalization - Initial or Prolonged;Anaemia
193713963;Neutropenia;NEULASTA;6;AMGEN;60;F;NA;Device adhesion issue
193715235;Psychiatric symptom;INVEGA SUSTENNA;117;JOHNSON AND JOHNSON;47;M;NA;Accidental exposure to product
193718953;Neutropenia;NEULASTA;6;AMGEN;59;M;NA;Device adhesion issue
193720555;NA;NA;NA;UNITED THERAPEUTICS;39;F;Other Serious (Important Medical Event);Abdominal pain
193721972;Prophylaxis against transplant rejection;ENVARSUS XR;3;VELOXIS PHARMACEUTICALS;64;F;Hospitalization - Initial or Prolonged;Acute kidney injury
193726472;Glycosylated haemoglobin increased;TRULICITY;0.75;ELI LILLY AND CO;80;F;Other Serious (Important Medical Event);Epistaxis
193730865;Neutropenia;NEULASTA;6;AMGEN;73;F;NA;Device physical property issue
193732754;Glioblastoma;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;64;M;Hospitalization - Initial or Prolonged;Chills
193736463;Diffuse large B-cell lymphoma;RITUXIMAB;679;ROCHE;73;F;Other Serious (Important Medical Event);Adenocarcinoma
193748736;Neutropenia;NEULASTA;6;AMGEN;36;F;NA;Application site haemorrhage
193749372;Plasma cell myeloma;POMALYST;2;CELGENE;70;M;NA;Oedema peripheral
193755234;Plasma cell myeloma;REVLIMID;15;CELGENE;78;M;Other Serious (Important Medical Event);Cardiac failure congestive
193755313;Chronic myeloid leukaemia;SPRYCEL;100;BRISTOL MYERS SQUIBB;57;F;Other Serious (Important Medical Event);Malaise
193757764;Prostate cancer;LUPRON;45;ABBVIE;84;M;Hospitalization - Initial or Prolonged;Aortic valve disease
193757843;Psoriasis;SKYRIZI;150;ABBVIE;70;F;Hospitalization - Initial or Prolonged;Asthenia
193759162;Psoriasis;SKYRIZI;150;ABBVIE;68;F;NA;Peripheral swelling
193759256;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;79;M;Death;Cerebrovascular accident
193760953;NA;NA;NA;UNITED THERAPEUTICS;49;M;Hospitalization - Initial or Prolonged;Acute kidney injury
193761202;NA;NA;NA;UNITED THERAPEUTICS;65;F;Other Serious (Important Medical Event);Respiratory failure
193765764;Breast cancer metastatic;ERDAFITINIB;8;JOHNSON AND JOHNSON;54;F;Other Serious (Important Medical Event);Constipation
193766902;Ovarian cancer;Dostarlimab;500;GLAXOSMITHKLINE;44;F;Life-Threatening;Diarrhoea
193767042;Unknown;BELANTAMAB MAFODOTIN;200;GLAXOSMITHKLINE;67;M;Other Serious (Important Medical Event);Acute kidney injury
193775794;NA;NA;NA;PFIZER;35;M;Disability;Febrile neutropenia
193779273;Colonoscopy;SUTAB;24;BRAINTREE;56;M;NA;Chills
193779497;Gastrointestinal stromal tumour;DCC 2618;150;DECIPHERA PHARMACEUTICALS;68;M;Other Serious (Important Medical Event);Wound dehiscence
193781492;Plasma cell myeloma;REVLIMID;25;CELGENE;78;F;NA;Arthralgia
193781722;Prostate cancer;ERLEADA;240;JOHNSON AND JOHNSON;81;M;Hospitalization - Initial or Prolonged;Failure to thrive
193782682;K-ras gene mutation;AMG 510;960;AMGEN;67;F;Hospitalization - Initial or Prolonged;Dyspnoea
193784994;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;50;M;NA;Needle issue
193786223;Plasma cell myeloma;REVLIMID;25;CELGENE;67;F;Other Serious (Important Medical Event);Abdominal pain upper
193787242;Plasma cell myeloma;REVLIMID;25;CELGENE;72;F;NA;Abdominal pain upper
193788712;Psoriasis;SKYRIZI;75;ABBVIE;68;M;Hospitalization - Initial or Prolonged;Dizziness
193789672;Asthma;DUPIXENT;600;SANOFI AVENTIS;51;F;NA;Heart rate increased
193790136;NA;NA;NA;RANBAXY;56;F;Other Serious (Important Medical Event);Asthenia
193795762;Haemoglobin decreased;MIRCERA;100;VIFOR;47;F;NA;Drug hypersensitivity
193796872;Oesophageal carcinoma;KANJINTI;150;AMGEN;59;M;NA;Intercepted medication error
193802263;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;71;F;Hospitalization - Initial or Prolonged;Febrile neutropenia
193813542;Unknown;NEXPLANON;1;ORGANON;12;F;NA;Device expulsion
193814072;Major depression;VENLAFAXINE HCL;225;PFIZER;21;F;Other Serious (Important Medical Event);Hypohidrosis
193814082;NA;NA;NA;PFIZER;61;F;NA;Abdominal discomfort
193818312;Blood glucose abnormal;GENOTROPIN;1.6;PFIZER;7;F;Hospitalization - Initial or Prolonged;Cardiac failure
193822492;COVID-19;Etesevimab 700mg;1400;ELI LILLY AND CO;55;M;Hospitalization - Initial or Prolonged;Death
193825283;Blood potassium decreased;VALSARTAN TEVA;160;TEVA;71;M;Life-Threatening;Acute myocardial infarction
193827022;Narcolepsy;WAKIX;8.9;HARMONY BIOSCIENCES;28;F;NA;Headache
193828633;Dyspnoea;ALBUTEROL SULFATE;180;PERRIGO;57;F;NA;Chemical burn of respiratory tract
193835372;COVID-19;Etesevimab 700mg;1400;ELI LILLY AND CO;73;M;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
193845573;Ovarian cancer;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;61;F;Death;COVID-19
193848203;Plasma cell myeloma;BORTEZOMIB;1.3;TAKEDA;72;M;Other Serious (Important Medical Event);Tumour lysis syndrome
193857963;Lung neoplasm malignant;ALUNBRIG;90;TAKEDA;76;M;Life-Threatening;Burning sensation
193861232;Plasma cell myeloma;POMALYST;4;CELGENE;64;F;NA;COVID-19
193865963;Hereditary angioedema;HAEGARDA;5000;CSL BEHRING;27;F;Hospitalization - Initial or Prolonged;Angioedema
193866322;Contraception;MIRENA;20;BAYER;30;F;Other Serious (Important Medical Event);Embedded device
193868333;Rheumatoid arthritis;HUMIRA;40;ABBVIE;70;M;Other Serious (Important Medical Event);Cholecystitis
193871432;Affective disorder;CLOZAPINE;50;MYLAN;23;M;Hospitalization - Initial or Prolonged;Hospitalisation
193891573;NA;NA;NA;MYLAN;18;F;Hospitalization - Initial or Prolonged;Maternal exposure during pregnancy
193893354;Nephrogenic anaemia;ARANESP;40;AMGEN;78;F;NA;Accidental exposure to product
193898642;Contraception;NEXPLANON;68;ORGANON;17;F;NA;Complication of device insertion
193899382;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;35;F;NA;Accidental exposure to product
193900383;Rheumatoid arthritis;Certolizumab pegol;400;UCB;56;F;Hospitalization - Initial or Prolonged;Pain in extremity
193901142;Crohn's disease;DUPIXENT;300;SANOFI AVENTIS;6;M;Death;Cellulitis
193901623;Metastatic renal cell carcinoma;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;64;M;Other Serious (Important Medical Event);Acute kidney injury
193901934;Astrocytoma;GSK1120212;0.025;NOVARTIS;2;M;Disability;Abdominal pain
193903533;Crohn's disease;HUMIRA;160;ABBVIE;59;F;Death;Anxiety
193905482;Contraception;MIRENA;20;BAYER;48;F;Hospitalization - Initial or Prolonged;Device difficult to use
193906502;Contraception;IMPLANON;1;ORGANON;34;F;Hospitalization - Initial or Prolonged;Device dislocation
193906632;Plasma cell myeloma recurrent;POMALYST;4;CELGENE;65;M;Other Serious (Important Medical Event);Neutropenia
193912554;Contraception;NEXPLANON;1;ORGANON;19;F;NA;Device breakage
193913092;Chronic graft versus host disease;IBRUTINIB;420;ABBVIE;15;F;Hospitalization - Initial or Prolonged;Influenza
193915262;Chronic inflammatory demyelinating polyradiculoneuropathy;GAMMAGARD;60;TAKEDA;52;F;Hospitalization - Initial or Prolonged;Coronary artery occlusion
193917522;NA;NA;NA;CELGENE;72;M;NA;Depression
193918552;NA;NA;NA;UNITED THERAPEUTICS;52;F;Hospitalization - Initial or Prolonged;Chest pain
193920723;Philadelphia positive chronic myeloid leukaemia;SPRYCEL;100;BRISTOL MYERS SQUIBB;76;M;Other Serious (Important Medical Event);Genital infection fungal
193921482;Arthralgia;LIDOCAINE HCL;1;PFIZER;80;M;Other Serious (Important Medical Event);Arthralgia
193923582;Plasma cell myeloma;REVLIMID;20;CELGENE;73;F;NA;Blood count abnormal
193932844;Neutropenia;NEULASTA;6;AMGEN;76;F;NA;Unintentional medical device removal
193932954;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;69;F;Hospitalization - Initial or Prolonged;Syncope
193940492;Erectile dysfunction;CAVERJECT IMPULSE;20;PFIZER;37;M;NA;Blood cholesterol decreased
193941234;NA;NA;NA;NOVARTIS;58;M;Other Serious (Important Medical Event);Dyspnoea
193943173;Growth hormone deficiency;GENOTROPIN;2.2;PFIZER;14;M;NA;Device breakage
193948033;Neutropenia;NEULASTA;6;AMGEN;63;F;NA;Accidental exposure to product
193950362;Computerised tomogram abdomen;OPTIRAY 350;110;GUERBET;57;M;NA;Lacrimation increased
193951792;Computerised tomogram abdomen;OPTIRAY 350;110;GUERBET;70;F;NA;Erythema
193953713;Heavy menstrual bleeding;MIRENA;20;BAYER;54;F;Life-Threatening;Abdominal pain
193954493;NA;NA;NA;ROCHE;64;F;NA;Herpes zoster
193956512;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;81;M;NA;Device leakage
193957122;Colorectal cancer metastatic;LONSURF;15;TAIHO ONCOLOGY INC;48;F;Hospitalization - Initial or Prolonged;Dehydration
193957712;Unknown;REPATHA;140;AMGEN;67;F;NA;Accidental exposure to product
193957872;Hormone replacement therapy;ESTRADIOL TRANSDERMAL SYSTEM;0.1;MYLAN;52;F;NA;Product adhesion issue
193958032;Alcoholism;VIVITROL;380;ALKERMES;64;F;Hospitalization - Initial or Prolonged;Inadequate analgesia
193958883;Immunodeficiency common variable;CUVITRU;10;TAKEDA;68;F;Other Serious (Important Medical Event);Breast cancer
193959422;Unknown;NEXPLANON;1;ORGANON;34;F;NA;Device breakage
193959514;Congenital hypogammaglobulinaemia;CUVITRU;24;TAKEDA;51;M;Death;Brain neoplasm
193963312;Ovarian clear cell carcinoma;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;49;F;Other Serious (Important Medical Event);Troponin I increased
193963364;Chronic lymphocytic leukaemia;VENCLEXTA;100;ABBVIE;80;F;Hospitalization - Initial or Prolonged;Fall
193966505;NA;NA;NA;UNITED THERAPEUTICS;63;M;Other Serious (Important Medical Event);Bacteraemia
193969843;Unknown;KESIMPTA;20;NOVARTIS;39;F;NA;Abdominal discomfort
193970782;Colitis;STELARA;390;JOHNSON AND JOHNSON;28;M;Hospitalization - Initial or Prolonged;Angioedema
193971515;Multiple sclerosis;TYSABRI;300;BIOGEN;31;F;Death;Progressive multifocal leukoencephalopathy
193971752;Ovarian cancer;ATEZOLIZUMAB;800;ROCHE;77;F;Other Serious (Important Medical Event);Intestinal perforation
193973302;Crohn's disease;HUMIRA;80;ABBVIE;68;F;Hospitalization - Initial or Prolonged;Haemoglobin decreased
193973843;Cerebrovascular accident;ACTIVASE;100;ROCHE;81;F;Hospitalization - Initial or Prolonged;Cerebrovascular accident
193974152;Neutropenia;NEULASTA;6;AMGEN;67;F;NA;Unintentional medical device removal
193975072;NA;NA;NA;BRISTOL MYERS SQUIBB;90;M;Other Serious (Important Medical Event);Asthenia
193976812;NA;NA;NA;ABBVIE;38;F;Other Serious (Important Medical Event);Blood iron decreased
193980832;Contraception;MIRENA;20;BAYER;41;F;Other Serious (Important Medical Event);Abdominal pain
193987402;NA;NA;NA;BRISTOL MYERS SQUIBB;68;M;Other Serious (Important Medical Event);Death
193990842;Psoriatic arthropathy;STELARA;90;JOHNSON AND JOHNSON;68;M;Hospitalization - Initial or Prolonged;Knee operation
193993382;COVID-19;Etesevimab 700mg;1400;ELI LILLY AND CO;80;F;Hospitalization - Initial or Prolonged;Acute respiratory failure
193994172;Insomnia;DAYVIGO;5;EISAI;28;F;NA;Diarrhoea
194000422;Ewing's sarcoma;PAZOPANIB;800;NOVARTIS;21;M;Other Serious (Important Medical Event);Headache
194004663;NA;NA;NA;NOVARTIS;37;F;NA;Chills
194004842;Alcoholism;VIVITROL;380;ALKERMES;31;M;NA;Injection site cellulitis
194007072;Contraception;NEXPLANON;1;ORGANON;20;F;NA;Complication associated with device
194012572;Plasma cell myeloma;REVLIMID;25;CELGENE;76;M;NA;Rash
194015802;Acute lymphocytic leukaemia recurrent;Ponatinib;45;TAKEDA;59;M;Other Serious (Important Medical Event);Abdominal cavity drainage
194024793;Neutropenia;NEULASTA;6;AMGEN;63;F;NA;Unintentional medical device removal
194027054;Non-small cell lung cancer;ATEZOLIZUMAB;1200;ROCHE;83;F;Hospitalization - Initial or Prolonged;Drug hypersensitivity
194033483;Non-small cell lung cancer;XL184;60;EXELIXIS;66;F;Other Serious (Important Medical Event);Abdominal pain
194049934;Contraception;NEXPLANON;1;ORGANON;22;F;Hospitalization - Initial or Prolonged;Complication associated with device
194052152;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;66;M;Hospitalization - Initial or Prolonged;Syncope
194052592;Chronic lymphocytic leukaemia;FLUDARABINE;70;FRESENIUS KABI;73;M;Other Serious (Important Medical Event);Urinary tract infection
194059745;Growth hormone deficiency;GENOTROPIN;2.6;PFIZER;46;F;NA;Device breakage
194065285;NA;NA;NA;CELGENE;71;M;Death;Neurotoxicity
194065573;NA;NA;NA;ALEXION;17;M;NA;Injection site atrophy
194067952;Non-small cell lung cancer stage IV;AMG 510;960;AMGEN;55;F;Life-Threatening;Respiratory failure
194069582;Computerised tomogram abdomen;OMNIPAQUE;500;GE HEALTHCARE;72;M;NA;Incorrect product formulation administered
194070054;Renal cell carcinoma;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;52;F;Hospitalization - Initial or Prolonged;Diverticulitis
194070522;Growth hormone deficiency;GENOTROPIN;0.8;PFIZER;8;M;NA;Device information output issue
194071643;Rheumatoid arthritis;SIMPONI;50;JOHNSON AND JOHNSON;81;F;NA;Accidental exposure to product
194071803;B-cell lymphoma refractory;VENETOCLAX;400;ROCHE;77;F;Other Serious (Important Medical Event);Dehydration
194073562;Acute myeloid leukaemia;AZACITIDINE;138;CELGENE;79;M;Other Serious (Important Medical Event);Febrile neutropenia
194075223;NA;NA;NA;ROCHE;61;F;Hospitalization - Initial or Prolonged;Anxiety
194077913;NA;NA;NA;UNITED THERAPEUTICS;59;F;Death;Anaphylactic reaction
194081652;Unknown;CRIZOTINIB;250;PFIZER;72;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
194081802;Non-Hodgkin's lymphoma;AXICABTAGENE CILOLEUCEL;1;GILEAD;60;F;Life-Threatening;COVID-19
194084393;Psoriatic arthropathy;TREMFYA;100;JOHNSON AND JOHNSON;60;F;NA;Device malfunction
194084473;Immune system disorder;FIRAZYR;30;TAKEDA;34;M;Other Serious (Important Medical Event);Abdominal pain upper
194089823;Contraception;NEXPLANON;1;ORGANON;33;F;NA;Complication of device insertion
194090963;Neutropenia;NEULASTA;6000;AMGEN;52;M;NA;Unintentional medical device removal
194099693;Congenital hypogammaglobulinaemia;DUPIXENT;300;SANOFI AVENTIS;64;F;Hospitalization - Initial or Prolonged;Fatigue
194101082;Rheumatoid arthritis;REMICADE;300;JOHNSON AND JOHNSON;79;M;Hospitalization - Initial or Prolonged;Hypotension
194101222;NA;NA;NA;AMGEN;88;M;NA;Wrong technique in product usage process
194103422;Lipodystrophy acquired;MYALEPT;2.5;AEGERION;32;M;NA;Blood triglycerides increased
194104122;Neutropenia;NEULASTA;6;AMGEN;63;F;NA;Unintentional medical device removal
194105793;Renal cell carcinoma;CABOMETYX;40;EXELIXIS;74;M;Hospitalization - Initial or Prolonged;Muscular weakness
194108832;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;69;M;Other Serious (Important Medical Event);Hypoxia
194109555;Endometrial cancer;ATEZOLIZUMAB;1200;ROCHE;75;F;Hospitalization - Initial or Prolonged;Hypertension
194110113;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;72;F;NA;Inappropriate schedule of product administration
194110122;Nephrogenic anaemia;MIRCERA;100;VIFOR;30;F;Other Serious (Important Medical Event);Drug hypersensitivity
194123394;Pancreatic carcinoma metastatic;ILARIS;250;NOVARTIS;49;M;Hospitalization - Initial or Prolonged;Influenza like illness
194132993;Non-small cell lung cancer stage IV;AMG 510;120;AMGEN;53;M;Death;Acute kidney injury
194134422;Unknown;GENOTROPIN;0.9;PFIZER;10;M;NA;Device breakage
194134985;Endometrial cancer stage IV;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;56;F;Other Serious (Important Medical Event);Hyperglycaemia
194135254;NA;NA;NA;PFIZER;70;F;Other Serious (Important Medical Event);Accident
194135963;Gastric cancer;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;72;M;Hospitalization - Initial or Prolonged;Syncope
194136252;Diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;65;M;NA;Device issue
194137843;Unknown;NEXPLANON;1;ORGANON;19;F;NA;Complication of device insertion
194142628;Neutropenia;NEULASTA;6;AMGEN;50;F;NA;Device physical property issue
194142972;Hormone-dependent prostate cancer;ERLEADA;240;JOHNSON AND JOHNSON;68;M;Hospitalization - Initial or Prolonged;Prostate cancer metastatic
194145522;B precursor type acute leukaemia;blinatumomab;15;AMGEN;7;M;Life-Threatening;Hyperammonaemia
194148282;NA;NA;NA;BRISTOL MYERS SQUIBB;43;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
194149684;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;68;F;Hospitalization - Initial or Prolonged;Device issue
194150502;Bile duct cancer;ATEZOLIZUMAB;1200;ROCHE;44;F;Hospitalization - Initial or Prolonged;Hypertension
194151275;Psoriasis;COSENTYX;300;NOVARTIS;62;M;Other Serious (Important Medical Event);Actinic keratosis
194156883;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;68;F;Hospitalization - Initial or Prolonged;COVID-19 immunisation
194164283;Migraine;AIMOVIG;140;AMGEN;56;M;NA;Device difficult to use
194171042;Asthma;FASENRA;30;ASTRAZENECA;69;F;NA;Device delivery system issue
194171793;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;28;F;NA;Device malfunction
194175502;Nephrogenic anaemia;MIRCERA;200;VIFOR;57;F;Other Serious (Important Medical Event);Drug hypersensitivity
194175562;Nephrogenic anaemia;MIRCERA;200;VIFOR;86;M;Other Serious (Important Medical Event);Drug hypersensitivity
194177022;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;59;F;NA;Arthralgia
194180122;Sickle cell disease;ADAKVEO;5;NOVARTIS;34;F;NA;Bone pain
194185172;Sickle cell anaemia with crisis;OXBRYTA;1500;GLOBAL BLOOD THERAPEUTICS;26;F;NA;Back pain
194188844;Mycobacterial infection;NUZYRA;300;PARATEK PHARMACEUTICALS;61;F;Other Serious (Important Medical Event);Anal skin tags
194188893;Anaemia;ARANESP;500;AMGEN;82;F;NA;Product storage error
194189212;Diffuse large B-cell lymphoma;Selinexor;60;KARYOPHARM THERAPEUTICS;70;F;Hospitalization - Initial or Prolonged;Hyponatraemia
194190382;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;NA;Diarrhoea
194193433;Psoriatic arthropathy;TREMFYA;100;JOHNSON AND JOHNSON;38;M;NA;Device issue
194194613;NA;NA;NA;NOVARTIS;15;M;Death;Agitation
194195025;Multiple sclerosis;KESIMPTA;20;NOVARTIS;49;M;NA;Asthenia
194197842;Triple positive breast cancer;DOCETAXEL;150;PFIZER;33;F;NA;Alopecia
194199753;Plasma cell myeloma;REVLIMID;10;CELGENE;85;M;Other Serious (Important Medical Event);Jaw fracture
194200763;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;55;F;Hospitalization - Initial or Prolonged;Lichen planus
194201033;Plasma cell myeloma;REVLIMID;5;CELGENE;83;F;Death;Infection
194201172;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;NA;Sinusitis
194201522;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;59;F;Other Serious (Important Medical Event);Device leakage
194204524;Unknown;UPTRAVI;1600;JOHNSON AND JOHNSON;74;M;Other Serious (Important Medical Event);Dehydration
194205092;Depression;LATUDA;20;SUNOVION;47;M;Hospitalization - Initial or Prolonged;Dyskinesia
194207253;Neutropenia;NEULASTA;6;AMGEN;69;F;NA;Device malfunction
194208402;Type 2 diabetes mellitus;OZEMPIC;1;NOVO NORDISK;75;M;Hospitalization - Initial or Prolonged;Cataract nuclear
194208522;Chronic lymphocytic leukaemia;VENETOCLAX;20;ROCHE;72;M;Other Serious (Important Medical Event);Alanine aminotransferase increased
194211172;Hairy cell leukaemia;BRAFTOVI;300;PFIZER;71;F;NA;Hypersensitivity
194211904;Philadelphia positive chronic myeloid leukaemia;TASIGNA;300;NOVARTIS;70;F;Other Serious (Important Medical Event);Abdominal pain upper
194215342;NA;NA;NA;BIOMARIN;5;F;Other Serious (Important Medical Event);Anaphylactic reaction
194219465;NA;NA;NA;ALCON;86;F;Other Serious (Important Medical Event);Blindness
194221102;Psoriasis;HUMIRA;40;ABBVIE;55;F;Hospitalization - Initial or Prolonged;Gastrectomy
194221462;Malignant melanoma;OPDIVO;100;BRISTOL MYERS SQUIBB;39;F;Other Serious (Important Medical Event);Cardiac disorder
194222422;Idiopathic pulmonary fibrosis;OFEV;150;BOEHRINGER INGELHEIM;77;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
194229763;Neutropenia;NEULASTA;6;AMGEN;59;F;NA;Unintentional medical device removal
194229912;Rheumatoid arthritis;HUMIRA;40;ABBVIE;50;F;Other Serious (Important Medical Event);Arthralgia
194231332;Blood cholesterol increased;REPATHA;140;AMGEN;74;F;NA;Accidental exposure to product
194233352;Atrial fibrillation;XARELTO;20;JOHNSON AND JOHNSON;60;M;NA;Diarrhoea
194237282;Trigeminal neuralgia;LYRICA;150;PFIZER;50;F;NA;Abdominal pain upper
194238683;Growth disorder;GENOTROPIN;12;PFIZER;14;F;NA;Device issue
194239592;Unknown;LIPITOR;10;PFIZER;88;M;Other Serious (Important Medical Event);Cerebrovascular accident
194240002;Hairy cell leukaemia;BRAFTOVI;450;PFIZER;70;F;Hospitalization - Initial or Prolonged;Lipase increased
194240662;Plasma cell myeloma;REVLIMID;25;CELGENE;56;F;NA;Arthralgia
194241202;Immunodeficiency common variable;GAMUNEX C;35;GRIFOLS;53;F;NA;Rash erythematous
194241242;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;38;F;Hospitalization - Initial or Prolonged;COVID-19
194249842;Plasma cell myeloma;REVLIMID;25;CELGENE;87;F;Hospitalization - Initial or Prolonged;Blood potassium decreased
194251192;Unknown;CIMZIA;200;UCB;62;F;Other Serious (Important Medical Event);Breast cancer
194252014;Ankylosing spondylitis;HUMIRA;40;ABBVIE;33;F;Other Serious (Important Medical Event);Adnexal torsion
194252535;Contraception;NEXPLANON;1;ORGANON;14;F;Hospitalization - Initial or Prolonged;Complication associated with device
194253872;Acute myeloid leukaemia;VENCLEXTA;100;ABBVIE;76;F;Hospitalization - Initial or Prolonged;Abdominal distension
194253953;Contraception;NEXPLANON;68;ORGANON;34;F;NA;Complication of device removal
194258403;Short-bowel syndrome;GATTEX;2.7;TAKEDA;60;F;Other Serious (Important Medical Event);Neuroendocrine tumour
194259794;Plasma cell myeloma;REVLIMID;10;CELGENE;83;M;Death;Death
194261014;Growth hormone deficiency;GENOTROPIN;1.4;PFIZER;13;F;NA;Device mechanical issue
194262312;Contraception;MIRENA;20;BAYER;40;F;Hospitalization - Initial or Prolonged;Embedded device
194263662;NA;NA;NA;ABBVIE;66;F;Other Serious (Important Medical Event);Hypercalcaemia
194263852;Acute myeloid leukaemia;VENETOCLAX;100;ABBVIE;83;F;Hospitalization - Initial or Prolonged;Leukopenia
194266043;Unknown;CIMZIA;400;UCB;64;F;Other Serious (Important Medical Event);Bone contusion
194271662;Contraception;MIRENA;20;BAYER;22;F;Hospitalization - Initial or Prolonged;Abdominal pain lower
194275012;Growth hormone deficiency;GENOTROPIN;1.2;PFIZER;9;F;NA;Device leakage
194275236;Ovarian cancer recurrent;COBIMETINIB;60;ROCHE;62;F;Hospitalization - Initial or Prolonged;Asthenia
194277812;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;41;M;Other Serious (Important Medical Event);Diarrhoea
194281142;Plasma cell myeloma;REVLIMID;5;CELGENE;84;F;NA;Rash
194284464;Rheumatoid arthritis;RINVOQ;15;ABBVIE;74;F;Life-Threatening;Cataract
194284842;Schizophrenia;CLOZAPINE;100;AUROBINDO;59;M;Death;Acute myocardial infarction
194290503;Unknown;ZEJULA;300;GLAXOSMITHKLINE;66;F;Hospitalization - Initial or Prolonged;Anaemia
194290652;Contraception;KYLEENA;17.5;BAYER;21;F;Other Serious (Important Medical Event);Complication of device insertion
194292653;Unknown;ELIQUIS;5;BRISTOL MYERS SQUIBB;83;F;NA;Weight decreased
194295282;Colitis ulcerative;HUMIRA;160;ABBVIE;72;M;Hospitalization - Initial or Prolonged;Arthralgia
194297883;NA;NA;NA;UNITED THERAPEUTICS;52;F;Other Serious (Important Medical Event);Abdominal abscess
194300005;Unknown;KESIMPTA;20;NOVARTIS;54;F;NA;Cough
194300152;Multiple sclerosis;OCREVUS;600;ROCHE;59;F;Hospitalization - Initial or Prolonged;Cystitis
194300322;Bone marrow transplant;REVLIMID;25;CELGENE;59;M;NA;Light chain analysis increased
194300575;Pulmonary arterial hypertension;SELEXIPAG;1200;JOHNSON AND JOHNSON;83;M;Death;Haemoglobin decreased
194301982;Psoriatic arthropathy;STELARA;45;JOHNSON AND JOHNSON;63;F;NA;Accidental exposure to product
194303026;Osteopenia;Alendronate Sodium Tablets USP 70mg;1;AUROBINDO;67;F;Other Serious (Important Medical Event);Blood pressure fluctuation
194308193;Unknown;NEXPLANON;1;ORGANON;41;F;NA;Complication of device insertion
194309373;Unknown;NEXPLANON;1;ORGANON;23;F;NA;Complication of device insertion
194310352;K-ras gene mutation;AMG 510;960;AMGEN;60;F;Other Serious (Important Medical Event);Diarrhoea
194312132;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;50;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194317122;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;51;F;Congenital Anomaly;Joint effusion
194317226;Non-small cell lung cancer stage IV;AMG 510;960;AMGEN;60;F;Other Serious (Important Medical Event);Acute respiratory distress syndrome
194317373;Osteosarcoma;TRASTUZUMAB DERUXTECAN;320;DAIICHI;19;M;Other Serious (Important Medical Event);Wound infection
194320672;Plasma cell myeloma;REVLIMID;15;CELGENE;72;F;NA;Abdominal discomfort
194321594;Psoriatic arthropathy;HUMIRA;40;ABBVIE;67;F;Hospitalization - Initial or Prolonged;Blood iron decreased
194322292;Myasthenic syndrome;FIRDAPSE;10;CATALYST PHARMA;61;F;NA;Inhibitory drug interaction
194322532;NA;NA;NA;CATALYST PHARMA;74;F;NA;Abdominal pain upper
194322962;Myasthenic syndrome;FIRDAPSE;10;CATALYST PHARMA;58;M;Hospitalization - Initial or Prolonged;Asthenia
194323082;NA;NA;NA;CATALYST PHARMA;66;F;Other Serious (Important Medical Event);Abdominal pain
194323222;NA;NA;NA;CATALYST PHARMA;61;F;Other Serious (Important Medical Event);Hypoaesthesia oral
194323962;Plasma cell myeloma;REVLIMID;25;CELGENE;73;F;Other Serious (Important Medical Event);Pneumonia
194325534;Malignant melanoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;75;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194325962;Renal cell carcinoma;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;74;M;Hospitalization - Initial or Prolonged;Drug-induced liver injury
194326624;NA;NA;NA;JOHNSON AND JOHNSON;41;M;NA;Accidental exposure to product
194330352;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;82;F;Other Serious (Important Medical Event);Fall
194331022;Type 2 diabetes mellitus;TRULICITY;0.75;ELI LILLY AND CO;64;F;Death;Death
194332562;Migraine;AIMOVIG;140;AMGEN;33;F;NA;Device difficult to use
194335322;Dermatitis atopic;DUPIXENT;600;SANOFI AVENTIS;28;F;NA;Injection site mass
194335772;Renal cell carcinoma;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;45;M;Other Serious (Important Medical Event);Dyspnoea
194345725;Neutropenia;NEULASTA;6000;AMGEN;46;M;NA;Device issue
194351063;Blood cholesterol increased;REPATHA;420;AMGEN;70;M;NA;Accidental exposure to product
194351783;Hereditary angioedema;HAEGARDA;6000;CSL BEHRING;67;F;Hospitalization - Initial or Prolonged;Chest pain
194357823;Ovarian epithelial cancer;GSK1120212;2;NOVARTIS;65;F;Other Serious (Important Medical Event);Pruritus
194360553;Nephrogenic anaemia;MIRCERA;200;VIFOR;49;M;Other Serious (Important Medical Event);Chest pain
194360923;Chronic obstructive pulmonary disease;TRELEGY ELLIPTA;1;GLAXOSMITHKLINE;74;F;Death;Lung neoplasm malignant
194362672;Plasma cell myeloma;REVLIMID;25;CELGENE;71;F;NA;Rash
194364123;Juvenile idiopathic arthritis;ILARIS;150;NOVARTIS;11;F;NA;Contusion
194365543;Renal cell carcinoma;NIVOLUMAB;229.5;BRISTOL MYERS SQUIBB;78;F;Hospitalization - Initial or Prolonged;Flank pain
194366002;Thrombosis prophylaxis;ELIQUIS;2.5;BRISTOL MYERS SQUIBB;72;F;Other Serious (Important Medical Event);Cerebellar haemorrhage
194366662;Contraception;NEXPLANON;1;ORGANON;28;F;Hospitalization - Initial or Prolonged;Breast cancer
194366842;Iron deficiency;VENOFER;100;AMERICAN REGENT;72;M;Death;Bradycardia
194368132;NA;NA;NA;UNITED THERAPEUTICS;53;F;Other Serious (Important Medical Event);Urosepsis
194371683;Renal cell carcinoma;CABOMETYX;40;EXELIXIS;69;M;Hospitalization - Initial or Prolonged;Death
194373382;Migraine without aura;NURTEC ODT;75;BIOHAVEN PHARMACEUTICALS;52;F;NA;Drug ineffective
194377022;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;50;F;NA;Device delivery system issue
194377232;NA;NA;NA;UNITED THERAPEUTICS;50;F;Hospitalization - Initial or Prolonged;COVID-19
194377294;Depression;BUPROPION HYDROCHLORIDE XL;300;LUPIN;61;M;NA;Drug ineffective
194380742;Plasma cell myeloma;BORTEZOMIB;2.625;TAKEDA;76;M;Other Serious (Important Medical Event);Urinary tract infection
194380984;NA;NA;NA;PFIZER;6;M;NA;Drug dose omission by device
194383342;Depression;SPRAVATO;56;JOHNSON AND JOHNSON;65;M;Other Serious (Important Medical Event);Aortic aneurysm
194383732;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;59;F;NA;Device leakage
194387253;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;88;M;Hospitalization - Initial or Prolonged;Haemorrhage
194389482;Unknown;IMBRUVICA;140;ABBVIE;87;M;Hospitalization - Initial or Prolonged;Death
194390313;NA;NA;NA;ROCHE;55;F;NA;Back pain
194390342;Rheumatoid arthritis;ORENCIA;750;BRISTOL MYERS SQUIBB;81;F;Other Serious (Important Medical Event);Death
194392155;NA;NA;NA;PFIZER;67;F;Hospitalization - Initial or Prolonged;Drug interaction
194393602;NA;NA;NA;PFIZER;81;M;Other Serious (Important Medical Event);Autoimmune neuropathy
194395684;Unknown;NEXPLANON;1;ORGANON;33;F;NA;Complication of device insertion
194397053;Unknown;DULERA;1;ORGANON;76;M;NA;Device malfunction
194398222;Plasma cell myeloma;POMALYST;2;CELGENE;74;F;NA;Contusion
194398472;Plasma cell myeloma;REVLIMID;10;CELGENE;81;M;NA;Decreased appetite
194400712;Blood cholesterol increased;REPATHA;140;AMGEN;69;F;NA;Device difficult to use
194403642;Diabetes mellitus;Metformin HCl;500;GRANULES INDIA;74;M;NA;Abdominal discomfort
194407393;Obesity;Semaglutide B 30 mg/ml PDS290;2.4;NOVO NORDISK;48;F;Hospitalization - Initial or Prolonged;Gastrointestinal inflammation
194409522;Crohn's disease;HUMIRA;40;ABBVIE;53;M;Other Serious (Important Medical Event);Abdominal adhesions
194410554;Ovarian cancer metastatic;BELEODAQ;600;AUROBINDO;60;F;Other Serious (Important Medical Event);Acute respiratory failure
194412603;Neutropenia;NEULASTA;6;AMGEN;69;F;NA;Device use error
194413192;Plasma cell myeloma;REVLIMID;25;CELGENE;61;M;NA;Adverse drug reaction
194416402;Seizure;LEVETIRACETAM;500;UCB;73;M;NA;COVID-19 immunisation
194416452;Blood cholesterol increased;REPATHA;140;AMGEN;70;F;NA;Wrong technique in product usage process
194419673;Hypothyroidism;SYNTHROID;88;ABBVIE;74;F;Other Serious (Important Medical Event);Anxiety
194429673;Irritable bowel syndrome;MOTEGRITY;2;TAKEDA;58;F;Hospitalization - Initial or Prolonged;Drug ineffective
194433902;Analgesic therapy;MORPHINE SULFATE;30;PFIZER;0;F;Hospitalization - Initial or Prolonged;Bladder dilatation
194435902;Relapsing multiple sclerosis;OCREVUS;600;ROCHE;45;M;NA;COVID-19
194436022;Psoriasis;STELARA;45;JOHNSON AND JOHNSON;41;F;NA;Product dose omission issue
194436362;Breast cancer metastatic;IBRANCE;125;PFIZER;71;F;Other Serious (Important Medical Event);Myelosuppression
194436532;Plasma cell myeloma;LENALIDOMIDE;25;CELGENE;54;M;Other Serious (Important Medical Event);Atrial fibrillation
194437892;Pulmonary embolism;APIXABAN;5;BRISTOL MYERS SQUIBB;84;F;Hospitalization - Initial or Prolonged;Contusion
194438713;NA;NA;NA;BOEHRINGER INGELHEIM;74;F;Life-Threatening;Abdominal pain
194439742;NA;NA;NA;BRISTOL MYERS SQUIBB;46;M;Other Serious (Important Medical Event);Death
194439756;Drug withdrawal syndrome;LUCEMYRA;0.18;ALKERMES;38;F;Other Serious (Important Medical Event);Nausea
194439942;Pulmonary arterial hypertension;AMBRISENTAN;10;GILEAD;74;M;Other Serious (Important Medical Event);Dehydration
194440482;Plasma cell myeloma;Ixazomib;3;TAKEDA;78;F;Other Serious (Important Medical Event);Embolic stroke
194441052;NA;NA;NA;ARBOR;64;M;Hospitalization - Initial or Prolonged;Aphasia
194442752;Rheumatoid arthritis;RINVOQ;15;ABBVIE;61;F;Other Serious (Important Medical Event);Fall
194443222;Pulmonary arterial hypertension;AMBRISENTAN;10;GILEAD;65;M;Hospitalization - Initial or Prolonged;Ventricular tachycardia
194443852;Pancreatic failure;CREON;36000;ABBVIE;54;F;Other Serious (Important Medical Event);Chronic obstructive pulmonary disease
194445153;Sickle cell anaemia with crisis;ADAKVEO;5;NOVARTIS;21;F;Hospitalization - Initial or Prolonged;Back pain
194449182;Phenylketonuria;PALYNZIQ;20;BIOMARIN;51;M;Disability;Ageusia
194453133;Rheumatoid arthritis;RINVOQ;15;ABBVIE;67;F;Death;Chronic obstructive pulmonary disease
194456072;Rheumatoid arthritis;HUMIRA;40;ABBVIE;65;F;Other Serious (Important Medical Event);Device issue
194456082;Glioblastoma multiforme;AMG 386;15;AMGEN;60;F;Hospitalization - Initial or Prolonged;Encephalopathy
194467772;Neutropenia;NEULASTA;6;AMGEN;61;F;NA;Unintentional medical device removal
194471202;Contraception;MIRENA;20;BAYER;35;F;Other Serious (Important Medical Event);Complication of device insertion
194471322;Contraception;MIRENA;20;BAYER;23;F;Other Serious (Important Medical Event);Abdominal pain lower
194471732;Rheumatoid arthritis;RINVOQ;15;ABBVIE;68;F;Hospitalization - Initial or Prolonged;Squamous cell carcinoma of skin
194473462;Pulmonary hypertension;AMBRISENTAN;10;GILEAD;38;F;Hospitalization - Initial or Prolonged;Dyspnoea
194477573;NA;NA;NA;UNITED THERAPEUTICS;53;F;Other Serious (Important Medical Event);Death
194478574;Drug use disorder;VIVITROL;380;ALKERMES;38;F;Hospitalization - Initial or Prolonged;Nausea
194481932;Unknown;NEURONTIN;800;PFIZER;57;F;Other Serious (Important Medical Event);Rash
194490362;Plasma cell myeloma;NINLARO;4;TAKEDA;82;F;Other Serious (Important Medical Event);Diarrhoea
194490457;Skin cancer;ATEZOLIZUMAB;1200;ROCHE;60;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194491232;Central nervous system lymphoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;60;F;Other Serious (Important Medical Event);Asthenia
194491452;Hypopituitarism;GENOTROPIN;2.4;PFIZER;15;M;NA;Device breakage
194493322;Diffuse large B-cell lymphoma;REVLIMID;20;CELGENE;71;M;NA;Platelet count decreased
194493832;COVID-19;Etesevimab 700mg;1400;ELI LILLY AND CO;62;F;Other Serious (Important Medical Event);Acute respiratory failure
194494594;Immune system disorder;Lanadelumab;300;TAKEDA;58;M;Other Serious (Important Medical Event);Colon neoplasm
194496603;NA;NA;NA;BAYER;52;M;Other Serious (Important Medical Event);Dizziness
194498414;NA;NA;NA;UNITED THERAPEUTICS;30;F;Hospitalization - Initial or Prolonged;Mental disorder
194498602;Sickle cell disease;CRIZANLIZUMAB;5;NOVARTIS;28;M;NA;Headache
194499572;Contraception;MIRENA;20;BAYER;20;F;Other Serious (Important Medical Event);Complication of device insertion
194499644;Plasma cell myeloma;REVLIMID;25;CELGENE;57;M;Other Serious (Important Medical Event);Back pain
194500305;Sickle cell anaemia with crisis;ADAKVEO;5;NOVARTIS;20;F;Other Serious (Important Medical Event);Abdominal pain
194502762;Blood cholesterol increased;REPATHA;420;AMGEN;81;F;NA;Wrong technique in product usage process
194504292;Colitis ulcerative;HUMIRA;40;ABBVIE;27;F;Hospitalization - Initial or Prolonged;Asthenia
194504662;Herpes zoster;GABAPENTIN;100;PFIZER;72;F;NA;Drug ineffective for unapproved indication
194504683;Unknown;TREMFYA;100;JOHNSON AND JOHNSON;59;M;NA;Accidental exposure to product
194506342;Breast cancer metastatic;IBRANCE;125;PFIZER;51;F;Hospitalization - Initial or Prolonged;Death
194506422;Psoriasis;SKYRIZI;150;ABBVIE;63;F;Other Serious (Important Medical Event);Urinary tract infection
194507195;Colorectal adenocarcinoma;AMG 510;960;AMGEN;71;F;Hospitalization - Initial or Prolonged;Cellulitis
194507592;Lung carcinoma cell type unspecified stage IV;TABRECTA;200;NOVARTIS;83;F;Other Serious (Important Medical Event);Abdominal distension
194510163;Myelodysplastic syndrome;VIDAZA;166;CELGENE;67;M;Other Serious (Important Medical Event);Acute myeloid leukaemia
194515372;NA;NA;NA;UNITED THERAPEUTICS;70;F;Other Serious (Important Medical Event);Dyspnoea
194516163;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;76;M;Hospitalization - Initial or Prolonged;Micrographic skin surgery
194516542;Multiple sclerosis;REBIF;44;EMD SERONO INC;62;F;Death;Myocardial infarction
194518183;Metastatic malignant melanoma;ALDESLEUKIN;600000;CLINIGEN;39;M;Other Serious (Important Medical Event);Thrombocytopenia
194518362;Plasma cell myeloma;DARZALEX;16;JOHNSON AND JOHNSON;71;M;Hospitalization - Initial or Prolonged;Streptococcal bacteraemia
194518542;Mucopolysaccharidosis II;Idursulfase;0.5;TAKEDA;19;M;Hospitalization - Initial or Prolonged;Dyspnoea
194520242;Colitis ulcerative;STELARA;520;JOHNSON AND JOHNSON;54;M;NA;Infusion related reaction
194523312;NA;NA;NA;UCB;33;F;Other Serious (Important Medical Event);Eating disorder
194523422;Contraception;MIRENA;20;BAYER;24;F;Other Serious (Important Medical Event);Device issue
194523465;Ovarian cancer metastatic;KISQALI;200;NOVARTIS;60;F;Hospitalization - Initial or Prolonged;Dyspnoea
194524982;Arthralgia;LIDOCAINE PATCH;5;MYLAN;78;F;NA;Off label use
194535392;NA;NA;NA;PFIZER;45;M;Other Serious (Important Medical Event);Cerebral cyst
194537022;Arthritis;XELJANZ XR;11;PFIZER;73;M;Other Serious (Important Medical Event);Asthenia
194538273;Psoriatic arthropathy;COSENTYX;300;NOVARTIS;55;F;NA;Condition aggravated
194540943;Growth hormone deficiency;GENOTROPIN;1.2;PFIZER;6;M;NA;Device delivery system issue
194541802;Non-small cell lung cancer metastatic;LENVATINIB;20;EISAI;58;M;NA;Sinus tachycardia
194542245;NA;NA;NA;NOVARTIS;0;M;Hospitalization - Initial or Prolonged;Mouth haemorrhage
194543692;Unknown;AZACITIDINE;85;CELGENE;13;M;Other Serious (Important Medical Event);Muscular weakness
194543804;Multiple sclerosis;TYSABRI;300;BIOGEN;30;F;Hospitalization - Initial or Prolonged;Chest pain
194544022;Renal cancer;CABOMETYX;40;EXELIXIS;39;M;Other Serious (Important Medical Event);Diarrhoea
194544114;Bladder cancer;NIVOLUMAB;360;BRISTOL MYERS SQUIBB;72;M;Hospitalization - Initial or Prolonged;Dyspnoea
194545233;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;61;F;Death;Headache
194545262;Short-bowel syndrome;Teduglutide;5.1;TAKEDA;59;F;Other Serious (Important Medical Event);Cellulitis
194545373;NA;NA;NA;NOVARTIS;0;M;Hospitalization - Initial or Prolonged;Contusion
194545513;NA;NA;NA;ROCHE;68;F;Other Serious (Important Medical Event);Dysphagia
194545865;Mucopolysaccharidosis IV;VIMIZIM;100;BIOMARIN;15;M;Death;Acute kidney injury
194547032;Colon cancer;LONSURF;60;TAIHO ONCOLOGY INC;50;M;Life-Threatening;Biopsy liver
194550705;Hormone receptor positive HER2 negative breast cancer;PALBOCICLIB;125;PFIZER;45;F;Hospitalization - Initial or Prolonged;Embolism
194551103;Amyloidosis;VYNDAMAX;61;PFIZER;88;M;Hospitalization - Initial or Prolonged;Haemorrhage
194553103;Follicular lymphoma;LENALIDOMIDE;20;CELGENE;70;M;Other Serious (Important Medical Event);COVID-19
194554362;Unknown;PERJETA;840;ROCHE;63;F;Other Serious (Important Medical Event);Breast cancer
194556812;Psoriasis;SKYRIZI;150;ABBVIE;62;F;Other Serious (Important Medical Event);Fall
194556912;Psoriasis;SKYRIZI;150;ABBVIE;44;F;Death;Chest pain
194557632;NA;NA;NA;CELGENE;70;M;Hospitalization - Initial or Prolonged;Anaemia
194557853;Neutropenia;NEULASTA;6;AMGEN;69;F;NA;Unintentional medical device removal
194558013;NA;NA;NA;UNITED THERAPEUTICS;51;F;Death;Cough
194560292;Unknown;REPATHA;140;AMGEN;71;F;NA;Device difficult to use
194561032;Dyslipidaemia;evolocumab;140;AMGEN;68;F;Hospitalization - Initial or Prolonged;Alcoholic pancreatitis
194561433;Crohn's disease;HUMIRA;20;ABBVIE;15;F;Life-Threatening;Abdominal pain lower
194563202;Unknown;PROLIA;60;AMGEN;63;F;NA;Drug dose omission by device
194563813;NA;NA;NA;HIKMA;70;M;Other Serious (Important Medical Event);Cough
194564742;NA;NA;NA;UNITED THERAPEUTICS;38;F;Other Serious (Important Medical Event);Pneumonia
194566624;B-cell lymphoma;CARBOPLATIN;575;NOVARTIS;73;M;Hospitalization - Initial or Prolonged;Atrial flutter
194568652;Blood cholesterol increased;REPATHA;140;AMGEN;68;M;NA;Accidental exposure to product
194569972;Contraception;MIRENA;20;BAYER;34;F;Death;Embedded device
194571913;Unknown;NEXPLANON;1;ORGANON;29;F;NA;Complication of device insertion
194573913;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;62;F;Other Serious (Important Medical Event);Asthenia
194575202;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;81;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
194575593;NA;NA;NA;UNITED THERAPEUTICS;73;F;Hospitalization - Initial or Prolonged;Asthenia
194578092;Cardiomyopathy;ENTRESTO;50;NOVARTIS;52;M;Other Serious (Important Medical Event);Death
194578302;Septo-optic dysplasia;GENOTROPIN;5;PFIZER;0;F;NA;Device leakage
194579692;Unknown;DEPO PROVERA;104;PFIZER;29;F;NA;Device issue
194579743;Contraception;DEPO PROVERA;104;PFIZER;24;F;NA;Drug dose omission by device
194582923;Growth hormone deficiency;GENOTROPIN;2.4;PFIZER;45;F;NA;Device information output issue
194584532;Plasma cell myeloma;REVLIMID;25;CELGENE;68;F;NA;Diarrhoea
194585132;Unknown;NEXPLANON;1;ORGANON;25;F;NA;Complication of device insertion
194586423;Endometriosis;ACTIVELLA;1;AMNEAL;40;F;Other Serious (Important Medical Event);Gastroenteritis
194588624;Angioedema;C1 Inhibitor (Human);2500;TAKEDA;79;F;Other Serious (Important Medical Event);Abdominal distension
194590762;Relapsing multiple sclerosis;ZEPOSIA;0.92;CELGENE;52;M;NA;Oedema peripheral
194591952;Unknown;NEXPLANON;1;ORGANON;35;F;Hospitalization - Initial or Prolonged;Hyperglycaemia
194592672;Short-bowel syndrome;Teduglutide;0.2;TAKEDA;67;F;Hospitalization - Initial or Prolonged;Renal failure
194593142;Primary progressive multiple sclerosis;OCRELIZUMAB;260;ROCHE;49;F;Other Serious (Important Medical Event);Clostridium difficile infection
194593652;NA;NA;NA;AMGEN;58;F;Death;Dehydration
194597083;Myelodysplastic syndrome;IPILIMUMAB;990;BRISTOL MYERS SQUIBB;73;M;Hospitalization - Initial or Prolonged;Acute respiratory failure
194600453;NA;NA;NA;UNITED THERAPEUTICS;43;F;Other Serious (Important Medical Event);Dyspnoea
194602122;Neutropenia;NEULASTA;6;AMGEN;67;F;NA;Unintentional medical device removal
194604622;Short-bowel syndrome;Teduglutide;0.25;TAKEDA;29;F;Hospitalization - Initial or Prolonged;Surgery
194605152;Plasma cell myeloma;REVLIMID;25;CELGENE;69;M;Other Serious (Important Medical Event);Cataract
194605222;Plasma cell myeloma;REVLIMID;25;CELGENE;68;M;NA;Full blood count decreased
194605582;NA;NA;NA;GILEAD;76;M;Hospitalization - Initial or Prolonged;Amnesia
194606083;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;43;F;NA;Accidental exposure to product
194608216;Neutropenia;NEULASTA;6;AMGEN;86;F;NA;Application site haemorrhage
194609353;Turner's syndrome;GENOTROPIN;3;PFIZER;13;F;NA;Device breakage
194610692;NA;NA;NA;CELGENE;55;F;Hospitalization - Initial or Prolonged;Hypotension
194610862;NA;NA;NA;GLAXOSMITHKLINE;63;F;NA;Arthralgia
194611022;NA;NA;NA;BAYER;76;F;Other Serious (Important Medical Event);Blood count abnormal
194614802;Unknown;KYNMOBI;20;SUNOVION;78;M;Other Serious (Important Medical Event);Confusional state
194616702;Squamous cell carcinoma of head and neck;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;64;M;Death;Decreased appetite
194617033;Contraception;DEPO PROVERA;104;PFIZER;38;F;NA;Drug dose omission by device
194617362;Plasma cell myeloma;REVLIMID;10;CELGENE;85;F;Hospitalization - Initial or Prolonged;Cystitis
194617823;NA;NA;NA;UNITED THERAPEUTICS;77;M;Life-Threatening;Dyspnoea
194618232;Plasma cell myeloma;REVLIMID;5;CELGENE;66;M;Other Serious (Important Medical Event);Death
194622992;Central nervous system lymphoma;IBRUTINIB;560;ABBVIE;60;F;Hospitalization - Initial or Prolonged;Asthenia
194623553;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;52;M;Death;Atrial fibrillation
194623913;Unknown;ABILIFY MAINTENA;400;OTSUKA;40;M;Other Serious (Important Medical Event);Blindness transient
194625583;Rheumatoid arthritis;CIMZIA;400;UCB;67;F;Hospitalization - Initial or Prolonged;Back disorder
194626443;Multiple sclerosis;MAYZENT;0.25;NOVARTIS;43;F;Other Serious (Important Medical Event);Burning sensation
194627113;Endometrial cancer metastatic;AXITINIB;5;PFIZER;65;F;Hospitalization - Initial or Prolonged;Abdominal pain
194628604;NA;NA;NA;ABBVIE;39;F;Life-Threatening;Depression
194629322;Contraception;IMPLANON;1;ORGANON;35;F;NA;Implant site pain
194629464;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;Hospitalization - Initial or Prolonged;Balance disorder
194634272;NA;NA;NA;VERTEX;56;M;Death;Cerebrovascular accident
194635222;Malignant atrophic papulosis;SOLIRIS;1200;ALEXION;57;F;Other Serious (Important Medical Event);Abdominal wall haematoma
194636312;NA;NA;NA;ELI LILLY AND CO;50;M;NA;Diarrhoea
194636803;Narcolepsy;XYREM;2.25;JAZZ;38;F;Other Serious (Important Medical Event);Lower limb fracture
194637092;Plasma cell myeloma;POMALYST;3;CELGENE;81;M;NA;Cyst
194637262;Transitional cell carcinoma;SACITUZUMAB GOVITECAN;10;GILEAD;67;M;Hospitalization - Initial or Prolonged;Dehydration
194638162;Acute lymphocytic leukaemia;KYMRIAH;14;NOVARTIS;23;F;Other Serious (Important Medical Event);Cytopenia
194638322;Pain;LIDOCAINE HYDROCHLORIDE;160;INTERNATIONAL MEDICATION SYSTEM;57;M;Hospitalization - Initial or Prolonged;Foreign body in gastrointestinal tract
194639063;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;31;M;Other Serious (Important Medical Event);Crohn's disease
194640995;Plasma cell myeloma;carfilzomib;20;AMGEN;70;F;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
194642094;Menstrual cycle management;NEXPLANON;68;ORGANON;27;F;NA;Abnormal uterine bleeding
194645203;Rheumatoid arthritis;RINVOQ;15;ABBVIE;56;F;Hospitalization - Initial or Prolonged;Malignant melanoma
194645753;NA;NA;NA;UNITED THERAPEUTICS;48;F;Other Serious (Important Medical Event);Hypokalaemia
194652684;Plasma cell myeloma;REVLIMID;15;CELGENE;76;F;Hospitalization - Initial or Prolonged;Pulmonary thrombosis
194655702;Psoriasis;COSENTYX;300;NOVARTIS;74;F;Other Serious (Important Medical Event);Hypersensitivity
194655792;Neoplasm;SACITUZUMAB GOVITECAN;67.1;GILEAD;81;F;Other Serious (Important Medical Event);Colitis
194656645;Chronic myeloid leukaemia;ICLUSIG;45;TAKEDA;85;F;Other Serious (Important Medical Event);Asthenia
194656804;Plasma cell myeloma;NINLARO;3;TAKEDA;72;F;Hospitalization - Initial or Prolonged;Death
194658053;Neoplasm malignant;REVLIMID;25;CELGENE;55;M;NA;Confusional state
194659432;Unknown;REPATHA;140;AMGEN;64;M;NA;Product storage error
194662902;Chronic lymphocytic leukaemia;VENCLEXTA;100;ABBVIE;65;M;Hospitalization - Initial or Prolonged;Asthenia
194663392;Spinal muscular atrophy;SPINRAZA;12;BIOGEN;37;M;Other Serious (Important Medical Event);Prescribed underdose
194663992;Psoriasis;SKYRIZI;150;ABBVIE;62;M;NA;Psoriasis
194665512;Metastatic malignant melanoma;denosumab;120;AMGEN;43;F;Hospitalization - Initial or Prolonged;Rash maculo-papular
194668124;Osteoporosis postmenopausal;EVENITY;210;AMGEN;69;F;Hospitalization - Initial or Prolonged;Transient ischaemic attack
194669482;Lung cancer metastatic;ALUNBRIG;180;TAKEDA;83;F;NA;Nausea
194672612;Non-small cell lung cancer;ALECENSA;600;ROCHE;74;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194681512;Plasma cell myeloma;POMALYST;4;CELGENE;64;M;NA;Myalgia
194683912;Schizophrenia;INVEGA TRINZA;819;JOHNSON AND JOHNSON;52;M;NA;Device leakage
194685733;Schizophrenia;CAPLYTA;42;INTRA-CELLULAR THERAPIES;40;M;Disability;Feeling cold
194686382;NA;NA;NA;ROCHE;45;F;NA;COVID-19
194688862;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;61;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
194691144;K-ras gene mutation;AMG 510;480;AMGEN;74;F;Other Serious (Important Medical Event);Hypokalaemia
194691802;NA;NA;NA;AUROBINDO;73;M;Other Serious (Important Medical Event);Neutrophilia
194692733;Plasma cell myeloma;DARATUMUMAB;16;JOHNSON AND JOHNSON;70;F;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
194695102;Plasma cell myeloma;REVLIMID;10;CELGENE;86;M;NA;Asthenia
194695462;Seizure;LEVETIRACETAM EXTENDED RELEASE TABLET USP, 500 MG;500;LUPIN;71;F;Death;Adverse drug reaction
194697382;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;63;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
194697522;Pulmonary arterial hypertension;SELEXIPAG;400;JOHNSON AND JOHNSON;80;F;Hospitalization - Initial or Prolonged;Syncope
194697582;Rheumatoid arthritis;Certolizumab pegol;400;UCB;69;F;Death;Drug ineffective
194698862;Psoriasis;COSENTYX;300;NOVARTIS;66;F;Hospitalization - Initial or Prolonged;Invasive ductal breast carcinoma
194700872;Unknown;VYONDYS 53;1800;SAREPTA THERAPEUTICS;16;M;NA;Device issue
194701792;Plasma cell myeloma;carfilzomib;27;AMGEN;64;M;Other Serious (Important Medical Event);Spinal cord compression
194706932;Non-small cell lung cancer stage IV;AMG 510;960;AMGEN;62;F;Hospitalization - Initial or Prolonged;Dyspnoea
194707122;Chronic myelomonocytic leukaemia;COBIMETINIB;60;ROCHE;72;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194707502;Plasma cell myeloma;REVLIMID;25;CELGENE;71;M;Other Serious (Important Medical Event);Abdominal discomfort
194709103;NA;NA;NA;ABBVIE;78;U;Hospitalization - Initial or Prolonged;Chest pain
194710833;Osteoporosis;FORTEO;20;ELI LILLY AND CO;68;F;Other Serious (Important Medical Event);Pulmonary embolism
194713002;Plasma cell myeloma;POMALYST;4;CELGENE;75;F;NA;Feeling cold
194713112;Psoriasis;SKYRIZI;150;ABBVIE;45;F;Other Serious (Important Medical Event);Ankle fracture
194713433;NA;NA;NA;NOVARTIS;70;M;Hospitalization - Initial or Prolonged;Platelet count decreased
194714772;COVID-19;Etesevimab 700mg;1400;ELI LILLY AND CO;76;M;Hospitalization - Initial or Prolonged;Abdominal pain
194714922;COVID-19;Etesevimab 700mg;1400;ELI LILLY AND CO;79;M;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
194715882;Migraine prophylaxis;AIMOVIG;70;AMGEN;58;F;NA;Accidental exposure to product
194716344;Rheumatoid arthritis;SIMPONI;50;JOHNSON AND JOHNSON;39;F;NA;Accidental exposure to product
194721803;B-cell lymphoma;MOSUNETUZUMAB;5;ROCHE;73;M;Other Serious (Important Medical Event);Uveitis
194723592;Contraception;NEXPLANON;1;ORGANON;19;F;NA;Complication of device removal
194724075;Hormone receptor negative HER2 positive breast cancer;PALBOCICLIB;125;PFIZER;45;F;Hospitalization - Initial or Prolonged;Embolism
194725943;Pulmonary arterial hypertension;UPTRAVI;1200;JOHNSON AND JOHNSON;76;F;Death;Asthenia
194726192;Plasma cell myeloma;REVLIMID;25;CELGENE;64;M;NA;Cough
194726413;Non-small cell lung cancer stage IV;AMG 510;960;AMGEN;76;F;Other Serious (Important Medical Event);Sepsis
194726472;Rheumatoid arthritis;ABATACEPT;125;BRISTOL MYERS SQUIBB;71;M;Hospitalization - Initial or Prolonged;Bacteraemia
194727902;Gastrooesophageal reflux disease;ZEGERID;40;BAUSCH AND LOMB;76;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194729583;Blood growth hormone abnormal;GENOTROPIN;0.2;PFIZER;40;F;Other Serious (Important Medical Event);Blindness
194730702;NA;NA;NA;BAYER;32;F;Hospitalization - Initial or Prolonged;Abdominal pain
194732933;NA;NA;NA;CELGENE;59;F;NA;Anaemia
194733412;NA;NA;NA;BIOVITRUM;64;F;Hospitalization - Initial or Prolonged;Antibody test abnormal
194734002;Unknown;NEXPLANON;1;ORGANON;16;F;NA;Circumstance or information capable of leading to medication error
194734122;NA;NA;NA;BAYER;71;M;Other Serious (Important Medical Event);Cardiac operation
194734232;NA;NA;NA;INTERCEPT PHARMACEUTICALS;74;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
194734552;Non-Hodgkin's lymphoma unspecified histology indolent;AXICABTAGENE CILOLEUCEL;68;GILEAD;68;F;Other Serious (Important Medical Event);Cellulitis
194734692;NA;NA;NA;ABBVIE;79;F;Other Serious (Important Medical Event);Dry age-related macular degeneration
194734792;Chronic lymphocytic leukaemia;OBINUTUZUMAB;100;ROCHE;63;F;Other Serious (Important Medical Event);Cellulitis
194737512;Plasma cell myeloma;REVLIMID;10;CELGENE;72;F;Hospitalization - Initial or Prolonged;Death
194738172;Myasthenia gravis;GAMUNEX C;10;GRIFOLS;71;F;NA;Rash
194741342;Blood cholesterol increased;REPATHA;140;AMGEN;69;F;NA;Accidental exposure to product
194743492;Non-small cell lung cancer stage IV;AMG 510;960;AMGEN;83;F;Hospitalization - Initial or Prolonged;Pleural effusion
194749742;NA;NA;NA;UNITED THERAPEUTICS;73;M;Other Serious (Important Medical Event);Death
194752085;Neutropenia;NEULASTA;6;AMGEN;70;F;NA;Device adhesion issue
194752923;Blood cholesterol increased;REPATHA;140;AMGEN;69;M;NA;Accidental exposure to product
194752995;Pulmonary arterial hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;76;F;Hospitalization - Initial or Prolonged;Back pain
194753454;Hyperkalaemia;VELTASSA;8.4;VIFOR;84;F;Hospitalization - Initial or Prolonged;Fall
194753602;Prophylaxis;NEULASTA;6;AMGEN;44;F;NA;Device use error
194754112;Rheumatoid arthritis;RINVOQ;15;ABBVIE;65;F;Hospitalization - Initial or Prolonged;Malignant melanoma
194757442;Breast cancer;KADCYLA;3.6;ROCHE;54;F;Life-Threatening;Device related infection
194760742;Non-Hodgkin's lymphoma;MESNA;9800;NOVARTIS;73;F;Death;Lip infection
194760872;Contraception;MIRENA;20;BAYER;51;F;Hospitalization - Initial or Prolonged;Abdominal pain lower
194764893;Contraception;NEXPLANON;1;ORGANON;44;F;Death;Complication of device removal
194764932;Unknown;Cholestyramine (ANDA 211119);4;AJANTA PHARMA;53;M;NA;Abdominal pain upper
194771302;Contraception;NEXPLANON;1;ORGANON;36;F;NA;Complication of device insertion
194772832;Unknown;IMPLANON;1;ORGANON;28;F;NA;Complication of device insertion
194775832;Plasma cell myeloma;REVLIMID;10;CELGENE;79;F;Other Serious (Important Medical Event);Dyspnoea
194777042;Unknown;NEXPLANON;1;ORGANON;18;F;NA;Complication of device insertion
194778712;Plasma cell myeloma;FLUDARABINE;60;FRESENIUS KABI;69;M;Death;Leukaemia
194779502;Psoriasis;COSENTYX;300;NOVARTIS;57;F;Life-Threatening;Abdominal distension
194781282;Crohn's disease;HUMIRA;40;ABBVIE;50;F;Hospitalization - Initial or Prolonged;Abdominal operation
194785442;Non-small cell lung cancer metastatic;RYBREVANT;350;JOHNSON AND JOHNSON;83;M;NA;Chest discomfort
194785802;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;42;M;NA;Asthenia
194787591;Myelodysplastic syndrome unclassifiable;REVLIMID;5;CELGENE;78;F;NA;Platelet count increased
194789132;NA;NA;NA;ABBVIE;80;M;Death;Acute kidney injury
194789492;Prophylaxis;NEULASTA;6;AMGEN;64;M;NA;Intercepted medication error
194789812;Back pain;LIDOCAINE PATCH;5;MYLAN;78;M;NA;Drug ineffective for unapproved indication
194790681;Mantle cell lymphoma;REVLIMID;20;CELGENE;75;M;NA;Thrombocytopenia
194791352;Hypercholesterolaemia;REPATHA;140;AMGEN;88;F;NA;Device difficult to use
194793501;Plasma cell myeloma;POMALYST;4;CELGENE;77;F;NA;Diarrhoea
194794233;NA;NA;NA;ALEXION;64;M;Hospitalization - Initial or Prolonged;Breakthrough haemolysis
194794263;Fabry's disease;FABRAZYME;65;SANOFI AVENTIS;53;F;Hospitalization - Initial or Prolonged;Infusion site haemorrhage
194794442;Unknown;Teduglutide;0.279;TAKEDA;54;F;Other Serious (Important Medical Event);Complication associated with device
194795402;Plasma cell myeloma;POMALYST;1;CELGENE;60;M;Hospitalization - Initial or Prolonged;Thrombosis
194795843;Oropharyngeal cancer;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;40;M;Other Serious (Important Medical Event);Dehydration
194797862;Unknown;AIMOVIG;140;AMGEN;53;F;NA;Accidental exposure to product
194797952;Plasma cell myeloma;FLUDARABINE PHOSPHATE;60;PFIZER;69;M;Other Serious (Important Medical Event);Acute myeloid leukaemia
194797982;Phenylketonuria;PALYNZIQ;40;BIOMARIN;24;F;Hospitalization - Initial or Prolonged;Asthenia
194798871;Pulmonary arterial hypertension;UPTRAVI;1600;JOHNSON AND JOHNSON;65;F;Hospitalization - Initial or Prolonged;Asthenia
194799744;Duchenne muscular dystrophy;EXONDYS 51;1100;SAREPTA THERAPEUTICS;21;M;Hospitalization - Initial or Prolonged;Pneumonia
194799842;NA;NA;NA;ELI LILLY AND CO;62;F;Other Serious (Important Medical Event);Stevens-Johnson syndrome
194803642;Unknown;EPCLUSA;1;GILEAD;33;F;NA;Bradycardia
194805923;Crohn's disease;HUMIRA;40;ABBVIE;68;F;Other Serious (Important Medical Event);Epistaxis
194806091;Renal disorder;MYCOPHENOLIC ACID;500;ACCORD;53;F;NA;Abdominal pain
194807991;Chronic lymphocytic leukaemia;OBINUTUZUMAB;1000;ROCHE;60;F;Hospitalization - Initial or Prolonged;Neutrophil count decreased
194808341;Migraine;AJOVY;225;TEVA;67;F;NA;Dizziness
194808703;Unknown;NEXPLANON;1;ORGANON;53;F;NA;Complication of device insertion
194809262;Myasthenia gravis;HIZENTRA;20;CSL BEHRING;54;F;Hospitalization - Initial or Prolonged;Arthralgia
194810363;Rheumatoid arthritis;HUMIRA;40;ABBVIE;55;F;Other Serious (Important Medical Event);Alanine aminotransferase increased
194811353;Neutropenia;NEULASTA;6;AMGEN;58;F;NA;Device use error
194812892;Rheumatoid arthritis;RINVOQ;15;ABBVIE;61;F;Other Serious (Important Medical Event);Squamous cell carcinoma of skin
194813181;Plasma cell myeloma;REVLIMID;15;CELGENE;84;F;NA;Thinking abnormal
194814402;Depression;SPRAVATO;84;JOHNSON AND JOHNSON;25;F;Other Serious (Important Medical Event);Product dose omission issue
194814511;Hepatocellular carcinoma;AVASTIN;1075;ROCHE;86;F;Hospitalization - Initial or Prolonged;Diarrhoea
194814561;Plasma cell myeloma;REVLIMID;20;CELGENE;72;F;NA;Anaemia
194815872;Plasma cell myeloma;BELANTAMAB MAFODOTIN;193.25;GLAXOSMITHKLINE;63;M;Hospitalization - Initial or Prolonged;Chills
194816731;Immune thrombocytopenia;RITUXAN;900;ROCHE;73;M;Hospitalization - Initial or Prolonged;Bradycardia
194818011;Rhesus antigen negative;RHOGAM ULTRA FILTERED PLUS;300;KENDRION BIOPHARMA;32;F;NA;Injection site pain
194819701;Plasma cell myeloma;REVLIMID;5;CELGENE;64;F;Hospitalization - Initial or Prolonged;Death
194819981;NA;NA;NA;ALKEM;74;F;NA;Aura
194821441;Diffuse large B-cell lymphoma;REVLIMID;20;CELGENE;84;M;NA;Anaemia
194821511;Relapsing multiple sclerosis;ZEPOSIA;0.92;CELGENE;21;F;NA;Lymphocyte count decreased
194821521;Plasma cell myeloma;REVLIMID;2.5;CELGENE;72;M;NA;Confusional state
194821531;Plasma cell myeloma;REVLIMID;25;CELGENE;61;F;NA;Full blood count decreased
194821541;Plasma cell myeloma;REVLIMID;20;CELGENE;90;M;NA;Constipation
194821881;Ovarian cancer;RUBRACA;600;CLOVIS ONCOLOGY;87;F;Hospitalization - Initial or Prolonged;Death
194822592;K-ras gene mutation;ATEZOLIZUMAB;1200;ROCHE;58;F;Hospitalization - Initial or Prolonged;Dehydration
194822998;Plasma cell myeloma;CC 4047;4;CELGENE;62;M;Hospitalization - Initial or Prolonged;Cerebrovascular accident
194824221;Plasma cell myeloma;REVLIMID;25;CELGENE;81;F;NA;Contusion
194826893;NA;NA;NA;ALEXION;38;F;Other Serious (Important Medical Event);Herpes zoster
194827821;NA;NA;NA;ROCHE;67;F;Hospitalization - Initial or Prolonged;Hallucination
194827892;Asthma;FASENRA;30;ASTRAZENECA;63;F;NA;Gout
194828631;Chronic inflammatory demyelinating polyradiculoneuropathy;GAMUNEX C;50;GRIFOLS;47;F;NA;Pruritus
194829891;NA;NA;NA;TAKEDA;61;F;Life-Threatening;Blood potassium increased
194830011;Contraception;NEXPLANON;1;ORGANON;17;F;Hospitalization - Initial or Prolonged;Complication of device removal
194831451;Plasma cell myeloma;REVLIMID;10;CELGENE;46;M;NA;Dysphonia
194832343;Plasma cell myeloma;REVLIMID;25;CELGENE;83;M;Other Serious (Important Medical Event);Acute myocardial infarction
194832662;Renal cell carcinoma;CABOMETYX;40;EXELIXIS;67;M;Other Serious (Important Medical Event);Blood glucose decreased
194832986;Pancreatic carcinoma metastatic;BEVACIZUMAB;631;ROCHE;82;F;Hospitalization - Initial or Prolonged;Acute kidney injury
194833991;Phenylketonuria;PALYNZIQ;20;BIOMARIN;23;M;Other Serious (Important Medical Event);Hyperammonaemia
194834302;Pulmonary arterial hypertension;ADCIRCA;40;ELI LILLY AND CO;69;F;Other Serious (Important Medical Event);Death
194835111;Depression;PRISTIQ EXTENDED RELEASE;50;PFIZER;80;M;Other Serious (Important Medical Event);Cerebrovascular accident
194835401;NA;NA;NA;ABBVIE;61;M;Hospitalization - Initial or Prolonged;Cerebrovascular accident
194835691;Deep vein thrombosis;APIXABAN;5;BRISTOL MYERS SQUIBB;71;F;Disability;Drug ineffective
194835754;Contraception;NEXPLANON;1;ORGANON;35;F;Life-Threatening;Complication associated with device
194837101;Unknown;CLONAZEPAM;0.5;ROCHE;59;F;NA;Asthenia
194837341;B-cell lymphoma;FLUDARABINE;52.5;FRESENIUS KABI;73;F;Other Serious (Important Medical Event);Myelodysplastic syndrome
194837631;Insomnia;KLONOPIN;0.25;ROCHE;56;F;NA;Abdominal pain upper
194838482;Hodgkin's disease;NIVOLUMAB;1440;BRISTOL MYERS SQUIBB;22;M;Hospitalization - Initial or Prolonged;Obstructive airways disorder
194838692;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;80;M;Hospitalization - Initial or Prolonged;Death
194839131;Contraception;NEXPLANON;1;ORGANON;23;F;NA;Abortion induced
194840191;Lymphoma;REVLIMID;10;CELGENE;68;M;Other Serious (Important Medical Event);Atrial fibrillation
194841201;Plasma cell myeloma;REVLIMID;10;CELGENE;92;F;Hospitalization - Initial or Prolonged;Haemoglobin decreased
194841221;Plasma cell myeloma;REVLIMID;25;CELGENE;58;M;Other Serious (Important Medical Event);Neuropathy peripheral
194841492;Psoriatic arthropathy;TREMFYA;100;JOHNSON AND JOHNSON;49;M;NA;Accidental exposure to product
194841531;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;84;M;NA;Drug ineffective
194842052;NA;NA;NA;BRISTOL MYERS SQUIBB;58;F;Other Serious (Important Medical Event);Post transplant lymphoproliferative disorder
194842631;Unknown;NEXPLANON;1;ORGANON;22;F;Death;Abortion induced
194843021;Allergy to arthropod sting;Epinephrine Injection USP Auto Injector;0.3;MYLAN;43;F;NA;Liquid product physical issue
194844161;NA;NA;NA;TAKEDA;67;M;Hospitalization - Initial or Prolonged;Blood potassium increased
194844605;Hodgkin's disease;brentuximab vedotin;1.8;SEATTLE GENETICS;75;M;Other Serious (Important Medical Event);Hypoxia
194845013;Diffuse large B-cell lymphoma recurrent;YESCARTA;68;GILEAD;66;M;Hospitalization - Initial or Prolonged;Cardiac arrest
194845621;Peripheral arterial occlusive disease;Clonidine HCl;0.1;UNICHEM;74;F;Other Serious (Important Medical Event);Drug ineffective for unapproved indication
194845811;Psoriatic arthropathy;CIMZIA;400;UCB;42;M;Hospitalization - Initial or Prolonged;Heat exhaustion
194846161;Embolism venous;XARELTO;20;JOHNSON AND JOHNSON;50;F;Disability;Postmenopausal haemorrhage
194846173;Pulmonary arterial hypertension;SELEXIPAG;800;JOHNSON AND JOHNSON;62;F;Other Serious (Important Medical Event);Anaemia
194846541;NA;NA;NA;UNITED THERAPEUTICS;40;F;Hospitalization - Initial or Prolonged;Fluid overload
194846553;NA;NA;NA;UNITED THERAPEUTICS;50;F;Other Serious (Important Medical Event);Dehydration
194846561;Monoclonal gammopathy;REVLIMID;10;CELGENE;80;F;NA;Rash
194846731;NA;NA;NA;UNITED THERAPEUTICS;51;F;Hospitalization - Initial or Prolonged;Back pain
194846752;NA;NA;NA;UNITED THERAPEUTICS;58;F;Other Serious (Important Medical Event);Scleroderma
194846871;NA;NA;NA;UNITED THERAPEUTICS;58;F;Hospitalization - Initial or Prolonged;Syncope
194847183;NA;NA;NA;UNITED THERAPEUTICS;62;F;Hospitalization - Initial or Prolonged;Chronic obstructive pulmonary disease
194848791;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;90;F;Death;Death
194849835;Colitis ulcerative;SIMPONI;100;JOHNSON AND JOHNSON;59;F;NA;Accidental exposure to product
194850082;Idiopathic pulmonary fibrosis;ESBRIET;80;ROCHE;83;M;Death;Tachycardia
194850232;NA;NA;NA;UNITED THERAPEUTICS;59;F;Other Serious (Important Medical Event);Hypotension
194850621;Plasma cell myeloma;POMALYST;4;CELGENE;71;F;NA;Fatigue
194850711;Plasma cell myeloma;REVLIMID;10;CELGENE;78;F;Hospitalization - Initial or Prolonged;Colitis ischaemic
194851493;Ankylosing spondylitis;CIMZIA;200;UCB;64;F;Hospitalization - Initial or Prolonged;Drug ineffective
194851602;Follicular lymphoma;VENETOCLAX;800;ROCHE;74;M;Hospitalization - Initial or Prolonged;COVID-19 pneumonia
194852121;NA;NA;NA;UNITED THERAPEUTICS;52;F;Hospitalization - Initial or Prolonged;Asthma
194854203;Cerebrovascular accident prophylaxis;ELIQUIS;2.5;BRISTOL MYERS SQUIBB;87;F;Hospitalization - Initial or Prolonged;Death
194854311;Colon cancer;LONSURF;60;TAIHO ONCOLOGY INC;60;M;Hospitalization - Initial or Prolonged;Death
194855731;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;73;M;NA;Abnormal behaviour
194856531;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;70;M;NA;Abnormal behaviour
194857071;Colitis ulcerative;HUMIRA;40;ABBVIE;61;M;Other Serious (Important Medical Event);Autoimmune disorder
194857791;Thrombocytopenia;DOPTELET;20;BIOVITRUM;63;F;Other Serious (Important Medical Event);Blood urine present
194858271;NA;NA;NA;PFIZER;63;M;NA;Anxiety
194859381;Crohn's disease;ENTYVIO;300;TAKEDA;62;M;NA;Off label use
194859521;Unknown;BREO ELLIPTA;1;GLAXOSMITHKLINE;75;M;NA;Drug ineffective
194861221;Chronic lymphocytic leukaemia;VENCLEXTA;400;ABBVIE;52;F;Other Serious (Important Medical Event);Neutrophil count decreased
194861282;Plasma cell myeloma;REVLIMID;10;CELGENE;72;M;Other Serious (Important Medical Event);Death
194861502;Osteoporosis postmenopausal;PROLIA;60;AMGEN;68;F;Hospitalization - Initial or Prolonged;Carbohydrate antigen 27.29 increased
194863102;Major depression;PRISTIQ EXTENDED RELEASE;100;PFIZER;70;F;Other Serious (Important Medical Event);Balance disorder
194863301;NA;NA;NA;BAYER;78;F;Hospitalization - Initial or Prolonged;Death
194863971;Non-Hodgkin's lymphoma;REVLIMID;10;CELGENE;63;M;Congenital Anomaly;Disease progression
194864001;Pulmonary arterial hypertension;ADEMPAS;0.5;BAYER;53;F;Other Serious (Important Medical Event);Death
194865341;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;37;F;NA;Device leakage
194865813;Follicular lymphoma;VENETOCLAX;800;ROCHE;74;M;Other Serious (Important Medical Event);Death
194867621;Alcoholism;VIVITROL;380;ALKERMES;28;M;Hospitalization - Initial or Prolonged;Hypertension
194867951;Chronic inflammatory demyelinating polyradiculoneuropathy;GAMUNEX C;60;GRIFOLS;66;F;NA;Rash
194868501;Immunodeficiency common variable;GAMUNEX C;20;GRIFOLS;74;F;NA;Pruritus
194868571;Plasma cell myeloma;REVLIMID;25;CELGENE;78;M;Other Serious (Important Medical Event);Death
194868641;Pain;BUPRENORPHINE;75;BIODELIVERY SCIENCES INTERNATIONAL;36;F;NA;Abdominal pain
194869191;Eye infection toxoplasmal;PYRIMETHAMINE;200;OAKRUM PHARMA;66;M;Hospitalization - Initial or Prolonged;Loss of consciousness
194869203;Cerebral toxoplasmosis;PYRIMETHAMINE;75;OAKRUM PHARMA;50;M;Other Serious (Important Medical Event);Asthenia
194869561;Diffuse large B-cell lymphoma;FLUDARABINE;64.5;FRESENIUS KABI;74;M;Other Serious (Important Medical Event);Myelodysplastic syndrome
194871112;Depression;SPRAVATO;84;JOHNSON AND JOHNSON;52;F;Hospitalization - Initial or Prolonged;Blood pressure systolic increased
194871864;NA;NA;NA;ALEXION;70;F;Other Serious (Important Medical Event);Mitral valve stenosis
194872451;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;74;F;NA;Product adhesion issue
194872563;Growth hormone deficiency;GENOTROPIN;0.2;PFIZER;80;F;NA;Device leakage
194872692;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;62;F;NA;Device leakage
194872822;Myalgia;EQUATE MENTHOL PAIN RELIEVING;5;MENTHOLATUM;64;F;Other Serious (Important Medical Event);Blister
194874032;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;48;M;NA;Accidental exposure to product
194875223;Contraception;DEPO PROVERA;150;PFIZER;31;F;Hospitalization - Initial or Prolonged;Anaphylactic reaction
194875231;Contraception;DEPO PROVERA;150;PFIZER;20;F;Hospitalization - Initial or Prolonged;Anaphylactic reaction
194875291;Contraception;DEPO PROVERA;150;PFIZER;23;F;Death;Anaphylactic reaction
194875411;Unknown;ABATACEPT;125;BRISTOL MYERS SQUIBB;69;F;Other Serious (Important Medical Event);Device malfunction
194875612;NA;NA;NA;UNITED THERAPEUTICS;22;M;Hospitalization - Initial or Prolonged;Sensitive skin
194876021;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;64;M;NA;Therapeutic response decreased
194876501;Pain;BUPRENORPHINE;75;BIODELIVERY SCIENCES INTERNATIONAL;68;F;NA;Incorrect route of product administration
194876891;Schizophrenia;ARISTADA;882;ALKERMES;43;F;NA;Off label use
194877241;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;71;M;NA;Therapeutic response decreased
194878701;Plasma cell myeloma;REVLIMID;20;CELGENE;69;M;Death;Benign neoplasm of bladder
194878727;Adenomatous polyposis coli;GUSELKUMAB;1;JOHNSON AND JOHNSON;58;F;Other Serious (Important Medical Event);Gamma-glutamyltransferase increased
194879162;Psoriatic arthropathy;TALTZ;80;ELI LILLY AND CO;39;F;NA;Maternal exposure during pregnancy
194880052;NA;NA;NA;BAYER;68;F;Other Serious (Important Medical Event);Anaemia
194881131;Thrombocytopenia;DOPTELET;20;BIOVITRUM;71;M;NA;Arthralgia
194881301;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;42;F;NA;Decreased activity
194882111;Polyneuropathy;GAMMAGARD LIQUID;50;TAKEDA;42;F;Other Serious (Important Medical Event);Chest discomfort
194882361;Hereditary angioedema;ORLADEYO;150;BIOCRYST PHARMACEUTICALS;49;F;NA;Colitis
194883101;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;69;F;NA;Drug ineffective
194884161;NA;NA;NA;BRISTOL MYERS SQUIBB;64;F;Hospitalization - Initial or Prolonged;Lung lobectomy
194884451;Pain;BUPRENORPHINE;300;BIODELIVERY SCIENCES INTERNATIONAL;84;F;NA;Oral administration complication
194884512;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;90;M;NA;Device mechanical issue
194884761;Neoplasm;TRASTUZUMAB DERUXTECAN;118.2;DAIICHI;49;F;Hospitalization - Initial or Prolonged;Anaemia
194885381;NA;NA;NA;GRIFOLS;18;F;NA;Urticaria
194886002;Contraception;DEPO PROVERA;150;PFIZER;20;F;Other Serious (Important Medical Event);Anaphylactic reaction
194886253;NA;NA;NA;BIOGEN;51;F;Other Serious (Important Medical Event);Multiple sclerosis
194886412;NA;NA;NA;ROCHE;36;M;Other Serious (Important Medical Event);COVID-19 pneumonia
194886891;Rheumatoid arthritis;Certolizumab pegol;400;UCB;31;F;Hospitalization - Initial or Prolonged;Depression
194887191;Plasma cell myeloma;REVLIMID;25;CELGENE;70;M;NA;Abdominal pain
194887621;Colitis ulcerative;HUMIRA;40;ABBVIE;88;F;Other Serious (Important Medical Event);Atrial flutter
194887742;Acute lymphocytic leukaemia;IBRANCE;125;PFIZER;44;M;Hospitalization - Initial or Prolonged;Pneumonia
194887871;Plasma cell myeloma;POMALYST;4;CELGENE;81;F;NA;Rash pruritic
194887972;Acute lymphocytic leukaemia recurrent;VINCRISTINE SULFATE;0.4;PFIZER;68;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
194888341;Plasma cell myeloma;REVLIMID;25;CELGENE;86;F;NA;Diarrhoea
194888732;Factor VIII deficiency;HEMLIBRA;330;ROCHE;31;M;Other Serious (Important Medical Event);Haemorrhage
194889032;Relapsing multiple sclerosis;OCREVUS;600;ROCHE;80;F;Hospitalization - Initial or Prolonged;COVID-19
194889152;Psoriatic arthropathy;CIMZIA;200;UCB;30;F;Hospitalization - Initial or Prolonged;Maternal exposure during pregnancy
194889162;NA;NA;NA;ALLERGAN;63;M;NA;Macular hole
194890022;NA;NA;NA;ABBVIE;61;M;Hospitalization - Initial or Prolonged;Large intestine polyp
194890262;Schizophrenia;INVEGA SUSTENNA;234;JOHNSON AND JOHNSON;46;F;NA;Inappropriate schedule of product administration
194890461;Uveal melanoma;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;58;F;Other Serious (Important Medical Event);COVID-19
194890741;Acute myeloid leukaemia;IPILIMUMAB;930;BRISTOL MYERS SQUIBB;62;M;Hospitalization - Initial or Prolonged;Febrile neutropenia
194891611;NA;NA;NA;UNITED THERAPEUTICS;59;F;Other Serious (Important Medical Event);Uterine mass
194891991;Plasma cell myeloma;NINLARO;4;TAKEDA;71;M;NA;Fatigue
194893362;NA;NA;NA;UNITED THERAPEUTICS;2;F;Hospitalization - Initial or Prolonged;Pulmonary arterial hypertension
194893973;Prostate cancer;ERLEADA;240;JOHNSON AND JOHNSON;83;M;NA;Incorrect dose administered
194895262;NA;NA;NA;UNITED THERAPEUTICS;67;F;Hospitalization - Initial or Prolonged;Dyspnoea
194895381;Migraine;AJOVY;225;TEVA;25;F;NA;Rash
194895432;Neutropenia;NEULASTA;6;AMGEN;63;M;NA;Device use error
194896371;NA;NA;NA;UNITED THERAPEUTICS;75;F;Disability;Fall
194896591;Bone density decreased;RECLAST;5;NOVARTIS;61;M;Hospitalization - Initial or Prolonged;Tinnitus
194898652;Psoriasis;SKYRIZI;150;ABBVIE;60;M;Hospitalization - Initial or Prolonged;Spinal operation
194898812;Unknown;NEXPLANON;1;ORGANON;21;F;NA;Complication of device insertion
194899802;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;41;M;NA;Accidental exposure to product
194900991;NA;NA;NA;JOHNSON AND JOHNSON;52;F;Hospitalization - Initial or Prolonged;Hypertension
194902141;Dementia;NUPLAZID;10;ACADIA PHARMACEUTICALS;82;F;Other Serious (Important Medical Event);Agitation
194904851;Pseudolymphoma;REVLIMID;25;CELGENE;36;F;NA;Contusion
194905072;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;72;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194905602;Unknown;OTEZLA;30;AMGEN;50;F;NA;Product dose omission issue
194905611;Chronic myeloid leukaemia;SPRYCEL;100;BRISTOL MYERS SQUIBB;75;F;Life-Threatening;Dyspnoea
194905691;Plasma cell myeloma;REVLIMID;25;CELGENE;76;F;Other Serious (Important Medical Event);White blood cell count decreased
194905723;Clostridium difficile infection;ZINPLAVA;875;MERCK;68;F;Death;Arthralgia
194906791;Chronic graft versus host disease;PREDNISONE;70;HIKMA;58;F;Hospitalization - Initial or Prolonged;Alanine aminotransferase increased
194907051;Plasma cell myeloma;REVLIMID;5;CELGENE;85;M;NA;Pyrexia
194908661;Pyrexia;TYLENOL;1;JOHNSON AND JOHNSON;34;M;NA;Inappropriate schedule of product administration
194908761;Plasma cell myeloma;REVLIMID;25;CELGENE;71;M;Other Serious (Important Medical Event);Cerebrovascular accident
194908791;Plasma cell myeloma;REVLIMID;25;CELGENE;65;M;NA;Insomnia
194909102;Cystic fibrosis;PULMOZYME;1;ROCHE;3;F;Hospitalization - Initial or Prolonged;Off label use
194911551;Nasal congestion;MUCINEX DM MAXIMUM STRENGTH;2400;RECKITT BENCKISER;32;M;NA;Abdominal discomfort
194912392;Renal transplant;CELLCEPT;250;ROCHE;75;F;Other Serious (Important Medical Event);Arteriosclerosis coronary artery
194912422;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;77;M;Other Serious (Important Medical Event);Hepatic cirrhosis
194912933;Plasma cell myeloma;REVLIMID;25;CELGENE;72;M;NA;Plasma cell myeloma
194912961;Plasma cell myeloma;REVLIMID;10;CELGENE;68;M;Hospitalization - Initial or Prolonged;Blood glucose increased
194925351;Plasma cell myeloma;REVLIMID;25;CELGENE;74;F;Hospitalization - Initial or Prolonged;Dehydration
194926201;Plasma cell myeloma;REVLIMID;25;CELGENE;85;F;NA;Neutropenia
194926212;NA;NA;NA;ROCHE;66;F;Other Serious (Important Medical Event);Contusion
194926711;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;78;F;NA;Eye disorder
194927043;Unknown;NEXPLANON;1;ORGANON;27;F;NA;Complication of device removal
194927312;Blood cholesterol increased;REPATHA;140;AMGEN;58;M;NA;Device difficult to use
194928511;Contraception;DEPO PROVERA;150;PFIZER;34;F;Hospitalization - Initial or Prolonged;Anaphylactic reaction
194928583;Unknown;NEULASTA;6;AMGEN;36;F;NA;Device issue
194929141;Mantle cell lymphoma;REVLIMID;15;CELGENE;84;M;NA;Rash
194929301;Plasma cell myeloma;VELCADE;2.8;TAKEDA;65;M;NA;No adverse event
194930431;Eczema;DUPILUMAB;600;SANOFI AVENTIS;60;F;Other Serious (Important Medical Event);Cardiac failure congestive
194931351;Relapsing multiple sclerosis;OCREVUS;300;ROCHE;51;F;Hospitalization - Initial or Prolonged;Anal incontinence
194931842;NA;NA;NA;AMGEN;73;M;NA;Device difficult to use
194932191;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;75;F;Other Serious (Important Medical Event);Dehydration
194933082;Plasma cell myeloma;REVLIMID;25;CELGENE;61;M;Death;Deep vein thrombosis
194933402;Plasma cell myeloma;REVLIMID;25;CELGENE;60;M;Hospitalization - Initial or Prolonged;Urinary tract infection
194933672;Hypogammaglobulinaemia;GAMMAGARD S/D;35;TAKEDA;44;F;NA;Poor venous access
194934442;Plasma cell myeloma;REVLIMID;25;CELGENE;82;F;Life-Threatening;Pneumonia
194934512;Idiopathic pulmonary fibrosis;ESBRIET;801;ROCHE;69;M;Other Serious (Important Medical Event);Death
194935381;Plasma cell myeloma;REVLIMID;10;CELGENE;76;F;Hospitalization - Initial or Prolonged;Dyspnoea
194935411;Plasma cell myeloma;REVLIMID;20;CELGENE;71;M;Hospitalization - Initial or Prolonged;Respiratory tract infection
194936031;Plasma cell myeloma;REVLIMID;25;CELGENE;77;F;Other Serious (Important Medical Event);Infection
194936452;Atrial fibrillation;DOFETILIDE;0.25;PFIZER;79;M;Disability;Electrocardiogram QT prolonged
194936552;K-ras gene mutation;AMG 510;960;AMGEN;72;F;Life-Threatening;Non-small cell lung cancer
194939412;Short-bowel syndrome;GATTEX;2.57;TAKEDA;61;M;Death;Death
194939784;Malignant melanoma;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;70;M;Hospitalization - Initial or Prolonged;Acute kidney injury
194940391;Cerebrovascular accident prophylaxis;APIXABAN;5;BRISTOL MYERS SQUIBB;76;M;Other Serious (Important Medical Event);Cardiac disorder
194940426;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;62;M;Hospitalization - Initial or Prolonged;Acute coronary syndrome
194940863;Rheumatoid arthritis;HUMIRA;40;ABBVIE;73;F;Hospitalization - Initial or Prolonged;Knee arthroplasty
194941142;Blood growth hormone abnormal;GENOTROPIN;0.5;PFIZER;3;M;NA;Device issue
194941153;Unknown;GENOTROPIN;0.2;PFIZER;2;F;NA;Device breakage
194941162;Hypothalamo-pituitary disorder;GENOTROPIN;0.4;PFIZER;70;M;NA;Device information output issue
194941781;Myelodysplastic syndrome;REVLIMID;10;CELGENE;68;F;Hospitalization - Initial or Prolonged;Dyspnoea
194941991;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;75;M;Death;Hip surgery
194942251;Plasma cell myeloma;REVLIMID;10;CELGENE;82;M;NA;Rash
194943001;Unknown;OMEPRAZOLE;20;TEVA;80;F;NA;Diarrhoea
194944302;Immunodeficiency common variable;CUVITRU;8;TAKEDA;69;F;Other Serious (Important Medical Event);Hernia hiatus repair
194944411;Eczema;DUPIXENT;300;SANOFI AVENTIS;19;F;NA;Injection site bruising
194944651;Plasma cell myeloma;NINLARO;3;TAKEDA;70;F;NA;Peripheral swelling
194944693;NA;NA;NA;UNITED THERAPEUTICS;77;F;Hospitalization - Initial or Prolonged;Dehydration
194944952;Non-small cell lung cancer;NIVOLUMAB;204;BRISTOL MYERS SQUIBB;82;M;Hospitalization - Initial or Prolonged;Cerebellar stroke
194945292;Parkinson's disease;DUOPA;100;ABBVIE;79;M;Other Serious (Important Medical Event);Back injury
194945422;Unknown;TREMFYA;100;JOHNSON AND JOHNSON;44;M;NA;Drug delivery system malfunction
194947081;NA;NA;NA;UNITED THERAPEUTICS;21;F;Hospitalization - Initial or Prolonged;Chest pain
194947714;NA;NA;NA;UNITED THERAPEUTICS;57;F;Hospitalization - Initial or Prolonged;Fluid overload
194947831;Colitis ulcerative;ENTYVIO;300;TAKEDA;79;M;NA;Pyrexia
194947881;Plasma cell myeloma;REVLIMID;25;CELGENE;46;M;Other Serious (Important Medical Event);Asthenia
194948742;Blood cholesterol increased;REPATHA;140;AMGEN;72;F;NA;Device difficult to use
194950032;Rheumatoid arthritis;RINVOQ;15;ABBVIE;53;F;NA;Abdominal discomfort
194950911;Plasma cell myeloma;REVLIMID;25;CELGENE;85;F;NA;Joint swelling
194951822;Psoriasis;SKYRIZI;150;ABBVIE;76;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
194951952;Psoriatic arthropathy;OTEZLA;30;AMGEN;63;F;Hospitalization - Initial or Prolonged;Arthralgia
194952016;Neutropenia;NEULASTA;6000;AMGEN;57;F;NA;Device adhesion issue
194952061;Philadelphia positive acute lymphocytic leukaemia;SPRYCEL;140;BRISTOL MYERS SQUIBB;44;F;Other Serious (Important Medical Event);Transaminases increased
194952881;Thrombocytopenia;DOPTELET;20;BIOVITRUM;55;M;Other Serious (Important Medical Event);Back injury
194954061;Iron deficiency anaemia;MONOFERRIC;1000;PHARMACOSMOS;67;F;NA;Fishbane reaction
194955072;Plasma cell myeloma;REVLIMID;25;CELGENE;72;F;NA;Neutropenia
194955091;Plasma cell myeloma;REVLIMID;15;CELGENE;76;M;NA;Dizziness
194955912;Migraine prophylaxis;AIMOVIG;70;AMGEN;61;F;NA;Device difficult to use
194956192;Rheumatoid arthritis;RINVOQ;15;ABBVIE;76;F;Other Serious (Important Medical Event);Bone fragmentation
194956883;Osteoporosis postmenopausal;PROLIA;60;AMGEN;82;F;Hospitalization - Initial or Prolonged;Osteonecrosis of jaw
194956981;Plasma cell myeloma;REVLIMID;25;CELGENE;67;F;NA;Full blood count decreased
194957301;NA;NA;NA;ROCHE;63;M;NA;COVID-19
194957331;Multiple sclerosis;PONVORY;20;JOHNSON AND JOHNSON;29;F;NA;Confusional state
194957371;Rheumatoid arthritis;RINVOQ;15;ABBVIE;67;F;Other Serious (Important Medical Event);Back disorder
194957431;NA;NA;NA;NOVARTIS;47;F;Hospitalization - Initial or Prolonged;Diarrhoea
194958422;Plasma cell myeloma;NINLARO;4;TAKEDA;87;F;Hospitalization - Initial or Prolonged;Constipation
194958841;Myelodysplastic syndrome;REVLIMID;5;CELGENE;82;M;NA;African trypanosomiasis
194960252;NA;NA;NA;NOVARTIS;58;F;Hospitalization - Initial or Prolonged;Internal haemorrhage
194961481;Plasma cell myeloma;POMALYST;2;CELGENE;74;F;NA;Plasma cell myeloma
194961826;Neutropenia;NEULASTA;6;AMGEN;68;F;NA;Device adhesion issue
194962051;Rheumatoid arthritis;CIMZIA;400;UCB;73;F;Other Serious (Important Medical Event);Joint swelling
194964382;Colitis ulcerative;HUMIRA;40;ABBVIE;53;F;Hospitalization - Initial or Prolonged;Endometrial cancer
194971023;Neutropenia;NEULASTA;6;AMGEN;58;F;NA;Unintentional medical device removal
194971441;Unknown;NEXPLANON;1;ORGANON;20;F;NA;Complication associated with device
194972521;Cerebrovascular accident prophylaxis;ELIQUIS;2.5;BRISTOL MYERS SQUIBB;89;F;Other Serious (Important Medical Event);Neoplasm malignant
194972981;Plasma cell myeloma;REVLIMID;25;CELGENE;55;F;Hospitalization - Initial or Prolonged;Osteomyelitis
194973303;Type 2 diabetes mellitus;LANTUS SOLOSTAR;20;SANOFI AVENTIS;56;M;Life-Threatening;Blood glucose increased
194975393;Uterine leiomyoma;ACTIVELLA;1;AMNEAL;39;F;Hospitalization - Initial or Prolonged;Depression
194976942;Depression;BUPROPION HYDROCHLORIDE;150;GLAXOSMITHKLINE;66;F;Hospitalization - Initial or Prolonged;Fall
194977651;NA;NA;NA;BAYER;59;F;Other Serious (Important Medical Event);Cardiac operation
194978153;Phaeochromocytoma;LUTATHERA;200;NOVARTIS;70;M;Other Serious (Important Medical Event);Troponin I increased
194979211;Thrombosis;ELIQUIS;5;BRISTOL MYERS SQUIBB;65;M;Hospitalization - Initial or Prolonged;Abdominal discomfort
194979691;NA;NA;NA;ELI LILLY AND CO;79;F;Other Serious (Important Medical Event);Blood iron decreased
194979871;Plasma cell myeloma;REVLIMID;25;CELGENE;81;M;Other Serious (Important Medical Event);Thrombosis
194979993;Short stature;GENOTROPIN;0.2;PFIZER;12;M;NA;Device leakage
194980083;Hypopituitarism;GENOTROPIN;0.6;PFIZER;65;M;NA;Device issue
194980584;Prostate cancer;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;65;M;Hospitalization - Initial or Prolonged;Osteolysis
194980631;Plasma cell myeloma;REVLIMID;25;CELGENE;51;F;NA;Diarrhoea
194980671;Plasma cell myeloma;REVLIMID;25;CELGENE;70;M;Other Serious (Important Medical Event);Neuropathy peripheral
194981351;Hodgkin's disease;NIVOLUMAB;1472;BRISTOL MYERS SQUIBB;14;F;Hospitalization - Initial or Prolonged;Appendicitis
194981761;Pain;BUPRENORPHINE;150;BIODELIVERY SCIENCES INTERNATIONAL;46;F;Life-Threatening;Drug withdrawal syndrome
194981853;Pulmonary arterial hypertension;UPTRAVI;200;JOHNSON AND JOHNSON;58;F;Other Serious (Important Medical Event);Arthropathy
194982183;Pulmonary arterial hypertension;SELEXIPAG;800;JOHNSON AND JOHNSON;57;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
194982261;Pulmonary hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;59;F;Other Serious (Important Medical Event);Bacterial infection
194982981;Pain;BUPRENORPHINE;300;BIODELIVERY SCIENCES INTERNATIONAL;63;F;NA;Therapeutic response decreased
194983321;Myelodysplastic syndrome;REVLIMID;10;CELGENE;61;F;Life-Threatening;Myocardial infarction
194983471;Unknown;NEXPLANON;1;ORGANON;32;F;NA;Device kink
194983671;Schizoaffective disorder bipolar type;ARISTADA;1064;ALKERMES;33;M;NA;Incorrect dose administered
194983762;Schizoaffective disorder depressive type;ARISTADA;662;ALKERMES;22;M;NA;Anxiety
194983851;Barrett's oesophagus;DEXILANT;15;TAKEDA;65;F;NA;Gastrooesophageal reflux disease
194983962;Unknown;KLONOPIN;5;ROCHE;63;F;Hospitalization - Initial or Prolonged;Drug hypersensitivity
194984181;Plasma cell myeloma;POMALYST;2;CELGENE;73;M;Other Serious (Important Medical Event);Chest discomfort
194985871;Unknown;NEXPLANON;68;ORGANON;31;F;NA;Complication of device insertion
194985991;Unknown;PLAVIX;1;SANOFI AVENTIS;85;M;Other Serious (Important Medical Event);Cardiac operation
194986701;Pain;BUPRENORPHINE;300;BIODELIVERY SCIENCES INTERNATIONAL;66;M;NA;Product adhesion issue
194986741;Pain;BUPRENORPHINE;900;BIODELIVERY SCIENCES INTERNATIONAL;60;M;NA;Headache
194986753;Contraception;NEXPLANON;1;ORGANON;15;F;NA;Implant site erythema
194986851;Constipation;POLYETHYLENE GLYCOL 3350;17;PERRIGO;30;F;Hospitalization - Initial or Prolonged;Focal dyscognitive seizures
194987232;Depression;SPRAVATO;56;JOHNSON AND JOHNSON;51;F;NA;Dissociation
194987751;Magnetic resonance imaging head;DOTAREM;15;GUERBET;63;F;NA;Erythema
194988041;Magnetic resonance imaging head;DOTAREM;15;GUERBET;55;F;NA;Lacrimation increased
194988271;NA;NA;NA;BAYER;69;M;Other Serious (Important Medical Event);Haemoglobin decreased
194988613;Monoclonal gammopathy;REVLIMID;15;CELGENE;62;M;Death;Asthenia
194988682;Plasma cell myeloma;CC 5013;25;CELGENE;70;M;Death;Second primary malignancy
194989111;Unknown;NEXPLANON;68;ORGANON;23;F;NA;Complication of device insertion
194989171;Acute myeloid leukaemia;AZACITIDINE;122;CELGENE;70;M;Hospitalization - Initial or Prolonged;Myocarditis
194989593;Acute myeloid leukaemia;AZACITIDINE;75;CELGENE;91;F;Hospitalization - Initial or Prolonged;Hepatic cancer stage IV
194989731;Magnetic resonance imaging;DOTAREM;11;GUERBET;67;F;NA;Blood pressure increased
194990041;Metastatic malignant melanoma;NIVOLUMAB;84;BRISTOL MYERS SQUIBB;31;M;Hospitalization - Initial or Prolonged;Enterocolitis
194990131;Plasma cell myeloma;POMALYST;4;CELGENE;74;F;Hospitalization - Initial or Prolonged;Tachycardia
194990151;Plasma cell myeloma;POMALYST;2;CELGENE;79;M;Other Serious (Important Medical Event);Cerebrovascular accident
194990611;Plasma cell myeloma;POMALYST;4;CELGENE;66;M;NA;Gout
194990951;Plasma cell myeloma;POMALYST;2;CELGENE;66;M;NA;Muscle spasms
194991011;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;NA;Pruritus
194991231;Cardiac failure;ENTRESTO;50;NOVARTIS;84;M;Hospitalization - Initial or Prolonged;Hypotension
194991442;Unknown;REPATHA;420;AMGEN;73;F;NA;Incorrect dose administered by device
194992303;Plasma cell myeloma;POMALYST;2;CELGENE;79;M;Hospitalization - Initial or Prolonged;Cellulitis
194992352;Cardiomyopathy;ENTRESTO;1;NOVARTIS;83;M;Hospitalization - Initial or Prolonged;Death
194993601;Cervix cancer metastatic;KEYTRUDA;200;MERCK;38;F;Hospitalization - Initial or Prolonged;Dermatitis
194996151;Magnetic resonance imaging head;DOTAREM;10;GUERBET;72;F;Other Serious (Important Medical Event);Bladder discomfort
194996792;NA;NA;NA;ELI LILLY AND CO;65;M;Hospitalization - Initial or Prolonged;Renal failure
194996801;NA;NA;NA;UNITED THERAPEUTICS;69;F;Hospitalization - Initial or Prolonged;Gastrointestinal bacterial infection
194997221;Colonoscopy;SUTAB;22;BRAINTREE;78;F;Other Serious (Important Medical Event);Arrhythmia
194998801;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;49;M;NA;Retching
194998842;Crohn's disease;HUMIRA;40;ABBVIE;53;F;NA;Blood iron decreased
194999351;Plasma cell myeloma;REVLIMID;25;CELGENE;68;F;Other Serious (Important Medical Event);Cerebrovascular accident
194999601;Plasma cell myeloma;REVLIMID;25;CELGENE;64;F;NA;Fatigue
195000052;Multiple sclerosis;TECFIDERA;240;BIOGEN;67;F;NA;Asthenia
195000351;Colon cancer;LONSURF;70;TAIHO ONCOLOGY INC;37;M;Other Serious (Important Medical Event);Death
195001341;Plasma cell myeloma;REVLIMID;15;CELGENE;77;M;NA;Gastrointestinal disorder
195001411;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;80;M;Other Serious (Important Medical Event);Brain stem haemorrhage
195001551;NA;NA;NA;IBSA INSTITUT BIOCHIMIQUE;62;F;Hospitalization - Initial or Prolonged;Asthenia
195005044;K-ras gene mutation;AMG 510;960;AMGEN;63;F;Other Serious (Important Medical Event);Respiratory failure
195005362;Crohn's disease;Certolizumab pegol;200;UCB;45;F;Death;Anaphylactic reaction
195005652;Bipolar disorder;LATUDA;20;SUNOVION;55;F;NA;Abdominal pain
195009611;NA;NA;NA;BRISTOL MYERS SQUIBB;59;M;Hospitalization - Initial or Prolonged;Dysphagia
195009621;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;78;F;Other Serious (Important Medical Event);Eye contusion
195009654;Small cell lung cancer;NIVOLUMAB;480;BRISTOL MYERS SQUIBB;65;F;Hospitalization - Initial or Prolonged;Encephalopathy
195010042;Migraine;AIMOVIG;140;AMGEN;40;F;NA;Accidental exposure to product
195011371;Anticoagulant therapy;CLOPIDOGREL;75;AUROBINDO;79;F;NA;Drug interaction
195013101;Diffuse large B-cell lymphoma;ZYNLONTA;16;ADC THERAPEUTICS;60;M;Other Serious (Important Medical Event);Death
195013383;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;71;M;NA;Accidental exposure to product
195014461;NA;NA;NA;UNITED THERAPEUTICS;53;F;Other Serious (Important Medical Event);Arrhythmia
195014941;Plasma cell myeloma;POMALYST;2;CELGENE;61;M;Life-Threatening;Hallucination
195015062;NA;NA;NA;UNITED THERAPEUTICS;43;F;Disability;Fluid overload
195016351;Mucopolysaccharidosis;ELAPRASE;36;TAKEDA;22;M;NA;Inappropriate schedule of product administration
195016701;Plasma cell myeloma;REVLIMID;10;CELGENE;79;F;NA;Dizziness
195019153;Breast cancer female;IBRANCE;100;PFIZER;74;F;Hospitalization - Initial or Prolonged;COVID-19
195019471;Chronic myeloid leukaemia;BOSULIF;500;PFIZER;55;M;NA;Diarrhoea
195020362;Plasma cell myeloma;REVLIMID;5;CELGENE;76;M;Other Serious (Important Medical Event);Death
195020551;Plasma cell myeloma;REVLIMID;25;CELGENE;76;F;NA;Diarrhoea
195020994;Hypertonic bladder;TOVIAZ;4;PFIZER;79;F;NA;Blood pressure increased
195021231;NA;NA;NA;BAYER;64;F;Hospitalization - Initial or Prolonged;Death
195022292;NA;NA;NA;ROCHE;60;F;Hospitalization - Initial or Prolonged;Dysstasia
195022473;Short stature;GENOTROPIN;0.6;PFIZER;5;F;NA;Device breakage
195022531;Juvenile idiopathic arthritis;TOCILIZUMAB;162;ROCHE;9;F;Death;Cystic fibrosis
195023692;Malignant melanoma;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;66;M;Other Serious (Important Medical Event);Colitis
195023863;Idiopathic pulmonary fibrosis;ESBRIET;267;ROCHE;80;F;Death;Fatigue
195025181;Pulmonary hypertension;ADEMPAS;2.5;BAYER;64;F;NA;Blood sodium decreased
195026023;NA;NA;NA;UNITED THERAPEUTICS;71;F;Hospitalization - Initial or Prolonged;Blood loss anaemia
195026981;Chronic tonsillitis;GADAVIST;7.5;BAYER;36;M;NA;Feeling hot
195027823;NA;NA;NA;GLAXOSMITHKLINE;73;F;Other Serious (Important Medical Event);Angioedema
195028362;NA;NA;NA;BIOMARIN;18;M;Hospitalization - Initial or Prolonged;Intensive care unit delirium
195028911;Unknown;ELIQUIS;2.5;BRISTOL MYERS SQUIBB;86;F;Life-Threatening;Death
195031141;Irritable bowel syndrome;TRULANCE;3;BAUSCH AND LOMB;68;F;NA;Abdominal discomfort
195031971;Pulmonary arterial hypertension;SELEXIPAG;200;JOHNSON AND JOHNSON;68;F;Other Serious (Important Medical Event);Aphasia
195032131;NA;NA;NA;QUAGEN PHARMACEUTICALS;12;M;Hospitalization - Initial or Prolonged;Crying
195032461;Strabismus;CELLCEPT;250;ROCHE;31;M;NA;Intentional product use issue
195032471;Immunosuppression;CELLCEPT;500;ROCHE;83;F;NA;Cataract operation
195032801;Unknown;CELLCEPT;500;ROCHE;57;F;NA;Nausea
195033163;Chronic inflammatory demyelinating polyradiculoneuropathy;HIZENTRA;0.2;CSL BEHRING;33;F;Hospitalization - Initial or Prolonged;Chronic inflammatory demyelinating polyradiculoneuropathy
195033661;Short-bowel syndrome;Teduglutide;0.35;TAKEDA;57;F;Hospitalization - Initial or Prolonged;Renal failure
195033941;Multiple sclerosis;Glatiramer Acetate Injection;40;MYLAN;46;M;Life-Threatening;Device issue
195035441;Pain;BUPRENORPHINE;600;BIODELIVERY SCIENCES INTERNATIONAL;39;F;NA;Product dose omission in error
195035472;Unknown;NEXPLANON;1;ORGANON;13;F;NA;Complication of device insertion
195036021;NA;NA;NA;UNITED THERAPEUTICS;63;F;Other Serious (Important Medical Event);Device dislocation
195036602;Colitis ulcerative;HUMIRA;40;ABBVIE;79;M;Hospitalization - Initial or Prolonged;Device issue
195038081;Plasma cell myeloma;REVLIMID;5;CELGENE;83;M;Other Serious (Important Medical Event);COVID-19
195038422;Growth hormone deficiency;GENOTROPIN;1.4;PFIZER;11;M;NA;Device information output issue
195038593;Endometrial cancer recurrent;LENVIMA;14;EISAI;55;F;Other Serious (Important Medical Event);Dizziness
195038901;Unknown;NEXPLANON;1;ORGANON;29;F;NA;Complication of device insertion
195039922;Hereditary angioedema;Lanadelumab;300;TAKEDA;31;F;Other Serious (Important Medical Event);Angioedema
195040631;NA;NA;NA;BAYER;95;F;Hospitalization - Initial or Prolonged;Death
195041081;Psoriasis;Certolizumab pegol RA;200;UCB;30;F;Hospitalization - Initial or Prolonged;Bronchitis
195041381;Diarrhoea;Cholestyramine (ANDA 211119);4;AJANTA PHARMA;72;M;NA;Choking sensation
195041741;NA;NA;NA;UCB;68;M;Other Serious (Important Medical Event);Agitation
195043131;Gastric cancer;LONSURF;75;TAIHO ONCOLOGY INC;71;M;Other Serious (Important Medical Event);Death
195043493;NA;NA;NA;UNITED THERAPEUTICS;8;F;Hospitalization - Initial or Prolonged;Escherichia sepsis
195043851;Colitis ulcerative;ZEPOSIA;0.46;CELGENE;58;F;NA;Drug ineffective
195044473;Plasma cell myeloma;POMALYST;3;CELGENE;77;M;Hospitalization - Initial or Prolonged;Cellulitis
195044491;Migraine prophylaxis;AIMOVIG;70;AMGEN;22;F;NA;Accidental exposure to product
195045091;Plasma cell myeloma;REVLIMID;15;CELGENE;73;F;Hospitalization - Initial or Prolonged;Thrombosis
195045612;Hypercholesterolaemia;REPATHA;140;AMGEN;62;M;NA;Accidental exposure to product
195046031;Plasma cell myeloma;REVLIMID;10;CELGENE;87;F;NA;Constipation
195046061;Plasma cell myeloma;POMALYST;2;CELGENE;73;M;Hospitalization - Initial or Prolonged;Chest discomfort
195046991;Neutropenia;NEULASTA;6;AMGEN;49;F;NA;Unintentional medical device removal
195047001;Blood cholesterol abnormal;REPATHA;140;AMGEN;75;F;NA;Accidental exposure to product
195047011;Neutropenia;NEULASTA;6;AMGEN;79;M;NA;Device adhesion issue
195047021;Blood cholesterol increased;REPATHA;140;AMGEN;74;F;NA;Blood glucose increased
195047053;Rheumatoid arthritis;SIMPONI;50;JOHNSON AND JOHNSON;22;F;NA;Underdose
195047812;Myelodysplastic syndrome;REVLIMID;10;CELGENE;86;F;Other Serious (Important Medical Event);Haemoglobin decreased
195048521;Unknown;ZANTAC;300;SANOFI AVENTIS;61;F;Other Serious (Important Medical Event);Neoplasm malignant
195048904;NA;NA;NA;UNITED THERAPEUTICS;60;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
195049243;NA;NA;NA;UNITED THERAPEUTICS;25;F;Hospitalization - Initial or Prolonged;Drug hypersensitivity
195049644;NA;NA;NA;ELI LILLY AND CO;34;F;Hospitalization - Initial or Prolonged;Cholecystitis acute
195049751;NA;NA;NA;NOVARTIS;65;M;Hospitalization - Initial or Prolonged;Gingival abscess
195050834;Plasma cell myeloma;REVLIMID;25;CELGENE;66;M;Hospitalization - Initial or Prolonged;Back disorder
195052523;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;63;M;NA;Accidental exposure to product
195052593;NA;NA;NA;ABBVIE;67;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
195053181;Invasive breast carcinoma;BLINDED PLACEBO FOR TUCATINIB;1200;SEATTLE GENETICS;46;F;Hospitalization - Initial or Prolonged;Non-cardiac chest pain
195053571;Osteoporosis;Ibandronate Sodium Tablets 150 mg;150;DR REDDYS;66;F;NA;Influenza like illness
195054591;Plasma cell myeloma;REVLIMID;25;CELGENE;80;M;Hospitalization - Initial or Prolonged;Dehydration
195055862;Relapsing-remitting multiple sclerosis;OCREVUS;300;ROCHE;47;F;Hospitalization - Initial or Prolonged;Headache
195057741;Brain neoplasm malignant;THALOMID;150;CELGENE;13;M;NA;Haemoglobin decreased
195058011;Contraception;NEXPLANON;1;ORGANON;38;F;NA;Breast pain
195058712;Clear cell renal cell carcinoma;PAZOPANIB;800;NOVARTIS;62;M;Death;Abdominal pain
195058992;NA;NA;NA;UNITED THERAPEUTICS;78;F;Hospitalization - Initial or Prolonged;Dyspnoea
195059621;Plasma cell myeloma;POMALYST;4;CELGENE;44;M;NA;Contusion
195060651;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;47;M;Hospitalization - Initial or Prolonged;Bladder cancer
195061141;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;46;F;Life-Threatening;Renal cancer
195061371;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;54;M;Other Serious (Important Medical Event);Nasal cavity cancer
195061561;Dyspepsia;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;48;F;Hospitalization - Initial or Prolonged;Breast cancer
195061652;Plasma cell myeloma;REVLIMID;25;CELGENE;77;F;NA;Laboratory test abnormal
195062271;Dyspepsia;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;70;M;Hospitalization - Initial or Prolonged;Bladder cancer
195062331;Colon cancer;LONSURF;60;TAIHO ONCOLOGY INC;77;M;Hospitalization - Initial or Prolonged;Diarrhoea
195062421;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;46;M;Hospitalization - Initial or Prolonged;Prostate cancer
195063335;Contraception;NEXPLANON;1;ORGANON;18;F;Other Serious (Important Medical Event);Device breakage
195064302;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;75;F;Death;Lung neoplasm malignant
195064401;Dyspepsia;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;45;M;Other Serious (Important Medical Event);Colorectal cancer
195064441;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;53;M;Hospitalization - Initial or Prolonged;Prostate cancer
195064662;Plasma cell myeloma;REVLIMID;25;CELGENE;66;F;Other Serious (Important Medical Event);Cyst
195065571;Plasma cell myeloma;REVLIMID;5;CELGENE;47;M;NA;Headache
195065961;Asthma;DUPIXENT;300;SANOFI AVENTIS;60;F;Hospitalization - Initial or Prolonged;Diabetes mellitus
195065992;Dyspepsia;ZANTAC;300;SANOFI AVENTIS;61;M;Hospitalization - Initial or Prolonged;Nasal cavity cancer
195066092;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;62;M;Hospitalization - Initial or Prolonged;Prostate cancer
195066442;Gastrooesophageal reflux disease;ZANTAC;300;SANOFI AVENTIS;85;M;Other Serious (Important Medical Event);Nasopharyngeal cancer
195066712;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;63;M;Other Serious (Important Medical Event);Non-Hodgkin's lymphoma
195066932;Chronic myeloid leukaemia;BOSULIF;400;PFIZER;78;M;Hospitalization - Initial or Prolonged;Leukopenia
195067342;Dyspepsia;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;60;M;Other Serious (Important Medical Event);Nasal cavity cancer
195067391;Abdominal pain upper;ZANTAC;75;SANOFI AVENTIS;57;M;Hospitalization - Initial or Prolonged;Bladder cancer
195067701;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;57;F;Hospitalization - Initial or Prolonged;Breast cancer
195067802;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;34;M;Life-Threatening;Colorectal cancer
195068974;Contraception;NEXPLANON;1;ORGANON;20;F;NA;Device breakage
195069043;Neutropenia;NEULASTA;6;AMGEN;60;M;NA;Device adhesion issue
195069381;Pulmonary arterial hypertension;SELEXIPAG;800;JOHNSON AND JOHNSON;51;F;Other Serious (Important Medical Event);Epistaxis
195069394;Contraception;NEXPLANON;1;ORGANON;22;F;NA;Device breakage
195069793;Pulmonary arterial hypertension;SELEXIPAG;600;JOHNSON AND JOHNSON;69;F;Other Serious (Important Medical Event);Renal disorder
195070401;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;33;M;Other Serious (Important Medical Event);Crohn's disease
195071012;Pulmonary arterial hypertension;SELEXIPAG;1200;JOHNSON AND JOHNSON;49;M;Hospitalization - Initial or Prolonged;Dizziness
195071232;Breast cancer metastatic;IBRANCE;125;PFIZER;48;F;Other Serious (Important Medical Event);Blood count abnormal
195071571;Pulmonary hypertension;UPTRAVI;1600;JOHNSON AND JOHNSON;83;M;Hospitalization - Initial or Prolonged;Myocardial infarction
195072262;Unknown;ELIQUIS;5;BRISTOL MYERS SQUIBB;56;F;Other Serious (Important Medical Event);Death
195072943;NA;NA;NA;MYLAN;59;M;Hospitalization - Initial or Prolonged;Hospitalisation
195073341;Dyspepsia;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;55;F;Other Serious (Important Medical Event);Breast cancer female
195073362;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;71;F;Hospitalization - Initial or Prolonged;Pancreatic carcinoma
195073491;Pulmonary arterial hypertension;UPTRAVI;1400;JOHNSON AND JOHNSON;49;F;Hospitalization - Initial or Prolonged;Pneumonia
195073751;Unknown;MIRENA;20;BAYER;43;F;NA;Procedural pain
195075341;Gastritis;ZANTAC;150;SANOFI AVENTIS;52;M;Hospitalization - Initial or Prolonged;Prostate cancer
195075391;Unknown;SPRAVATO;84;JOHNSON AND JOHNSON;37;F;NA;Burning sensation
195075961;Follicular lymphoma;REVLIMID;20;CELGENE;84;M;Life-Threatening;Death
195076702;Short stature;GENOTROPIN;0.8;PFIZER;7;M;NA;Device breakage
195076812;Skin cosmetic procedure;XEOMIN;33;MERZ;55;F;NA;Injection site mass
195077163;NA;NA;NA;BAYER;71;F;Hospitalization - Initial or Prolonged;Asthenia
195077911;Dyspepsia;ZANTAC;300;SANOFI AVENTIS;75;M;Hospitalization - Initial or Prolonged;Bladder cancer
195078041;Plasma cell myeloma;REVLIMID;15;CELGENE;83;F;NA;Chills
195079601;Plasma cell myeloma;REVLIMID;20;CELGENE;80;F;NA;Erythema
195079671;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;47;F;Hospitalization - Initial or Prolonged;Breast cancer female
195080491;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;70;M;Hospitalization - Initial or Prolonged;Colorectal cancer
195081721;Plasma cell myeloma;REVLIMID;5;CELGENE;48;M;Death;B precursor type acute leukaemia
195082542;Myeloproliferative neoplasm;INREBIC;200;CELGENE;73;F;Disability;Death
195082663;Unknown;AFINITOR;1;NOVARTIS;69;F;Other Serious (Important Medical Event);Breast cancer metastatic
195082901;Plasma cell myeloma;POMALYST;4;CELGENE;83;F;Other Serious (Important Medical Event);Death
195083701;Multiple sclerosis;KESIMPTA;20;NOVARTIS;42;M;NA;Chills
195084581;Lymphoma;REVLIMID;20;CELGENE;62;M;Hospitalization - Initial or Prolonged;Asthenia
195085001;Rheumatoid arthritis;HUMIRA;40;ABBVIE;66;F;Hospitalization - Initial or Prolonged;Blood count abnormal
195085302;NA;NA;NA;PFIZER;41;F;Other Serious (Important Medical Event);Headache
195086352;Non-Hodgkin's lymphoma;KYPROLIS;52.9;AMGEN;72;F;Other Serious (Important Medical Event);Hypotension
195087241;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;39;M;Other Serious (Important Medical Event);Testis cancer
195088752;Bladder cancer;NIVOLUMAB;360;BRISTOL MYERS SQUIBB;41;F;Hospitalization - Initial or Prolonged;Diarrhoea
195089412;Blood cholesterol abnormal;REPATHA;140;AMGEN;83;F;NA;Blood triglycerides increased
195090273;0;Human Immunoglobulin;0;TAKEDA;86;M;Other Serious (Important Medical Event);Acute kidney injury
195090304;Spinal muscular atrophy;SPINRAZA;12;BIOGEN;16;M;Other Serious (Important Medical Event);Acute respiratory failure
195090421;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;45;M;Other Serious (Important Medical Event);Bladder cancer
195090481;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;58;F;Death;Breast cancer female
195090561;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;63;F;Other Serious (Important Medical Event);Breast cancer
195091031;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;61;M;Other Serious (Important Medical Event);Thyroid cancer
195091232;Dyspepsia;ZANTAC;120;SANOFI AVENTIS;60;M;Hospitalization - Initial or Prolonged;Nasal neoplasm
195091741;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;62;M;Hospitalization - Initial or Prolonged;Prostate cancer
195092051;Chronic inflammatory demyelinating polyradiculoneuropathy;HIZENTRA;20;CSL BEHRING;60;F;Hospitalization - Initial or Prolonged;Angina unstable
195092089;Neutropenia;NEULASTA;6;AMGEN;41;F;NA;Accidental exposure to product
195092661;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;60;M;Other Serious (Important Medical Event);Colorectal cancer
195093121;Drug withdrawal syndrome;CLONAZEPAM;0.5;PRINSTON PHARMACEUTICAL;68;F;NA;Drug screen negative
195093371;Blood pressure abnormal;LISINOPRIL;5;PRINSTON PHARMACEUTICAL;49;F;NA;Abdominal pain upper
195093391;Blood pressure abnormal;LISINOPRIL;10;PRINSTON PHARMACEUTICAL;64;F;NA;Alopecia
195093431;Hypertension;LISINOPRIL;10;PRINSTON PHARMACEUTICAL;79;M;NA;Blood pressure increased
195094862;NA;NA;NA;UNITED THERAPEUTICS;63;M;Other Serious (Important Medical Event);Cardiac failure
195097182;Unknown;ZANTAC;150;SANOFI AVENTIS;80;F;Hospitalization - Initial or Prolonged;Pancreatic carcinoma
195097202;Diverticulitis;ZANTAC;150;SANOFI AVENTIS;70;F;Hospitalization - Initial or Prolonged;Pancreatic carcinoma
195097721;Seizure;LACOSAMIDE;200;UCB;70;M;Death;Road traffic accident
195099251;Hypertension;EXFORGE HCT;10;NOVARTIS;72;F;Hospitalization - Initial or Prolonged;Hyperkalaemia
195099351;Contraception;NEXPLANON;1;ORGANON;20;F;NA;Intermenstrual bleeding
195099711;Schizophrenia;CAPLYTA;42;INTRA-CELLULAR THERAPIES;41;M;NA;Chills
195099811;Schizophrenia;CAPLYTA;42;INTRA-CELLULAR THERAPIES;30;M;NA;Burning sensation
195100581;Hereditary neuropathic amyloidosis;TEGSEDI;284;AKCEA THERAPEUTICS;59;M;NA;Device delivery system issue
195100591;Mucopolysaccharidosis IV;VIMIZIM;65;BIOMARIN;10;F;NA;Diplopia
195100641;Hyperphenylalaninaemia;PALYNZIQ;10;BIOMARIN;41;M;NA;Angioedema
195100671;Transitional cell cancer of the renal pelvis and ureter;SACITUZUMAB GOVITECAN;10;GILEAD;67;M;Other Serious (Important Medical Event);Anaemia
195100712;Phenylketonuria;PALYNZIQ;10;BIOMARIN;24;F;NA;Arthralgia
195102041;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;57;M;Hospitalization - Initial or Prolonged;Renal cancer
195102461;Throat clearing;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;76;F;Other Serious (Important Medical Event);Breast cancer female
195102511;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;58;M;Other Serious (Important Medical Event);Prostate cancer
195102722;Contraception;MEDROXYPROGESTERONE ACETATE;1;PFIZER;26;F;Hospitalization - Initial or Prolonged;Back pain
195103191;Plasma cell myeloma;REVLIMID;25;CELGENE;75;M;NA;Haemoglobin decreased
195103351;Unknown;NAGLAZYME;40;BIOMARIN;27;F;NA;Chest discomfort
195105332;Plasma cell myeloma;POMALYST;4;CELGENE;75;M;Other Serious (Important Medical Event);Acute respiratory distress syndrome
195105902;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;64;M;Hospitalization - Initial or Prolonged;Bladder cancer
195106123;Unknown;REPATHA;420;AMGEN;59;F;NA;Wrong technique in product usage process
195106291;Seizure;SABRIL;750;LUNDBECK;10;F;Other Serious (Important Medical Event);Pneumonia
195106363;Neoplasm;PROLEUKIN;600000;CLINIGEN;58;M;Other Serious (Important Medical Event);Atrial fibrillation
195106663;Vascular graft;REPATHA;140;AMGEN;78;F;NA;Accidental exposure to product
195106703;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;39;F;NA;Needle issue
195107152;Endometrial cancer;ATEZOLIZUMAB;1200;ROCHE;71;F;Hospitalization - Initial or Prolonged;Enterovesical fistula
195107213;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;52;F;NA;Needle issue
195107731;Plasma cell myeloma;REVLIMID;10;CELGENE;88;F;NA;Muscle spasms
195108672;NA;NA;NA;LUPIN;52;F;NA;Drug ineffective
195109012;NA;NA;NA;UNITED THERAPEUTICS;49;F;Other Serious (Important Medical Event);Acute respiratory failure
195109201;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;41;F;Other Serious (Important Medical Event);Breast cancer female
195109231;Hyperchlorhydria;ZANTAC;75;SANOFI AVENTIS;63;M;Other Serious (Important Medical Event);Prostate cancer
195109271;Dyspepsia;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;56;M;Hospitalization - Initial or Prolonged;Thyroid cancer
195109331;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;60;M;Other Serious (Important Medical Event);Bladder cancer
195109463;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;60;M;Hospitalization - Initial or Prolonged;Prostate cancer
195109532;Duodenal ulcer;ZANTAC;75;SANOFI AVENTIS;56;F;Other Serious (Important Medical Event);Breast cancer
195112573;Neutropenia;NEULASTA;6;AMGEN;59;F;NA;Device adhesion issue
195113171;Unknown;TERAZOSIN;10;APNAR PHARMA;78;M;Death;Acute kidney injury
195113642;Immunodeficiency;XELJANZ XR;11;PFIZER;55;F;Hospitalization - Initial or Prolonged;Cellulitis
195114947;Transitional cell carcinoma;ASG 22CE;1.25;ASTELLAS;69;M;Other Serious (Important Medical Event);Hyperbilirubinaemia
195116072;Neutropenia;NEULASTA;6;AMGEN;68;F;NA;Intercepted product preparation error
195116643;Sickle cell disease;OXBRYTA;1000;GLOBAL BLOOD THERAPEUTICS;29;M;Life-Threatening;Anaemia
195117401;Myelodysplastic syndrome;REVLIMID;10;CELGENE;60;F;NA;Endoscopy gastrointestinal
195117821;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;63;F;Disability;Breast cancer
195118571;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;30;F;Other Serious (Important Medical Event);Colorectal cancer
195118651;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;53;M;Other Serious (Important Medical Event);Prostate cancer
195118741;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;70;F;Hospitalization - Initial or Prolonged;Thyroid cancer
195118771;Abdominal pain upper;ZANTAC;150;SANOFI AVENTIS;66;F;Other Serious (Important Medical Event);Breast cancer
195119101;Barrett's oesophagus;ZANTAC;300;SANOFI AVENTIS;69;M;Hospitalization - Initial or Prolonged;Bladder cancer
195119152;Gastrointestinal disorder;ZANTAC;150;SANOFI AVENTIS;59;F;Hospitalization - Initial or Prolonged;Colorectal cancer
195119161;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;60;M;Other Serious (Important Medical Event);Prostate cancer
195119362;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;29;M;Death;Testis cancer
195119541;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;47;M;Other Serious (Important Medical Event);Prostate cancer
195119581;Dyspepsia;RANITIDINE HYDROCHLORIDE;300;SANOFI AVENTIS;80;M;Other Serious (Important Medical Event);Colorectal cancer
195119591;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;53;M;Hospitalization - Initial or Prolonged;Prostate cancer
195119611;Gastrooesophageal reflux disease;ZANTAC;300;SANOFI AVENTIS;56;F;Hospitalization - Initial or Prolonged;Breast cancer
195119701;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;26;F;Other Serious (Important Medical Event);Testis cancer
195119712;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;60;F;Hospitalization - Initial or Prolonged;Hepatic cancer
195120081;Unknown;RANITIDINE HYDROCHLORIDE;75;SANOFI AVENTIS;55;M;Other Serious (Important Medical Event);Prostate cancer
195120122;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;69;F;Hospitalization - Initial or Prolonged;Pancreatic carcinoma
195120391;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;67;F;Hospitalization - Initial or Prolonged;Thyroid cancer
195120841;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;49;F;Hospitalization - Initial or Prolonged;Breast cancer
195121772;NA;NA;NA;AMGEN;55;F;Hospitalization - Initial or Prolonged;Osteonecrosis of jaw
195123152;NA;NA;NA;ELI LILLY AND CO;65;M;Hospitalization - Initial or Prolonged;Death
195126441;Unknown;NEXPLANON;1;ORGANON;20;F;NA;Complication of device insertion
195126551;Plasma cell myeloma;POMALYST;4;CELGENE;85;F;NA;Rash
195127373;Neutropenia;NEULASTA;6;AMGEN;55;M;NA;Unintentional medical device removal
195127854;Plasma cell myeloma;POMALYST;4;CELGENE;59;F;NA;Cough
195128272;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;71;M;NA;Device leakage
195130573;NA;NA;NA;PFIZER;41;F;NA;Syringe issue
195130832;Headache;GADAVIST;9;BAYER;53;F;NA;Vomiting
195130902;Procedural pain;FENTANYL TRANSDERMAL SYSTEM;37.5;MYLAN;41;F;NA;Off label use
195131813;Endometrial cancer;LENVIMA;20;EISAI;55;F;Death;Hypersensitivity
195132771;Seizure;SABRIL;500;LUNDBECK;1;F;Other Serious (Important Medical Event);Bronchiolitis
195133631;Still's disease;SANDIMMUN NEORAL;70;NOVARTIS;12;F;Other Serious (Important Medical Event);Anaemia
195133691;Gallbladder cancer metastatic;FLUOROURACIL (Manufacturer unknown);2400;FRESENIUS KABI;71;M;Hospitalization - Initial or Prolonged;Abdominal pain
195133881;Anaemia;FERRIPROX;2500;CHIESI;17;F;Death;Bone marrow transplant
195134531;Colonoscopy;SUTAB;12;BRAINTREE;24;F;Life-Threatening;Anaphylactic reaction
195134801;NA;NA;NA;BAYER;77;F;Hospitalization - Initial or Prolonged;Dizziness
195135152;NA;NA;NA;UNITED THERAPEUTICS;60;F;Other Serious (Important Medical Event);Cardiac failure
195135201;Cholangiocarcinoma;FLUOROURACIL (Manufacturer unknown);4490;FRESENIUS KABI;73;F;Other Serious (Important Medical Event);Cholangiocarcinoma
195137071;NA;NA;NA;FRESENIUS KABI;72;M;Other Serious (Important Medical Event);Subclavian vein thrombosis
195137841;Plasma cell myeloma;REVLIMID;25;CELGENE;76;F;NA;Diarrhoea
195137861;Ankylosing spondylitis;HUMIRA;40;ABBVIE;53;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
195138351;Contraception;NEXPLANON;1;ORGANON;27;F;NA;Implant site erythema
195139072;Bipolar disorder;LATUDA;60;SUNOVION;43;F;Other Serious (Important Medical Event);Road traffic accident
195139471;Myelofibrosis;INREBIC;300;CELGENE;74;F;Hospitalization - Initial or Prolonged;Rectal haemorrhage
195139533;NA;NA;NA;UNITED THERAPEUTICS;71;F;Other Serious (Important Medical Event);Cerebral haemorrhage
195140521;Mucopolysaccharidosis IV;VIMIZIM;50;BIOMARIN;11;F;NA;Dyspnoea
195140551;Phenylketonuria;KUVAN;1100;BIOMARIN;21;F;NA;Weight increased
195140651;Phenylketonuria;KUVAN;1900;BIOMARIN;36;M;NA;Weight increased
195141731;Blood cholesterol increased;ATORVASTATIN CALCIUM;20;GRAVITI PHARMACEUTICALS;72;F;NA;Muscle spasms
195142461;NA;NA;NA;TEVA;57;F;Hospitalization - Initial or Prolonged;Dysuria
195142501;Unknown;ATORVASTATIN CALCIUM;40;GRAVITI PHARMACEUTICALS;71;F;NA;Urinary incontinence
195142573;Non-Hodgkin's lymphoma;VENCLEXTA;400;ABBVIE;62;M;Other Serious (Important Medical Event);Death
195142591;Blood cholesterol increased;ATORVASTATIN CALCIUM;10;GRAVITI PHARMACEUTICALS;92;F;NA;Rash
195142843;NA;NA;NA;UNITED THERAPEUTICS;10;F;Hospitalization - Initial or Prolonged;Blood iron decreased
195142982;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;60;M;Other Serious (Important Medical Event);Plasma cell myeloma
195143142;Non-small cell lung cancer;NIVOLUMAB;100;BRISTOL MYERS SQUIBB;64;F;Other Serious (Important Medical Event);Blood creatine phosphokinase increased
195143191;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;63;M;Hospitalization - Initial or Prolonged;Prostate cancer
195143501;Abdominal pain upper;ZANTAC;75;SANOFI AVENTIS;32;M;Hospitalization - Initial or Prolonged;Thyroid cancer
195143521;NA;NA;NA;UNITED THERAPEUTICS;52;F;Hospitalization - Initial or Prolonged;Dyspnoea
195143641;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;56;M;Other Serious (Important Medical Event);Thyroid cancer
195143741;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;48;F;Hospitalization - Initial or Prolonged;Renal cancer
195143762;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;49;F;Hospitalization - Initial or Prolonged;Breast cancer female
195143771;Abdominal pain upper;ZANTAC;150;SANOFI AVENTIS;70;M;Death;Lung neoplasm malignant
195143901;Gastrooesophageal reflux disease;ZANTAC;300;SANOFI AVENTIS;56;F;Hospitalization - Initial or Prolonged;Breast cancer female
195143971;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;57;M;Other Serious (Important Medical Event);Prostate cancer
195144001;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;47;F;Other Serious (Important Medical Event);Colorectal cancer
195144211;Unknown;ZANTAC;75;SANOFI AVENTIS;39;M;Hospitalization - Initial or Prolonged;Hepatic cancer
195145191;Type 2 diabetes mellitus;FARXIGA;10;ASTRAZENECA;64;F;NA;Fatigue
195146421;Follicular lymphoma;REVLIMID;15;CELGENE;72;M;NA;Dehydration
195146435;Ewing's sarcoma;TALAZOPARIB;500;PFIZER;13;M;Other Serious (Important Medical Event);Decreased appetite
195147481;Pollakiuria;TROSPIUM CHLORIDE;60;PERRIGO;78;F;NA;Confusional state
195147491;Pollakiuria;TROSPIUM CHLORIDE;60;PERRIGO;65;M;NA;Condition aggravated
195147841;Plasma cell myeloma;REVLIMID;25;CELGENE;76;M;Other Serious (Important Medical Event);Dizziness
195148291;B-cell lymphoma;REVLIMID;20;CELGENE;71;F;Disability;Myocardial necrosis marker increased
195148411;Hodgkin's disease;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;52;M;Hospitalization - Initial or Prolonged;Confusional state
195148742;Pulmonary arterial hypertension;UPTRAVI;200;JOHNSON AND JOHNSON;45;F;Other Serious (Important Medical Event);Haemoptysis
195148761;NA;NA;NA;TAKEDA;70;F;Hospitalization - Initial or Prolonged;Diarrhoea
195148994;Gastrointestinal stromal tumour;DCC 2618;150;DECIPHERA PHARMACEUTICALS;60;F;Other Serious (Important Medical Event);Pain
195149233;Persistent depressive disorder;PRISTIQ EXTENDED RELEASE;100;PFIZER;57;M;Hospitalization - Initial or Prolonged;Aortic aneurysm
195149282;Glioblastoma;NIVOLUMAB;980.1;BRISTOL MYERS SQUIBB;58;M;Other Serious (Important Medical Event);Encephalitis autoimmune
195149482;Computerised tomogram thorax;OMNIPAQUE;120;GE HEALTHCARE;52;F;Hospitalization - Initial or Prolonged;Anaphylactic reaction
195151191;Plasma cell myeloma;REVLIMID;25;CELGENE;70;M;NA;Psoriasis
195151681;Hyperchlorhydria;ZANTAC;150;SANOFI AVENTIS;61;M;Other Serious (Important Medical Event);Prostate cancer
195151691;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;45;F;Death;Neoplasm malignant
195151832;Lung neoplasm malignant;Brigatinib;180;TAKEDA;56;M;Other Serious (Important Medical Event);Abdominal pain
195152231;Plasma cell myeloma;REVLIMID;10;CELGENE;88;F;NA;Muscle spasms
195152518;Acute myeloid leukaemia;VENETOCLAX;100;ABBVIE;77;M;Hospitalization - Initial or Prolonged;Enterobacter sepsis
195152521;Plasma cell myeloma;REVLIMID;10;CELGENE;66;M;NA;Arthralgia
195153041;NA;NA;NA;FRESENIUS KABI;80;M;NA;Arthralgia
195153351;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;56;F;NA;Device malfunction
195155112;Hodgkin's disease;brentuximab vedotin;549.9;SEATTLE GENETICS;22;M;Life-Threatening;Obstructive airways disorder
195155315;NA;NA;NA;UNITED THERAPEUTICS;69;M;Other Serious (Important Medical Event);Device dislocation
195155941;Follicular lymphoma;REVLIMID;10;CELGENE;86;M;NA;Asthenia
195156033;Unknown;KESIMPTA;20;NOVARTIS;30;F;NA;Fatigue
195158632;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;51;F;NA;Amnesia
195158862;Plasma cell myeloma;REVLIMID;25;CELGENE;63;M;NA;Disorientation
195161263;Hypertonic bladder;MYRBETRIQ;25;ASTELLAS;69;F;Hospitalization - Initial or Prolonged;Urinary retention
195164682;Colitis ulcerative;STELARA;90;JOHNSON AND JOHNSON;43;M;NA;Product dose omission issue
195166621;Chronic lymphocytic leukaemia;CYCLOPHOSPHAMIDE FOR INJECTION, USP;700;BAXTER;57;M;Other Serious (Important Medical Event);Cytokine release syndrome
195166952;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;20;M;NA;Product dose omission issue
195168252;Contraception;NEXPLANON;1;ORGANON;16;F;NA;Device kink
195168274;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;74;M;NA;Device malfunction
195168344;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;59;F;NA;Accidental exposure to product
195168455;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;50;F;NA;Accidental exposure to product
195168892;Rheumatoid arthritis;ENBREL;50;AMGEN;74;M;NA;Accidental exposure to product
195169276;Neutropenia;NEULASTA;6;AMGEN;46;M;NA;Device occlusion
195169481;Chronic lymphocytic leukaemia;CALQUENCE;100;ASTRAZENECA;68;M;NA;Palpitations
195169824;NA;NA;NA;AMGEN;52;M;NA;Back pain
195169902;Parkinson's disease;DUOPA;100;ABBVIE;63;M;Hospitalization - Initial or Prolonged;Autonomic neuropathy
195171441;Hodgkin's disease;NIVOLUMAB;3;BRISTOL MYERS SQUIBB;49;F;Life-Threatening;Colitis
195171856;Neutropenia;NEULASTA;6;AMGEN;69;F;NA;Device adhesion issue
195172441;Hepatobiliary cancer;LEUCOVORIN;400;HIKMA;71;M;Death;Abdominal pain
195172491;Dyspepsia;ZANTAC;300;SANOFI AVENTIS;40;F;Other Serious (Important Medical Event);Breast cancer
195173491;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;59;M;Hospitalization - Initial or Prolonged;Prostate cancer
195173541;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;450;SANOFI AVENTIS;48;M;Other Serious (Important Medical Event);Colorectal cancer
195173631;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;63;M;Death;Prostate cancer
195176941;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;47;F;Hospitalization - Initial or Prolonged;Breast cancer
195177251;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;61;M;Other Serious (Important Medical Event);Prostate cancer
195177753;Neutropenia;NEULASTA;6;AMGEN;88;M;NA;Device use error
195177931;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;58;M;Other Serious (Important Medical Event);Renal cancer
195178161;Plasma cell myeloma;REVLIMID;15;CELGENE;76;F;Hospitalization - Initial or Prolonged;Asthenia
195178391;Plasma cell myeloma;REVLIMID;10;CELGENE;69;F;NA;Diarrhoea
195178552;Plasma cell myeloma;REVLIMID;25;CELGENE;59;M;NA;Liver function test increased
195178591;Plasma cell myeloma;REVLIMID;10;CELGENE;90;F;NA;Asthenia
195178761;Plasma cell myeloma;REVLIMID;10;CELGENE;84;M;Other Serious (Important Medical Event);Body temperature increased
195178891;Plasma cell myeloma;REVLIMID;25;CELGENE;74;M;NA;Leukopenia
195179062;Crohn's disease;HUMIRA;40;ABBVIE;71;M;Hospitalization - Initial or Prolonged;Precancerous lesion of digestive tract
195180231;Unknown;ZANTAC;300;SANOFI AVENTIS;49;F;Other Serious (Important Medical Event);Breast cancer
195180251;Dyspepsia;ZANTAC;300;SANOFI AVENTIS;61;M;Other Serious (Important Medical Event);Prostate cancer
195180692;Relapsing-remitting multiple sclerosis;OCREVUS;300;ROCHE;62;M;Hospitalization - Initial or Prolonged;Acute kidney injury
195181472;Parkinson's disease psychosis;NUPLAZID;34;ACADIA PHARMACEUTICALS;71;F;NA;Gait disturbance
195182554;Acute lymphocytic leukaemia;METHOTREXATE;12.5;HIKMA;18;M;Hospitalization - Initial or Prolonged;Anaemia
195182681;Plasma cell myeloma;REVLIMID;25;CELGENE;75;F;Hospitalization - Initial or Prolonged;Neuropathy peripheral
195182711;Inappropriate schedule of product administration;TASIGNA;300;NOVARTIS;73;F;NA;Inappropriate schedule of product administration
195182772;Plasma cell myeloma;REVLIMID;25;CELGENE;67;M;NA;Rash
195182812;B precursor type acute leukaemia;blinatumomab;28;AMGEN;70;M;Death;Sepsis
195183201;Immunodeficiency;PRIVIGEN;40;CSL BEHRING;0;F;NA;Vomiting
195184471;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;65;M;Hospitalization - Initial or Prolonged;Bladder cancer
195184601;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;72;M;Life-Threatening;Bladder cancer
195184631;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;60;M;Other Serious (Important Medical Event);Bladder cancer
195188411;Plasma cell myeloma;REVLIMID;25;CELGENE;61;M;NA;Joint swelling
195188921;Haemochromatosis;FERRIPROX;2000;CHIESI;77;F;Hospitalization - Initial or Prolonged;Death
195188971;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;42;F;Other Serious (Important Medical Event);Neoplasm malignant
195189033;Unknown;TADALAFIL;20;ELI LILLY AND CO;76;F;NA;Decreased appetite
195189092;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;64;M;Hospitalization - Initial or Prolonged;Prostate cancer
195189101;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;44;M;Hospitalization - Initial or Prolonged;Renal cancer
195190621;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;42;F;Other Serious (Important Medical Event);Breast cancer female
195190801;Thrombosis;XARELTO;10;JOHNSON AND JOHNSON;80;F;NA;Body height decreased
195191281;Relapsing-remitting multiple sclerosis;Glatiramer Acetate Injection;40;MYLAN;60;F;Hospitalization - Initial or Prolonged;Anaphylactic reaction
195195182;Diarrhoea;COLESTIPOL HCL;5;PFIZER;92;F;Other Serious (Important Medical Event);Choking
195196053;Unknown;VIGABATRIN;16.5;AMNEAL;1;M;Hospitalization - Initial or Prolonged;Circumcision
195196271;Pain;TYLENOL 8HR;650;JOHNSON AND JOHNSON;71;M;NA;Inappropriate schedule of product administration
195196631;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;48;M;Other Serious (Important Medical Event);Bladder cancer
195197372;Anaphylactic reaction;ADRENACLICK;0.3;AMNEAL;38;F;Hospitalization - Initial or Prolonged;Device failure
195199652;Rheumatoid arthritis;REMICADE;650;JOHNSON AND JOHNSON;64;F;NA;Product dose omission issue
195200501;NA;NA;NA;BAYER;68;F;Other Serious (Important Medical Event);Death
195200531;Chronic lymphocytic leukaemia;FLUDARABINE;50;FRESENIUS KABI;57;M;Hospitalization - Initial or Prolonged;Cytokine release syndrome
195200632;Unknown;IMPLANON;1;ORGANON;18;F;NA;Complication of device insertion
195200901;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;59;F;Other Serious (Important Medical Event);Renal cancer
195200921;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;64;F;Other Serious (Important Medical Event);Breast cancer
195201951;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;75;SANOFI AVENTIS;60;M;Hospitalization - Initial or Prolonged;Nasopharyngeal cancer
195202141;NA;NA;NA;BAYER;78;M;Life-Threatening;Death
195202421;Neurofibromatosis;AZD6244;35;ASTRAZENECA;9;M;Hospitalization - Initial or Prolonged;Anaemia
195202432;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;62;M;Hospitalization - Initial or Prolonged;Neoplasm malignant
195202641;Epilepsy;LEVETIRACETAM;750;MYLAN;46;F;Other Serious (Important Medical Event);Abdominal pain upper
195202942;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;54;F;Hospitalization - Initial or Prolonged;Breast cancer female
195203061;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;38;M;Other Serious (Important Medical Event);Colorectal cancer
195203311;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;60;M;Hospitalization - Initial or Prolonged;Prostate cancer
195203563;Migraine;EMGALITY;240;ELI LILLY AND CO;20;F;Hospitalization - Initial or Prolonged;Anaphylactic reaction
195203642;Uterine leiomyoma;ACTIVELLA;1;AMNEAL;51;F;Other Serious (Important Medical Event);Pain
195203874;Pulmonary arterial hypertension;SELEXIPAG;800;JOHNSON AND JOHNSON;48;F;Death;Adverse drug reaction
195206101;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;42;F;Hospitalization - Initial or Prolonged;Colorectal cancer
195206751;Gastrointestinal disorder;ZANTAC;75;SANOFI AVENTIS;49;F;Hospitalization - Initial or Prolonged;Breast cancer
195208231;Plasma cell myeloma;REVLIMID;25;CELGENE;69;M;Life-Threatening;Tremor
195208961;Cystic fibrosis;TOBI PODHALER;112;NOVARTIS;18;M;Other Serious (Important Medical Event);Infective pulmonary exacerbation of cystic fibrosis
195209051;Plasma cell myeloma;REVLIMID;20;CELGENE;51;F;Disability;Neuropathy peripheral
195209091;Myelodysplastic syndrome;REVLIMID;10;CELGENE;74;M;Hospitalization - Initial or Prolonged;Haemorrhage intracranial
195209741;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;62;M;Life-Threatening;Renal cancer
195209752;Dermatitis atopic;DUPILUMAB;600;SANOFI AVENTIS;20;F;Other Serious (Important Medical Event);Dry skin
195209761;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;38;F;Hospitalization - Initial or Prolonged;Breast cancer
195210293;Rheumatoid arthritis;SIMPONI ARIA;143;JOHNSON AND JOHNSON;70;F;NA;Injection site extravasation
195210401;NA;NA;NA;BAYER;85;F;Other Serious (Important Medical Event);Death
195211021;Immune system disorder;Lanadelumab;300;TAKEDA;68;M;Life-Threatening;Bladder disorder
195211051;Pulmonary arterial hypertension;UPTRAVI;200;JOHNSON AND JOHNSON;2;F;Hospitalization - Initial or Prolonged;Seizure
195211242;Psoriasis;Certolizumab pegol;400;UCB;57;M;Hospitalization - Initial or Prolonged;Injection site mass
195211821;Erectile dysfunction;MUSE;500;MYLAN;71;M;Other Serious (Important Medical Event);Drug effect less than expected
195212442;Rheumatoid arthritis;ABATACEPT;125;BRISTOL MYERS SQUIBB;76;F;NA;Product supply issue
195212461;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;73;F;Hospitalization - Initial or Prolonged;Bladder cancer
195212471;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;59;F;Death;Breast cancer
195212671;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;54;M;Other Serious (Important Medical Event);Pancreatic carcinoma
195213381;Seizure;TOPAMAX;300;JOHNSON AND JOHNSON;20;F;NA;Gait disturbance
195215171;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;85;F;NA;Blood glucose increased
195215341;Metastatic malignant melanoma;OPDIVO;100;BRISTOL MYERS SQUIBB;79;M;NA;Body temperature abnormal
195217331;Renal cancer;INLYTA;5;PFIZER;73;M;Hospitalization - Initial or Prolonged;Heart rate increased
195217802;Blood cholesterol increased;REPATHA;140;AMGEN;75;M;NA;Accidental exposure to product
195218082;Schizoaffective disorder;Clozapine 100 mg Tablet USP;1;AUROBINDO;62;F;Other Serious (Important Medical Event);Pneumonia aspiration
195218401;Myasthenia gravis;GAMUNEX C;50;GRIFOLS;59;M;NA;Rash
195218701;Dyspepsia;ZANTAC;300;SANOFI AVENTIS;70;M;Hospitalization - Initial or Prolonged;Nasal cavity cancer
195218721;Gastrooesophageal reflux disease;ZANTAC;300;SANOFI AVENTIS;76;F;Other Serious (Important Medical Event);Breast cancer female
195218821;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;58;M;Hospitalization - Initial or Prolonged;Renal cancer
195218841;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;300;SANOFI AVENTIS;54;M;Other Serious (Important Medical Event);Prostate cancer
195219913;Plasma cell myeloma;NINLARO;3;TAKEDA;85;M;Death;Asthenia
195220521;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;58;M;Hospitalization - Initial or Prolonged;Prostate cancer
195220621;Abdominal pain upper;ZANTAC;150;SANOFI AVENTIS;57;M;Other Serious (Important Medical Event);Colorectal cancer
195221471;Abdominal pain upper;ZANTAC;75;SANOFI AVENTIS;65;M;Other Serious (Important Medical Event);Prostate cancer
195222171;Plasma cell myeloma;REVLIMID;25;CELGENE;74;M;NA;Eye infection
195222191;Plasma cell myeloma;REVLIMID;25;CELGENE;81;M;Other Serious (Important Medical Event);Plasma cell myeloma
195222741;K-ras gene mutation;AMG 510;360;AMGEN;50;F;Other Serious (Important Medical Event);Immune-mediated hepatitis
195225711;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;33;F;Hospitalization - Initial or Prolonged;Neoplasm malignant
195226422;Pulmonary hypertension;UPTRAVI;800;JOHNSON AND JOHNSON;73;F;Hospitalization - Initial or Prolonged;Dizziness
195226892;NA;NA;NA;UNITED THERAPEUTICS;66;F;Other Serious (Important Medical Event);Asthenia
195227021;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;65;M;Other Serious (Important Medical Event);Hospitalisation
195229541;Chronic lymphocytic leukaemia;VENETOCLAX;400;ABBVIE;65;F;Other Serious (Important Medical Event);Acute kidney injury
195229841;Hormone replacement therapy;Levothyroxine Sodium Tablets, USP;25;MYLAN;52;F;NA;Alopecia
195230212;Pulmonary hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;68;F;Hospitalization - Initial or Prolonged;Arthritis infective
195236864;Multiple sclerosis;TECFIDERA;240;BIOGEN;73;M;Life-Threatening;Cerebral infarction
195239421;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;63;M;Other Serious (Important Medical Event);Pericardial effusion
195241572;Plasma cell myeloma;REVLIMID;10;CELGENE;86;F;Disability;Abdominal pain lower
195244812;HER2 positive breast cancer;Tucatinib;300;SEATTLE GENETICS;43;F;Hospitalization - Initial or Prolonged;Hyponatraemia
195246252;Plasma cell myeloma;REVLIMID;15;CELGENE;84;F;Life-Threatening;Fall
195248174;Hereditary angioedema;HAEGARDA;2000;CSL BEHRING;28;F;Other Serious (Important Medical Event);Hereditary angioedema
195254651;Graft versus host disease;PREDNISONE;30;HIKMA;28;M;Other Serious (Important Medical Event);Abdominal pain
195255961;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;48;M;Other Serious (Important Medical Event);Bladder cancer
195256852;NA;NA;NA;APOTEX;63;F;Other Serious (Important Medical Event);Hypokinesia
195258634;NA;NA;NA;UNITED THERAPEUTICS;56;F;Other Serious (Important Medical Event);Chest discomfort
195259711;Type 2 diabetes mellitus;NOVOLOG;26;NOVO NORDISK;67;M;Hospitalization - Initial or Prolonged;Blood glucose abnormal
195260782;Type 2 diabetes mellitus;TRULICITY;0.75;ELI LILLY AND CO;61;M;Other Serious (Important Medical Event);Pancreatitis
195262881;Deep vein thrombosis;ELIQUIS;10;BRISTOL MYERS SQUIBB;59;F;NA;Constipation
195264532;NA;NA;NA;HIKMA;71;M;Hospitalization - Initial or Prolonged;Abdominal pain
195266721;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;62;M;NA;Device malfunction
195268692;Asthma;ASMANEX;2;ORGANON;58;F;NA;Circumstance or information capable of leading to device use error
195276903;NA;NA;NA;CELGENE;77;F;Hospitalization - Initial or Prolonged;Myelodysplastic syndrome
195277781;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;45;F;Other Serious (Important Medical Event);Fluid overload
195278993;Plasma cell myeloma;REVLIMID;25;CELGENE;81;F;Hospitalization - Initial or Prolonged;Asthenia
195280191;Dyspepsia;RANITIDINE HYDROCHLORIDE;300;SANOFI AVENTIS;56;M;Hospitalization - Initial or Prolonged;Renal cancer
195280821;Pulmonary arterial hypertension;UPTRAVI;200;JOHNSON AND JOHNSON;48;F;Hospitalization - Initial or Prolonged;Hip arthroplasty
195281602;Dyspepsia;RANITIDINE HYDROCHLORIDE;300;SANOFI AVENTIS;66;F;Other Serious (Important Medical Event);Malignant mesenteric neoplasm
195281621;Pulmonary arterial hypertension;UPTRAVI;800;JOHNSON AND JOHNSON;18;F;Other Serious (Important Medical Event);Food poisoning
195282061;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;39;F;Hospitalization - Initial or Prolonged;Thyroid cancer
195282252;Hyperchlorhydria;ZANTAC;75;SANOFI AVENTIS;22;M;Hospitalization - Initial or Prolonged;Gastrointestinal stromal tumour
195282361;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;54;M;Other Serious (Important Medical Event);Prostate cancer
195282591;Mucopolysaccharidosis IV;VIMIZIM;50;BIOMARIN;11;F;NA;Infusion related reaction
195289762;Rheumatoid arthritis;HUMIRA;40;ABBVIE;77;F;Hospitalization - Initial or Prolonged;Ankle fracture
195292192;NA;NA;NA;UNITED THERAPEUTICS;51;F;Other Serious (Important Medical Event);Cerebrovascular accident
195292671;Hormone replacement therapy;ESTRADIOL TRANSDERMAL SYSTEM;0.075;MYLAN;59;F;NA;Application site reaction
195292692;Plasma cell myeloma;REVLIMID;5;CELGENE;83;F;Hospitalization - Initial or Prolonged;Death
195293971;Prostate cancer;ORGOVYX;120;MYOVANT SCIENCES;67;M;NA;Myalgia
195296761;Psoriasis;HUMIRA;40;ABBVIE;55;M;Hospitalization - Initial or Prolonged;COVID-19
195297062;Plasma cell myeloma;REVLIMID;25;CELGENE;64;M;Other Serious (Important Medical Event);COVID-19
195299431;Plasma cell myeloma;REVLIMID;5;CELGENE;73;M;Hospitalization - Initial or Prolonged;Death
195308382;NA;NA;NA;ABBVIE;64;F;Other Serious (Important Medical Event);Inflammation
195310031;NA;NA;NA;CELGENE;52;F;Other Serious (Important Medical Event);Febrile neutropenia
195310061;Myelodysplastic syndrome;REVLIMID;10;CELGENE;77;M;Death;Full blood count decreased
195311021;NA;NA;NA;BAYER;90;F;Hospitalization - Initial or Prolonged;Death
195311774;HIV infection;Dolutegravir;50;VIIV;31;F;Other Serious (Important Medical Event);Foetal death
195312551;NA;NA;NA;GLAXOSMITHKLINE;46;U;Death;Aphasia
195313371;Contraception;NEXPLANON;1;ORGANON;21;F;NA;Heavy menstrual bleeding
195317381;Hypercholesterolaemia;REPATHA;140;AMGEN;69;M;NA;Injection site haemorrhage
195321971;Deep vein thrombosis;APIXABAN;2.5;BRISTOL MYERS SQUIBB;67;M;Other Serious (Important Medical Event);Dysphagia
195325083;Infertility female;PREGNYL;10000;ORGANON;37;F;NA;Headache
195325221;NA;NA;NA;ROCHE;65;F;Death;Allergy to arthropod bite
195325451;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;63;M;Other Serious (Important Medical Event);Bladder cancer
195326911;Unknown;ZANTAC;300;SANOFI AVENTIS;66;M;Other Serious (Important Medical Event);Renal cancer
195327442;Parkinson's disease;Rotigotine;6;UCB;88;F;Hospitalization - Initial or Prolonged;Rheumatoid arthritis
195329332;NA;NA;NA;UNITED THERAPEUTICS;72;M;Other Serious (Important Medical Event);Dyspnoea
195332691;Hodgkin's disease;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;57;F;Other Serious (Important Medical Event);Sepsis
195334322;NA;NA;NA;UNITED THERAPEUTICS;47;F;Death;Dyspnoea
195336711;Computerised tomogram abdomen;OPTIRAY 350;100;GUERBET;80;F;Hospitalization - Initial or Prolonged;Urticaria
195339471;NA;NA;NA;SANOFI AVENTIS;59;F;Other Serious (Important Medical Event);Blood glucose abnormal
195343301;Plasma cell myeloma;REVLIMID;25;CELGENE;59;M;Hospitalization - Initial or Prolonged;Thrombosis
195351471;Gastric ulcer;ZANTAC;150;SANOFI AVENTIS;75;F;Hospitalization - Initial or Prolonged;Breast cancer
195352551;Unknown;ZANTAC;150;SANOFI AVENTIS;42;F;Other Serious (Important Medical Event);Breast cancer
195352752;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;69;M;Other Serious (Important Medical Event);Renal cancer
195352981;Bladder cancer;ATEZOLIZUMAB;1200;ROCHE;65;M;Hospitalization - Initial or Prolonged;Cytokine release syndrome
195353252;Hypopituitarism;GENOTROPIN;1.4;PFIZER;12;M;NA;Device information output issue
195353753;NA;NA;NA;FRESENIUS KABI;57;F;NA;Cholestasis
195356281;NA;NA;NA;UNITED THERAPEUTICS;38;M;Hospitalization - Initial or Prolonged;Death
195356421;Follicular lymphoma;REVLIMID;15;CELGENE;80;F;Death;Urinary tract infection
195367641;Plasma cell myeloma;REVLIMID;15;CELGENE;71;M;Hospitalization - Initial or Prolonged;Groin pain
195371291;Thrombosis;ENOXAPARIN SODIUM;120;AMPHASTAR;67;F;NA;Incorrect dose administered
195380701;Contraception;NEXPLANON;1;ORGANON;18;F;NA;Device kink
195380912;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;52;F;Other Serious (Important Medical Event);Breast cancer female
195381191;NA;NA;NA;UNITED THERAPEUTICS;37;F;Other Serious (Important Medical Event);Escherichia urinary tract infection
195381241;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;53;M;Hospitalization - Initial or Prolonged;Prostate cancer
195382611;Gastric disorder;ZANTAC;75;SANOFI AVENTIS;58;F;Hospitalization - Initial or Prolonged;Gastric cancer
195382731;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;300;SANOFI AVENTIS;54;F;Life-Threatening;Thyroid cancer
195382801;Dyspepsia;ZANTAC;75;SANOFI AVENTIS;54;M;Death;Renal cancer
195383561;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;63;F;Other Serious (Important Medical Event);Breast cancer female
195384961;Gastrointestinal disorder;ZANTAC;75;SANOFI AVENTIS;60;M;Hospitalization - Initial or Prolonged;Colorectal cancer
195384991;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;57;F;Hospitalization - Initial or Prolonged;Colorectal cancer
195385371;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;68;F;Life-Threatening;Breast cancer
195385841;Gastrooesophageal reflux disease;RANITIDINE HYDROCHLORIDE;150;SANOFI AVENTIS;57;M;Hospitalization - Initial or Prolonged;Prostate cancer
195386271;Diarrhoea;Cholestyramine (ANDA 211119);4;AJANTA PHARMA;61;F;NA;Product solubility abnormal
195386292;Psoriasis;SKYRIZI;150;ABBVIE;67;M;Hospitalization - Initial or Prolonged;Basal cell carcinoma
195386711;Gastrooesophageal reflux disease;ZANTAC;75;SANOFI AVENTIS;74;M;Other Serious (Important Medical Event);Thyroid cancer
195387361;Genital herpes;Valacyclovir Hydrochloride Tablets 1g;1;AUROBINDO;61;M;NA;Drug ineffective
195391034;Juvenile idiopathic arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;17;F;NA;Device issue
195391664;Metastatic carcinoma of the bladder;BALVERSA;8;JOHNSON AND JOHNSON;73;M;Other Serious (Important Medical Event);Abdominal discomfort
195394711;Plasma cell myeloma;REVLIMID;25;CELGENE;68;F;NA;Nasopharyngitis
195396111;NA;NA;NA;CELGENE;74;F;NA;Rash
195396162;Pleural mesothelioma malignant;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;65;M;Life-Threatening;Chest pain
195400561;Pulmonary arterial hypertension;SELEXIPAG;800;JOHNSON AND JOHNSON;4;M;Hospitalization - Initial or Prolonged;Off label use
195402181;Anxiety;Atomoxetine Capsules USP [25mg];25;GLENMARK;20;M;NA;Vomiting
195404991;Seizure;VIGABATRIN;800;AMNEAL;1;F;Other Serious (Important Medical Event);Cyanosis
195408881;Chronic obstructive pulmonary disease;TRELEGY ELLIPTA;1;GLAXOSMITHKLINE;67;M;Hospitalization - Initial or Prolonged;Cardiac failure
195412981;Plasma cell myeloma;REVLIMID;25;CELGENE;58;F;Hospitalization - Initial or Prolonged;Diarrhoea
195414422;Blood cholesterol increased;REPATHA;140;AMGEN;65;F;NA;Device difficult to use
195416521;Rheumatoid arthritis;RITUXAN;1000;ROCHE;73;M;Hospitalization - Initial or Prolonged;Chest discomfort
195419571;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;79;M;NA;Device malfunction
195427802;Growth hormone deficiency;GENOTROPIN;2.6;PFIZER;15;M;NA;Device issue
195427871;Hormone therapy;GENOTROPIN;1.5;PFIZER;10;M;NA;Device information output issue
195429962;Hepatitis C;HARVONI;1;GILEAD;67;F;NA;Dyspepsia
195432222;Blood cholesterol increased;REPATHA;140;AMGEN;88;M;NA;Device difficult to use
195433142;Plasma cell myeloma;NINLARO;3;TAKEDA;91;M;NA;Peripheral swelling
195434131;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;63;F;NA;Dizziness
195434811;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;39;F;Other Serious (Important Medical Event);Breast cancer
195436431;Sarcoma;ERIBULIN;1.4;EISAI;62;M;Hospitalization - Initial or Prolonged;Pneumonia
195437911;NA;NA;NA;BAYER;77;F;Other Serious (Important Medical Event);Death
195438023;Glioblastoma multiforme;NIVOLUMAB;315;BRISTOL MYERS SQUIBB;56;M;Hospitalization - Initial or Prolonged;Confusional state
195440422;Pulmonary arterial hypertension;SELEXIPAG;1200;JOHNSON AND JOHNSON;68;F;Hospitalization - Initial or Prolonged;Blood magnesium decreased
195441471;Orthostatic hypotension;NORTHERA;100;LUNDBECK;70;F;Other Serious (Important Medical Event);Fall
195448802;Crohn's disease;STELARA;90;JOHNSON AND JOHNSON;66;F;NA;Device issue
195455913;NA;NA;NA;JOHNSON AND JOHNSON;63;M;NA;Accidental exposure to product
195456124;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;78;F;Other Serious (Important Medical Event);Hypotension
195460641;Plasma cell myeloma;POMALYST;2;CELGENE;81;M;Other Serious (Important Medical Event);Cerebrovascular accident
195463223;Major depression;Venlafaxine hydrochloride extended release capsules 75mg;75;AUROBINDO;57;F;Hospitalization - Initial or Prolonged;Drug ineffective
195463981;Plasma cell myeloma;REVLIMID;25;CELGENE;70;M;Hospitalization - Initial or Prolonged;Drug hypersensitivity
195464051;Myelodysplastic syndrome;REVLIMID;10;CELGENE;86;M;NA;Neutropenia
195464673;NA;NA;NA;BOEHRINGER INGELHEIM;59;F;Life-Threatening;Asthma
195465961;Pulmonary arterial hypertension;UPTRAVI;1600;JOHNSON AND JOHNSON;15;F;Hospitalization - Initial or Prolonged;Catheterisation cardiac
195466441;NA;NA;NA;UNITED THERAPEUTICS;80;F;NA;Anxiety
195474282;NA;NA;NA;UNITED THERAPEUTICS;79;F;Hospitalization - Initial or Prolonged;Clostridium difficile infection
195475251;Pulmonary hypertension;UPTRAVI;400;JOHNSON AND JOHNSON;45;F;Hospitalization - Initial or Prolonged;Therapy change
195476773;NA;NA;NA;UNITED THERAPEUTICS;22;F;Other Serious (Important Medical Event);Malaise
195478786;Neutropenia;NEULASTA;6;AMGEN;84;F;NA;Device adhesion issue
195479341;NA;NA;NA;UNITED THERAPEUTICS;37;M;Other Serious (Important Medical Event);Dyspnoea
195479692;NA;NA;NA;BAYER;74;F;Hospitalization - Initial or Prolonged;Headache
195479731;Plasma cell myeloma;POMALYST;1;CELGENE;84;F;Other Serious (Important Medical Event);Eye haemorrhage
195479821;Myelodysplastic syndrome;REVLIMID;10;CELGENE;82;F;NA;Vaginal haemorrhage
195480493;Pulmonary arterial hypertension;UPTRAVI;800;JOHNSON AND JOHNSON;70;F;Hospitalization - Initial or Prolonged;Atrial fibrillation
195480603;Blood cholesterol increased;XARELTO;20;JOHNSON AND JOHNSON;78;M;Other Serious (Important Medical Event);Haematocrit decreased
195483121;Plasma cell myeloma;REVLIMID;25;CELGENE;75;M;Other Serious (Important Medical Event);Dizziness
195485921;NA;NA;NA;BAYER;75;F;Other Serious (Important Medical Event);Hospitalisation
195487392;NA;NA;NA;BRISTOL MYERS SQUIBB;63;F;Other Serious (Important Medical Event);Drug hypersensitivity
195487612;Prostate cancer metastatic;ATEZOLIZUMAB;1200;ROCHE;74;M;Other Serious (Important Medical Event);Blood creatinine increased
195487638;Thrombolysis;Tenecteplase;19.25;ROCHE;72;M;Other Serious (Important Medical Event);Anaemia
195488991;Psoriatic arthropathy;ORENCIA;250;BRISTOL MYERS SQUIBB;76;M;NA;Product storage error
195495781;Pulmonary arterial hypertension;UPTRAVI;400;JOHNSON AND JOHNSON;87;F;Other Serious (Important Medical Event);Sepsis
195495981;Dermatitis atopic;DUPIXENT;300;SANOFI AVENTIS;16;F;NA;Off label use
195496301;Pulmonary arterial hypertension;SELEXIPAG;200;JOHNSON AND JOHNSON;79;F;Hospitalization - Initial or Prolonged;Thrombosis
195497271;Pulmonary arterial hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;95;F;Other Serious (Important Medical Event);Syncope
195497811;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;56;M;NA;Cough
195497854;Hypogammaglobulinaemia;HIZENTRA;8;CSL BEHRING;74;M;Life-Threatening;Device infusion issue
195500221;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;56;M;NA;Fatigue
195500691;Basal cell carcinoma;VISMODEGIB;150;ROCHE;70;F;Hospitalization - Initial or Prolonged;Colitis
195501941;5q minus syndrome;REVLIMID;10;CELGENE;75;F;Disability;Haemoglobin decreased
195503921;Plasma cell myeloma;POMALYST;10;CELGENE;72;M;NA;Bronchitis
195506791;NA;NA;NA;ROCHE;70;F;Other Serious (Important Medical Event);Blister
195508712;Erectile dysfunction;MUSE;250;MYLAN;83;M;Other Serious (Important Medical Event);Drug ineffective
195509162;Chronic spontaneous urticaria;XOLAIR;300;ROCHE;38;F;Other Serious (Important Medical Event);Angioedema
195512522;Unknown;NEXPLANON;1;ORGANON;22;F;NA;Complication associated with device
195513901;Plasma cell myeloma;DARZALEX;1400;JOHNSON AND JOHNSON;77;M;Hospitalization - Initial or Prolonged;Hip arthroplasty
195514172;NA;NA;NA;EXELIXIS;64;F;Other Serious (Important Medical Event);Malignant melanoma
195514571;Non-Hodgkin's lymphoma;REVLIMID;25;CELGENE;86;F;Other Serious (Important Medical Event);Arthritis
195515541;Pulmonary hypertension;BOSENTAN;125;JOHNSON AND JOHNSON;74;F;Other Serious (Important Medical Event);Surgery
195516971;Acute myeloid leukaemia;ONUREG;300;CELGENE;75;M;NA;Decreased appetite
195517472;NA;NA;NA;UNITED THERAPEUTICS;13;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
195517954;Neutropenia;NEULASTA;6;AMGEN;69;F;NA;Device adhesion issue
195518031;Colon cancer;LONSURF;20;TAIHO ONCOLOGY INC;71;F;Life-Threatening;Death
195518173;Psoriasis;SKYRIZI;150;ABBVIE;70;F;Hospitalization - Initial or Prolonged;Pulmonary embolism
195519351;NA;NA;NA;NOVARTIS;13;F;Other Serious (Important Medical Event);Acute kidney injury
195523972;Renal cancer;LENVIMA;18;EISAI;53;F;Disability;Adrenal insufficiency
195525641;NA;NA;NA;SANOFI AVENTIS;59;F;Hospitalization - Initial or Prolonged;Alopecia
195526281;Plasma cell myeloma;REVLIMID;15;CELGENE;81;F;NA;Diarrhoea
195526641;Psoriasis;TREMFYA;100;JOHNSON AND JOHNSON;53;F;Other Serious (Important Medical Event);Rash
195527475;Psoriasis;COSENTYX;300;NOVARTIS;63;F;Hospitalization - Initial or Prolonged;Bronchitis
195528891;Plasma cell myeloma;REVLIMID;25;CELGENE;74;F;NA;Dehydration
195530112;Cardiac failure;ENTRESTO;1;NOVARTIS;77;M;NA;Confusional state
195531891;Plasma cell myeloma;REVLIMID;5;CELGENE;73;F;NA;Abdominal discomfort
195531952;Contraception;IMPLANON;1;ORGANON;26;F;Hospitalization - Initial or Prolonged;Device dislocation
195532033;Prophylaxis;HAEGARDA;6000;CSL BEHRING;44;F;Other Serious (Important Medical Event);C1 esterase inhibitor decreased
195532682;NA;NA;NA;UNITED THERAPEUTICS;72;F;Other Serious (Important Medical Event);Fall
195536521;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;64;M;Other Serious (Important Medical Event);Renal cancer
195536861;Endometrial cancer;ATEZOLIZUMAB;1200;ROCHE;69;F;Hospitalization - Initial or Prolonged;Embolism venous
195537131;NA;NA;NA;BAYER;81;F;Hospitalization - Initial or Prolonged;Death
195538422;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;63;U;NA;Device delivery system issue
195539913;Breast cancer;Niraparib;200;GLAXOSMITHKLINE;39;F;Life-Threatening;Pancreatitis acute
195540031;Pulmonary arterial hypertension;SELEXIPAG;1600;JOHNSON AND JOHNSON;77;F;Hospitalization - Initial or Prolonged;Urinary tract infection
195540913;Immune system disorder;C1 Inhibitor (Human);1000;TAKEDA;59;F;Life-Threatening;Ankle fracture
195541602;Pulmonary arterial hypertension;SELEXIPAG;1400;JOHNSON AND JOHNSON;84;M;Other Serious (Important Medical Event);Dyspnoea
195544131;Plasma cell myeloma;REVLIMID;25;CELGENE;77;M;NA;Dyspepsia
195549872;Alcoholism;VIVITROL;380;ALKERMES;44;M;NA;Off label use
195551601;Plasma cell myeloma;REVLIMID;25;CELGENE;75;F;Other Serious (Important Medical Event);Blood glucose decreased
195551612;Contraception;IMPLANON;1;ORGANON;27;F;NA;Device breakage
195551831;Diffuse large B-cell lymphoma;REVLIMID;10;CELGENE;62;M;NA;Platelet count decreased
195552388;Neutropenia;NEULASTA;6;AMGEN;59;M;NA;Device adhesion issue
195556381;Gastrooesophageal reflux disease;PREVACID 24 HR;15;PERRIGO;66;F;Hospitalization - Initial or Prolonged;Chronic kidney disease
195557811;NA;NA;NA;UNITED THERAPEUTICS;30;F;NA;Joint swelling
195565583;Contraception;MIRENA;20;BAYER;36;F;Other Serious (Important Medical Event);Device dislocation
195566101;Contraception;NEXPLANON;1;ORGANON;26;F;NA;Complication of device insertion
195568102;Unknown;NEXPLANON;1;ORGANON;25;F;NA;Device expulsion
195568571;Dermatitis atopic;DUPIXENT;600;SANOFI AVENTIS;8;M;NA;Off label use
195570252;NA;NA;NA;UNITED THERAPEUTICS;74;F;Hospitalization - Initial or Prolonged;Clostridium difficile colitis
195570971;Unknown;ENTRESTO;25;NOVARTIS;61;M;NA;Weight decreased
195575421;Multiple sclerosis;AVONEX PEN;30;BIOGEN;51;F;NA;Jaw disorder
195576581;Plasma cell myeloma;REVLIMID;10;CELGENE;75;F;NA;Diarrhoea
195576802;NA;NA;NA;BAYER;71;F;Other Serious (Important Medical Event);Death
195576831;NA;NA;NA;BAYER;84;F;Death;Death
195578091;NA;NA;NA;BRISTOL MYERS SQUIBB;70;M;Other Serious (Important Medical Event);Death
195578993;Pulmonary embolism;ELIQUIS;5;BRISTOL MYERS SQUIBB;83;F;NA;Extra dose administered
195579581;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;87;F;NA;Dyspepsia
195579661;Cerebrovascular accident prophylaxis;ELIQUIS;5;BRISTOL MYERS SQUIBB;80;F;Hospitalization - Initial or Prolonged;Death
195579851;Plasma cell myeloma;REVLIMID;25;CELGENE;65;F;NA;Erythema
195580731;NA;NA;NA;ABBVIE;40;F;NA;Bone density decreased
195582741;Rheumatoid arthritis;RINVOQ;15;ABBVIE;59;F;Other Serious (Important Medical Event);Blood magnesium decreased
195582771;Cholangiocarcinoma;FLUOROURACIL (Manufacturer unknown);4040;FRESENIUS KABI;72;M;Other Serious (Important Medical Event);Blood bilirubin increased
195583251;Plasma cell myeloma;REVLIMID;25;CELGENE;77;M;NA;Eye swelling
195584171;Plasma cell myeloma;REVLIMID;25;CELGENE;70;F;NA;Rash
195584201;Plasma cell myeloma;REVLIMID;25;CELGENE;73;F;NA;Haemoglobin decreased
195593381;Pancreatic carcinoma;SYLVANT;11;EUSA PHARMA;59;M;Other Serious (Important Medical Event);Atrial fibrillation
195595431;Diffuse large B-cell lymphoma;ATEZOLIZUMAB;840;ROCHE;65;F;Hospitalization - Initial or Prolonged;Disease progression
195595533;Neutropenia;NEULASTA;6;AMGEN;60;F;NA;Unintentional medical device removal
195595883;Psoriatic arthropathy;TREMFYA;100;JOHNSON AND JOHNSON;53;F;NA;Product dose omission issue
195603093;B-cell lymphoma;GLOFITAMAB;2.5;ROCHE;78;F;Hospitalization - Initial or Prolonged;Cytokine release syndrome
195604141;Fracture pain;LIDOCAINE PATCH;5;MYLAN;76;M;NA;Off label use
195604251;Pulmonary arterial hypertension;SELEXIPAG;600;JOHNSON AND JOHNSON;73;F;Other Serious (Important Medical Event);Procedural complication
195605501;NA;NA;NA;CELGENE;57;F;Other Serious (Important Medical Event);Thrombosis
195605881;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;73;F;NA;Blood pressure increased
195606121;Contraception;NEXPLANON;1;ORGANON;21;F;NA;Device breakage
195606801;Plasma cell myeloma;REVLIMID;15;CELGENE;86;M;NA;Nasopharyngitis
195606811;Plasma cell myeloma;POMALYST;4;CELGENE;85;M;NA;Asthenia
195607061;Unknown;PROBUPHINE;4;TITAN PHARMACEUTICALS;31;F;NA;Complication of device removal
195607651;Contraception;NEXPLANON;1;ORGANON;27;F;NA;Complication associated with device
195611241;Rheumatoid arthritis;ORENCIA;125;BRISTOL MYERS SQUIBB;57;F;NA;Device breakage
195612961;Relapsing multiple sclerosis;ZEPOSIA;0.92;CELGENE;39;F;NA;Dental restoration failure
195612991;Plasma cell myeloma;REVLIMID;25;CELGENE;73;M;NA;Asthenia
195613091;Plasma cell myeloma;REVLIMID;25;CELGENE;83;F;NA;Headache
195614081;Plasma cell myeloma;REVLIMID;25;CELGENE;75;M;NA;Candida infection
195615354;Prophylaxis;NEULASTA;6;AMGEN;81;F;NA;Device adhesion issue
195615361;Chronic lymphocytic leukaemia;IBRUTINIB;420;ABBVIE;75;F;Death;Death
195615382;Gastric cancer;PHESGO;600;ROCHE;61;M;Other Serious (Important Medical Event);Cholangitis
195618001;Schizophrenia;ZYPREXA RELPREVV;405;ELI LILLY AND CO;36;M;Hospitalization - Initial or Prolonged;Agitation
195618091;Breast cancer metastatic;IBRANCE;125;PFIZER;64;F;Other Serious (Important Medical Event);White blood cell count decreased
195620141;Psoriatic arthropathy;Certolizumab pegol;400;UCB;49;F;Hospitalization - Initial or Prolonged;Alopecia
195620835;Pulmonary hypertension;AMBRISENTAN;10;GILEAD;11;F;Other Serious (Important Medical Event);Haemoptysis
195622131;NA;NA;NA;FRESENIUS KABI;70;M;Other Serious (Important Medical Event);Hypotension
195625674;Noonan syndrome;GSK1120212;0.012;NOVARTIS;0;M;Hospitalization - Initial or Prolonged;Bradycardia
195627121;Dermatomyositis;GAMUNEX C;35;GRIFOLS;45;F;NA;Urticaria
195627471;Non-Hodgkin's lymphoma;REVLIMID;25;CELGENE;90;F;NA;Rash
195627741;Plasma cell myeloma;REVLIMID;10;CELGENE;54;M;NA;Drug intolerance
195627762;Still's disease;ILARIS;300;NOVARTIS;47;M;NA;Arthralgia
195627932;Neoplasm malignant;ATEZOLIZUMAB;1200;ROCHE;88;M;Hospitalization - Initial or Prolonged;Pulmonary hypertension
195628162;Diffuse large B-cell lymphoma;REVLIMID;25;CELGENE;81;M;NA;Constipation
195628181;Unknown;NICOTINE POLACRILEX;1;PL DEVELOPMENTS;65;F;NA;Hypoaesthesia
195630431;Unknown;ESTRADIOL TRANSDERMAL SYSTEM;0.025;MYLAN;79;F;NA;Drug ineffective
195632021;Pulmonary arterial hypertension;SELEXIPAG;1400;JOHNSON AND JOHNSON;70;M;Hospitalization - Initial or Prolonged;Chest pain
195633484;NA;NA;NA;ABBVIE;86;F;Other Serious (Important Medical Event);Back pain
195633561;Multiple sclerosis;ZEPOSIA;0.92;CELGENE;56;F;NA;Gastrointestinal disorder
195633761;Irritable bowel syndrome;Cholestyramine (ANDA 211119);4;AJANTA PHARMA;50;F;NA;Foreign body in throat
195636132;Plasma cell myeloma;REVLIMID;25;CELGENE;51;F;Other Serious (Important Medical Event);Atrial fibrillation
195636681;Colon cancer;LONSURF;15;TAIHO ONCOLOGY INC;39;F;Hospitalization - Initial or Prolonged;Death
195640002;Rheumatoid arthritis;HUMIRA;40;ABBVIE;72;M;Hospitalization - Initial or Prolonged;Eyelid ptosis
195642073;Plasma cell myeloma;NINLARO;2.3;TAKEDA;73;F;Hospitalization - Initial or Prolonged;Angioedema
195642443;Neutropenia;NEULASTA;6;AMGEN;70;M;NA;Unintentional medical device removal
195643513;Failure to thrive;GENOTROPIN;1.4;PFIZER;14;F;NA;Device breakage
195644403;Failure to thrive;GENOTROPIN;1.4;PFIZER;14;F;NA;Device breakage
195645693;Acute lymphocytic leukaemia;INOTUZUMAB OZOGAMICIN;0.3;PFIZER;47;M;Hospitalization - Initial or Prolonged;Hyperglycaemia
195646791;NA;NA;NA;UNITED THERAPEUTICS;24;F;NA;Device infusion issue
195647211;Unknown;NEXPLANON;1;ORGANON;23;F;NA;Complication of device insertion
195648821;Plasma cell myeloma;POMALYST;2;CELGENE;73;M;Hospitalization - Initial or Prolonged;Death
195648911;Myelodysplastic syndrome;REVLIMID;25;CELGENE;66;M;NA;Hot flush
195649481;Pulmonary arterial hypertension;MACITENTAN;10;JOHNSON AND JOHNSON;57;F;Life-Threatening;Atrial fibrillation
195649942;Hypereosinophilic syndrome;MEDROL;4;PFIZER;74;M;Hospitalization - Initial or Prolonged;Body fat disorder
195651741;Pulmonary arterial hypertension;BOSENTAN;31.25;JOHNSON AND JOHNSON;3;M;Other Serious (Important Medical Event);Cardiac valve disease
195651882;NA;NA;NA;BRISTOL MYERS SQUIBB;62;M;Hospitalization - Initial or Prolonged;Bronchostenosis
195653584;Lung cancer metastatic;AFATINIB;40;BOEHRINGER INGELHEIM;47;M;Hospitalization - Initial or Prolonged;Ventricular arrhythmia
195654101;Renal cell carcinoma;NIVOLUMAB;413;BRISTOL MYERS SQUIBB;62;M;Other Serious (Important Medical Event);Chills
195654462;Ovarian cancer;NIVOLUMAB;240;BRISTOL MYERS SQUIBB;72;F;Death;Acute myocardial infarction
195656803;Bipolar disorder;ARISTADA;1064;ALKERMES;33;M;NA;Drug ineffective
195657581;Asthma;BREO ELLIPTA;1;GLAXOSMITHKLINE;85;U;Hospitalization - Initial or Prolonged;Asthma
195660271;Hormone replacement therapy;ESTRADIOL TRANSDERMAL SYSTEM;0.037;MYLAN;65;F;NA;Application site irritation
195660422;Pulmonary embolism;XARELTO;20;JOHNSON AND JOHNSON;59;F;Hospitalization - Initial or Prolonged;Pulmonary embolism
195663611;Motion sickness;Scopolamine Transdermal System;1;MYLAN;76;F;NA;Dizziness
195667431;Plasma cell myeloma;REVLIMID;25;CELGENE;70;F;NA;Plasma cell myeloma
195667541;Factor VIII deficiency;HEMLIBRA;285;ROCHE;14;M;Other Serious (Important Medical Event);Duodenal ulcer
195667633;Idiopathic urticaria;XOLAIR;300;ROCHE;61;M;Hospitalization - Initial or Prolonged;Anaphylactic reaction
195669012;Endometriosis;ELAGOLIX/ESTRADIOL/NORETHINDRONE ACETATE;200;ABBVIE;32;F;NA;Liver function test increased
195669161;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;58;M;Other Serious (Important Medical Event);Prostate cancer
195669331;Dyspepsia;ZANTAC;150;SANOFI AVENTIS;34;F;Hospitalization - Initial or Prolonged;Renal cancer
195669701;Gastrooesophageal reflux disease;ZANTAC;150;SANOFI AVENTIS;65;M;Other Serious (Important Medical Event);Colorectal cancer
195670891;Plasma cell myeloma;REVLIMID;20;CELGENE;76;F;Death;Death
195672642;HIV infection;EMTRICITABINE/TENOFOVIR ALAFENAMIDE;1;GILEAD;0;F;Other Serious (Important Medical Event);Foetal exposure during pregnancy
195673501;Plasma cell myeloma;REVLIMID;10;CELGENE;75;F;NA;Nausea
195674771;Unknown;NEXPLANON;1;ORGANON;22;F;NA;Complication of device insertion
195674912;Type 2 diabetes mellitus;BYDUREON BCISE;2;ASTRAZENECA;76;M;NA;Device delivery system issue
195675192;Plasma cell myeloma;REVLIMID;10;CELGENE;77;M;Hospitalization - Initial or Prolonged;Haemoglobin decreased
195676601;NA;NA;NA;OTSUKA;73;M;Other Serious (Important Medical Event);Dyspnoea
195676711;Unknown;ORAVERSE;2;SEPTODONT;22;F;NA;Gingival swelling
195678801;Unknown;RYBELSUS;7;NOVO NORDISK;56;M;Hospitalization - Initial or Prolonged;Anaphylactic reaction
195681211;Chronic lymphocytic leukaemia;FLUDARABINE;59;FRESENIUS KABI;61;F;Other Serious (Important Medical Event);Febrile neutropenia
195683044;Growth disorder;GENOTROPIN;2.8;PFIZER;17;M;NA;Device information output issue
195683351;Plasma cell myeloma;REVLIMID;15;CELGENE;81;F;Other Serious (Important Medical Event);Pyrexia
195683982;Non-small cell lung cancer metastatic;DOCETAXEL;55;SANOFI AVENTIS;40;F;Other Serious (Important Medical Event);Activated partial thromboplastin time shortened
195685173;Colitis ulcerative;ZEPOSIA;0.46;CELGENE;31;F;NA;Abdominal distension
195685201;Plasma cell myeloma;POMALYST;4;CELGENE;78;F;Hospitalization - Initial or Prolonged;Bronchitis
195686122;Growth hormone deficiency;GENOTROPIN;2.2;PFIZER;16;M;NA;Device power source issue
195686151;NA;NA;NA;PFIZER;9;M;NA;Device physical property issue
195687562;Colorectal cancer;XL184;40;EXELIXIS;57;F;Hospitalization - Initial or Prolonged;Large intestine perforation
195687891;NA;NA;NA;BRISTOL MYERS SQUIBB;37;M;Other Serious (Important Medical Event);Diverticulitis
195688733;Short-bowel syndrome;Teduglutide;2.5;TAKEDA;52;M;Death;Acute kidney injury
195690652;Prostate cancer;KEYTRUDA;200;MERCK;73;M;Other Serious (Important Medical Event);Product use in unapproved indication
195690993;Philadelphia positive acute lymphocytic leukaemia;METHOTREXATE;35;HIKMA;18;M;Hospitalization - Initial or Prolonged;Acute respiratory distress syndrome
195691942;5q minus syndrome;REVLIMID;20;CELGENE;79;F;Other Serious (Important Medical Event);Cholelithiasis
195693922;Hallucination;CLOZAPINE;25;MYLAN;67;F;Hospitalization - Initial or Prolonged;Neutropenia
195694083;Contraception;NEXPLANON;1;ORGANON;24;F;Life-Threatening;Complication of device removal
195695131;Lymphoma;REVLIMID;20;CELGENE;84;F;Hospitalization - Initial or Prolonged;Cardiac failure congestive
195697024;NA;NA;NA;ESPERION THERAPEUTICS;69;F;Other Serious (Important Medical Event);Abdominal pain upper
195697852;Pulmonary arterial hypertension;SELEXIPAG;1000;JOHNSON AND JOHNSON;32;F;Other Serious (Important Medical Event);Adverse drug reaction
195698174;Renal cell carcinoma;Cabozantinib;40;EXELIXIS;79;F;Death;Colitis
195699011;Nephroblastoma;LENVATINIB;8;EISAI;5;M;Hospitalization - Initial or Prolonged;Tendon rupture
195699301;Tremor;KEPPRA;250;UCB;66;F;Hospitalization - Initial or Prolonged;Musculoskeletal pain
195699792;Plasma cell myeloma;REVLIMID;10;CELGENE;82;M;Hospitalization - Initial or Prolonged;Dermatitis
195699851;Plasma cell myeloma;POMALYST;3;CELGENE;68;M;NA;Diarrhoea
195700482;Crohn's disease;HUMIRA;40;ABBVIE;66;F;Death;Contusion
195700651;Plasma cell myeloma;REVLIMID;10;CELGENE;62;F;NA;Peripheral swelling
195701312;Cardiomyopathy;ENTRESTO;1;NOVARTIS;82;F;Other Serious (Important Medical Event);Anger
1050274610;Psoriasis;SIMPONI;50;JOHNSON AND JOHNSON;73;M;Death;Basal cell carcinoma
1060995424;Hypertonic bladder;TOVIAZ;8;PFIZER;69;F;Death;Accident
1069603012;NA;NA;NA;PFIZER;42;F;NA;Diarrhoea
1077050710;Seizure;GABAPENTIN;800;PFIZER;40;F;Other Serious (Important Medical Event);Anaphylactic reaction
1131227612;Trigeminal neuralgia;LYRICA;75;PFIZER;53;F;Hospitalization - Initial or Prolonged;Arthralgia
1134211617;Acromegaly;SOMAVERT;20;PFIZER;82;F;Other Serious (Important Medical Event);Arterial occlusive disease
1153925510;Fibromyalgia;LYRICA;3;PFIZER;68;F;NA;Cough
1157922110;Mucopolysaccharidosis II;Idursulfase;0.33;TAKEDA;7;M;Hospitalization - Initial or Prolonged;Anaphylactic reaction
1194491311;Neuropathy peripheral;LYRICA;100;PFIZER;68;M;NA;Aphonia
1229966032;Rheumatoid arthritis;XELJANZ;5;PFIZER;69;F;Hospitalization - Initial or Prolonged;Arthropathy
1233264515;Renal cancer metastatic;INLYTA;4;PFIZER;77;F;Other Serious (Important Medical Event);Blood pressure increased
1238861812;Back disorder;LYRICA;200;PFIZER;63;M;Other Serious (Important Medical Event);Concussion
1239109926;Breast cancer metastatic;IBRANCE;100;PFIZER;65;F;Death;Alopecia
1239140710;Narcolepsy;XYREM;2.25;JAZZ;56;F;Hospitalization - Initial or Prolonged;Abdominal pain
1247127515;Pain;LYRICA;150;PFIZER;59;F;Hospitalization - Initial or Prolonged;Cataract
1251999814;Neuralgia;LYRICA;300;PFIZER;57;M;Other Serious (Important Medical Event);Arthralgia
1256570432;Breast cancer metastatic;IBRANCE;125;PFIZER;65;F;Other Serious (Important Medical Event);Abdominal discomfort
1266393113;Migraine;LYRICA;500;PFIZER;52;F;Other Serious (Important Medical Event);Abdominal pain upper
1268481611;NA;NA;NA;GLAXOSMITHKLINE;42;F;Hospitalization - Initial or Prolonged;Sepsis
1273907011;Arthritis;CELEBREX;100;PFIZER;73;F;Death;Bone swelling
1274383813;Post herpetic neuralgia;LYRICA;75;PFIZER;82;F;Life-Threatening;Arthralgia
1287777410;Cardiac hypertrophy;RAPAMUNE;1;PFIZER;71;M;Other Serious (Important Medical Event);Blood count abnormal
1292916515;Non-small cell lung cancer;XALKORI;250;PFIZER;80;F;Other Serious (Important Medical Event);Acute kidney injury
1299404811;Pain;LYRICA;75;PFIZER;56;M;NA;Blood pressure diastolic increased
1307292525;Pain;LYRICA;100;PFIZER;62;F;Hospitalization - Initial or Prolonged;Back pain
1334715216;Fibromyalgia;LYRICA;300;PFIZER;50;F;NA;Anxiety
1339040816;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;65;F;Death;Chest pain
1343558411;Neuralgia;LYRICA;400;PFIZER;64;M;NA;Drug ineffective
1353948121;Neuropathy peripheral;LYRICA;150;PFIZER;68;M;Other Serious (Important Medical Event);Cataract
1376832112;Astrocytoma, low grade;AFINITOR;10;NOVARTIS;7;F;Hospitalization - Initial or Prolonged;Acne cystic
1382394014;Hepatocellular carcinoma;ATEZOLIZUMAB;1200;ROCHE;64;M;Other Serious (Important Medical Event);Encephalitis autoimmune
1387281810;Spinal osteoarthritis;LYRICA;225;PFIZER;57;M;Hospitalization - Initial or Prolonged;Anxiety
1393852624;Plasma cell myeloma;THALOMID;100;CELGENE;34;F;Other Serious (Important Medical Event);Human chorionic gonadotropin increased
1406921815;Pain;LYRICA;150;PFIZER;79;F;Hospitalization - Initial or Prolonged;Drug ineffective
1412186710;NA;NA;NA;MYLAN;23;M;Other Serious (Important Medical Event);Device failure
1434359316;Breast cancer stage IV;IBRANCE;125;PFIZER;77;F;Hospitalization - Initial or Prolonged;Alopecia
1435140411;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;68;F;Hospitalization - Initial or Prolonged;Anxiety
1442452810;Breast cancer metastatic;IBRANCE;125;PFIZER;59;F;Other Serious (Important Medical Event);Abdominal discomfort
1454906210;Breast cancer female;IBRANCE;125;PFIZER;64;F;NA;Alopecia
1456610125;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;74;F;Death;Aphonia
1462589612;Factor IX deficiency;BENEFIX;6500;PFIZER;32;M;Hospitalization - Initial or Prolonged;Haemarthrosis
1465388820;NA;NA;NA;PFIZER;55;F;Other Serious (Important Medical Event);Abdominal pain upper
1465980037;Relapsing multiple sclerosis;ALEMTUZUMAB;12;SANOFI AVENTIS;34;F;Hospitalization - Initial or Prolonged;Acute kidney injury
1472401012;Hyperkalaemia;VELTASSA;16.8;VIFOR;41;M;Other Serious (Important Medical Event);Blood potassium increased
1473195212;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;74;F;Hospitalization - Initial or Prolonged;Ageusia
1481604515;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;69;F;Other Serious (Important Medical Event);Blindness unilateral
1491872611;Gastrointestinal stromal tumour;SUTENT;50;PFIZER;82;M;Hospitalization - Initial or Prolonged;Abdominal distension
1504173211;Relapsing-remitting multiple sclerosis;OCREVUS;600;ROCHE;35;F;Other Serious (Important Medical Event);Adnexal torsion
1510690511;Alopecia;XELJANZ;5;PFIZER;33;M;NA;Hordeolum
1510718222;Diabetic neuropathy;LYRICA;100;PFIZER;74;F;Other Serious (Important Medical Event);Balance disorder
1513156718;Multiple sclerosis;TYSABRI;300;BIOGEN;54;M;Other Serious (Important Medical Event);Immune reconstitution inflammatory syndrome
1514777514;Pain;LYRICA;300;PFIZER;58;M;Other Serious (Important Medical Event);Cataract
1515007218;Diabetic neuropathy;LYRICA;100;PFIZER;70;M;Hospitalization - Initial or Prolonged;Bradyphrenia
1525530112;Neuralgia;LYRICA;150;PFIZER;63;F;Other Serious (Important Medical Event);Asthenia
1526554815;Factor VIII deficiency;ELOCTATE;3000;SANOFI AVENTIS;20;M;Hospitalization - Initial or Prolonged;Arthropathy
1527962710;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;78;F;Death;Drug ineffective
1531705517;Neuropathy peripheral;LYRICA;100;PFIZER;69;M;Other Serious (Important Medical Event);Acute kidney injury
1532457810;Neuropathy peripheral;LYRICA;75;PFIZER;75;F;NA;Condition aggravated
1532773111;Narcolepsy;XYREM;4;JAZZ;70;M;Hospitalization - Initial or Prolonged;Appendix cancer
1542909117;Growth hormone deficiency;GENOTROPIN;1;PFIZER;6;M;NA;Device breakage
1543666612;Polyneuropathy;LYRICA;200;PFIZER;31;M;Other Serious (Important Medical Event);Amnesia
1545455910;Septo-optic dysplasia;GENOTROPIN;0.8;PFIZER;8;M;NA;Aspartate aminotransferase increased
1548927216;Pain in extremity;LYRICA;300;PFIZER;65;M;NA;Dyspnoea
1549250113;Radiculopathy;LYRICA;75;PFIZER;68;M;Other Serious (Important Medical Event);Cough
1551607919;Back disorder;LYRICA;150;PFIZER;82;F;Hospitalization - Initial or Prolonged;Drug ineffective
1551766811;Fibromyalgia;LYRICA;300;PFIZER;62;F;Hospitalization - Initial or Prolonged;Amnesia
1556485913;Neuropathy peripheral;LYRICA;150;PFIZER;76;M;Hospitalization - Initial or Prolonged;Alopecia
1559778311;Nerve injury;LYRICA;150;PFIZER;69;F;Death;Chest pain
1561303215;Chronic myeloid leukaemia;Ponatinib;45;TAKEDA;70;F;Hospitalization - Initial or Prolonged;Adverse drug reaction
1564034013;Relapsing multiple sclerosis;KESIMPTA;20;NOVARTIS;45;F;Hospitalization - Initial or Prolonged;Pneumonia
1565941420;Pancreatic carcinoma metastatic;SELICRELUMAB;16;ROCHE;60;M;Hospitalization - Initial or Prolonged;Atrial fibrillation
1568377312;Diffuse large B-cell lymphoma;POLATUZUMAB VEDOTIN;149;ROCHE;73;M;Other Serious (Important Medical Event);Fatigue
1574546216;Hypertension;NORVASC;10;PFIZER;79;F;Other Serious (Important Medical Event);Blindness unilateral
1576637611;Post herpetic neuralgia;LYRICA;50;PFIZER;80;M;Hospitalization - Initial or Prolonged;Constipation
1576649413;Seizure;LYRICA;200;PFIZER;46;F;Other Serious (Important Medical Event);Amnesia
1579234811;Multiple sclerosis;TECFIDERA;120;BIOGEN;52;M;Other Serious (Important Medical Event);Cerebrovascular accident
1585867010;Diabetic neuropathy;LYRICA;300;PFIZER;76;F;NA;Illness
1586646313;Neuropathy peripheral;LYRICA;300;PFIZER;58;F;NA;Drug ineffective
1589581824;Pancreatic carcinoma metastatic;SELICRELUMAB;16;ROCHE;60;M;Hospitalization - Initial or Prolonged;Cholecystitis
1598937510;Neuralgia;LYRICA;75;PFIZER;81;F;Other Serious (Important Medical Event);Ear pruritus
1603823312;Hyperkalaemia;VELTASSA;8.4;VIFOR;81;M;Hospitalization - Initial or Prolonged;Ageusia
1608935110;Rheumatoid arthritis;XELJANZ;5;PFIZER;67;M;Death;Condition aggravated
1618849814;Lymphangioma;GSK1120212;0.5;NOVARTIS;19;F;Other Serious (Important Medical Event);Acne
1619931612;Fibromyalgia;LYRICA;75;PFIZER;64;F;Hospitalization - Initial or Prolonged;Arnold-Chiari malformation
1623824517;Complex regional pain syndrome;LYRICA;150;PFIZER;42;F;Hospitalization - Initial or Prolonged;Drug dependence
1625031411;Pain;LYRICA;75;PFIZER;65;F;Other Serious (Important Medical Event);Depressed mood
1629973514;Atrophic vulvovaginitis;PREMARIN;1;PFIZER;88;F;Hospitalization - Initial or Prolonged;Illness
1633002418;Diffuse large B-cell lymphoma;RITUXIMAB;754;ROCHE;54;M;Other Serious (Important Medical Event);Actinomycotic abdominal infection
1639174011;Diffuse large B-cell lymphoma;RITUXIMAB;570;ROCHE;62;F;Death;Neutropenia
1639982010;Factor VIII deficiency;ELOCTATE;5600;SANOFI AVENTIS;29;M;Hospitalization - Initial or Prolonged;Arthropathy
1640602313;Migraine;LYRICA;75;PFIZER;65;F;Other Serious (Important Medical Event);Dizziness
1642549315;NA;NA;NA;PFIZER;56;F;Death;Behaviour disorder
1643205812;Diffuse large B-cell lymphoma;POLATUZUMAB VEDOTIN;95;ROCHE;51;F;Hospitalization - Initial or Prolonged;Bacteraemia
1643914727;Genital labial adhesions;PREMARIN;0.5;PFIZER;98;F;Other Serious (Important Medical Event);Body height decreased
1646326118;Arthralgia;LYRICA;50;PFIZER;74;F;Hospitalization - Initial or Prolonged;Ageusia
1649559911;Neuropathy peripheral;LYRICA;75;PFIZER;78;F;Other Serious (Important Medical Event);Condition aggravated
1653543811;NA;NA;NA;ROCHE;61;F;Hospitalization - Initial or Prolonged;Arthralgia
1658496612;Polyneuropathy;LYRICA;100;PFIZER;79;F;Other Serious (Important Medical Event);Back pain
1659905622;Hepatocellular carcinoma;LENVATINIB;12;EISAI;72;M;Other Serious (Important Medical Event);Hepatic encephalopathy
1661212714;Chemotherapy;FLUDARABINE PHOSPHATE;52;NOVARTIS;53;M;Death;Febrile neutropenia
1663085110;Neuropathy peripheral;LYRICA;150;PFIZER;52;F;Hospitalization - Initial or Prolonged;Diabetes mellitus
1666985810;Amyloidosis;VYNDAQEL;80;PFIZER;89;M;Other Serious (Important Medical Event);Body height decreased
1667865112;Fibromyalgia;LYRICA;75;PFIZER;66;F;Other Serious (Important Medical Event);Amnesia
1671227016;Breast cancer metastatic;IBRANCE;125;PFIZER;80;F;Hospitalization - Initial or Prolonged;Alopecia
1671600121;Nerve injury;LYRICA;100;PFIZER;51;F;NA;Anger
1672869315;Ovarian cancer recurrent;Niraparib;200;GLAXOSMITHKLINE;76;F;Other Serious (Important Medical Event);Hyperglycaemia
1672941418;Muscle disorder;PREMPRO;2;PFIZER;67;F;NA;Abnormal weight gain
1673573313;NA;NA;NA;PFIZER;54;F;NA;Arthralgia
1675057212;Small fibre neuropathy;LYRICA;300;PFIZER;73;F;Hospitalization - Initial or Prolonged;Asthma
1676714113;Alopecia areata;XELJANZ;5;PFIZER;71;F;NA;Condition aggravated
1677927715;Nerve injury;LYRICA;150;PFIZER;61;F;NA;Nasopharyngitis
1680761718;Diffuse large B-cell lymphoma;POLATUZUMAB VEDOTIN;111;ROCHE;75;F;Hospitalization - Initial or Prolonged;Confusional state
1684642212;Dyslipidaemia;evolocumab;140;AMGEN;77;F;Hospitalization - Initial or Prolonged;Carcinoid tumour pulmonary
1685113418;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;56;F;Hospitalization - Initial or Prolonged;Angle closure glaucoma
1686367319;Ovarian cancer;Niraparib;300;GLAXOSMITHKLINE;63;F;Hospitalization - Initial or Prolonged;Adverse drug reaction
1687175417;Hypoparathyroidism;Parathyroid Hormone;100;TAKEDA;39;F;Hospitalization - Initial or Prolonged;Abdominal pain
1691047912;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;56;F;NA;Bronchitis
1691482819;0;Human Immunoglobulin;0;TAKEDA;61;F;Other Serious (Important Medical Event);Adverse drug reaction
1692753611;NA;NA;NA;NOVARTIS;61;F;Death;Cardiac disorder
1695200811;Neoplasm malignant;DABRAFENIB;300;NOVARTIS;71;F;Other Serious (Important Medical Event);Myocarditis
1697654411;Severe myoclonic epilepsy of infancy;DIACOMIT;1500;BIOCODEX;3;F;Hospitalization - Initial or Prolonged;Alopecia
1698807920;Primary immunodeficiency syndrome;CUVITRU;15;TAKEDA;70;F;Hospitalization - Initial or Prolonged;COVID-19 immunisation
1703968114;Mycobacterium abscessus infection;LAMPRENE;100;NOVARTIS;61;F;Other Serious (Important Medical Event);Arthralgia
1704181713;0;Human Immunoglobulin;0;TAKEDA;56;F;Other Serious (Important Medical Event);Blepharitis
1706824021;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;39;F;Hospitalization - Initial or Prolonged;Blood pressure fluctuation
1708426318;NA;NA;NA;NOVARTIS;50;F;Other Serious (Important Medical Event);Abdominal discomfort
1709111611;Unknown;CUVITRU;8;TAKEDA;63;F;Other Serious (Important Medical Event);Bronchitis
1712908713;Chronic lymphocytic leukaemia;IMBRUVICA;140;ABBVIE;71;F;Death;Cholecystitis acute
1713718510;Incontinence;DETROL LA;4;PFIZER;59;F;Hospitalization - Initial or Prolonged;Fall
1713989610;Chronic lymphocytic leukaemia;IMBRUVICA;140;ABBVIE;68;F;Death;Pneumonia
1717309415;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;25;M;Other Serious (Important Medical Event);Chills
1718762414;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;49;F;Hospitalization - Initial or Prolonged;Agitation
1718763415;0;Human Immunoglobulin;0;TAKEDA;75;F;Hospitalization - Initial or Prolonged;Chronic sinusitis
1720862413;Rheumatoid arthritis;XELJANZ XR;11;PFIZER;78;F;Hospitalization - Initial or Prolonged;Abdominal pain lower
1726251619;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;59;M;Other Serious (Important Medical Event);Anxiety
1726268811;Non-small cell lung cancer;COMPARATOR CARBOPLATIN;550;NOVARTIS;82;M;Hospitalization - Initial or Prolonged;Cardio-respiratory arrest
1726577812;Immunodeficiency common variable;CUVITRU;8;TAKEDA;54;F;Hospitalization - Initial or Prolonged;Autoimmune disorder
1728493919;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;61;M;Hospitalization - Initial or Prolonged;Arthralgia
1731582812;Headache;LYRICA;100;PFIZER;64;F;Other Serious (Important Medical Event);Agitation
1731726330;Alpha-1 antitrypsin deficiency;ALFA 1 ANTITRYPSIN;4476;TAKEDA;86;F;Other Serious (Important Medical Event);Asthenia
1732468516;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;56;F;Hospitalization - Initial or Prolonged;Adverse drug reaction
1733225511;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;71;F;Hospitalization - Initial or Prolonged;COVID-19
1733363910;Immunodeficiency common variable;CUVITRU;20;TAKEDA;60;F;Other Serious (Important Medical Event);Alopecia
1733954011;Lung neoplasm malignant;ALUNBRIG;90;TAKEDA;69;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
1734035216;Ovarian cancer;Niraparib;300;GLAXOSMITHKLINE;75;F;Death;Asthenia
1735512414;NA;NA;NA;NOVARTIS;67;F;Life-Threatening;Candida infection
1736156611;Pain;LYRICA;100;PFIZER;83;F;NA;Arthropathy
1739344110;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;53;F;Hospitalization - Initial or Prolonged;Blood pressure decreased
1741760610;Hepatocellular carcinoma;XL184;40;EXELIXIS;67;M;Hospitalization - Initial or Prolonged;Transaminases increased
1743024614;Breast cancer metastatic;IBRANCE;125;PFIZER;67;F;Death;Blood pressure increased
1747550714;Vaginal haemorrhage;ESTRING;7.5;PFIZER;77;F;NA;Intermenstrual bleeding
1748973627;Immunodeficiency common variable;CUVITRU;8;TAKEDA;72;F;Hospitalization - Initial or Prolonged;Anxiety
1749609029;Immunodeficiency common variable;GAMMAGARD LIQUID;400;TAKEDA;52;F;Other Serious (Important Medical Event);Abdominal pain upper
1750810515;Congenital hypogammaglobulinaemia;CUVITRU;8;TAKEDA;71;F;Other Serious (Important Medical Event);Ataxia
1754239013;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;48;F;NA;Asthenia
1756503310;NA;NA;NA;TAKEDA;60;M;Life-Threatening;Anxiety
1756555811;Neuralgia;LYRICA;75;PFIZER;53;M;Hospitalization - Initial or Prolonged;Cough
1756929310;0;Human Immunoglobulin;0;TAKEDA;48;F;Other Serious (Important Medical Event);Bronchitis
1759517910;Pulmonary arterial hypertension;TREPROSTINIL;55;NOVARTIS;53;F;Hospitalization - Initial or Prolonged;Angina pectoris
1760396317;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;63;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
1762338212;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;63;F;Hospitalization - Initial or Prolonged;Arthralgia
1763586011;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;59;F;Other Serious (Important Medical Event);Back pain
1763854010;Prophylaxis;DIPHENHYDRAMINE HCL;25;PFIZER;72;M;Hospitalization - Initial or Prolonged;Pneumonia aspiration
1765783211;0;Human Immunoglobulin;0;TAKEDA;23;F;Other Serious (Important Medical Event);Adverse reaction
1768026721;Immunodeficiency common variable;CUVITRU;4;TAKEDA;43;F;Other Serious (Important Medical Event);Adenovirus infection
1768366014;Congenital hypogammaglobulinaemia;CUVITRU;15;TAKEDA;71;F;Other Serious (Important Medical Event);Asthma
1768614713;0;Human Immunoglobulin;0;TAKEDA;59;M;Hospitalization - Initial or Prolonged;Arthritis infective
1770582810;Growth hormone deficiency;GENOTROPIN;3.2;PFIZER;14;M;NA;Device breakage
1770627810;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;74;M;Life-Threatening;Asthenia
1772821412;NA;NA;NA;NOVARTIS;36;F;Other Serious (Important Medical Event);Abdominal pain upper
1774622114;Congenital generalised lipodystrophy;Metreleptin;2.5;AEGERION;45;F;Hospitalization - Initial or Prolonged;COVID-19
1774639410;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;70;F;Hospitalization - Initial or Prolonged;Cellulitis
1776746423;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;74;F;Other Serious (Important Medical Event);Abdominal distension
1778263915;Immunodeficiency common variable;CUVITRU;8;TAKEDA;67;F;Other Serious (Important Medical Event);Arthropod bite
1778371315;Plasma cell myeloma;REVLIMID;25;CELGENE;49;F;Life-Threatening;Blood gonadotrophin increased
1782172414;Pulmonary fibrosis;OFEV;100;BOEHRINGER INGELHEIM;78;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
1782861613;Still's disease;KINERET;40;BIOVITRUM;2;F;NA;Agitation
1784153710;Growth hormone deficiency;GENOTROPIN;1.7;PFIZER;8;M;NA;Device breakage
1784768312;Immunodeficiency common variable;CUVITRU;25;TAKEDA;49;F;Hospitalization - Initial or Prolonged;Adverse drug reaction
1785393912;Relapsing-remitting multiple sclerosis;TYSABRI;300;BIOGEN;46;M;Hospitalization - Initial or Prolonged;Colon cancer metastatic
1787229916;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;39;F;Death;Asthma
1788913313;0;Human Immunoglobulin;0;TAKEDA;27;M;Hospitalization - Initial or Prolonged;Candida infection
1789185116;Ovarian cancer;Niraparib;100;GLAXOSMITHKLINE;69;F;Life-Threatening;Abdominal discomfort
1789382810;B-cell lymphoma;MOSUNETUZUMAB;1;ROCHE;55;F;Other Serious (Important Medical Event);Cellulitis
1789578515;NA;NA;NA;NOVARTIS;61;F;Other Serious (Important Medical Event);Catheter site pruritus
1789760322;Spinal muscular atrophy;ZOLGENSMA;49.5;NOVARTIS;1;F;Hospitalization - Initial or Prolonged;Alanine aminotransferase increased
1792001110;0;Human Immunoglobulin;0;TAKEDA;61;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
1792517012;Chronic lymphocytic leukaemia;IMBRUVICA;420;ABBVIE;91;M;Life-Threatening;Anaemia
1797989319;Spinal muscular atrophy;ZOLGENSMA;49.5;NOVARTIS;1;F;Hospitalization - Initial or Prolonged;Alanine aminotransferase increased
1799968511;Immunodeficiency common variable;CUVITRU;16;TAKEDA;69;M;Hospitalization - Initial or Prolonged;Asthenia
1800211612;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;71;F;Other Serious (Important Medical Event);Adverse drug reaction
1801781510;Non-small cell lung cancer stage IV;Brigatinib;60;TAKEDA;52;F;Death;Abdominal pain upper
1803934715;Hypoparathyroidism;Parathyroid Hormone;50;TAKEDA;24;M;Hospitalization - Initial or Prolonged;Acute kidney injury
1805001419;Immunodeficiency common variable;CUVITRU;20;TAKEDA;72;F;Other Serious (Important Medical Event);Alopecia
1805570311;0;Human Immunoglobulin;0;TAKEDA;62;F;Other Serious (Important Medical Event);Fatigue
1806664310;Immunodeficiency common variable;CUVITRU;16;TAKEDA;62;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
1807212518;Fallopian tube cancer;ZEJULA;100;GLAXOSMITHKLINE;73;F;NA;Abdominal pain
1808407812;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;58;F;Other Serious (Important Medical Event);Bacterial infection
1809541311;Malignant melanoma;DCC 2618;150;DECIPHERA PHARMACEUTICALS;66;M;Other Serious (Important Medical Event);Abdominal pain
1809863111;Colon cancer;ATEZOLIZUMAB;840;ROCHE;66;F;Other Serious (Important Medical Event);Acute kidney injury
1813199013;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;65;F;Other Serious (Important Medical Event);Dyspnoea
1813725612;Immunodeficiency common variable;CUVITRU;16;TAKEDA;58;F;Death;Arthrodesis
1813926510;Immunodeficiency common variable;CUVITRU;8;TAKEDA;60;F;Hospitalization - Initial or Prolonged;Dyspnoea exertional
1815255717;Cervix carcinoma;NIVOLUMAB;360;BRISTOL MYERS SQUIBB;61;F;Other Serious (Important Medical Event);Anal incontinence
1815312310;Immunoglobulins abnormal;CUVITRU;18;TAKEDA;65;F;Hospitalization - Initial or Prolonged;Candida infection
1815811510;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;74;F;Other Serious (Important Medical Event);Asthma
1816488313;NA;NA;NA;TAKEDA;67;F;Hospitalization - Initial or Prolonged;Abdominal discomfort
1817200010;Immunodeficiency common variable;CUVITRU;6;TAKEDA;68;F;Death;Device leakage
1817595010;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;62;M;Hospitalization - Initial or Prolonged;Blood pressure decreased
1819767710;Menopausal symptoms;PREMPRO;1;PFIZER;84;F;Hospitalization - Initial or Prolonged;Agitation
1819936812;Ovarian cancer;Niraparib;200;GLAXOSMITHKLINE;72;F;Hospitalization - Initial or Prolonged;Alopecia
1820122210;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;64;F;Death;Dehydration
1820673410;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;65;F;Other Serious (Important Medical Event);Arthritis
1822080511;0;Human Immunoglobulin;0;TAKEDA;58;F;Death;Abdominal distension
1823001113;Ovarian cancer;ZEJULA;200;GLAXOSMITHKLINE;71;F;Other Serious (Important Medical Event);Adverse drug reaction
1827209913;Hormone-refractory prostate cancer;Enzalutamide;160;ASTELLAS;66;M;Other Serious (Important Medical Event);Hypertensive emergency
1828127910;0;Human Immunoglobulin;0;TAKEDA;82;F;Hospitalization - Initial or Prolonged;Abdominal distension
1828722610;Duchenne muscular dystrophy;EXONDYS 51;2900;SAREPTA THERAPEUTICS;16;M;Other Serious (Important Medical Event);Device related bacteraemia
1830093815;Malignant melanoma;LENVATINIB;20;EISAI;74;M;Other Serious (Important Medical Event);Embolism
1830596010;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;72;F;Other Serious (Important Medical Event);Abdominal distension
1831302710;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;57;F;Death;Blood pressure fluctuation
1832066712;Breast cancer;IBRANCE;125;PFIZER;77;F;Hospitalization - Initial or Prolonged;Ankle fracture
1832224216;Ovarian cancer;ZEJULA;2;GLAXOSMITHKLINE;74;F;Life-Threatening;Chills
1833049612;Non-Hodgkin's lymphoma;DEXAMETHASONE SODIUM PHOSPHATE;40;NOVARTIS;50;F;Hospitalization - Initial or Prolonged;Febrile neutropenia
1833131311;0;Human Immunoglobulin;0;TAKEDA;77;M;Death;Dizziness
1835022911;Duchenne muscular dystrophy;EXONDYS 51;1800;SAREPTA THERAPEUTICS;15;M;Hospitalization - Initial or Prolonged;Blister
1839609911;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;73;M;Other Serious (Important Medical Event);Cataract
1843063012;B-cell lymphoma;DEXAMETHASONE SODIUM PHOSPHATE;40;NOVARTIS;50;F;Death;Dyspnoea
1845947012;Hypopituitarism;GENOTROPIN;0.4;PFIZER;50;F;Life-Threatening;Accidental overdose
1849444419;Immune system disorder;Lanadelumab;300;TAKEDA;53;F;Death;Choking sensation
1853107710;Diabetes mellitus;JARDIANCE;25;BOEHRINGER INGELHEIM;68;F;Hospitalization - Initial or Prolonged;Diabetes mellitus
1855076912;Immunodeficiency common variable;CUVITRU;30;TAKEDA;71;F;Other Serious (Important Medical Event);Arrhythmia
1855647810;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;78;F;Death;Choking
1859982513;Myelodysplastic syndrome;AZACITIDINE;75;CELGENE;83;M;Hospitalization - Initial or Prolonged;Pneumonia
1860725318;Colorectal cancer;LENVATINIB;20;EISAI;51;F;Other Serious (Important Medical Event);Hypertensive urgency
1861513811;Blood immunoglobulin A;CUVITRU;1;TAKEDA;38;F;Other Serious (Important Medical Event);Candida infection
1866372119;NA;NA;NA;AUROBINDO;71;F;Other Serious (Important Medical Event);Abdominal pain
1868738913;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;71;F;Other Serious (Important Medical Event);Blood pressure increased
1876380013;Renal cell carcinoma;AXITINIB;5;PFIZER;92;M;Other Serious (Important Medical Event);Cardiac failure
1879130313;0;HUMAN NORMAL IMMUNOGLOBULIN;0;TAKEDA;62;F;Hospitalization - Initial or Prolonged;Arthralgia
1879576516;Squamous cell carcinoma of head and neck;LENVATINIB;20;EISAI;62;M;Hospitalization - Initial or Prolonged;Pharyngeal haemorrhage
1879664719;Hereditary angioedema;HAEGARDA;3000;CSL BEHRING;52;F;Death;Hereditary angioedema
1882013110;Anaplastic thyroid cancer;DABRAFENIB;150;NOVARTIS;65;M;Hospitalization - Initial or Prolonged;Abdominal pain
1887913511;Astrocytoma;DABRAFENIB;30;NOVARTIS;2;M;Hospitalization - Initial or Prolonged;Astrocytoma
1889067612;Relapsing-remitting multiple sclerosis;OCRELIZUMAB;312;ROCHE;55;F;Hospitalization - Initial or Prolonged;Disseminated varicella zoster virus infection
1898598310;Primary immunodeficiency syndrome;CUVITRU;12;TAKEDA;42;F;Other Serious (Important Medical Event);Bronchitis
1914996814;NA;NA;NA;NOVARTIS;51;F;Hospitalization - Initial or Prolonged;Asthenia
1917937810;Endometrial cancer;Dostarlimab;500;GLAXOSMITHKLINE;58;F;Hospitalization - Initial or Prolonged;Sepsis
1920251310;NA;NA;NA;GLAXOSMITHKLINE;69;F;Other Serious (Important Medical Event);Cardiomyopathy
1922078610;Malignant melanoma;GSK1120212;0.5;NOVARTIS;60;M;Other Serious (Important Medical Event);Dermatitis acneiform
1925633911;Plasma cell myeloma;REVLIMID;25;CELGENE;61;F;NA;Blood pressure fluctuation
1927638910;Synovitis;TURALIO;400;DAIICHI;52;F;Hospitalization - Initial or Prolonged;Abdominal pain upper
1929894012;Chronic lymphocytic leukaemia;IMBRUVICA;140;ABBVIE;83;M;Hospitalization - Initial or Prolonged;Aortic stenosis
1930738511;Bile duct cancer;LENVATINIB;20;EISAI;68;M;Disability;Blood bilirubin increased
1945284511;Pulmonary arterial hypertension;SELEXIPAG;1000;JOHNSON AND JOHNSON;78;M;Hospitalization - Initial or Prolonged;Arthralgia
